A Dissertation<br>Presented to<br>The Academic Faculty

## By

Kerry M. Strickland

In Partial Fulfillment<br>Of the Requirements for the Degree<br>Doctor of Philosophy in the<br>School of Chemistry and Biochemistry

Georgia Institute of Technology
May 2020

# NEW STRATEGIES IN THE EXPRESSION, PURIFICATION, AND RECONSTITUTION OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR BIOCHEMICAL AND BIOPHYSICAL CHARACTERIZATION IN DIFFERENT LIPID ENVIRONMENTS 

Approved by:

Dr. Ingeborg Schmidt-Krey, Advisor School of Chemistry and Biochemistry
School of Biological Sciences Georgia Institute of Technology

Dr. Bridgette Barry
School of Chemistry and Biochemistry
Georgia Institute of Technology
Dr. Raquel Lieberman
School of Chemistry and Biochemistry Georgia Institute of Technology

Dr. Nael A. McCarty
Marcus Professor of Cystic Fibrosis
Emory University School of Medicine
Dr. Loren Williams
School of Chemistry and Biochemistry Georgia Institute of Technology

Date Approved: [December 11, 2019]

To my friends and family.
Thank you for all of your support and love in this journey.

## ACKNOWLEDGMENTS

Thank you to my advisor, Dr. Inga Schmidt-Krey, and my collaboration advisors, Dr. Nael McCarty and Dr. JC Gumbart, for the constant reassurance, cheer, criticisms, and love in my growth as a scientist. The work presented would not be possible without your guidance and support.

Thank you to the many former and current lab members for invaluable discussions, comradery, favors, and support. I would like to thank Ms. Maureen Metcalfe, Dr. Yusuf Uddin, and Mr. Kasahun Neselu of the Schmidt-Krey Lab for guidance in transmission electron microscopy and image processing. I would like to thank Dr. Guiying Cui, Dr. Brandon Stauffer, Mr. Barry Imhoff, and Mrs. Kirsten Cottrill of the McCarty Lab for training me in a plethora of biochemical and biophysical techniques. Thank you all for accepting into the lab and treating me as your own. I would like to thank Mr. Gorman

Stock and Dr. Curtis Balusek of the Gumbart Lab for assistance in computational simulations and modeling. I would like to thank all of the following undergraduate, master's, and rotation students from all labs who were instrumental in fueling my love of science: Mr. Justin Dehorty, Ms. Carolann Epsy, Ms. Jess Hoffman, Ms. Isabela Povkov, and Mr. Cam Hedden.

Thank you to my husband, Andy Strickland, for your understanding, encouragement, praise, and love through this journey and many more. "For better, for worse, in sickness and in health, and through a Ph.D."

Thank you to my friends and family that have provided ample support, laughter, and love throughout this challenging journey. I want to thank my dad for reminding me that no matter where you go, there you are. I want to thank my mom for encouraging me with everything happens for a reason. I want to thank my siblings, Katy, K.C., and Keleigh, for reminding me to laugh. And I want to thank my friends, many already listed, and too many to count.

And finally, thank you to the bands whose music inspired me always to move forward, live to the fullest, and stay strong.
Page
ACKNOWLEDGMENTS ..... iv
TABLE OF CONTENTS ..... v
LIST OF TABLES ..... xiv
LIST OF FIGURES ..... xv
LIST OF SYMBOLS AND ABBREVIATIONS ..... $\mathbf{x x x}$
SUMMARY ..... xliii
CHAPTER 1. INTRODUCTION
1.1. INTRODUCTION. ..... 1
1.1.1. Publications resulting from this chapter. ..... 1
1.2. MEMBRANE PROTEINS. ..... 1
1.2.1. Adenosine triphosphate (ATP) binding cassette (ABC) transporters. ..... 1
1.3. CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR). ..... 6
1.3.1. CFTR architecture. ..... 6
1.3.2. CFTR biogenesis and trafficking. ..... 7
1.3.2.1. CFTR CO-TRANSLATIONAL FOLDING. ..... 10
1.3.2.2. CFTR FOLDING AND MATURATION. ..... 11
1.3.2.3. CFTR TRAFFICKING TO THE PLASMAMEMBRANE (PM).
1.3.3 Biochemical and biophysical studies of CFTR. ..... 14
1.3.3.1. R-DOMAIN PHOSPHORYLATION. ..... 15
1.3.3.2. ATPase ACTIVITY. ..... 15
1.3.3.3 CHLORIDE ION PORE. ..... 17
1.3.4. Disease-relevance of CFTR. ..... 20
1.4. CFTR STRUCTURES. ..... 23
1.4.1. Initial full-length CFTR structures. ..... 25
1.4.2. CFTR homology models. ..... 25
1.4.3. Recent CFTR structures. ..... 26
1.4.4. The need for more CFTR structures. ..... 28
1.5. MEMBRANE PROTEINS AND LIPIDS. ..... 31
1.5.1. Advancements in studying membrane proteins in lipid ..... 31 bilayers.
1.5.2. "Standard" nanodiscs. ..... 31
1.5.3. Native nanodises. ..... 32
1.5.3.1. STYRENE-MALEIC ACID LIPID PARTICLES ..... 36(SMALPs).
1.5.3.2. OTHER COPOLYMER VARIANTS. ..... 37
1.5.4. Downstream studies of membrane proteins in nanodiscs. ..... 38
1.6. CONCLUSIONS ..... 41

## CHAPTER 2. ATP SIGNALING IN A REVISED HOMOLOGY MODEL OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR)

2.1. INTRODUCTION. ..... 43
2.1.1. Individual contributions to the work. ..... 43
2.1.2. Publications resulting from this chapter. ..... 43
2.1.3. Introduction. ..... 43
2.2. METHODS. ..... 46
2.2.1. Flexible fitting. ..... 47
2.2.2. MD simulations and analysis. ..... 48
2.2.3. Pore analysis. ..... 49
2.2.4. Preparation of oocytes and cRNA. ..... 50
2.2.5. Electrophysiology. ..... 50
2.2.6. Source of reagents. ..... 51
2.2.7. $\quad$ Statistical analysis. ..... 51
2.3. RESULTS. ..... 512.3.1. MDFF fitting of the homology model to the cryo-EM map ofcrystallized CFTR.52
2.3.2. ATP-stabilized dimerization of NBDs is improved in fitted models as compared to the original homology model. ..... 56
2.3.3. Analysis of simulations shows the development of a partial pore in the crystallographic-fit model. ..... 58
2.3.4. Extended simulations of the crystallographic-fit model display a complete pore in the ATP-bound state.652.3.5. Comparison of the crystallographic-fit model with a recent3.2 Å resolution outward-facing human CFTR structure.68
2.3.6. Identification and experimental validation of a salt bridge between ICL3 and NBD1. ..... 72
2.4. DISCUSSION. ..... 80
CHAPTER 3. THREE DIFFERENT CFTR EXPRESSION SYSTEMS
3.1. INTRODUCTION. ..... 83
3.1.1. Individual contributions. ..... 83
3.1.1.1. SF9 EXPRESSION SYSTEM. ..... 83
3.1.1.2 BHK EXPRESSION SYSTEM. ..... 84
3.1.1.3. CHO EXPRESSION SYSTEM. ..... 84
3.1.2. Publications resulting from this chapter. ..... 84
3.2. METHODS. ..... 85
3.2.1. Sf9 expression system. ..... 85
3.2.1.1. MOLECULAR CLONING FOR hCFTR EXPRESSION
IN SF9 CELLS. ..... 85
3.2.1.2. MAINTENANCE OF SF9 CELLS. ..... 86
3.2.1.3. BACLULOVIRUS PRODUCTION. ..... 86
3.2.1.4. INFECTION OF SF9 SUSPENSION CULTURE. ..... 89
3.2.1.5. PROTEIN EXPRESSION SCREENING VIA WESTERN
BLOT ANALYSIS. ..... 89
3.2.1.6. HIS-TAG ACCESSIBILITY DETERMINATION. ..... 90
3.2.2 BHK-CFTR-10xHis Expression System. ..... 90
3.2.2.1 MAINTENANCE OF BHK-CFTR-10xHIS CELLS. ..... 90
3.2.2.2. HIS-TAG ACCESSIBILITY DETERMINATION. ..... 91
3.2.2.3. TRANSITION OF ADHERENT BHK-CFTR-10xHIS CELLS TO SUSPENSION CULTURE. ..... 91
3.2.2.4. CFTR PURIFICATION FROM BHK-CFTR-10xHIS CELLS. ..... 92
3.2.2.5. ANALYSIS OF CFTR PURIFICATION. ..... 94
3.2.3. $\quad$ T-Rex ${ }^{\mathrm{TM}} \mathbf{C H O}$ expression system. ..... 95
3.2.3.1 MOLECULAR CLONING. ..... 95
3.2.3.2. MAINTENANCE OF T-REX ${ }^{\mathrm{TM}}$ CHO CELLS. ..... 98
3.2.3.3. GENERATION OF STABLY TRANSFECTED T- REX ${ }^{\mathrm{TM}}$ CHO-CFTR EXPRESSION SYSTEM. ..... 98
3.2.3.4. ANALYSIS OF CFTR EXPRESSION AND PURIFICATION. ..... 101
3.2.3.5. CFTR PURIFICATION FROM STABLY TRANSFECTED T-REX ${ }^{\circledR}$ CHO CELLS. ..... 102
3.3. RESULTS. ..... 103
3.3.1. Expression of CFTR by baculoviral infection of Sf 9 cells. ..... 103
3.3.1.1. PRODUCTION OF MUTANT AND WT-hCFTR CONTAINING BACMID. ..... 103
3.3.1.2. TRANSFECTION OF SF9 CELLS WITH BACMID TO PRODUCE BACYLOVIRUS. ..... 1053.3.1.3. HIS-TAG IS NOT ACCESSIBLE IN CFTR PRODUCEDBY SF9 CELLS.108
3.3.2 CFTR purification from the BHK-CFTR-10xHis expression system. ..... 109
3.3.2.1 HIS-TAG OF RECOMBINANT CFTR IS ACCESSIBLEIN THE BHK-CFTR-10xHIS CELL LINE.109
3.3.2.2 TRANSITION OF ADHERENT BHK-CFTR-10xHIS
CELLS TO SUSPENSION CULTURE DOES NOTAFFECT CFTR EXPRESSION.110
3.3.2.3. IMPROVEMENTS TO DETERGENT-SOLUBILIZED
CFTR PURIFICATION TO INCREASE OVERALL YIELD. ..... 111
3.3.3. CHO-CFTR-3xFlag expression system. ..... 114
3.3.3.1. PRODUCTION OF A STABLY TRANSFECTED CHO- CFTR-3XFLAG CELL LINE. ..... 114
3.3.3.2. PURIFICATION OF DETERGENT-SOLUBILIZED CFTR FROM CHO-CFTR-3XFLAG CELL LINE. ..... 115
3.4. DISCUSSION. ..... 116
CHAPTER 4. CFTR RECONSTITUTION AND FUNCTION
4.1. INTRODUCTION. ..... 118
4.1.1. Individual contributions. ..... 119
4.1.2. Publications resulting from this chapter. ..... 119
4.2. METHODS. ..... 119
4.2.1. Preparation of BioBeads ${ }^{\mathrm{TM}}$. ..... 119
4.2.2. MSP1D1 expression and purification. ..... 120
4.2.3. Formation of empty nanodisc controls. ..... 124
4.2.4. Reconstitution of CFTR into nanodises. ..... 125
4.2.5. ATPase Activity Assay. ..... 126
4.2.6. Reconstitution of CFTR into proteoliposomes. ..... 127
4.2.7. Planar lipid bilayer measurements of CFTR channel activity. ..... 129
4.2.8. Transmission Electron Microscopy (TEM) of CFTR- nanodiscs. ..... 130
4.3. RESULTS. ..... 130
4.3.1. The process of cleaning and storing BioBeads ${ }^{\mathrm{TM}}$ affects the efficiency of nanodisc formation. ..... 130
4.3.2. Empty nanodiscs were formed using two different types of lipids. ..... 132
4.3.3. CFTR was incorporated into POPC-based nanodiscs. ..... 135
4.3.4. ATPase activity of CFTR is improved in a lipid environment over a detergent environment. ..... 138
4.3.5. Purified CFTR has the same channel function as BHK cellular membranes. ..... 139
4.3.6. Preliminary class averaging for CFTR-nanodiscs displaysexpected characteristics of successful reconstitution of CFTRinto nanodisc.143
4.4. DISCUSSION. ..... 144
CHAPTER 5. DETERMINATION OF THE LIPID ENVIRONMENT OF CFTR
5.1. INTRODUCTION. ..... 146
5.1.1. Individual contributions. ..... 147
5.1.2. Publications resulting from this chapter. ..... 147
5.2. METHODS. ..... 147
5.2.1 BHK-CFTR-10xHis expression system. ..... 147
5.2.1.1. CFTR PURIFICATION FROM BHK-CFTR-10xHIS CELLS. ..... 147
5.2.1.2. SMALP-SOLUBILIZATION AND PURIFICATION OF
CFTR. ..... 147
5.2.2. Untargeted lipidomics. ..... 148
5.2.2.1. PREPARATION OF DETERGENT-SOLUBILIZED
SAMPLES FOR LIPIDOMICS MASS
SPECTROMETRY. ..... 148
5.2.2.2. PREPARATION OF SMALP-CFTR SAMPLES FOR
LIPIDOMICS MASS SPECTROMETRY. ..... 149
5.2.2.3. ULTRA-PERFORMANCE LIQUIDCHROMATOGRAPHY-MASS SPECTROMETRY(UPLC-MS).149
5.2.2.4. DATA ANALYSIS FOR DETERGENT-SOLUBILIZED
CFTR SAMPLES. ..... 150
5.2.2.5. DATA ANALYSIS FOR SMALP-CFTR SAMPLES. ..... 150
5.3. RESULTS. ..... 152
5.3.1 SMALP-CFTR purification requires further optimization. ..... 152
5.3.2. Lipidomics Mass Spectrometry (MS) of detergent-solubilized CFTR. ..... 153
5.3.3 Lipidomics Mass Spectrometry (MS) SMALP-CFTR. ..... 154
5.4. DISCUSSION. ..... 155
CHAPTER 6. CONCLUSIONS AND FUTURE DIRECTIONS.
6.1. INTRODUCTION. ..... 157
6.2. REVIEW OF WORK. ..... 157
6.2.1. CFTR homology models and understanding transition states. ..... 157
6.2.2. CFTR expression and purification. ..... 159
6.2.3. CFTR reconstitution and functional studies. ..... 160
6.2.4. Determination of the lipid environment of CFTR. ..... 162
6.3. FINAL REMARKS. ..... 164
APPENDIX A ..... 165
REFERENCES ..... 260

## LIST OF TABLES

Table 1.1: Table of Human ABC transporter subclasses-ABCA through ABCG. For each subclass a common alias, the number of genes currently identified, a general functional, and an example member is listed.

## Table 1.2: Current released CFTR structures and the conditions of protein.

Table 1.3: Structures of SMA derivatives and current characterization.
The use of polymers to solubilize membrane proteins and package lipids into nanodiscs is a relatively new technology, and each polymer provides a unique set of advantages.

Table 2.1: Experimentally validated interactions in the original homology model and fitted structures. Numbers in brackets are references for the listed interactions.

Table 5.1: Schymanski level of confidence for MS identification.
Table 5.2: Lipidomics results of detergent-solubilized CFTR and analysis results. The abbreviation FC is the fold change, and CV is the coefficient of variation.

Table A.1: Lipidomics results of detergent-solubilized CFTR and analysis results. The abbreviation FC is the fold change. The listed features were identified by the mass list developed by members of systems MS lipidomics core, giving a confidence level of 4 .

Table A.2: Lipidomics results of detergent-solubilized CFTR and analysis results. The abbreviation FC is the fold change. As only a formula can be determined for these features, this gives a level 4 confidence.

Table A.3: Lipidomics results of detergent-solubilized CFTR and analysis results. The abbreviation FC is the fold change. For these listed features, only molecular weight and retention time (RT) can be determined, and thus determined at a level 5 confidence.

Table A.4: Lipidomics results of CFTR-SMALPs and analysis results. The abbreviation FC is the fold change. These features determined at a confidence level of 4 with the identification of the formulas only.

Table A.5: Lipidomics results of CFTR-SMALPs and analysis results.
The abbreviation FC is the fold change. These features determined at a confidence level of 5 with identification of the retention time (RT) only.

## LIST OF FIGURES

Figure 1.1: Model of an ABC transporter in a lipid bilayer and ATPbinding at the NBD interface. (A) The general architecture of most human ABC transporters is shown. The Transmembrane Domains (TMDs), boxed in forest green, exist in the lipid bilayer and are the site of substrate binding. The intracellular loops (ICLs), boxed in orange, translate conformation changes by ATP binding and hydrolysis at the nucleotide binding domains (NBDs), boxed in purple. TMD1 is gray, TMD2 is green, NBD1 is pink, and NBD2 is blue. Some ABC transporters contain a unique motif known as the lasso motif (red). (B) The interface of NBDs bound with ATP (green) and coordinated $\mathrm{Mg}^{2+}$ (cyan) is shown. Both images were developed using PDB ID: 6MSM.

Figure 1.2: The currently proposed ATP hydrolysis reaction path of ABC transporters. While the mechanism of ATP hydrolysis in ABC transporters has been elusive, recent computational studies of the acidic residue just after the Walker B motif predict the above hydrolysis mechanism. For hCFTR, this acidic residue is glutamic acid.

Figure 1.3: Scheme of the proposed mechanistic models of ABC transporters. There are three commonly accepted mechanisms for substrate transport in ABC transporters-alternating access model, switch model, and constant contact model. In the alternating access model, ATP binding induces conformational changes that allow for substrate binding. Substrate binding induces conformational changes in the transmembrane domains (TMDs) that open the substrate pocket to the opposite side of the membrane. ATP hydrolysis and release cause conformational changes to release the substrate and prepare the protein for a new transport cycle. In the switch model, substrate binding induces conformational changes and allows for ATP binding. ATP binding induces conformational changes to release the substrate, and ATP hydrolysis and release prepares the protein for a new transport cycle. In the constant contact model, ATP binding at only one site can open the substrate binding pocket and ATP hydrolysis and release at only one binding site prepares the protein for the next transport cycle.

Figure 1.4: Two different representations (schematic and cartoon) of CFTR architecture. Structural domains depicted in both styles (schematic-top and cartoon-bottom): the lasso motif (red), TMD1 (gray), NBD1 (pink), TMD2 (green), and NBD2 (blue). (A) In the schematic representation, several more features of CFTR are displayed. The R-domain (yellow) is phosphorylated at several sites (orange circles), extracellular loop 4 (ECL4) is glycosylated at two sites (cyan hexagons), and the C-terminus contains the PDZ binding domain (purple box). (B) The cartoon representation was built using PDB ID: 6MSM and is one of the recently released structures of CFTR.

Figure 1.5: Simplified depiction of the four CFTR folding checkpoints. In the ER, CFTR will proceed through four processing checkpoints. These checkpoints occur both co-translationally and post-translationally and ensure properly folded CFTR can exit the ER and proceed to the Golgi. At one of these checkpoints, CFTR is glycosylated, known as Band B, and can be distinguished from CFTR that is glycosylated further in the Golgi (Band C).

Figure 1.6: Sequence of the R-domain highlighting the positions of phosphorylation. There are nine phosphorylation sites (bolded and underlined), all with varying levels of functional consequences to CFTR.

Figure 1.7: Diagram of ATP (magenta) binding sites at the interface of the nucleotide binding domain 1 (NBD1, pink) and nucleotide binding domain (NBD2, blue). As discussed in Figure 1.1, there are two ATP binding sites in ABC transporters formed from the Walker A, Walker B, and ABC Signature motifs in the nucleotide binding domains. (A) The sequences of these motifs for hCFTR are tableted. (B) The consensus site (ATP binding site 2, marked by the black circle) is discussed further. Highlighted in this figure is the Walker A of NBD 2 (yellow) and ABC Signature of NBD 1 (orange), which form the ATP binding site stabilized by several residues of NBD2: Y1219 in A-loop (dark green), H1402 in H-loop (light green), Q1292 of Q-loop (purple), and D1320 of Walker B in NBD2 (cyan). A coordinated $\mathrm{Mg}^{2+}$ is gray.

Figure 1.8: Scheme of CFTR gating and opening cycle. CFTR is a chloride ion channel regulated by phosphorylation of the R-domain. After phosphorylation of the R-domain, the fully open pore is regulated by two different gating stages. The NBD-mediated gating (blue background) occurs with the binding of one ATP molecule (yellow) at a consensus site and one ATP molecule (yellow) at a degenerate site in the nucleotide binding domains (NBDs; NBD1 is pink, and NBD2 is blue). Then the pore is regulated by pore gating (pink background) in which CFTR has several subconductance states (s1 and s 2 , thin red arrow) but will process to a fully conducting pore (f, thick red arrow). Hydrolysis of ATP (yellow) at the consensus site and the release of ADP (orange) and inorganic phosphate causes the channel to close by inducing conformational changes in the Transmembrane Domains (TMDs, TMD1 is gray, and TMD2 is green).

Figure 1.9: Depiction of residues believed to be important in pore formation of CFTR. A full structure of CFTR (right) highlights the general architecture of CFTR with TMD1 in gray, NBD1 in pink, TMD2 in green, and NBD2 in blue. The black circle highlights four transmembrane helices, TM1 as pale orange, TM6 as orange, TM12 as forest green and TM11 as yellow, and the residues on those helices that are important in pore formation. Residues accessible from the extracellular side are blue, from the intracellular side are purple, or both are red.

Figure 1.10: Diagram of classes for CFTR mutations. The 346 currently identified disease-causing mutations are classified into one of the five above described classes. Each mutation class houses mutations that affect one of the following: protein production (class 1), protein processing (class 2), protein gating (class 3), protein conduction (class 4), or insufficient protein on the cell surface (class 5). However, many mutations can contribute to multiple classes of disfunction. The most common mutation, $\Delta \mathrm{F} 508$, is classified as a class 2 mutation.

Figure 1.11: Diagram of the current CF modulators and the tableted list of FDA-approved mutations. Currently, four different modulator therapies have been approved in single, double, or triple combination therapies and treat 39 of the 346 disease-causing mutations. These modulators are either potentiators, like ivacaftor (VX-770), or correctors, like lumacaftor (VX-809), tezacaftor (VX-661), and elexacaftor (VX-445).

Figure 1.12: Electrostatic salt bridge triad identified in homology models of CFTR and molecular dynamics and confirmed by electrophysiological techniques. This catalytic triad has been investigated in the translation of ATP binding at the nucleotide binding domains (NBDs, NBD1 is pink, and NBD2 is blue) to the Transmembrane Domains (TMDs, TMD1 is gray, and TMD2 is green). This triad is investigated further in chapter II of this dissertation.

Figure 1.13: Depiction of the Lasso motif in CFTR. The lasso motif (red) is a motif found in several members of the ABC transporter superfamily of proteins, in which the N -terminus tucks into the lipid bilayer. For orientation, Transmembrane Domain 1 (TMD1) is gray, nucleotide binding domain 1 (NBD1) is pink, TMD2 is green, and NBD2 is blue. PDB ID: 6MSM used to generate the figure.

Figure 1.14: A structure of nanodisc formed by Membrane Scaffold Protein (MSP). An individual MSP (orange) wraps around an individual leaflet of the lipid bilayer (gray). Thus, two MSP molecules form a single nanodisc composed of a lipid bilayer. From the top-down view (A), the nanodisc in this image is of MSP1D1 and has a diameter of 9.7 nm . In the side-on view (B), a nanodisc has a height of approximately 5 nm . Images were built in Visual Molecular Dynamics (VMD) software from PDB ID: 6CM1 to show a top-down view (left) and side-on view (right) of a nanodisc.

Figure 1.15: Depiction of the lipids first and commonly used to generate nanodiscs. All three lipids have the same head group (phosphatidylcholine) but differ in tail composition. The abbreviations are the following: 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dipalmitoyl-sn-glycero-3phosphocholine (DPPC), or 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC).

Figure 1.16: Schematic of nanodisc formation. The incubation of the membrane protein (MP) of interest, membrane scaffold protein (MSP) and lipids (DMPC, DPPC, POPC, etc.) in a particular ratio with the removal of detergent, either via BioBeads ${ }^{\mathrm{TM}}$ or dialysis, will form membrane proteinloaded nanodiscs (full nanodiscs) or lipid-only nanodiscs (empty nanodiscs).

Figure 1.17: Schematic of native nanodiscs formation. Cell membranes containing several endogenous membrane proteins and CFTR incubated with Styrene Maleic Acid (SMA) polymer. SMA will self-insert into the membrane and form native nanodiscs. The membrane protein or membrane proteins of interest can be separated from endogenous membrane proteins using affinity chromatography. The following PDB IDs were used to generate this image: 5UAR, 5IRZ, 6F46, and 1HRK.

Figure 1.18: Reaction diagram of SMA formation. Styrene and maleic anhydride monomers are mixed and polymerized, forming a polymer of varying uniformity. The final step in the formation of SMA is the hydrolysis of maleic anhydride to maleic acid under basic conditions. The final SMA polymer is used to solubilize membrane proteins and surrounding lipids embedded from the lipid bilayer.

Figure 2.1: Cartoon depictions of our two MDFF-fitted structures ("crystallographic" on the left and "averaged" on the right) and the Rahman et al. homology model that served as the starting point for MDFF. The domains are colored as follows: NBD1, pink; NBD2, blue; TMD1, gray; TMD2, green. A slight twist of the NBDs relative to the original model is indicated by the gray rectangles in the refined models. The additional curvature of TMs 7 and 8 , as compared to the homology model, is highlighted by the purple rectangles. The pink circle magnifies the proximity of residue S341 (pink) on TM6 and L1135 (blue) and N1138 (yellow) on TM12.

Figure 2.2: Plot of NBD-NBD distance for the three different CFTR homology models simulated with ATP bound. The separation was calculated by taking the difference in centers of mass of the $\alpha$-carbons in each NBD. Both refined models, averaged and crystallographic, display tighter NBDs dimerization than the original Rahman et al. homology model. The dashed line and the solid line each represent a different trial.

Figure 2.3: Pore analysis of the three different CFTR homology models simulated in ATP-apo (black), ATP semibound (green), and ATP-bound states (blue). The pore radius plotted for each model was evaluated near F337. The dashed line indicates the radius of a chloride ion ( $1.8 \AA$ ). Only the crystallographic-fit model shows widening in both bound and semibound states. See Figure 2.4 for repeated runs of the bound and apo states of each model.

Figure 2.4: Pore analysis of the second runs of the three different CFTR homology models in ATP-apo (black) and ATP-bound states (blue). The pore radius plotted for each model was evaluated near F337. The dashed line indicates the radius of a chloride ion (1.8 A). Only the crystallographic-fit model shows widening in both bound and semi-bound states.

Figure 2.5: Comparison of the averaged-fit (red) and crystallographic-fit (green) models for the first run of each. (A,B) Comparison at 0 (A) and 100 ns (B) viewed from the membrane plane (the intracellular side is on the bottom). TM9 is indicated. (C,D) Comparison at $0(\mathrm{C})$ and $100 \mathrm{~ns}(\mathrm{D})$ viewed from the extracellular side. TM9 and TM12 are indicated.

Figure 2.6: Radius of gyration $\left(\mathbf{R}_{\mathbf{G}}\right)$ analysis for the three CFTR homology models simulated in ATP-apo, ATP-semibound, and ATP-bound states. (upper left) Cartoon representation of the TMDs of the crystallographic-fit CFTR (extracellular side at the top). The TMDs have been divided on the basis of their position along the pore axis into three sections. $\mathrm{R}_{\mathrm{G}}$ for the upper section (yellow) is plotted here for the indicated structures, and the middle (gray) and bottom (blue) sections are plotted in Figure 2.7 and 2.8. The crystallographicfit model shows significant widening for the uppermost section in the ATPbound state.

Figure 2.7: Radius of gyration $\left(R_{G}\right)$ vs. time for slice 1 from the second runs of the Rahman et al. homology (A), averaged-fit model (B), and crystallographic-fit model (C).

Figure 2.8: Radius of gyration $\left(R_{G}\right)$ vs. time for slices 2 and 3 from the first runs of the Rahman et al. homology model ( $\mathrm{A}, \mathrm{B}$ ) and averaged-fit model (C,D).

Figure 2.9: Radius of gyration $\left(\mathbf{R}_{\mathbf{G}}\right)$ vs. time for the first crystallographicfit run, extended to 300 ns . The graphs labeled Slice 1-3 correspond to the colored sections of the figure in the top left.

Figure 2.10: Pore analysis of the crystallographic-fit model in (A) ATPbound and (B) ATP-apo states after 280 ns of simulation each. TMD1 is shown in gray, transparent and TMD2 is in green; NBDs are not shown. In parts A and B , the pore in CFTR is shown according to the following color scheme: radius $>2.3 \AA$ is blue, $1.15-2.3 \AA$ is yellow, and $<1.15 \AA$ is red. The dashed lines indicate the position of the membrane. (C) Plot of pore radius as a function of position along the channel axis (normal to the membrane) for both bound (blue) and apo (black) states at 280 ns . The shaded area indicates the position of the membrane, and the dashed line at $1.8 \AA$ is the radius of a chloride ion. Second runs of the bound and apo states are shown in Figure 2.11.

Figure 2.11: Pore analysis of the second 300 -ns runs of the crystallographicfit model in (A) ATP-bound and (B) ATP-apo states. TMD1 is shown in grey, transparent and TMD2 is in green; NBDs are not shown. In (A) and (B), the pore in CFTR is shown according to the following color scheme: radius $>2.3$ $\AA$ is blue, $1.15-2.3 \AA$ is yellow, and $<1.15 \AA$ is red. The dashed lines indicate the position of the membrane. (C) Plot of pore radius as a function of position along the channel axis (normal to the membrane) for both bound (blue) and apo (black) states at 300 ns . The shaded area indicates the position of the membrane, and the dashed line at $1.8 \AA$ is the radius of a chloride ion.

Figure 2.12: Differences between ATP-bound (green) and ATP-apo (orange) states of CFTR. Structures are taken after 280 ns of the first run starting from the crystallographic-fit model (see also Fig. 2.10). (A) NBDs viewed from the cytoplasm. ATP molecules in the bound state are shown in purple. (B) ICLs viewed from the cytoplasm in the same orientation as the NBDs in (A). The bottom of TM9, connected to ICL3, is also indicated. (C) Side-view of ICLs (bottom) and TMDs with one of the discovered salt bridges highlighted. (D) TMDs viewed from the extracellular side. The red $x$ marks the position of the putative initial pore.

Figure 2.13: Structural comparison of the outward-facing hCFTR structure (PDB ID 6MSM) in orange and the hCFTR outward-facing crystallographic-fit model in blue. (A) Aligned structures. The root-meansquare deviation between the structures is $5.8 \AA$. (B) The alignments of TM6, TM7, and TM8 are highlighted to show major differences.

Figure 2.14: Comparison between the Rahman et. al. homology model (blue) and closed-state cryo-EM structure of human CFTR (orange; PDB 5UAK). The full structures are shown in (A) and TMs 6, 7, and 8 are highlighted in (B).

Figure 2.15: Sequence alignment of CFTR and related proteins. The sequence segments in the alignment correspond to ICL2 (top) and ICL4 (bottom). Residues E267 and K1060, which appear to contribute to a salt bridge, are highlighted in red.

Figure 2.16. Snapshot of the bound crystallographic-fit trajectory after 200 ns (top), focusing on the interface between NBDs and ICLs (bottom). The domains of CFTR are labeled accordingly, and E543, K968, and K1292 are shown as sticks and colored by residue type (acidic in red and basic in blue).

Figure 2.17: Salt-bridge distances over time for the crystallographic-fit ATP-bound simulation. Three experimentally verified salt bridges are tracked over time in (A) run 1 and (B) run 2. (C) Two salt bridges newly discovered and experimentally confirmed here for both runs.

Figure 2.18: Mean activation time changed in mutants compared to wtCFTR. Sample traces of inside-out macropatch currents of (A) WT-, (B) E543K-, (C) K968A-, (D) E543K/K968E-, (E) K1292E-, and (F) E543K/K1292E-CFTR recorded under the experimental conditions listed in the panels. Control, 150 mM Cl - intracellular solution; INH172, $10 \mu \mathrm{M}$ CFTRinh172. (G) Summary data for mean activation time for WT and mutants. Statistical data are as follows: $\mathrm{n}=30$ for WT; $\mathrm{n}=11$ for E543K; $\mathrm{n}=7$ for $\mathrm{K} 1292 \mathrm{E} ; \mathrm{n}=18$ for K968A; $\mathrm{n}=11$ for $\mathrm{E} 543 \mathrm{~K} / \mathrm{K} 968 \mathrm{E}$; $\mathrm{n}=10$ for E543K/K1292E. ${ }^{* * *}, \mathrm{P}<0.001$ compared to WT; **, P < 0.01 compared to WT-CFTR.

Figure 2.19: 1 mM MgATP reactivated WT and mutant CFTR after channels were fully activated by ATP + PKA. (A) WT-CFTR was fully activated with 1 mM MgATP and $127.6 \mathrm{U} / \mathrm{ml}$ PKA, deactivated by removal of ATP and PKA using control solution, and then reactivated by 1 mM MgATP alone. Representative current traces for E543K (B), K968A (C), and E543K/K968A-CFTR (D) were recorded with the same experimental conditions as WT-CFTR. Summary data are shown in E. Y axis indicate the ratio of maximum current in ATP alone ( $\mathrm{I}_{(\text {ATP })}$ ) divided by maximum current in ATP and PKA ( $\left.\mathrm{I}_{(\mathrm{ATP}+\mathrm{PKA})}\right)$. Statistical data are follows: $\mathrm{n}=4$ for WT ; $\mathrm{n}=6$ for E543K; n=8 for K968A; n=6 for E543K/K968E. **, P < 0.01 compared to WT.

Figure 2.20: Representative fits of the ATP-induced activation of phosphorylated CFTR and deactivation after washout of ATP. All activation and deactivation data were fit in Igor using a double exponential (without an X-offset), as follows: (A) WT-CFTR activation, (B) WT-CFTR deactivation, (C) K968A-CFTR activation, (D) K968A-CFTR deactivation, (E) E543K-CFTR activation, (F) E543K-CFTR deactivation, (G) E543K/K968ECFTR activation, and (H) E543K/K968E-CFTR deactivation. The differences between the raw data and the double exponential fit were calculated and plotted above each fit. Goodness of fit was also analyzed by Chi-square value. The activation traces for each single mutant (K968A-CFTR or E543K-CFTR) were impossible to fit using a double exponential function; however, the double mutant (E543K/K968E-CFTR) seems to partially restore to WT-CFTR channel behavior, although not completely, thus enabling the data to be fit.

Figure 2.21: K968A exhibited similar single-channel behavior to WT-
pore architecture of CFTR. The Journal of General Physiology 144, 159-179. $\mathrm{N}=5$ for K968A-CFTR. ***, $\mathrm{P}<0.001$ compared to WT.

Figure 3.1: Plasmid map of WT-hCFTR in pFastBacDual vector. This plasmid was used for wt-hCFTR expression in Sf9 cells, but also for the generation of mutant hCFTR constructs and expression in Sf9 cells.

Figure 3.2: Depiction for the overall flow of baculovirus production. The purified donor plasmid is transformed into DH10Bac E. coli. Bacteria containing the recombined CFTR-containing bacmid will survive antibiotic selection and can be further screened using Blue-White screening. CFTRcontaining bacmid is transfected into Sf 9 cells to generate Baculovirus (within media). Baculovirus can be used to infect Sf 9 cells for CFTR protein production and purification.

Figure 3.3: Size Exclusion Chromatography (SEC) Standards on Superdex ${ }^{\text {TM }} 200$ 10/300 GL column. Molecular Weight standards for SEC were loaded onto Superdex ${ }^{\text {TM }} 20010 / 300$ GL column and run at a flow rate of $0.25 \mathrm{mg} / \mathrm{mL}$. Based on these standards and the molecular weight of CFTR ( $\sim 170$ kDa , CFTR and is anticipated to elute at 11 mL . CFTR-nanodiscs would be much larger, eluting at $<11 \mathrm{~mL}$ but $>9 \mathrm{~mL}$.

Figure 3.4: Plasmid map of WT-hCFTR with a 3x-FLAG-tag in ECL4 for stable transfection of T-Rex ${ }^{\text {TM }} \mathbf{C H O}$ cells. WT-hCFTR with a 3x FLAG-tag in extracellular loop 4 (ECL4) cloned from this construct and inserted into pcDNA5/TO containing an internal ribosomal entry site (IRES) and cyan fluorescent protein (CFP) for transfection and protein production reporting in T-Rex ${ }^{\text {TM }} \mathrm{CHO}$ cells.

Figure 3.5: Restriction digestion of pCF595 (McCarty Lab). Results of restriction digestion, using PvuI, of pCF595 purified from three different bacterial colonies (c1, c2, c3) on a $1 \%$ agarose gel stained with $0.5 \mu \mathrm{~g} / \mathrm{mL}$ ethidium bromide. Theoretical gel (left) was produced for ease of interpretation of experimental gel (right). Proper insertion and digestion will display two bands, one at just under 10 kbp and one between 3 kbp and 2 kbp . All three colonies (c1, c2, and c3) show expected digestion bands.

Figure 3.6: Microscopy of a T-Rex $\mathbf{C H O}$ cell kill curve at $450 \mu \mathrm{~g} / \mathrm{mL}$ hygromycin. The concentration of selection agent that will show some cell death at 4 days and complete cell death after 8 days must be determined before the generation of a stable cell line by selection agent. A range of hygromycin concentrations was tested ( $0 \mu \mathrm{~g} / \mathrm{mL}$ to $1.5 \mathrm{mg} / \mathrm{mL}$ ) and a concentration of 450 $\mu \mathrm{g} / \mathrm{mL}$ hygromycin fits this profile. Depicted in this figure is the concentration of $450 \mu \mathrm{~g} / \mathrm{mL}$, which displays cell death on Day 4, but the most on Day 8.

Figure 3.7: Generation of stably transfected T-Rex ${ }^{\text {TM }} \mathbf{C H O}$ cells with inducible CFTR-3xFLAG. The pcDNA5/TO containing an inducible WThCFTR cloned with a 3x-FLAG-tag in ECL4 and a CFP-reporting system was transiently transfected into T-Rex ${ }^{\mathrm{TM}} \mathrm{CHO}$ cells. (A) T-Rex CHO cells were induced and were single-cell sorted by flow cytometry using the CFP reportingsystem. The first plot of untransfected cells and the second of transfected cells show increased cell debris and death reported by the large side-scatter signal (SSC-A). The third plot shows the fluorescent channel separation of transfected cells from untransfected cells. (B) Representative individual colonies several days after sorting shows growth. (C) Images of two colonies that express CFTR, as well as the CFP-reporting system. (D) Western blot shows CFTR expression in colony B2, but not in several other colonies screened (D12 and F4). The first negative control is parental T-Rex ${ }^{\mathrm{TM}} \mathrm{CHO}$ cells, and the second negative control is uninduced B2 colony. Immunoblotting for CFTR: Primary - mouse antiCFTR 596 antibody, 1:1,500 and Secondary - IRDye ${ }^{\circledR}$ 680RD goat anti-mouse antibody, 1:10,000 (LI-COR).

Figure 3.8: Images of representative agar plates utilizing Blue/White screening to confirm successful bacmid production after transformation. (A) Initial transformants plated on LB-agar plates with $50 \mu \mathrm{~g} / \mathrm{mL}$ kanamycin, 7 $\mu \mathrm{g} / \mathrm{mL}$ gentamicin, $10 \mu \mathrm{~g} / \mathrm{mL}$ tetracycline, and $100 \mu \mathrm{~g} / \mathrm{mL}$ Bluo-gal and 40 $\mu \mathrm{g} / \mathrm{mL}$ IPTG. Colonies that have been transformed with plasmid and have correctly produced recombinant bacmid are white. (B) Selected colonies from the first plate were restreaked on new LB-agar plates (containing previously mentioned additives) to confirm the homogeneity of each selected colony.

Figure 3.9: PCR amplification of a section of CFTR from purified WTCFTR and mutant CFTR bacmid. Primers, designed in house, were used to amplify a specific region of CFTR from purified bacmid to confirm CFTR gene insertion into bacmid. The positive control is the WT-CFTR plasmid (pCF340, McCarty Lab) and the negative control is ABCC4 in pGEMHE construct. Both mutant and WT Bacmid show similar size bands to positive control suggesting the proper insertion of CFTR into the bacmid.

Figure 3.10: Images of transfected $\mathbf{S f 9}$ cells to confirm viral infection and baculovirus production. (A) Images are comparing Sf9 cells that were transfected with bacmid (WT) to produce baculovirus. After 7 days, transfected Sf9 cells will appear larger in size when compared to untransfected cells and will contain many intracellular vesicles. Infected Sf9 cells will eventually leave a region of no cell growth or a plaque under plaque assay conditions. Individual plaques are collected and can be used to infect more copious amounts of cells. (B) Visualization of Sf9 cells infected with plaque-purified p1 virus for WTCFTR (Wt 8 and Wt 3) or mutant CFTR (mutant 2 or mutant 3, D110C/K892C). Again, cells infected by baculovirus are identified by swelling and the presence of small vacuoles.

Figure 3.11: Western blot analysis to determine high-expressing WTCFTR p1 viral stock. High-expressing CFTR plaque purified p1 viral stocks, single 1 and single 2 , or mixed plaques, mixed 1 , mixed 2 , mixed 3 , and mixed 4, were determined by western blot analysis using an anti-CFTR antibody (A), but were not detected by anti-His-tag antibody (B). Positive controls are CFTR expressed in BHK cells (A) and His-tagged sphingomyelinase, purified (B). Immunoblotting for CFTR: Primary - mouse anti-CFTR 596 antibody, 1:1,500 and Secondary - goat anti-mouse antibody conjugated to HRP, 1:1,000. Immunoblotting for His-tag: Primary - rabbit anti-His-Tag antibody, 1:1,000 and Secondary - goat anti-rabbit antibody conjugated to HRP, 1:1,000.

Figure 3.12: Western blot analysis of crude CFTR purification from infected Sf9 cells expressing WT-hCFTR. Sf9 cells were infected with a high CFTR expressing p1 virus (WT, mixed 3) at an MOI of 20. Infected cells were lysed in Roche A buffer and $0.1 \%$ DDM. CFTR could not be separated from the lysate using His-tag affinity resin, confirming the inaccessibility of His-tag. Immunoblotting for CFTR: Primary - mouse anti-CFTR 596 mouse antibody, 1:1,500 and Secondary - goat anti-mouse antibody conjugated to HRP, 1:1,000.

Figure 3.13: Western blot analysis of crude CFTR purification from BHK cells stably transfected to express WT-hCFTR. Stably transfected BHK cells expressing WT-hCFTR were lysed in Roche A buffer and 0.1\% DDM. CFTR was separated from the endogenous protein in the lysate using His-tag affinity resin. The ability to separate CFTR confirms the accessibility of the His-tag in this cell expression system. Immunoblotting for CFTR: Primary - mouse antiCFTR 596 antibody, 1:1,500 and Secondary - goat anti-mouse antibody conjugated to HRP, 1:1,000.

Figure 3.14: CFTR expression is unchanged under suspension cell culture conditions. CFTR expressed in the stably transfected BHK cell line. Cells were transitioned to suspension culture, growing as "pearls" for purification. (A) BHK-CFTR-10xHis pearls after a few days under suspension culture conditions. (B) Western blot comparing CFTR expression under suspension and adherent cell culture conditions. Immunoblotting for CFTR: Primary - mouse anti-CFTR 596 antibody, 1:1,500 and Secondary - IRDye ${ }^{\circledR}$ 680RD goat antimouse antibody, 1:10,000. Immunoblotting for Actin: Primary - mouse antiactin antibody, 1:5,000 and Secondary - IRDye ${ }^{\circledR}$ 800CW goat anti-mouse antibody, 1:10,000.

Figure 3.15: Microscopic confirmation of at least > 90\% lysed cells. BHK cells are lysed using a Dounce Homogenizer. Cells imaged before (A) and after (B) lysis.

Figure 3.16: CFTR solubilization is improved by slow-dropwise addition of detergent. The method of solubilization for CFTR not only increases the amount of CFTR from the membrane fraction but also improves the overall
yield. Immunoblotting for CFTR: Primary - 596 mouse anti-CFTR antibody, 1:1,500 and Secondary - LI-COR goat anti-mouse antibody, 1:10,000

Figure 3.17: CFTR purity improved by changing the His-tag affinity resin used in purification. Silver stained Mini-PROTEAN ${ }^{\circledR}$ TGX $^{\mathrm{TM}}$ pre-cast $4-15 \%$ acrylamide: bisacrylamide gradient SDS-PAGE gel showing the improvement in purity by changing the resin type. The elution fraction between the Roche ${ }^{\circledR}$ His-resin (A) and the HisPur ${ }^{\mathrm{TM}}$ Ni-NTA resin (B), shows a dramatic improvement to the number of protein bands in the elution lane in the HisPur ${ }^{\text {TM }}$ $\mathrm{Ni}-\mathrm{NTA}$ resin.

Figure 3.18: SDS-PAGE analysis of CFTR purification. Each lane, and lane label, represents the sample at each stage of the purification process described. Silver stain of $8 \%$ acrylamide: bisacrylamide hand-cast SDS-PAGE gel showing the overall purification, especially improving the purity of CFTR. An unknown copurified protein was mostly eluted in wash 3 and wash 4 . However, this protein can still be seen in the final elution lane of CFTR ([Elution]).

Figure 3.19: Size Exclusion Chromatography (SEC) of CFTR purified from BHK cells. (A) Full UV-spectra chromatogram from SEC with a Superdex ${ }^{\text {TM }} 200$ 10/300 GL Column after injection with concentrated CFTR elution fractions. Void volume is marked by a black arrow and the monomeric CFTR peak is marked by a blue arrow. Several peaks present in the SEC chromatogram shows the presence of multiple proteins. (B) Silver stained 8\% acrylamide: bisacrylamide hand-cast SDS-PAGE gel comparing the purity of CFTR from pooled elution fractions [Elution] to purity of CFTR after SEC fraction [SEC].

Figure 3.20: Analysis of purification of CFTR from CHO cells using Size Exclusion Chromatography (SEC) and Western blot. (A) Western blot analysis shows some CFTR binding to and eluting from resin, especially of Band B. Immunoblotting for CFTR: Primary - mouse anti-CFTR antibody 596, 1:1500, and Secondary - IRDye ${ }^{\circledR}$ 680RD goat anti-mouse antibody, 1:10,000. (B) Full UV-spectra chromatogram from SEC with a Superdex ${ }^{\text {TM }} 200$ 10/300 GL column after injection with concentrated CFTR elution fractions. Void volume is marked by a black arrow, monomeric CFTR peak is marked by a blue arrow, and the FLAG $^{\circledR}$ peptide is marked by a green arrow.

Figure 4.1: pMSP1D1 plasmid map. The pMSP1D1 construct is purified from DH5 $\alpha$ E. coli and transformed into BL21 (DE3) E. coli for production of MSP1D1 protein, which can be purified using His-tag affinity chromatography and used in the formation of nanodiscs.

Figure 4.2: Restriction digestions of pMSP1D1. Results of restriction digestions, using PvuI (A) or HincII and HindIII (B), of pMSP1D1 purified from three different DH5 $\alpha$ E. coli bacterial colonies (c1, c2, c3) on a 1\% agarose
gel stained with $0.5 \mu \mathrm{~g} / \mathrm{mL}$ ethidium bromide. Theoretical gel for restriction digestion (left) was produced for ease of interpretation of experimental gel (right). Colony c3 was chosen as the source of pMSP1D1because the results of both restriction digestion experiments displayed anticipated banding patterns.

Figure 4.3: Purification of MSP1D1 from BL21 (DE3) E. coli. (A) Hand-cast $12 \%$ acrylamide: bisacrylamide SDS-PAGE stained with Coomassie to analyze MSP1D1 purity and efficiency of purification. Each lane represents a sample at each stage of the purification process. MSP1D1 begins eluting from the Roche ${ }^{\text {® }}$ cOmplete His-Tag resin (resin packed in a gravity-flow column) at elution fraction E1 and continues until fraction E3. The most concentrated MSP1D1 fraction is E3, which was further purified using Size Exclusion Chromatography. (B) Full SEC UV-spectra chromatogram of affinity chromatography purified His-tagged MSP1D1 using a Superdex ${ }^{\text {TM }} 200$ 10/300 GL column. Void volume is marked by a black arrow and MSP peak is marked by an orange arrow.

Figure 4.4: Phosphorylation of CFTR in detergent or in nanodiscs before ATPase activity measurements. CFTR in detergent and in nanodiscs was phosphorylated by Promega ${ }^{\circledR}$ PKA $\alpha$-catalytic subunit at $100 \mathrm{U} / \mathrm{mL}$ in 1 mM ATP for 2 hours at $4^{\circ} \mathrm{C}$. PKA, excess ATP, and ADP separated from CFTR in detergent or in nanodiscs using SEC. (A) Phosphorylation of CFTR in detergent confirmed by Western blot and hand-cast $8 \%$ acrylamide: bisacrylamide SDSPAGE gel stained with Pro-Q ${ }^{\mathrm{TM}}$ Diamond phosphorylation stain. Immunoblotting for phosphorylation: Primary - rabbit anti-phospho-(Ser/Thr) antibody (abcam17464), 1:1000 and Secondary - IRDye ${ }^{\circledR}$ 800CW goat antirabbit antibody, 1:10,000. (B) Phosphorylation of CFTR in nanodiscs confirmed by hand-cast $8 \%$ acrylamide: bisacrylamide SDS-PAGE gel stained with Pro$Q^{\mathrm{TM}}$ Diamond phosphorylation stain.

Figure 4.5: Comparison of old Bio-Beads ${ }^{\mathrm{TM}}$ to new Bio-Beads ${ }^{\mathrm{TM}}$. Old BioBeads ${ }^{\mathrm{TM}}$ (left), appeared to be clumped, yellowish in color, and had moisture along all walls of the bottle. New Bio-Beads ${ }^{\mathrm{TM}}$ moved freely, appeared white, and had no moisture in the bottle.

Figure 4.6: Confirmation of empty nanodises formed with two different lipids-DMPC and POPC. Empty nanodiscs formed under control buffer conditions with DMPC (A) and POPC (B) were evaluated using SEC and SDSPAGE. Full UV-spectra chromatogram from SEC with a Superdex ${ }^{\text {TM }} 200$ 10/300 GL Column after injection with empty nanodiscs on the left and key fractions analyzed for the presence of MSP on $12 \%$ acrylamide: bisacrylamide hand-cast SDS-PAGE gel stained by Coomassie on the right.

Figure 4.7: Transmission electron micrograph of liposomes present in the SEC void volume of POPC lipids. Even at the recommended Lipid-to-Protein (LPR) ratio for MSP and POPC, a void volume can be seen and contained what
appears to be small liposomes. Samples were stained in $2 \%$ uranyl acetate. The scale bar corresponds to 50 nm .

Figure 4.8: Micrograph of negatively stained ( $2 \%$ uranyl acetate) empty POPC Nanodiscs. The POPC nanodiscs show a preferred "side-view" orientation, providing critical information on successful formation of nanodiscs with a thickness and diameter of approximately 8 nm by 10 nm , respectively. These nanodiscs devoid of CFTR also provide an important control for reconstitution of CFTR into CFTR-nanodisc. The scale bar corresponds to 20 nm .

Figure 4.9: CFTR-nanodises generated from CFTR purified from BHK cells screened SEC and western blot. (A) UV-spectra chromatogram from SEC with a Superdex ${ }^{\text {TM }} 200$ 10/300 GL Column after injection with CFTRnanodiscs. Arrows indicate the following: void (black), CFTR-nanodiscs (purple), CFTR (blue), and empty nanodiscs (orange). (B) Western blot SEC fractions identifying CFTR ( 168 kDa ) and MSP ( 24 kDa ) in the same fractions. Immunoblotting for CFTR: Primary - mouse anti-CFTR 596 antibody, 1:1,500 and Secondary - IRDye ${ }^{\circledR}$ 680RD goat anti-mouse antibody, 1:10,000. Immunoblotting for MSP: Primary - rabbit anti-His-tag antibody, 1:1,000 and Secondary IRDye ${ }^{\circledR} 800$ CW goat anti-rabbit antibody, $1: 10,000$.

Figure 4.10: CFTR-nanodiscs generated from CFTR purified from BHK cells screened by TEM. (A) Micrograph of negatively stained CFTRnanodiscs. A few examples of particles are boxed in blue. The micrograph shows a good distribution of particles and no aggregation. Scale bar represents 50 nm . (B) A CFTR-nanodiscs model was built of hCFTR (PDB ID: 5UAK) in a nanodisc (PDB ID: 4V6M), in Visual Molecular Dynamics (VMD). The lipids in front of CFTR in a nanodisc have been cut away to show TMDs.

Figure 4.11: ATPase activity of CFTR-nanodiscs or CFTR in detergent (DDM) measured by Malachite Green Assay. After phosphorylation (Figure 4.4), PKA, excess ATP, and ADP were separated from phosphorylated CFTR using SEC. Inorganic phosphate produced by ATPase activity of CFTR was measured by Malachite green complexation for the following range of ATP concentrations in $100 \mu \mathrm{~L}$ volumes: 10 mM to 0.1 pM . Michaelis-Menten kinetics were determined in IgorPro and plotted as "fit". CFTR-nanodiscs exhibit a higher ATPase activity than CFTR in detergent. Error bars are SEM for three trials.

Figure 4.12: Micrograph of negatively stained ( $2 \%$ uranyl acetate) CFTR proteoliposomes. Purified detergent-solubilized CFTR was reconstituted into POPC-based proteoliposomes and screened by TEM. The scale bar corresponds to 100 nm .

Figure 4.13: Planar lipid bilayer (7:3 POPE:POPS ratio) single-channel recordings of CFTR from BHK cellular membranes. Recordings of CFTR under an applied driving force of -90 mV for $\mathrm{Cl}^{-}$. PKA and ATP ( $50 \mathrm{U} / \mathrm{mL}$ and 0.5 mM final) were added to the cis chamber. Top graphs are of the planar lipid bilayer recordings pre-treatment with INH172 (A) and post-treatment with INH172 (B). A histogram for both pre-INH172 (A) and post-INH172 (B) treatments were plotted for each state- 3 open channels, 2 open channels, 1 open channel or closed channels. Before the addition of INH172 (A), three CFTR channels can be seen in a single recording, each with a current amplitude of $-0.70 \mathrm{pA},-0.61 \mathrm{pA},-0.53 \mathrm{pA}$ and an average amplitude of -0.61 pA . The open probability for CFTR in this recording was $37 \%$, as expected for CFTR. After the addition of INH172 (B), only a single CFTR channel can be seen in a single recording, a current amplitude of -0.52 pA . The open probability for CFTR in this recording was $4 \%$. This represents $94 \%$ inhibition of CFTR by $10 \mu \mathrm{M}$ INH172.

Figure 4.14: Planar lipid bilayer (7:3 POPE:POPS ratio) single-channel recordings of CFTR from proteoliposomes. Recordings of CFTR under an applied driving force of -90 mV for $\mathrm{Cl}^{-}$. PKA and ATP ( $50 \mathrm{U} / \mathrm{mL}$ and 0.5 mM final) were added to the cis chamber. Top graphs are of the planar lipid bilayer recordings pre-treatment with INH172 (A) and post-treatment with INH172 (B). A histogram for both pre-INH172 (A) and post-INH172 (B) treatments were plotted for each state- 1 open channel or closed channels. Before the addition of INH172 (A), a single CFTR channel can be seen in a single recording displaying a current amplitude of -0.68 pA with an open probability of $32 \%$ for CFTR in this recording, as expected. After the addition of INH172 (B), a single CFTR channel can be seen in a single recording displaying a current amplitude of -0.72 pA and an open probability of $24 \%$ for CFTR in this recording. This represents $25 \%$ inhibition of CFTR by $10 \mu \mathrm{M}$ INH172.

Figure 4.15: Preliminary class averages of CFTR-nanodiscs. Initial 2D class averages were generated with EMAN2.3 from a total of 918 particles.

Figure 5.1: Western blot analysis of SMALP-CFTR. CFTR is present in the soluble fraction, but the majority of CFTR remains mostly in the insoluble fraction. CFTR-SMALPs also were present in the elution fraction, which indicates minimal binding of SMALP-CFTR to the resin. Immunoblotting for CFTR: Primary - mouse anti-CFTR 596 antibody, 1:1,500 and Secondary IRDye ${ }^{\circledR} 680$ RD goat anti-mouse antibody, 1:10,000.

Figure 5.2: SDS-PAGE analysis of CFTR-SMALPs. Hand-cast $8 \%$ acrylamide: bisacrylamide SDS-PAGE gel, silver stained. CFTR-SMALPs can be seen in the elution fraction, along with several other copurified proteins.

Figure 5.3: Structures of cholesterol, zymosterol, and cholesteryl hemisuccinate (CHS). There are apparent structural differences between the
three sterol derivatives-cholesterol (A), zymosterol (B), and CHS (C). These structural differences include the double bond between C-5 and C-6 of the B ring in cholesterol and CHS, but only a single bond in zymosterol. Zymosterol has a double bond present between C-8 and C-9 of the B ring, which is a single bond in cholesterol and CHS. Zymosterol also includes another double bond present between C-24 and C-25, which is a single bond in both cholesterol and CHS.

## LIST OF SYMBOLS AND ABBREVIATIONS

| ${ }^{\circ} \mathrm{C}$ | degrees Celsius |
| :---: | :---: |
| $\mu \mathrm{L}$ | microliter |
| $\mu \mathrm{s}$ | microsecond |
| 2D | 2-dimensional |
| 3D | 3-dimensional |
| Å | angstrom |
| ABC transporter | ATP binding cassette Transporter |
| ABCA | subclass A of human ABC transporters |
| ABCA4/ABCR | ABC transporter Subclass A number 4 |
| ABCB | subclass B of human ABC transporters |
| ABCC | subclass C of human ABC transporters |
| ABCC7 | ABC transporter Subclass C number 7/ CFTR |
| ABCD | subclass D of human ABC transporters |
| ABCD2/X-ALD | ABC transporter Subclass D number 2/ X-linked |
|  | Adrenoleukodystrophy |
| ABCE | subclass E of human ABC transporters |
| ABCE1/OABP | organic anion binding protein/ ABC transporter |
|  | subclass E number 1 |
| ABCF | subclass F of human ABC transporters |
| ABCF2 | ABC transporter Subclass F number 2 |
| ABCG | subclass G of human ABC transporters |


| ABCG2/BCRP | ABC transporter Subclass G number 2/breast c |
| :---: | :---: |
|  | resistance protein |
| ADP | adenosine diphosphate |
| AFT | arginine-framed tripeptides |
| ALD | adrenoleukodystrophy protein |
| A-loop | particular loop structure in CFTR |
| AMP-PNP | adenylyl-imidodiphosphate |
| Arf1 | ADP-ribosylation factor 1 |
| atm | atmosphere |
| ATP | adenosine triphosphate |
| BCA | bicinchoninic acid |
| BHK | baby hamster kidney cells |
| BSA | bovine serum albumin |
| $\mathrm{Ca}^{2+}$ | calcium cation |
| CAL | CFTR-associated ligand protein |
| ccc | cross-correlation coefficient |
| CF | Cystic Fibrosis |
| CFF | Cystic Fibrosis Foundation |
| CFP | cyan fluorescent protein |
| CFTR | Cystic Fibrosis Transmembrane conductance |
|  | Regulator |
| CFTRinh172 | specific CFTR inhibitor |


| CHARMM36 | Chemistry at Harvard Macromolecular Mechanics, |
| :---: | :---: |
|  | force field |
| chCFTR | chicken CFTR |
| CHIP | a carboxy terminus HSP-70 interacting protein |
| CHO | Chinese hamster ovary cells |
| CHS | cholesteryl hemisuccinate |
| CNX | chaperone lectins calnexin |
| COPII | coat protein II |
| cRNA | complementary RNA |
| cryo-EC | electron cryo-crystallography |
| cryo-EM | electron cryo-microscopy |
| CTF | contrast transfer function |
| CV | coefficient of variation |
| cyclic AMP/cAMP | adenosine 3',5'-monophosphate |
| D110C | aspartic acid at position 92 in WT-hCFTR substituted |
|  | with cysteine |
| D565/A566/D567 | diacidic export motif in WT-hCFTR |
| D924 | aspartic acid at position 924 in WT-hCFTR |
| D993 | aspartic acid at position 993 in WT-hCFTR |
| DDM | n-dodecyl $\beta$-d-maltoside |
| DIBMA | diisobutylene maleic acid |
| DIBMALP | diisobutylene maleic acid lipid particles |
| DMEM | Dulbecco's Modified Eagle Medium |


| DMPC | 1,2-dimyristoyl-sn-glycero-3-phosphocholine |
| :---: | :---: |
| DMSO | dimethyl sulfoxide |
| DNA | deoxyribonucleic acid |
| DPPC | 1,2-dipalmitoyl-sn-glycero-3-phosphocholine |
| DTT | dithiothreitol |
| E267 | glutamic acid at position 267 in WT-hCFTR |
| E543 | glutamic acid at position 543 in WT-hCFTR |
| E92 | glutamic acid at position 92 in WT-hCFTR |
| ECL1 | extracellular loop 1 |
| ECL2 | extracellular loop 2 |
| ECL3 | extracellular loop 3 |
| ECL4 | extracellular loop 4 |
| ECLs | extracellular loops |
| EDTA | ethylenediaminetetraacetic acid |
| EGTA | ethylene glycol-bis( $\beta$-aminoethyl ether)- $\mathrm{N}, \mathrm{N}, \mathrm{N}^{\prime}, \mathrm{N}^{\prime}-$ tetraacetic acid |
| ER | endoplasmic reticulum |
| ERQC | ER quality control machinery |
| EtBr | ethidium bromide |
| F12 | Ham's F12 nutrient mixture |
| F337 | phenylalanine at position 337 in WT-hCFTR |
| FBS | fetal bovine serum |
| FC | fold change |

GERAD

GGN20
GTPase
hApo1
hCFTR
HCl

HDL
HEPES
His-tag

HOLE

Hsp70
Hsp90
Hz
ICL

IPTG
IRES
I-V

K

K1060

K1292
femtoseconds
glycoprotein ER-associated degradation pathway alias for subclass F of ABC transporter family guanidine triphosphatase human apolipoprotein 1 human CFTR hydrochloric acid
high-density lipoprotein complex
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid histidine-based affinity chromatography tagging system program to explore pore dimensions in ion channel molecular structures heat shock protein 70 heat shock protein 90

Hertz
intracellular loops
isopropyl $\beta$ - d-1-thiogalactopyranoside
internal ribosomal entry site
Current-Voltage relationship
Kelvin
lysine at position 1060 in WT-hCFTR
lysine at position 1292 in WT-hCFTR

| K892C | lysine at position 892 in WT-hCFTR substituted with |
| :---: | :---: |
|  | cysteine |
| K95 | lysine at position 95 in WT-hCFTR |
| K968 | lysine at position 968 in WT-hCFTR |
| KCl | potassium chloride |
| kHz | kiloHertz |
| L1135 | leucine at position 1135 in WT-hCFTR |
| LmrA | ATP binding cassette ( ABC ) multidrug transporter |
|  | found in Lactococcus lactis |
| LPR | lipid to protein ratio |
| M | molarity |
| mA | milliAmps |
| $\mathrm{M} \beta$ CD | methyl-beta-cyclodextrin |
| MD | molecular dynamics |
| MDFF | molecular dynamics flexible fitting |
| MDR | multidrug resistance |
| mg | milligrams |
| $\mathrm{Mg}^{2+}$ | magnesium cation |
| MgATP | ATP magnesium salt |
| $\mathrm{MgCl}_{2}$ | magnesium chloride |
| mL | milliliter |
| mM | millimolar |
| MOI | multiplicity of infection |


| MRP | multidrug resistance-associated protein |
| :---: | :---: |
| MRP1 (ABCC1) | multidrug resistance protein 1/ ABC transporter |
|  | subclass C number 1 |
| MRP7 | multidrug resistance protein 7 |
| MRP9 | multidrug resistance protein 9 |
| ms | milliseconds |
| MS | mass spectrometry |
| MsbA | lipid ABC exporter |
| MSD1 | membrane spanning domain 1 |
| MSP | membrane scaffold protein |
| mV | milliVolts |
| MWCO | molecular weight cut-off |
| $\mathrm{M} \Omega$ | megaohm |
| N1138 | asparagine at position 1138 in WT-hCFTR |
| N894 | asparagine at position 894 in WT-hCFTR |
| N900 | asparagine at position 900 in WT-hCFTR |
| $\mathrm{Na}^{+}$ | sodium cation |
| NaCl | sodium chloride |
| $\mathrm{NaH}_{2} \mathrm{PO}_{4}$ | sodium phosphate monobasic |
| NAMD | Nanoscale Molecular Dynamics |
| NBD | nucleotide binding domain |
| NBD1 | nucleotide binding domain 1 |
| NBD2 | nucleotide binding domain 2 |

NBF
ng
NHERF-1

NMDG

NMDG-Cl

NTA
OST

P/S

PBS

PBST
pCDNA3.1
pcDNA5/TO

PDB
PDZ-binding domain
pGEMHE
P-gp (ABCB1)
pH
$P_{i}$

PIC

PKA

PKC

PLB
nucleotide binding fold
nanogram
$\mathrm{Na}^{+} / \mathrm{H}^{+}$exchanger regulatory factor proteins
N -methyl-d-glycamine
N -methyl-d-glucamine chloride salt nitrilotriacetic acid oligosaccharyltransferase penicillin/streptomycin phosphate buffered saline phosphate buffered saline plus Tween 20 mammalian expression vector vector for protein expression in T-Rex ${ }^{\mathrm{TM}} \mathrm{CHO}$ cells Protein Database post synaptic density protein, Drosophila disc large tumor suppressor, and zonula occludens-1 protein oocyte expression vector P-glycoprotein/ ABC transporter subclass B number 1 $\log$ of $\left[\mathrm{H}^{+}\right]$ inorganic phosphate protease inhibitor cocktail protein kinase A

Protein kinase C
planar lipid bilayer

| PM | plasma membrane |
| :---: | :---: |
| $\mathrm{P}_{0}$ | open probablity |
| POPC | 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine |
| pS | picoSiemens |
| PVDF | polyvinylidene difluoride |
| Q-loop | particular loop structure in CFTR |
| R1128 | arginine at position 1128 in WT-hCFTR |
| R29/Q30/R31 | one of 4 RXR motifs in WT-hCFTR |
| R303 | arginine at position 303 in WT-hCFTR |
| R347 | arginine at position 347 in WT-hCFTR |
| R516/Y517/R518 | one of 4 RXR motifs in WT-hCFTR |
| R553/A554/R555 | one of 4 RXR motifs in WT-hCFTR |
| R764/R765/R766 | one of 4 RXR motifs in WT-hCFTR |
| R899 | arginine at position 899 in WT-hCFTR |
| R933 | arginine at position 933 in WT-hCFTR |
| Rab1a/Rab2 | GTPase proteins important in secretory trafficking |
| R-domain | Regulatory domain |
| $\mathrm{R}_{\mathrm{G}}$ | radius of gyration |
| RIPA | radioimmunoprecipitation Assay |
| RMSD | root mean square deviation |
| RPM | revolutions per minute |
| RT | room temperature |
| RTC | Ribosome-Sec61 translocon complex |

RXR motif
S341

S422

S660
S670
S686
S686

S700
S700
S712

S737
S753

S768
S790
S795
S813
S898

Sav1866
SDS-PAGE

Sec 24

Sec61

SEM

ER retention/retrieval motif of membrane proteins serine at position 341 in WT-hCFTR serine at position 422 in WT-hCFTR serine at position 660 in WT-hCFTR serine at position 670 in WT-hCFTR serine at position 686 in WT-hCFTR serine at position 686 in WT-hCFTR serine at position 700 in WT-hCFTR serine at position 700 in WT-hCFTR serine at position 712 in WT-hCFTR serine at position 737 in WT-hCFTR serine at position 753 in WT-hCFTR serine at position 768 in WT-hCFTR serine at position 790 in WT-hCFTR serine at position 795 in WT-hCFTR serine at position 813 in WT-hCFTR serine at position 898 in WT-hCFTR ABC transporter from Staphylococcus aureus sodium dodecyl sulfate-polyacrylamide gel electrophoresis protein involved in ER transport vesicles formation protein involved in membrane protein translocation standard error of the mean

SMALP

SMA-QA
SMA-SH
SMI
SMILPs

SNARE
SPA
SRP
SUR1
SUR2

T1134
T338
T690
T787
T788

TAP
TBS

TBST
TEM

TES
immortalized cell line from Spodoptera frugiperda styrene maleic acid styrene maleic acid lipid particles SMA with a quaternary ammonium SMA with exposed sulfhydryls styrene maleimide stryene maleimide lipid particles protein complex that mediates vesicle fusion single particle analysis signal recognition particle sulfonylurea receptors 1 sulfonylurea receptors 2 threonine at position 1134 in WT-hCFTR threonine at position 338 in WT-hCFTR threonine at position 690 in WT-hCFTR threonine at position 787 in WT-hCFTR threonine at position 788 in WT-hCFTR transporter associated with antigen processing Tris-buffered saline

Tris-buffered saline with Tween-20 transmission electron microscopy 2-[(2-Hydroxy-1,1bis(hydroxymethyl)ethyl)amino]ethanesulfonic acid,

|  | N-[Tris(hydroxymethyl)methyl]-2- |
| :--- | :--- |
|  | aminoethanesulfonic acid |
| TIP3P | water modeling system |
| TM1 | transmembrane helix 1 |
| TM10 | transmembrane helix 10 |
| TM11 | transmembrane helix 11 |
| TM12 | transmembrane helix 12 |
| TM2 | transmembrane helix 2 |
| TM3 | transmembrane helix 4 |
| TM4 | transmembrane helix 5 |
| TM5 | transmembrane helix 6 |
| TM6 | transmembrane helix 7 |
| TM7 | transmembrane helix 8 |
| UGGT | trandycoprotein glucosyltransferase |
| TM8 | transmembrane elix 9 |
| TM9 | transmembrane domain |
| TMD | transmembrane domain 1 CHO cell line for protein expression |
| TMD | Tris |
| TMD | CHO |

x-loop
zCFTR
zSMA
zSMALP
$\Delta$ F508
$\Delta \mathrm{R}_{708-835 \mathrm{CFTR}}$
volts
valine at position 350 in WT-hCFTR
Visual Molecular Dynamics
wildtype
particular loop structure in CFTR
zebrafish CFTR
derivative of SMA
derivative of SMALPs
mutant version of CFTR, deletion of phenylalanine at position 508 in WT-hCFTR
mutant version of WT-hCFTR

## SUMMARY

Membrane proteins are difficult to study in solution due to the use of detergent to protect the hydrophobic portion of the protein that interacts with the fatty acid tails of the lipid bilayer. However, a recent technology called nanodiscs provides a packaged lipid bilayer system in which membrane proteins can be studied in solution in a lipid environment and thus without the use of detergent. Nanodiscs have revolutionized the study of membrane proteins, even difficult and complex membrane proteins. A particularly challenging membrane protein, the Cystic Fibrosis Transmembrane conductance Regulator (CFTR), has shown to be very sensitive to the detergent and lipid environment, especially during purification and reconstitution. This dissertation explored new methods of expression, purification, reconstitution, functional assays, and structurally important lipids for human CFTR. The development of multiple expression systems improved detergent purification methods and increased the yield of functional CFTR. The utilization of nanodiscs technology has provided a method of measuring changes in CFTR's ATPase activity dependent on the environment and may provide a new method for determining structureinduced changes to CFTR that are dependent on the environment. The identification of possibly key structural lipids in detergent-solubilized CFTR and some preliminary investigation into the annular lipid environment of CFTR was completed by lipidomics mass spectrometry. This dissertation also utilized both traditional and nontraditional molecular modeling methods to refine a CFTR homology model and study a key interaction in the translation of ATP binding in the nucleotide binding domains (NBDs) to the transmembrane domains (TMDs).

## CHAPTER I

INTRODUCTION

### 1.1. INTRODUCTION.

### 1.1.1. Publications resulting from this chapter.

Parts of this chapter will be published in Methods in Molecular Biology on the reconstitution of membrane proteins. Other parts of this chapter will be published in downstream manuscripts.

### 1.2. MEMBRANE PROTEINS.

Membrane proteins are essential for maintaining physiological processes and are the main target of pharmaceutical drugs. Studying membrane proteins can be challenging due to the hydrophobic region of the protein that interacts with the fatty acid tails of the lipid bilayer. Detergents can protect the hydrophobic region of membrane proteins from the aqueous environment by housing those regions in a non-physiological environment. However, studying membrane proteins in a lipid environment, the more physiologically relevant environment, has traditionally been more difficult. New technologies, discussed below, have improved traditional challenges and revealed the importance of the lipid environment to membrane proteins (1). Understanding the role the lipidic environment plays in maintaining or altering membrane protein structure and function can improve our understanding of drug design (2).

### 1.2.1. Adenosine triphosphate (ATP) binding cassette (ABC) transporters.

The adenosine triphosphate (ATP) binding cassette (ABC) transporters represent a superfamily of mainly membrane proteins, expressed in both prokaryotes and eukaryotes.

Of the 49 known human ABC transporters, almost $50 \%$ are involved in the regulation of the lipid bilayer (3, 4). The human ABC transporters are organized into 7 subclasses$\mathrm{ABCA}, \mathrm{ABCB}, \mathrm{ABCC}, \mathrm{ABCD}, \mathrm{ABCE}, \mathrm{ABCF}$, and ABCG (Table 1.1) (5). While each

Table 1.1: Table of Human ABC transporter subclasses-ABCA through ABCG. For each subclass a common alias, the number of genes currently identified, a general functional, and an example member is listed.
$\left.\begin{array}{|l|l|l|l|l|}\hline \text { Subclasses } & \text { Alias } & \begin{array}{l}\text { Number } \\ \text { of genes }\end{array} & \begin{array}{l}\text { General } \\ \text { function }\end{array} & \begin{array}{l}\text { Examples (alternate name, } \\ \text { disease relevance) }\end{array} \\ \hline \text { ABCA } & \text { ABCI } & 12 & \begin{array}{l}\text { Mostly lipid } \\ \text { trafficking }\end{array} & \begin{array}{l}\text { ABCA4 (ABCR, Stargardt } \\ \text { Disease) }\end{array} \\ \hline \text { ABCB } & \text { MDR/TAP } & 11 & \begin{array}{l}\text { Mostly } \\ \text { multidrug } \\ \text { resistance }\end{array} & \begin{array}{l}\text { ABCB1 (P-glycoprotein, P- } \\ \text { gp, drug inefficacy) }\end{array} \\ \hline \text { ABCC } & \text { MRP } & 13 & \begin{array}{l}\text { Mostly toxin } \\ \text { excretion }\end{array} & \begin{array}{l}\text { ABCC1 (Multidrug } \\ \text { resistance-associated protein } \\ \text { 1, MRP1, drug inefficacy) } \\ \text { ABCC7 (Cystic Fibrosis }\end{array} \\ \text { Transmembrane conductance } \\ \text { Regulator, CFTR, cystic } \\ \text { fibrosis) }\end{array}\right\}$

Adapted from Vasiliou, V., et al. (2008). "Human ATP-binding cassette (ABC) transporter family." Human Genomics 3(3): 281.
of the subclasses has a particular architecture, all have the following motifs in the nucleotide binding domains (NBDs), or nucleotide binding folds (NBFs): the Walker A motif and the Walker B motif, and the ABC signature motif, which is located upstream of the Walker B motif in the primary sequence (6). Most of these human subclasses, all but ABCE and ABCF , contain two transmembrane domains (TMDs). The TMDs contain anywhere from 6-12 membrane-spanning helices, allowing access to the substratebinding site from only one side of the membrane at a time (3) (Figure 1.1A). The movement of bound substrates across the membrane is powered by the cooperative binding of ATP at two sites in the interface of the NBDs, forming a head-to-tail dimer, and possibly the hydrolysis of ATP at either both sites or only one site (7-15) (Figure 1.1B), although the notion that ATP hydrolysis powers substrate movement has been contested recently (16). An ATP binding site that can hydrolyze ATP is known as a consensus site, and an ATP binding site that cannot hydrolyze ATP is known as a degenerate site $(14,17)$ (Figure 1.1B). ATP binding, and possibly hydrolysis, initiates conformational changes translated through the interface of NBDS and TMDs (8) (Figure 1.1A). For many $A B C$ transporters this transmission interface utilizes cross-matched intracellular loops (ICLs) with the NBDs to translate conformational changes to the corresponding TMDs (7, 9) (Figure 1.1A); however, the mechanism of transport, including how ABC transporters transition from an open state to a closed state and how ATP is hydrolyzed, is still debated. First, the reaction path of ATP hydrolysis has been elusive $(6,18,19)$, until a recent study proposed a three-step mechanism of hydrolysis (16) (Figure 1.2). Second, whether ATP is hydrolyzed symmetrically or even with every transport cycle is still unknown (17). Third, the model for ATP binding and release is


Figure 1.1: Model of an ABC transporter in a lipid bilayer and ATP-binding at the NBD interface. (A) The general architecture of most human ABC transporters is shown. The Transmembrane Domains (TMDs), boxed in forest green, exist in the lipid bilayer and are the site of substrate binding. The intracellular loops (ICLs), boxed in orange, translate conformation changes by ATP binding and hydrolysis at the nucleotide binding domains (NBDs), boxed in purple. TMD1 is gray, TMD2 is green, NBD1 is pink, and NBD2 is blue. Some ABC transporters contain a unique motif known as the lasso motif (red). (B) The interface of NBDs bound with ATP (green) and coordinated $\mathrm{Mg}^{2+}$ (cyan) is shown. Both images were developed using PDB ID: 6MSM.


Figure 1.2: The currently proposed ATP hydrolysis reaction path of ABC transporters. While the mechanism of ATP hydrolysis in ABC transporters has been elusive, recent computational studies of the acidic residue just after the Walker B motif predict the above hydrolysis mechanism. For hCFTR, this acidic residue is glutamic acid.

Adapted from Prieß, M., Göddeke, H., Groenhof, G., and Schäfer, L. V. (2018) Molecular Mechanism of ATP Hydrolysis in an ABC Transporter. ACS Central Science.
highly contested. While many models have been proposed, it is becoming more accepted that a "one model fits all ABC transporters" theory may not be accurate (17). Initially, the alternating access model, proposed in 1966 by Jardetzky (20), was modified to propose a transport mechanism of P-glycoprotein (P-gp) (21) and then for LmrA (22) (Figure 1.3). This mechanism was the most accepted theory, with structural and biophysical data from multiple ABC transporters supporting this mechanism (7, 8, 13, 21, 23-26). In the alternating access model, ATP binding in the NDBs forms a tight dimer, which opens the high-affinity substrate binding site. ATP binding then induces a conformational change in the TMDs, opening the substrate binding site to the other side of the cell. ATP hydrolysis induces a structural change to release the substrate—possibly inducing a lower affinity binding site-and disrupts the NBD dimer, allowing the release of adenosine diphosphate (ADP) and inorganic phosphate $\left(\mathrm{P}_{\mathrm{i}}\right)(7,17,21,22)$. For eukaryotic ABC transporters, this conformational change is typically from the inwardfacing conformation, where the substrate binding site is accessible intracellularly to outward-facing, where the substrate binding site is accessible extracellularly (19, 21, 27, 28). There were two other mechanistic theories that emerged later to accommodate other structural and biochemical data. These models were the switch model, also called the tweezers-like (12) or processive clamp (29) models, and the constant contact model (6). In the switch model, substrate binding prepares the NBDs for ATP binding. Once ATP binds in the interface of the NBD dimer, the TMDs undergoes a conformational change, exposing the substrate to the other side of the membrane. ATP hydrolysis allows for the release of the NBD dimer and also $\operatorname{ADP}(30,31)$ (Figure 1.3). While this model has structural, biochemical, and other biophysical data in support (32), there is mounting
evidence in support of the constant contact model (14, 33-36). In the constant contact model, the NBDS remain dimerized as ATP binding at one site can induce structural changes to allow substrate binding and conformational changes in the TMDs to provide the substrate access to the opposite side of the membrane (31, 33) (Figure 1.3). Controversial new data suggest that ATP hydrolysis is not sufficient for "the power stroke" of ABC transporters (16), and thus other mechanisms are gaining support (37). With the mounting evidence for each mechanistic model and the variety of substrates for individual ABC transporters across the superfamily, both eukaryotic and prokaryotic known proteins, the concept that one proposed mechanism might work for all ABC transporters would be fallible (17). This is especially true for the Cystic Fibrosis Transmembrane conductance Regulator (CFTR)—the only chloride ion channel ATP in the $A B C$ transporter superfamily, since substrate-induced conformational changes are unlikely in this case.

### 1.3. CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

 (CFTR).CFTR, also known as ABCC7 or MRP7 (multidrug resistance protein 7), is a chloride ion channel regulated by the phosphorylation of a large intrinsically disordered domain called the Regulatory-domain (R-domain) and ATP binding in both a consensus ATP site and a degenerate ATP site (38). Thus, CFTR is the only chloride ion channel in the ABC transporter superfamily, and as the name suggests, this channel protein is of great medical importance.

### 1.3.1. CFTR architecture.

CFTR was first identified as an ABC transporter by the characteristic motifs when the
gene was discovered in 1989 (38). CFTR is a monomeric protein of 1480 amino acids composed of 5 domains. Four of the domains are consistent with most ABC transporters-TMD1, NBD1, TMD2, and NBD2; however, CFTR has a linking region connecting NBD1 to TMD2, called the R-domain. While many ABC transporters have linking regions $(39,40)$, CFTR has the largest at about 240 residues and is the only ABC transporter known to be tightly regulated by phosphorylation of this linker (41, 42). Like other ABC transporters, CFTR contains two ATP binding sites. Unlike most ABC transporters, which have a somewhat strict stoichiometric ratio of ATP consumption to substrate transported, CFTR forms a diffusive pore at the surface of the cell (43). CFTR classically contains ICLs that cross-interact with the NBDs, as well as extensive flexible extracellular loops (ECLs). One of these loops, ECL4, is glycosylated during CFTR biogenesis and is used in tracking CFTR maturation in the cell (44) (Figure 1.4). Both termini of CFTR have key structural features found in other ABC transporters. The first is the PDZ-binding domain located at the C-terminus, which aids in trafficking and anchoring CFTR to the cell surface (45-47). The second is the lasso motif (48), which has been found in a few other ABC transporters, including multidrug resistance protein 1 (MRP1) and sulfonylurea receptors 1 and 2 (SUR1 and SUR2) (49-51) and might aid in trafficking $(52,53)$.

### 1.3.2. CFTR biogenesis and trafficking.

During its biogenesis, CFTR undergoes several post- and co-translational modifications. These modifications play critical roles in the folding of CFTR and, thus, its trafficking through the endoplasmic reticulum (ER) and Golgi and, finally, insertion into the plasma membrane (PM).


Switch Model


## Constant Contact Model



Figure 1.3: Scheme of the proposed mechanistic models of ABC transporters. There are three commonly accepted mechanisms for substrate transport in ABC transporters-alternating access model, switch model, and constant contact model. In the alternating access model, ATP binding induces conformational changes that allow for substrate binding. Substrate binding induces conformational changes in the transmembrane domains (TMDs) that open the substrate pocket to the opposite side of the membrane. ATP hydrolysis and release cause conformational changes to release the substrate and prepare the protein for a new transport cycle. In the switch model, substrate binding induces conformational changes and allows for ATP binding. ATP binding induces conformational changes to release the substrate, and ATP hydrolysis and release prepares the protein for a new transport cycle. In the constant contact model, ATP binding at only one site can open the substrate binding pocket and ATP hydrolysis and release at only one binding site prepares the protein for the next transport cycle.


Figure 1.4: Two different representations (schematic and cartoon) of CFTR architecture. Structural domains depicted in both styles (schematic-top and cartoonbottom): the lasso motif (red), TMD1 (gray), NBD1 (pink), TMD2 (green), and NBD2 (blue). (A) In the schematic representation, several more features of CFTR are displayed. The R-domain (yellow) is phosphorylated at several sites (orange circles), extracellular loop 4 (ECL4) is glycosylated at two sites (cyan hexagons), and the Cterminus contains the PDZ binding domain (purple box). (B) The cartoon representation was built using PDB ID: 6MSM and is one of the recently released structures of CFTR.

### 1.3.2.1. CFTR CO-TRANSLATIONAL FOLDING.

During the synthesis of TMD1, the emergence of the signal sequence on transmembrane helix 1 (TM1) from the ribosome is believed to be inefficient at being recognized by the signal recognition particle (SRP) due to two charged residues-E92 and K95 (54). The inefficient recognition of this signal sequence prevents a C-trans orientation of CFTR but does possibly promote initial location to the ER and Sec61. The signal sequence on transmembrane helix 2 (TM2) that interacts with SRP does promote proper insertion of the N-terminal flanking sequence into the ER through Sec61, thus forming the ribosomeSec61 translocon complex (RTC) (N-trans orientation) (54). Proper insertion of TM1 is then believed to be mediated by extracellular loop 1 (ECL1) (54). Next, both transmembrane helix 3/ transmembrane helix 4 (TM3/4) and transmembrane helix 5/ transmembrane helix 6 (TM5/6) are believed to be inserted into Sec61 as helical hairpins due to the short extracellular loop 2 (ECL2) and extracellular loop 3 (ECL3) (54, 55). NBD1 and the R-domain are believed to fold in the cytosol co-translationally $(55,56)$. While little is known about the "folding" of the R-domain due to its intrinsically disordered nature, much has been done to understand the folding mechanism of NBD1 because the most common disease-relevant mutation occurs in this domain ( $\Delta \mathrm{F} 508$ ). First, studies showed that NBD1 experiences consecutive folding of each subdomain, the first being the N-terminal ATP-binding subdomain (57). The next domains to be folded are the $\alpha$-helical subdomain and the $\alpha / \beta$-core subdomain, which most likely use the first formed domain as a scaffold; however, the folding order of these subdomains is still debated (58). Other studies have shown that in order to prevent steric clashing during translation of NBD1 and the R-domain, the ribosome must transiently detach from the

RTC (56, 59, 60). Whether the same or a different translocon is used for translation of TMD2 is unknown. Transmembrane helix 7 (TM7) directs membrane targeting and translocation of extracellular loop 4 (ECL4), while TM8 terminates translocation causing redirection of ICL3 into the cytosol. This mechanism only occurs in conjunction with TM7, which is a cooperative property specific to CFTR (55, 61, 62). The remaining transmembrane helix 9/ transmembrane helix 10 (TM9/10) and transmembrane helix 11/ transmembrane helix 12 (TM11/12) are believed to be inserted into the translocon similarly to TM3/4 and TM5/6 as helical hairpins (55, 62). Finally, NBD2 is believed to fold co-translationally, very similarly to NBD1 (56). Once each major domain has folded, CFTR must also undergo significant domain reorganization to achieve the native architecture of the mature protein through at least two distinct folding events (63).

### 1.3.2.2. CFTR FOLDING AND MATURATION.

Throughout the process of CFTR folding, both co-translationally and posttranslationally, CFTR must pass through at least four checkpoints of the ER quality control machinery (ERQC) (Figure 1.5). The first checkpoint precedes the first domain reorganization event, which requires CFTR to be released from the RTC and the related chaperones $(64,65)$. At this first checkpoint, before the release of RTC, CFTR emerges from the ribosome as a nascent polypeptide and interacts with cytosolic chaperones such as heat shock protein 70 (Hsp70) and heat shock protein 90 (Hsp90) and several cochaperones $(58,63)$. These chaperones play critical roles in both folding and partitioning between wildtype (WT-CFTR) and mutant, misfolded CFTR (64, 66-71). Any misfolded mutant CFTR is trapped by these chaperones and signaled for degradation through the E3 ubiquitin ligase CHIP ((carboxyl) c-terminal of Hsp70 Interacting Protein) pathway
(72). Once successfully passing this checkpoint, CFTR is released from the RTC and related chaperones and allowed to move to the second checkpoint. The second checkpoint involves the proper folding of CFTR through N-linked glycosylation and processing in the ER. Before the release of CFTR from the ribosome, nascent CFTR receives core N glycosylation (14-unit oligosaccharide-two N -acetylglucosamine, nine mannose, and three glucose residues) in the lumen of the ER by OST (oligosaccharyltransferase) at two residues N894 and N900 of ECL4, each containing a glycosylation consensus sequence DXS/T (62, 73). The release of CFTR from the RTC, after checkpoint 1, initiates glycosylation processing in which the partially glycosylated structure is recognized by chaperone lectins calnexin (CNX) and the calreticulin ER lumenal chaperones that assist in CFTR folding (74-76). At this step, misfolded CFTR is targeted to UDP (Uridine diphosphate)-glycoprotein glucosyltransferase (UGGT), which induces the reglycosylation process (77). Lengthy processing time at this stage indicates improper folding, and CFTR could be trafficked to the glycoprotein ER-associated degradation (GERAD) pathway (66). However, proper folding of CFTR leads to the third checkpoint, which involves the arginine-framed tripeptides (AFTs) pathway. CFTR's ability to be exported from the ER to the Golgi is confirmed by the following four retention/retrieval (RXR) motifs: R29/Q30/R31, R516/Y517/R518, R553/A554/R555, and R764/R765/R766 (78). Failing this checkpoint, due to the exposure or accessibility of these motifs, causes the imprisonment of CFTR in the ER (79). The fourth and final checkpoint is critical for exiting the ER and relies on the specific export diacidic motif D565/A566/D567), allowing CFTR packaging into coat protein (COP) II-coated vesicles, specifically with $\operatorname{Sec} 24$, at the ER exit site (80). Mutation of this motif almost
completely prevents CFTR processing to the Golgi, especially in the absence of low temperature correction (80-82).


Figure 1.5: Simplified depiction of the four CFTR folding checkpoints. In the ER, CFTR will proceed through four processing checkpoints. These checkpoints occur both co-translationally and post-translationally and ensure properly folded CFTR can exit the ER and proceed to the Golgi. At one of these checkpoints, CFTR is glycosylated, known as Band B, and can be distinguished from CFTR that is glycosylated further in the Golgi (Band C).

Adapted from Farinha, C. M., and Canato, S. (2017) From the endoplasmic reticulum to the plasma membrane: mechanisms of CFTR folding and trafficking. Cellular and Molecular Life Sciences 74, 3955

### 1.3.2.3. CFTR TRAFFICKING TO THE PLASMA MEMBRANE (PM).

Once it passes these checkpoints, CFTR is trafficked to the plasma membrane, either by traditional or non-traditional processes. First, CFTR is transported in COPI vesicles to the trans-Golgi either through typical traffickers like Arf1, Rab1a/Rab2, or Golgi SNARE. As CFTR moves through the Golgi, the core-glycosylation (high-mannose oligosaccharide structures sensitive to endoglycosidase $H$, known as Band $B$ in reference to its apparent molecular weight by SDS-PAGE) is modified with the removal of some glycan units and the addition of more complex units, like fucose, neuraminic acid, or sialic acid. After this glycosylation event, CFTR has matured (now appearing as Band C) (83). Another well-accepted theory, however, is that CFTR experiences a mode of anterograde trafficking between the ER and Golgi. In some cell types, CFTR is dependent on the late-endosomal target-SNARE syntaxin 13 pathway ( 84,85 ). Finally, CFTR is delivered to the plasma membrane from the trans-Golgi network, experiencing three distinct processes of balancing CFTR levels at the plasma membrane-anterograde trafficking, endocytosis, and recycling. These processes are regulated by a variety of interacting partners with CFTR. The incorporation of CFTR into clathrin-coated vesicles is dependent on a small sequence motif on the C-terminal tail. There are two types of endocytic motifs-tyrosine-based (NPXY or YXX $\varphi$ ) or dileucine-based (D/EXXXLL/I and DXXLL). CFTR has two confirmed endocytic motifs-the YDSI (at 1424) and the LL motifs (at 1430); however, FVLI (at 1413) is not believed to be an endocytic motif but is needed for CFTR maturation (86-88). These signals are recognized by the assembly polypeptide-2 system that forms a complex with clathrin to promote the internalization of CFTR (89). Another route of CFTR recycling is regulated by small GTPases of the

Rab family (88, 90). Furthermore, while these are mechanisms to balance CFTR levels by recycling, there are also mechanisms to anchor CFTR to the plasma membrane, including the PDZ domain proteins. The C-terminus of CFTR contains a consensus PDZ binding motif (DTRL), which binds to multiple $\mathrm{Na}^{+} / \mathrm{H}^{+}$exchanger regulatory factor proteins (NHERF-1, NHERF-2, and NHERF-3) and to CFTR-associated ligand protein (CAL). Interactions with the proteins stabilize CFTR expression at the cell surface (9198).

### 1.3.3. Biochemical and biophysical studies of CFTR.

Since the identification of the CFTR gene, it has been the hope that understanding the function of CFTR will establish how each mutant version is linked to the disease Cystic Fibrosis (CF). One of the key features of CF is the abnormally high sweat chloride levels of patients; thus, it was suspected that CFTR is a chloride ion channel or that CFTR might regulate the expression of a chloride ion channel (38). Some of the first functional studies of CFTR identified it as a chloride ion channel regulated by adenosine $3^{\prime}, 5^{\prime}$ monophosphate (cyclic AMP, cAMP) signaling (43, 99-102). Later studies showed that cAMP-mediated stimulation induced the phosphorylation of CFTR in its R-domain (42, 102-108). Moreover, further studies identified the need for ATP binding at the NBD interface (107, 109-114) to allow for chloride ion pore formation in the TMDs of CFTR.

### 1.3.3.1. R-DOMAIN PHOSPHORYLATION.

The R-domain contains nine consensus protein kinase A (PKA) phosphorylation sites (R-R/K-X-S*/T*, where the asterisk indicates the phosphorylated residues) at resides S660, S686, S700, S712, S737, S768, T788, S795, and S813 (Figure 1.6). Also, to note, there is one phosphorylation site outside of the R-domain in NBD1 (S422) (105). If all

10 of these sites are mutated, S753 was found to be phosphorylated (115). Phosphorylation studies of purified R-domain peptide show that only five sites are phosphorylated by PKA (S660, S700, S737, S795, S813), and two sites (S686 and S700) can be phosphorylated by protein kinase C (PKC) $(106,116)$; however, whole-cell experiments suggest that stimulation of PKC enhances phosphorylation of CFTR by PKA $(102,117)$. While each of these sites can be phosphorylated, not all sites contribute equally to the activation of CFTR. In fact, phosphorylation at S737 (in oocytes) or S768 shows an inhibitory effect on CFTR (118-120) in the presence of all other phosphorylated residues; however, when all possible residues are mutated to alanine, these residues show stimulatory effects (121). Residues S660, S737, S795, and S813 have been proposed to contribute the most to CFTR regulation by showing the most dramatic reduction in current when mutated to alanine (122). Only when all 11 sites discussed earlier, as well as four other residues (S670, T690, T787, S790) are mutated to alanine, is CFTR no longer regulated by PKA (123). Mutation of these sites individually, or multiple sites, reduced the rate of channel opening without changing the

| 650 | dqfsaerrn $\underline{\mathbf{S}}$ | iltetlhrfs | 670 |  | etkkqsfkqt | 690 | gefgekrknS |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 700 | ilnpinsirk | f S $_{\text {ivquktplq }}$ | 720 | mngieedsde | plerrl $\underline{\text { S }}$ lvp | 740 | dseqgeailp |
| 750 | risvistgpt | lqarrrqS ${ }^{\text {v }}$ | 770 | nlmthsvnqg | qnihrkt Tas $^{\text {a }}$ | 790 | trkvSlapqa |
| 800 | nlteldiysr | rlSqetglei | 820 | seeineedlk | ecffddmesi | 840 | pavtt |

Figure 1.6: Sequence of the R-domain highlighting the positions of phosphorylation. There are nine phosphorylation sites (bolded and underlined), all with varying levels of functional consequences to CFTR.

Adapted from Sheppard, D. N., and Welsh, M. J. (1999) Structure and Function of the CFTR Chloride Channel. Physiological Reviews 79, S23-S45
channel closing rate, but also reduced the affinity of CFTR for binding ATP; thus, phosphorylation of the R-domain regulates the interaction of ATP with the NBDs (108, 124). Complete deletion of the R-domain produces a non-functional CFTR channel (103); however, partial deletion (residues 708-835) produces a CFTR channel ( $\Delta \mathrm{R}_{708}$ ${ }_{835}$ CFTR) with similar biophysical properties, minus regulation by PKA and reduced $(1 / 3)$ open probability $\left(\mathrm{P}_{\mathrm{o}}\right)$ or the fraction of time a channel is open during a recording (103, 108, 125). In these specific $\Delta \mathrm{R}_{708-835}$ CFTR mutant channels, incubation with AMPPNP (adenylyl-imidodiphosphate) could not stabilize CFTR's open state. The instability of the open state in the $\Delta \mathrm{R}_{708-835} \mathrm{CFTR}$ mutant indicates the possibility that the R -domain also plays a role in stabilizing ATP binding in the NBDs. In this mutant phosphorylation no longer regulates CFTR, only binding of MgATP can (125).

### 1.3.3.2. ATPase ACTIVITY.

After phosphorylation, WT-CFTR channels are activated by the binding of ATP to the NBDs. Specific motifs in both NBDs not only indicated ATP binding and hydrolysis but also that CFTR was a member of the ABC transporter superfamily. These motifs, which exist is both NBDs, are the Walker A motif (G-X-X-G-X-G-K-s/t), the Walker B motif (R-X-X-X-X-X-X-X-h-h-h-h-D) and the ABC signature motif (L-S-G-G-Q) and forms two ATP binding sites. (38). ATP binding site 2 is composed of the Walker motifs of NBD2 and the ABC signature motif of NBD1 and is known as the consensus site in CFTR. As mentioned before, the other ATP binding site (ATP binding site 1 ) is known as the degenerate site with respect to ATP hydrolysis and is composed of the Walker motifs of NBD1 and the slightly altered ABC signature (L-S-H-G-H) of NBD2 (38, 48, 126-128) (Figure 1.7). Studies of CFTR's single-channel behavior reveal that after

## A

|  | Walker $\boldsymbol{A}$ | Walker B | ABC signature |
| :--- | :--- | :--- | :--- |
| NBD 1 | GSTGAGKT | RAVYKDADLYLLD | LSGGQ |
| NBD 2 | GRTGSGKS | RSVLSKAKILLLD | LSHGH |
| Motif Sequence | GXXGXGKs/t | RXXXXXXXhhhD | ISGGQ |



Figure 1.7: Diagram of ATP (magenta) binding sites at the interface of the nucleotide binding domain 1 (NBD1, pink) and nucleotide binding domain (NBD2, blue). As discussed in Figure 1.1, there are two ATP binding sites in ABC transporters formed from the Walker A, Walker B, and ABC Signature motifs in the nucleotide binding domains. (A) The sequences of these motifs for hCFTR are tableted. (B) The consensus site (ATP binding site 2, marked by the black circle) is discussed further. Highlighted in this figure is the Walker A of NBD 2 (yellow) and ABC Signature of NBD 1 (orange), which form the ATP binding site stabilized by several residues of NBD2: Y1219 in A-loop (dark green), H1402 in H-loop (light green), Q1292 of Q-loop (purple), and D1320 of Walker B in NBD2 (cyan). A coordinated $\mathrm{Mg}^{2+}$ is gray.


Figure 1.8: Scheme of CFTR gating and opening cycle. CFTR is a chloride ion channel regulated by phosphorylation of the R-domain. After phosphorylation of the Rdomain, the fully open pore is regulated by two different gating stages. The NBDmediated gating (blue background) occurs with the binding of one ATP molecule (yellow) at a consensus site and one ATP molecule (yellow) at a degenerate site in the nucleotide binding domains (NBDs; NBD1 is pink, and NBD2 is blue). Then the pore is regulated by pore gating (pink background) in which CFTR has several subconductance states (s1 and s2, thin red arrow) but will process to a fully conducting pore (f, thick red arrow). Hydrolysis of ATP (yellow) at the consensus site and the release of ADP (orange) and inorganic phosphate causes the channel to close by inducing conformational changes in the Transmembrane Domains (TMDs, TMD1 is gray, and TMD2 is green).
phosphorylation, increasing the concentration of MgATP leads to a decreased mean closed time, but no change in mean open time. These data suggest a minimal model of at least two closed states and a single open state $\left(\mathrm{C}_{1}, \mathrm{C}_{2}, \mathrm{O}_{1}\right)(124)$. Further characterization of the single-channel behavior of CFTR shows another short-lived subconductance state $\left(\mathrm{O}_{2}\right)$ and asymmetric transitions between these states in the CFTR gating cycle (124). These data, and more, reveal that CFTR has a very complex gating cycle, transitioning between multiple states (Figure 1.8) $(124,129,130)$. Several studies have shown that the presence of MgATP before phosphorylation cannot activate CFTR, but the addition of only MgATP after the removal of PKA and ATP does activate CFTR channels (124). Nevertheless, in the case of deleting part of the R-domain, CFTR still retains ATPase activity and some channel activity (125). In the initial studies of purified recombinant NBD1 and NBD2, both have ATPase activity without the presence of TMD1, TMD2, or the R-domain (113, 131). While ATPase activity assays are used to demonstrate functional CFTR, especially in the case of purified protein, the reconstitution of the purified protein into planar lipid bilayers reveals substantial details about the chloride channel function of CFTR discussed below (48, 132-134).

### 1.3.3.3. CHLORIDE ION PORE.

The earliest electrophysiological studies of CFTR revealed its high anion selectivity over cations (99, 132); however, there is much less selectivity between anions (99, 135). Several experiments have shown that $\mathrm{Cl}^{-}$might not be the only physiologically relevant anion that permeates through CFTR, including bicarbonate $(135,136)$ and possibly glutathione and thiocyanate $(137,138)$. Thus, it is generally accepted that the minimum pore diameter of CFTR is around $5 \AA$ (139). For $\mathrm{Cl}^{-}$, CFTR demonstrates a linear I-V
relationship under symmetrical conditions, with one of the lowest single-channel conductances of any channel ranging from 6 pS to 10 pS , depending on buffer conditions, $\mathrm{Cl}^{-}$concentration, and temperature $(104,132,140,141)$. When phosphorylated CFTR is reconstituted into planar lipid bilayers and is in the presence of ATP, the open probability ( $\mathrm{P}_{\mathrm{o}}$ ) of WT-CFTR is measured to be $\sim 0.3$ to $\sim 0.5$, depending on buffer conditions, with the observation of the aforementioned subconductance states (112, 132, 142, 143). Further exploration of these subconductance states reveals that mutations not only in the TMDs (144-148) but also in the NDBs can affect the frequency of these states $(143,149)$. As high-resolution structures of CFTR were unavailable until recently, identifying key residues that lined the pore of CFTR was accomplished through a combination of sitedirected mutagenesis, cysteine accessibility studies, and introduction of various pore blockers, with the evaluation of changes to CFTR by electrophysiology. Detailed reviews of these studies identified several key residues in TM1, TM6, TM11, and TM12 (124, $150,151)$, many of which were confirmed in the several newly released structures of CFTR $(126,128)$ (Figure 1.9). A narrow region in the pore of CFTR, first identified by electrophysiology in combination with the techniques mentioned above, most likely composes the selectivity filter. In this region are residues S341 (TM6), T338 (TM6), and F377 (TM6) $(139,152)$. Every study investigating the chloride pore, ATP binding, and phosphorylation builds on our understanding of how mutations in each domain of CFTR affect the function of this protein and its clinical relevance.


Figure 1.9: Depiction of residues believed to be important in pore formation of CFTR. A full structure of CFTR (right) highlights the general architecture of CFTR with TMD1 in gray, NBD1 in pink, TMD2 in green, and NBD2 in blue. The black circle highlights four transmembrane helices, TM1 as pale orange, TM6 as orange, TM12 as forest green and TM11 as yellow, and the residues on those helices that are important in pore formation. Residues accessible from the extracellular side are blue, from the intracellular side are purple, or both are red.

Adapted from Linsdell, P. (2014) Functional architecture of the CFTR chloride channel. Mol Membr Biol. 2014 Feb;31(1):1-16.

### 1.3.4. Disease-relevance of CFTR.

More than 2000 mutations have been identified within the gene of CFTR (http://www.genet.sickkids.on.ca/), and 346 of those mutations are identified as CFcausing (cftr2.org/mutations_history). These mutations are categorized into five different classes-production mutations (class I), processing mutations (class II), gating mutations (class III), conductance mutations (class IV), and amount/localization mutations (class $\mathrm{V})(153)$ (Figure 1.10). In recent years, four different CFTR modulator therapies have been released for many processing, gating, and conductance mutations and some production and amount/localization mutations. These CFTR modulators are single, double, and triple combination therapies known clinically as Kalydeco® (Ivacaftor/VX770), Orkambi® (ivacaftor/VX-770 and lumacaftor/VX-809), Symdeko® (ivacaftor/VX-770 and tezacaftor/VX-661), and Trikafta® (ivacaftor/VX-770; tezacaftor/VX-661; and elexacaftor/VX-445) (Figure 1.11). These compounds are classified as either correctors-molecules that enable proper folding or trafficking-or potentiators-molecules that increase PKA regulated chloride channel gating of CFTR (154). Currently, many mutations are being treated with these modulators, but not all mutants are impacted by these compounds, especially in the production and amount/localization class of mutations. Single mutations in CFTR can impart complex molecular defects suggesting recategorization of mutation classes to allow current therapies to be tested on orphan mutations. This reclassification can also enable connecting the functional consequences of these mutations with the structure of CFTR (155).


Figure 1.10: Diagram of classes for CFTR mutations. The 346 currently identified disease-causing mutations are classified into one of the five above described classes. Each mutation class houses mutations that affect one of the following: protein production (class 1), protein processing (class 2), protein gating (class 3), protein conduction (class 4), or insufficient protein on the cell surface (class 5). However, many mutations can contribute to multiple classes of disfunction. The most common mutation, $\Delta \mathrm{F} 508$, is classified as a class 2 mutation.

Adapted from cftr2.org/mutations_history and https://www.cff.org/Care/Clinician-Resources/Network-News/August-2017/Know-Your-CFTR-Mutations.pdf.
KalydecO ${ }^{\circledR}$ (VX-770)

| $2789+5 G \rightarrow$ A | G551D | G1069R | D1270N |
| :--- | :--- | :--- | :--- |
| 711+3A $\rightarrow$ G | A1067T | S1255P | D110H |
| $3849+10 \mathrm{kbC} \rightarrow$ T | S1251N | D110E | R352Q |
| 3272-26A $\rightarrow$ G | R74W | R347H | S945L |
| P67L | L206W | D579G | R1070W |
| R117C | A455E | R117H | D1152H |
| F1074L | S977F | F1052V | S549N |
| E193K | G551S | R1070Q | G1349D |
| E831X | E56K | S549R | G178R |
|  | G1244E | K1060T |  |

Orkambi® (VX-770+VX-809)
$\Delta \mathrm{F} 508 / \Delta \mathrm{F} 508$

Symdeko ${ }^{\oplus}$ (VX-770+VX-661)

| $\Delta \mathrm{F} 508 / \Delta \mathrm{F} 508$ | L206W | D110E | D1270N |
| :--- | :--- | :--- | :--- |
| $2789+5 \mathrm{G} \rightarrow \mathrm{A}$ | A455E | R347H | D110H |
| $3272-26 \mathrm{~A} \rightarrow \mathrm{G}$ | S977F | D579G | R352Q |
| $711+3 \mathrm{~A} \rightarrow$ G | D1152H | R1070W | S945L |
| $3849+10 \mathrm{kbC} \rightarrow \mathrm{T}$ | F1074L | F1052V | R117C |
|  | E56K | E831X | R74W |
|  | E193K | E193K | K1060T |
|  | P67L | A1067T |  |

Trikafta® (VX-770+VX-661+VX-445) | $\Delta F 508 / \Delta F 508$ | $\Delta F 508 / x x x x$ |
| :--- | :--- |

Figure 1.11: Diagram of the current CF modulators and the tableted list of FDAapproved mutations. Currently, four different modulator therapies have been approved in single, double, or triple combination therapies and treat 39 of the 346 disease-causing mutations. These modulators are either potentiators, like ivacaftor (VX-770), or correctors, like lumacaftor (VX-809), tezacaftor (VX-661), and elexacaftor (VX-445).

### 1.4. CFTR STRUCTURES.

Structural characterization of CFTR is of great importance as structures can aid in understanding the complex molecular defects imposed by single mutations, elucidating the complex transitions from different closed and open states, and clarifying the chloride channel function of CFTR as a member of the ABC transporter superfamily.

### 1.4.1. Initial full-length CFTR structures.

Two structures of hCFTR were solved by 2D (two-dimensional) electron
crystallography-one in 2004 at a resolution of $20 \AA$ and one in 2011 at a resolution of $9 \AA(156,157)$. Both structures confirmed the general architecture of CFTR predicted in an initial gene discovery study (38). The first study showed two different global conformations, and the second study revealed an outward-facing conformation of CFTR without the presence of ATP or phosphorylation. The traditional terms of outward- and inward-facing for ABC transporters are used to describe general conformations states of CFTR, especially when a conformation lacks a fully conducting pore. In the interim of waiting for more structures of CFTR, several homology models of CFTR were developed.

### 1.4.2. CFTR homology models.

Several structures of ABC transporters were released, providing a variety of scaffolds for homology models $(9,158)$. The first of these models investigated the molecular interface of the most common mutation ( $\Delta \mathrm{F} 508$ ) and key interactions necessary to reestablish channel function (159, 160). The next several homology models investigated the transitions of CFTR from the inward-facing conformation to the outward-facing conformation and the formation of a fully conducting pore (130, 161-165). These models not only confirmed several key interactions but unveiled new interactions significant to CFTR's conformational transitions. One of these interactions includes E543 in the Xloop of NBD1 and K968 in ICL3, which our lab investigated further (166) (Figure 1.12). While these models were built keeping functional information in mind and rigorously evaluated, the NBDs are anticipated to have similar structures across ABC transporters, but the variety of substrates of ABC transporters compared to the chloride channel function of CFTR results in skepticism for the validity of the models.


Figure 1.12: Electrostatic salt bridge triad identified in homology models of CFTR and molecular dynamics and confirmed by electrophysiological techniques. This catalytic triad has been investigated in the translation of ATP binding at the nucleotide binding domains (NBDs, NBD1 is pink, and NBD2 is blue) to the Transmembrane Domains (TMDs, TMD1 is gray, and TMD2 is green). This triad is investigated further in chapter II of this dissertation.

Republished from Strickland, K. M., Stock, G., Cui, G., Hwang, H., Infield, D. T., Schmidt-Krey, I., McCarty, N. A., and Gumbart, J. C. (2019) ATP-Dependent Signaling in Simulations of a Revised Model of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). The Journal of Physical Chemistry B 123, 3177-3188.

### 1.4.3. Recent CFTR structures.

In three years, eight structures of 3 orthologs of detergent-solubilized CFTR were released from two laboratories in a broad range of resolutions-all solved by single particle electron cryo-microscopy (cryo-EM, see below). The first structures were of ATP-free, dephosphorylated zebrafish CFTR (zfCFTR) (inward-facing conformation) at a resolution of $3.7 \AA$ and hCFTR under the same conditions at a resolution of $3.9 \AA$. In both structures, the NBDs were of significantly lower resolution, and thus, crystal structures of the NBDs were used to construct the final models $(48,126)$. From the same lab, the phosphorylated, ATP-bound structures (outward-facing) of zfCFTR and hCFTR were solved at resolutions of $3.4 \AA$ and $3.2 \AA(127,128)$. All four of these structures revealed that CFTR contains a structural motif called the lasso motif. The lasso motif is found in several other ABC transporters (SUR1, SUR2, and MRP1) in which the N terminus loops into the lipid bilayer (Figure 1.13). These structures also exhibit a rearrangement of TM7 and TM8 and a kink in TM8, which is not seen in other similar ABC transporters. The functional consequence of the rearrangement and the kink in TM8 is still highly unclear and continues to be debated (167-169). The release of two more structures of hCFTR with different potentiators bound, Vertex potentiator VX-770 (resolution at $3.3 \AA$ ) or Galapagos potentiator GLPG1837 (resolution at $3.2 \AA$ ), showed both potentiators bound in the pocket created by the kink in TM8 (170). Whether this identified binding pocket is the physiological binding pocket for either or both of these potentiators or if these potentiators are correcting detergent-induced structural deformations has yet to be investigated. From a different lab, two other structures of recombinant thermostabilized chicken CFTR (chCFTR), one dephosphorylated, ATP-
absent (inward-facing) structure (resolution at $4.3 \AA$ ) and one phosphorylated, ATPbound (outward-facing) structure (resolution at $6.6 \AA$ ) also have been released. These structures show TM8 to be fully helical (171), and thus do not present the significant rearrangement of TM 7 and TM8 nor the kink in TM8. There are other peculiar structural characteristics in TM7 for these structures in which TM7 is almost orthogonal to the fatty acid tails of the lipid bilayer. As more structures are released, the kink in TM8 has been thought to be detergent-induced and not physiological (172).


Figure 1.13: Depiction of the Lasso motif in CFTR. The lasso motif (red) is a motif found in several members of the ABC transporter superfamily of proteins, in which the N-terminus tucks into the lipid bilayer. For orientation, Transmembrane Domain 1 (TMD1) is gray, nucleotide binding domain 1 (NBD1) is pink, TMD2 is green, and NBD2 is blue. PDB ID: 6MSM used to generate the figure.

Table 1.2: Current released CFTR structures and the conditions of protein.

| Protein | Organism | Res | Environment | Modification | State | Method | Year | Expression system |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| hCFTR | human | $\begin{aligned} & 20 \\ & \AA \end{aligned}$ | Lipids | - |  | 2D electron crystallography | 2004 | BHK cells, stables |
| hCFTR | human | $\begin{aligned} & 11 \\ & \AA \end{aligned}$ | Lipids | - | Closed (?), outward-facing, dephosphorylated, apo-ATP | 2D electron crystallography | 2011 | BHK cells, stables |
| zfCFTR | zebrafish | $\begin{aligned} & 3.7 \\ & \AA \end{aligned}$ | Detergent (LMNG, digitonin, CHS) | - | Closed, inwardfacing, dephosphorylated, apo-ATP | Single Particle | 2016 | Sf9 virus, HEK cells |
| hCFTR | human | $\begin{aligned} & 3.9 \\ & \AA \end{aligned}$ | Detergent (LMNG, digitonin, CHS) | - | Closed, inwardfacing, dephosphorylated, apo-ATP | Single Particle | 2017 | Sf9 virus, HEK cells |
| zfCFTR | zebrafish | $\begin{aligned} & \hline 3.4 \\ & \AA \end{aligned}$ | Detergent (LMNG, digitonin, CHS) | E1372Q | Closed, outwardfacing, phosphorylated, ATP-bound | Single Particle | 2017 | Sf9 virus, HEK cells |
| chCFTR | chicken | $\begin{aligned} & \hline 4.3 \\ & \AA \end{aligned}$ | Detergent (DMNG, digitonin) | $\begin{aligned} & \hline \Delta \mathrm{RI} / \\ & 1404 \mathrm{~S} / \end{aligned}$ 1441X | Closed, outwardfacing, dephosphorylated, ATP-present | Single Particle | 2018 | BHK cells, stable |
| chCFTR | chicken | $\begin{aligned} & \hline 6.6 \\ & \AA \end{aligned}$ | Detergent (DMNG, digitonin) | $\begin{aligned} & \hline \Delta \mathrm{RI} / \\ & 1404 \mathrm{~S} / \\ & 1441 \mathrm{X} \end{aligned}$ | Closed, outwardfacing, phosphorylated, ATP-present | Single Particle | 2018 | BHK cells, stable |
| hCFTR | human | $\begin{aligned} & \hline 3.2 \\ & \AA \end{aligned}$ | Detergent (LMNG, digitonin, CHS) | E1371Q | Closed, outwardfacing, <br> Phosphorylated, ATP-bound | Single Particle | 2018 | Sf9 virus, HEK cells |
| hCFTR | human | $\begin{aligned} & 3.3 \\ & \AA \end{aligned}$ | Detergent (LMNG, digitonin, CHS) | E1371Q | Closed, outwardfacing, <br> Phosphorylated, ATP-bound, VX-770-bound | Single Particle | 2019 | Sf9 virus, HEK cells |
| hCFTR | human | $\begin{aligned} & 3.2 \\ & \AA \end{aligned}$ | Detergent (LMNG, digitonin, CHS) | E1371Q | Closed, outwardfacing, <br> Phosphorylated, ATP-bound, GLPG1837bound | Single Particle | 2019 | Sf9 virus, HEK cells |

### 1.4.4. Need for more CFTR structures.

While these structures have provided invaluable information, confirming many interactions identified previously by functional experiments, there is still a need for additional structures to understand the function of CFTR fully. All high-resolution structures published to date are of protein entirely solubilized in detergent (Table 1.2). Current studies have shown that the solubilization detergent or stabilization detergent dramatically alters CFTR ATPase activity, even after reconstitution into lipids (133); in fact, the choice of reconstitution lipid affects the ATPase activity (134). Thus, it is likely that structures of CFTR in a lipid environment could be very different from those in detergent. Additionally, all of the various transition states of CFTR in opening and closing and the disease-causing mutations have yet to be explored in terms of a detailed structural description. These data suggest the need for more structures and simulations of these structures to connect CFTR structure and function.

### 1.5. MEMBRANE PROTEINS AND LIPIDS.

The importance of the lipid environment in maintaining membrane protein structure has been recognized; however, studying purified membrane proteins reconstituted into a lipidic environment has been limited to relatively large structural complexes-bicelles and sheets-due to the nature of lipids (173). Many recent advancements in small lipid bilayer complexes have been and are continuing to be developed, thus improving our understanding of the importance of the lipid bilayer on membrane protein structure and function by improving membrane protein stabilization during purification and reconstitution (174-177).

### 1.5.1. Advancements in purifying and studying membrane proteins in lipid bilayers.

Studying membrane proteins in a lipidic environment has presented many challenges, especially for functional assays, due to the structures that lipid bilayers form-bicelles and sheets (173). Thus, studying some individual membrane proteins in a lipid environment was almost impossible until recently. The use of amphipathic polymers to stabilize the hydrophobic portions of the membrane proteins or lipids in an aqueous environment has dramatically improved studies of individual membrane proteins (178). Nanodiscs use amphipathic polymers to protect the hydrophobic tails of lipid molecules while keeping the entire protein-lipid complex soluble in an aqueous environment (179, 180). Depending on the type of amphipathic polymer and technique used, a membrane protein can be solubilized and purified in detergent before reconstitution into a lipid bilayer, or the membrane protein and the surrounding annular lipid environment can be solubilized and purified directly for biochemical or structural analysis $(1,181)$.

### 1.5.2. "Standard" nanodises.

The first type of nanodisc, termed "standard nanodiscs," was developed in 1998 in Dr. Steven Sligar's lab by modifying the human Apolipoprotein-1 (hApo1)—a naturally occurring protein that packages lipid molecules into high-density lipoprotein complex, known as HDL (182). Replacing the large globular N-terminal domain of hApo1 with a Histidine tag (His-tag) and cleavage site left a $\sim 200$ amino acid peptide polymer that spontaneously folds into $\alpha$-helices referred to as the Membrane Scaffold Protein (MSP) (183). Incubation of MSP with detergent-solubilized lipids leads to the spontaneous formation of the nanodisc (Figure 1.14) of regular diameter as the detergent is being removed (183). The length of MSP determines the diameter of the nanodisc. The first developed MSP constructs are still the most commonly used and create nanodiscs with
either 9.7 nm or 11.9 nm diameter (184). Although the diameter can be increased and decreased by altering the length of MSP (185-187), changing the length of MSP will ultimately change the number of lipids accommodated upon insertion and thus will require optimization of the Lipid-to-Protein ratio (LPR) in each experiment $(183,185)$. Originally, nanodiscs were formed from one of three common lipid types-1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dipalmitoyl-sn-glycero-3phosphocholine (DPPC), or 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) (183, 184) (Figure 1.15); however, now nanodiscs are being generated from different types of lipids and lipid combinations with relative ease (188). There are a few restrictions in forming these nanodiscs. The first is that the LPR and temperature during nanodisc formation are highly dependent on lipid type and its phase transition temperature $(179,187)$. Nanodiscs form most easily and consistently when the mixture is incubated at temperatures above the phase transition temperature $(179,187)$. The most likely explanation for this is that lipids behave as a liquid above the phase transition temperature and as gel-like below the phase transition temperature, thus preventing the necessary interactions for forming nanodiscs $(179,187)$. It is also important that all detergent from membrane protein solubilization and lipid solubilization must be completely removed, either by absorption of the detergent using BioBeads ${ }^{\mathrm{TM}}$ or by dialysis (Figure 1.16). The incomplete removal of detergent will also prevent nanodisc formation, and thus the amount of BioBeads ${ }^{\mathrm{TM}}$ or length of incubation must be optimized (179). While at first MSP was limited to reconstituting detergent purified membrane proteins, methods have been identified to solubilize membrane proteins with their native lipid environment (189, 190), albeit still using detergent to disrupt the membrane. As
newer amphipathic polymers are discovered, the opportunity to solubilize the membrane without detergent will be a major advantage to studying membrane proteins both structurally and functionally (181).


Figure 1.14: A structure of nanodisc formed by Membrane Scaffold Protein (MSP). An individual MSP (orange) wraps around an individual leaflet of the lipid bilayer (gray). Thus, two MSP molecules form a single nanodisc composed of a lipid bilayer. From the top-down view (A), the nanodisc in this image is of MSP1D1 and has a diameter of 9.7 nm . In the side-on view (B), a nanodisc has a height of approximately 5 nm . Images were built in Visual Molecular Dynamics (VMD) software from PDB ID: 6CM1 to show a top-down view (left) and side-on view (right) of a nanodisc.



Figure 1.15: Depiction of the lipids first and commonly used to generate nanodiscs. All three lipids have the same head group (phosphatidylcholine) but differ in tail composition. The abbreviations are the following: 1,2-dimyristoyl-sn-glycero-3phosphocholine (DMPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), or 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC).


Figure 1.16: Schematic of nanodisc formation. The incubation of the membrane protein (MP) of interest, membrane scaffold protein (MSP) and lipids (DMPC, DPPC, POPC, etc.) in a particular ratio with the removal of detergent, either via BioBeads ${ }^{\mathrm{TM}}$ or dialysis, will form membrane protein-loaded nanodiscs (full nanodiscs) or lipid-only nanodiscs (empty nanodiscs).

### 1.5.3. Native nanodiscs.

The term "native nanodiscs" is used to describe the solubilization of a membrane protein with its native lipid environment using a synthetic polymer (191). While the term is used in a more global capacity to describe any discoidal bilayer system containing a membrane protein and its native lipid environment, the first native nanodisc utilized the synthetic styrene-maleic acid (SMA) polymer to solubilize small portions of the native lipid environment around the membrane protein of interest into uniformly sized discoidal particles $(191,192)$ (Figure 1.17). Initially, these lipid-bound SMA particles were called styrene-maleic acid lipid particles (SMALPs) (192); they also are called lipodisqs when formed from the commercially available SMA called Lipodisq ${ }^{\circledR}$ (193).


Figure 1.17: Schematic of native nanodiscs formation. Cell membranes containing several endogenous membrane proteins and CFTR incubated with Styrene Maleic Acid (SMA) polymer. SMA will self-insert into the membrane and form native nanodiscs. The membrane protein or membrane proteins of interest can be separated from endogenous membrane proteins using affinity chromatography. The following PDB IDs were used to generate this image: 5UAR, 5IRZ, 6F46, and 1HRK.

### 1.5.3.1. STYRENE-MALEIC ACID LIPID PARTICLES (SMALPs).

SMA is a synthetic copolymer formed by radical polymerization of maleic anhydride and styrene and then hydrolysis of the maleic anhydride moiety (Figure 1.18) (192). Several different ratios of styrene to maleic acid copolymers are available, with $2: 1$ and $3: 1$ being the most common and available commercially under the brand name Lipodisq ${ }^{\circledR}$, as well as in ratios of 3:1, 2.3:1, and 1.2:1 under the SMALP brand name (194). Computational simulations of SMA in the proximity of a lipid bilayer show that styrene inserts into hydrophobic tails of the lipids in about 20 ns (195). After about 400 ns , the SMA polymer is completely inserted into the membrane. Unlike MSP, SMA solubilizes the membrane by wrapping around the membrane without a clear orientation (195). SMA requires particular buffer conditions for SMALP formation, which can introduce many disadvantages for specific membrane proteins (194). First, the presence of divalent cations, like $\mathrm{Mg}^{2+}$ or $\mathrm{Ca}^{2+}$, as well as low pH , inhibit the formation of SMALPs (194, 196, 197). Several studies show SMA preferentially binds lipids in a fluid phase over a


Figure 1.18: Reaction diagram of SMA formation. Styrene and maleic anhydride monomers are mixed and polymerized, forming a polymer of varying uniformity. The final step in the formation of SMA is the hydrolysis of maleic anhydride to maleic acid under basic conditions. The final SMA polymer is used to solubilize membrane proteins and surrounding lipids embedded from the lipid bilayer.
gel phase or an ordered phase (198). Several other studies show SMA solubilizes certain types of lipids preferentially over others, including cholesterol $(199,200)$. Thus, SMA might not be as efficient at solubilizing a cholesterol-heavy lipid environment, causing preferential SMALP formation of non-cholesterol-associated membrane proteins. However, several varieties of SMA have been developed to combat some of these disadvantages, especially those related to the buffer conditions.

### 1.5.3.2. OTHER COPOLYMER VARIANTS.

Since the first production of SMA, many copolymers have been identified that can form nanodiscs providing their unique advantages and disadvantages; this discussion is summarized in Table 1.3. The first of these new polymers, called zSMA, modified the carboxyl groups of the SMA copolymer to phosphatidylcholine groups (201); thus, lipid particles formed from this copolymer are referred to as zSMALPs. The zSMA copolymer shows dramatically improved buffer compatibilities for a pH range of 4-10 and a divalent cation concentration of up to 20 mM . The ability of zSMA to solubilize membrane proteins from E. coli shows dramatic improvement over the first SMA copolymer for two membrane proteins (201). Further efforts to improve the first SMA copolymer led to the development of the diisobutylene maleic acid copolymer (DIBMA) (202). DIBMA forms similarly shaped discoidal particles to SMA and MSP, called DIBMA lipid particles (DIBMALPs), but with a slightly larger diameter at about 20 nm (202). DIBMALPs have one definite advantage to both SMALPs and standard nanodiscs. The DIBMA copolymer lacks UV-absorbing rings, allowing for more accurate spectrometry results of the incorporated membrane protein (202). DIBMA has another advantage over SMA, as DIBMA is not as sensitive to divalent cations. However, DIBMA is not as effective at
solubilizing membrane proteins from E. coli membranes as the commonly used detergent DDM (n-dodecyl $\beta$-d-maltoside) (202).

DIBMA and zSMA are not the only new variants developed. Another new variant is the styrene maleimide (SMI) copolymer, forming SMI lipid particles (SMILPs) (203). Interestingly, SMILPs are slightly smaller in diameter than DIBMALPs at 11 nm , but similar in size to the standard nanodisc diameter. The SMI copolymer is even more tolerant of divalent cations than any predecessor, showing lipid solubilization at up to 100 mM for both $\mathrm{Ca}^{2+}$ and $\mathrm{Mg}^{2+}$. SMI can solubilize membrane proteins from E. coli membranes as well as detergent (DDM) at physiologically low pH . SMI is much improved over the SMA copolymer; however, SMI is not as efficient at solubilizing membrane proteins from E. coli membranes at neutral pH as SMA and detergent (DDM) (203). The copolymer showing the most dramatic improvement to the disadvantages of the first SMA copolymer is styrene maleimide quaternary ammonium (SMA-QA) (204). Nanodiscs formed by this copolymer show no sensitivity to divalent cations (up to 200 mM ) or too low, neutral or high pH , and this copolymer shows the ability to control the diameter of the nanodiscs by regulating the ratio of polymer to lipid; however, the ability of this copolymer to solubilize membrane proteins remains to be tested (204). One of the most recent, yet attractive, copolymers developed again modifies the first SMA copolymer by forming an amide bond on the carboxylic moiety of the maleic acid through the addition of cystamine. This new polymer, called SMA-SH, does not improve the buffer condition solubility of SMA, but it does allow for membrane protein purification strategies and a plethora of fluorescent studies $(205,206)$. These polymer variants and advantages and disadvantages are summarized in Table 1.3.

Table 1.3: Structures of SMA derivatives and current characterization. The use of polymers to solubilize membrane proteins and package lipids into nanodiscs is a relatively new technology, and each polymer provides a unique set of advantages.

| Polymer | Structure | Advantages | Disadvantages |
| :---: | :---: | :---: | :---: |
| SMA (Styrene <br> Maleic Acid) |  | - Original polymer <br> - Heavily characterized <br> - Commercially available | - Precipitates in the presence of divalent cations <br> - pH sensitive <br> - Preferential lipid binding |
| zSMA |  | - pH range of 4-10 <br> - Divalent cation concentration $<20 \mathrm{mM}$ | - Not commercially available <br> - UV-absorbing moiety |
| DIBMA <br> (Diisobutylene <br> Maleic Acid) |  | - Large particle diameter ( 20 nm ) <br> - No UV-absorbing moiety | - Lipid preference |
| SMI (Styrene Maleimide) |  | - Divalent cation concentration <100 nM <br> - Good lipid solubilization at low pH | - Poor lipid solubilization at high pH |
| SMA-QA <br> (Styrene Maleimide <br> Quaternary Ammonium) |  | - Divalent cation concentration < 200 mM <br> - No pH sensitivity <br> - Size is controllable | - Has not been tested for membrane protein solubilization |
| SMA-SH |  | - Modified cystamine allows for purification strategies and fluorescent studies. | - No improvements on buffer conditions from SMA |

### 1.5.4. Downstream studies of membrane proteins in nanodiscs.

Using traditional biochemical and biophysical techniques to study individual membrane proteins in a lipid bilayer has been difficult. The use of nanodiscs, both the original and native, has vastly increased the number of studies providing both functional and structural data for membrane proteins. This nanodisc technology is especially crucial for membrane proteins involved in lipid regulation and synthesis (179).

### 1.6. CONCLUSIONS.

The improved technologies of nanodiscs have created an entirely new environment for studying membrane proteins and allows for the investigation of a multitude of new questions about the importance of the lipid environment for membrane proteins. This work describes the initial optimization strategies for building the foundation to investigate the importance of the environment for the very complex, but medically relevant membrane protein CFTR. The following chapters describe the optimization of three different expression cell systems of CFTR and two different affinity chromatography tagging systems. As CFTR has a complex biogenesis, the determination of an appropriate cell expression system and the location of tag for affinity chromatography is highly important for the purification of properly folded, functional CFTR. For our purified CFTR, both the channel function and the ATPase activity were evaluated. In other studies, the ATPase activity of CFTR depended on the detergent used for solubilization, even after reconstitution into a lipid environment (133). Another study reported that CFTR ATPase activity also depends on the lipid environment as studied by destabilized proteoliposomes, which are destabilized by the presence of detergent (134). We hypothesize that we will also see reduced ATPase activity of CFTR in detergent as
compared to in a lipid environment. Because of the differences in ATPase activity, we also hypothesize that the channel activity of CFTR will vary depending on the lipid environment. From one of the aforementioned detergent-solubilized structures of human CFTR, several lipid tail-like densities and a cholesterol-shaped electron density can be seen. This suggests that these lipids play an important structural role for CFTR. We determined the co-purified lipids in our detergent-solubilized purified CFTR sample. These newly released detergent-solubilized structures provide new structural information on CFTR, but before the release of these structures, structural studies relied on homology models. We hypothesized that a homology model could be refined by flexibly fitting in low-resolution maps of the protein determined from 2D lipid crystals. We analyzed these new models with traditional and non-traditional molecular dynamics methods and discussed more in the next chapter.

## CHAPTER II

# ATP SIGNALING IN A REVISED HOMOLOGY MODEL OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) 

### 2.1. INTRODUCTION.

### 2.1.1. Publications resulting from this chapter.

Reprinted with permission from Kerry M. Strickland, Gorman Stock, Guiying Cui, Hyea
Hwang, Daniel T. Infield, Ingeborg Schmidt-Krey, Nael A. McCarty, and James C.
Gumbart (2019) ATP-Dependent Signaling in Simulations of a Revised Model of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). J Phys Chem B. 123(15):3177-3188. Copyright (2019) American Chemical Society.

### 2.1.2. Individual contributions to the work.

Original concept proposed by Dr. JC Gumbart. Initial simulations designed and prepared by Gorman Stock with guidance from Dr. Gumbart. Final simulations prepared and run by Dr. Hyea "Sunny" Hwang. I analyzed simulation data in preparation for the manuscript in conjunction with Dr. Gumbart. Dr. Guiying Cui initially designed and performed the electrophysiological experiments, while $I$ further analyzed electrophysiological data using a variety of software tools. I wrote the manuscript and edited after reviewer recommendations and have updated the chapter here for inclusion in the thesis.

### 2.1.3. Introduction.

Ever since the discovery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in 1989 (38), the corresponding protein, CFTR, has been studied intensely
due to its role in the disease cystic fibrosis ( CF ). CF is a debilitating disease that significantly diminishes the quality and length of life of affected individuals. With nearly 2000 mutations identified in the gene of human CFTR (http://www.genet.sickkids.on.ca/app) and more than 300 currently identified as diseasecausing (207) understanding the structure-function relationship of this protein is critical for overcoming these defects of function. Studying CFTR has been particularly challenging, as it functions as a channel instead of a transporter, making it unique among the proteins in the ABC (ATP-binding cassette) transporter superfamily (208). ABC transporters represent a family of transmembrane proteins with typically four domains: two nucleotide-binding domains (NBDs) and two transmembrane domains (TMDs) (209). ABC transporters, either importers or exporters, move a preferred substrate in a single direction across the membrane with a strict relationship between the amount of substrate transported and ATP consumed. The energy of ATP binding at (typically) two distinct sites in the NBDs is used to enable conformational change in the TMDs; hydrolysis of ATP leads to transport of the substrate across the membrane (210). CFTR, on the other hand, evolved to use ATP to form a diffusive pathway for chloride ions; it is the only member of the ABC transporter superfamily known to act as a channel with no strict stoichiometry between ATP usage and substrate transport. CFTR uses a modified "alternating access" transport mechanism (211) in which a pore opens in the TMDs on the time scale of a second (114). In the alternating access model, the substrate has access to the binding site from inside the cell (inward-facing state) or from outside the cell (outward-facing state) but not both at the same time (20). In contrast, in CFTR, the outward-facing state is no longer closed to the inside, but instead, it can form a
channel connecting both sides. One of CFTR's NBDs bears a degenerate ATP-binding site, a feature found in some ABC exporters (212), and thus, CFTR can only hydrolyze ATP at one of the two binding sites. CFTR also possesses a unique $\sim 240$-residue regulatory domain (R-domain) between NBD1 and TMD2 (38). Flexible linker domains are found in some other ABC transporters $(39,40)$; however, the R-domain of CFTR is the largest found to date. Furthermore, it is the only linker known to tightly regulate the protein based on its phosphorylation state $(41,42)$. The majority of what is presently known about CFTR has been gained through a variety of biophysical techniques. Most prominent among these techniques, due to the channel function of CFTR, is electrophysiology, which was used to characterize and classify many clinically relevant mutations as they were identified (43, 213, 214). Electrophysiology combined with mutagenesis led to the identification of numerous functionally important residues (124). However, until recently, high resolution structural data, necessary to confirm the locations of these residues, lagged far behind functional data on CFTR, in spite of considerable effort. In 2004 and in 2011, a $20 \AA$ and a $9 \AA$ structure of CFTR were published, respectively (156, 157). In both cases, CFTR was crystallized twodimensionally, and its structure was determined using electron cryo-microscopy (cryoEM). Both structures confirmed the general topology of CFTR but did not reveal specific residue positions. Within the last several years, four 3-4 A resolution structures of CFTR have been solved by single-particle cryo-EM: an inward-facing zebrafish CFTR (zCFTR) (48), an outward-facing zCFTR (127), an inward-facing human CFTR (hCFTR) (126), and an outward-facing hCFTR (128), although none of them display an open pore. While these structures and models provide information on a few conformations of CFTR, its
complex gating cycle suggests there are numerous transitory states (215). Molecular dynamics simulations have the potential to reveal these otherwise "invisible" states, simultaneously providing more information on the transitional interactions formed and broken to translate structural information from one domain to another. Prior to the release of the 3-4 A resolution structures of CFTR, structures of several other ABC transporters were solved (7, 14, 158, 216). These structures were used as templates for several CFTR homology models (130, 159, 161-165). While the homology of the NBDs across transporters is relatively high due to their conserved functions of ATP binding and hydrolysis, the TMDs are quite diverse due to the manifold substrates transported. To address this variability, experimental data on CFTR have been incorporated as hard constraints during homology-model building in efforts to capture the unique pore characteristics of CFTR (130, 164). Nonetheless, concerns about the validity of these models remain, since they were based upon the structures of distantly related paralogs. In this study, we have further refined an existing homology model of CFTR, that from Rahman et al. (130), by applying molecular dynamics flexible fitting (MDFF) to fit it to a cryo-EM map of CFTR (157, 217). Extended simulations of the best fit structure displayed the formation of a complete pore, albeit one that is not yet conductive. These simulations also revealed a novel pair of salt bridges involving three residues in the NBDs and intracellular loops (ICLs), which were transiently formed during the channel opening process and thus would not be represented in the static cryo-EM structures. Both salt bridges were experimentally confirmed to be functionally relevant, pointing to a putative allosteric mechanism for signaling the state of ATP occupancy in the NBDs to the pore.

### 2.2. METHODS.

### 2.2.1. Flexible fitting.

The starting model of CFTR was taken from the 2013 homology-model study performed by Rahman et al. (130). Briefly, this outward-facing model was constructed by aligning the human CFTR sequence with the Sav1866 crystal structure (PDB 2HYD) in Modeler (7,218). Additional experimental constraints, consisting of known interactions lining the pore of CFTR, e.g., salt bridges, were also used to refine the model (130). Here, we further refined the open-channel CFTR homology model using molecular dynamics flexible fitting (MDFF) $(217,219)$ and a cryo-EM map of CFTR reported in 2011 (130, 157). This map contains 12 copies of the protein arranged in two tightly packed crystal planes, which we refer to as the crystallographic map. In addition to the full map, MDFF was also performed on a second map created by averaging the 12 copies of the protein in the crystallographic map, referred to as the average map. For each of the two maps, the homology model was rigid-body docked using the Situs package (220), after which MDFF was performed using NAMD (221). The fitting was carried out with secondarystructure restraints. For the crystallographic map, the homology model was replicated and translated to match the 12 proteins apparent within the EM map. To prevent distortions at the edges of the map, symmetry restraints were applied to all 12 copies using the crystallographic symmetry parameters (222). MDFF simulations were set up as recommended in the MDFF tutorial (http://www.ks.uiuc.edu/Training/Tutorials/science/mdff/tutorial_mdff.pdf); alternative simulation parameters were not attempted. Fitting was run until the root-mean-square deviation of the backbone stopped increasing, roughly 2 ns each. Fitting to the crystallographic map increased the cross-correlation coefficient (ccc) from 0.26 to 0.40 ;
fitting to the averaged map increased it from 0.46 to 0.56 , comparable to the values obtained in Simhaev et al. for a different model (0.50-0.53) (223). Even a perfect fit is not expected to yield a ccc of 1.0 , as there is extraneous density due to, e.g., bound detergent molecules. Although the crystallographic-map fit contains 12 copies, the symmetry restraints are increased over the course of the simulation to such a degree that, by the end, the copies are in identical conformations (Simulation System Construction). Careful consideration went into the placement of ATP in our refined model. The degenerate binding site of CFTR was modeled after the human CFTR NBD1 homodimer crystal structure (PDB: 2PZE) (224). The crystal structure was aligned to NBD1 of the model by comparing their ABC binding motifs, namely, the ABC signature sequence, Walker A, and Walker B motifs. The corresponding ATP in the crystal structure was placed into the fits by this alignment. Because the NBD1 homodimer structure does not contain a canonical binding site, we used the crystal structure of human ABCB6 (PDB: 3NH9) (225) to model the second ATP in a procedure similar to the first. The three models, namely, the original homology model along with the two fitted models, were each inserted into a POPC lipid membrane slab generated using VMD (Visual Molecular Dynamics) (226). This membrane slab was roughly $140 \AA$ by $75 \AA$ and, after deleting lipids that overlapped with the protein, contained 344 lipid molecules. This system was then solvated above and below the membrane with $\sim 72,000$ water molecules. $\mathrm{Na}^{+}$and $\mathrm{Cl}^{-}$ions were added at a concentration of 0.15 M to mimic biological conditions and to neutralize the system. The total atom count of each system was roughly 280,000 atoms.

### 2.2.2. MD simulations and analysis.

All simulations were performed using the NAMD Molecular Dynamics package (221).

The CHARMM36 force field (227-229) was utilized along with TIP3P water (230). Periodic boundary conditions were imposed. Constant pressure at 1 atm and temperature at 300 K were maintained during the simulations. A $12 \AA$ cutoff with a force-based switching function beginning at $10 \AA$ was employed for van der Waals interactions. A time step of 2 fs was used for all simulations, with long-range electrostatic interactions calculated every other time step using the particle-mesh Ewald method (231). Systems were equilibrated in stages as follows (232). First, all atoms except those in the lipid tails were restrained, allowing the tails to melt for 0.5 ns . Then, all of the atoms belonging to the protein were restrained, allowing the rest of the membrane to relax for an additional 0.5 ns . Next, only the backbone of the protein was restrained, allowing the side chain positions to relax for 0.5 ns . Finally, the systems were run at equilibrium fully unrestrained. Both fits as well as the original homology model were run for 100 ns in each of the three ATP states described, namely, with 0 , one, or two ATP bound at the NBDs. In addition, the crystallographic-fit simulations were extended for 200 ns more, giving a total of 300 ns .

### 2.2.3. Pore analysis.

Pore analysis was performed using the modified Fortran code HOLE (233) and the Python package MDanalysis (234). The analysis was run with default parameters, i.e., an end-point radius of $22.0 \AA$, a search direction of the $z$-axis perpendicular to the membrane, a sample point distance of $0.2 \AA$, and no center point of the pore specified. The program uses the following van der Waals radii: $1.85 \AA$ for carbon atoms, $1.65 \AA$ for oxygen atoms, $2.00 \AA$ for sulfur atoms, $1.75 \AA$ for nitrogen atoms, $1.00 \AA$ for hydrogen atoms, and $2.10 \AA$ for phosphorus atoms. All trajectories were divided into 1 ns snapshots
that were then supplied to HOLE. The program output the pore radius as a function of position along the pore axis. To ensure faster calculation, only the TMDs and some of the surrounding lipids were included in the analysis. Finally, we employed a modified radius of gyration $\left(\mathrm{R}_{\mathrm{G}}\right)$ method to analyze the splaying of the TMDs. While normally $\mathrm{R}_{\mathrm{G}}$ is a three dimensional quantity, here we only considered the in-plane ( $x$ and $y$ ) distribution of the protein-backbone atoms. The trajectories were aligned along the z -axis prior to measuring the modified $\mathrm{R}_{\mathrm{G}}$.

### 2.2.4. Preparation of oocytes and cRNA.

Mutant constructs of human CFTR were generated using site-directed mutagenesis via the Quikchange protocol (Agilent Technologies, La Jolla, CA) of the original (wildtype) WT-hCFTR gene in the pGEMHE vector (graciously provided by Dr. D. Gadsby, Rockefeller University). Mutations were confirmed by sequencing the entire open reading frame before cRNA generation. A 2-10 ng aliquot of CFTR cRNAs was injected into Xenopus laevis oocytes, and incubation occurred at $17{ }^{\circ} \mathrm{C}$ in modified Liebovitz's L-15 media supplemented with HEPES ( pH 7.5 ), penicillin, and streptomycin. Oocytes were typically incubated between 48 and 96 h after cRNA injections before recording. Animal handling methods and oocyte collection are in accordance with National Institute of Health (NIH) guidelines, as well as with protocols approved by the Institutional Animal Care and Use Committee (IACUC) of Emory University.

### 2.2.5. Electrophysiology.

Oocytes were shrunk in hypertonic solution; then, the vitelline membrane was manually removed. Pipettes used for inside-out macropatch recordings were pulled from borosilicate glass (Sutter Instrument Co., Novato, CA) and had resistances between 1 and
$2 \mathrm{M} \Omega$ after being filled with chloride-containing pipet solution: 150 mM NMDG-Cl, 5 $\mathrm{mM} \mathrm{MgCl}_{2}, 10 \mathrm{mM}$ TES ( pH 7.5 ). To activate surface-expressed channels, the cytoplasmic side of excised patches was exposed to solution containing the following: 150 mM NMDG-Cl, 1.1 mM MgCl 2 , 2 mM Tris-EGTA, 10 mM TES, 1 mM MgATP (adenosine $5^{\prime}$-triphosphate magnesium), and $1 \mu \mathrm{~L} / \mathrm{mL}(127.6 \mathrm{U} / \mathrm{mL})$ of PKA ( pH 7.5 ). All macropatch recordings, at RT $\left(22-23^{\circ} \mathrm{C}\right)$, were performed using an Axopatch 200B amplifier operated by pClamp 8.2 software; data were filtered at 100 Hz with a four-pole Bessel filter and acquired at 2 kHz . The following voltage protocol was applied every 5 s : hold at $\mathrm{Vm}=0 \mathrm{mV}$, then step to +100 mV for 50 ms followed by a ramp down to -100 mV over 300 ms prior to returning to 0 mV .

### 2.2.6. Source of reagents.

The medium L-15 was obtained from Gibco/BRL (Gaithersburg, MD), and the PKA catalytic subunit was obtained from Promega (Madison, WI). Stock CFTR inh 172 was initially prepared as 50 mM in Dimethyl Sulfoxide (DMSO). All chemicals were diluted to the stated final concentration in recording solution immediately before use.

### 2.2.7. Statistical analysis.

Unless noted in the figure legend or body of text, statistical analysis values are the mean $\pm$ SEM. For data, a $t$-test for unpaired or paired measurements in Sigmaplot 12.3 (San Jose, CA) was used to evaluate statistical significance; only values of $\mathrm{P}<0.05$ were considered significantly different as denoted as follows: represented by * are values of P $<0.05$, represented by ${ }^{* *}$ are values of $\mathrm{P}<0.01$, and represented by ${ }^{* * *}$ are values of P < 0.001 .

### 2.3. RESULTS.

### 2.3.1. MDFF fitting of the homology model to the cryo-EM map of crystallized

## CFTR.

Many groups have tried to circumvent the previous lack of structural knowledge by making homology models of CFTR using structures of closely related ABC transporters (159, 161-165, 235), including one from our work (130). To refine the Rahman et al. homology model (130), molecular dynamics flexible fitting (217) simulations were run on the outward-facing structure, which resulted from 10 ns of targeted MD (130), utilizing the $9 \AA$ resolution cryo-EM map of wild-type human CFTR from Rosenberg et al. (157). The map may represent an artificially stabilized state of CFTR due to its crystallization (223), which differs from the single-particle cryo-EM used for the higher resolution structures recently released (48, 126-128); nonetheless, it is used here, as it represents a physically possible conformation that can aid improvement of existing homology models. Furthermore, all cryo-EM maps to date have been determined for CFTR in detergent, which may also alter its accessible conformations. MD simulations of a cryo-EM determined or fitted CFTR in a native-like membrane can allow it to relax to a more physiologically relevant state. Two approaches were used in fitting the Rahman et al. homology model to the map. In the first approach, we imposed crystallographic conditions matching the dimensions of the cryo-EM map, i.e., 12 copies of the protein with crystallographic symmetry restraints between them (see Methods). In the second approach, a single copy of CFTR was fit to a spatially averaged map provided by R. Ford (personal communication). Thus, two fitting approaches produced two new conformations of the homology model; we will refer to the first as the "crystallographicfit model" and the second as the "averaged-fit model", named after the corresponding
maps to which they were fit. As mentioned above, the homology model was built with constraints on experimentally supported interactions specific to the open state of CFTR (130). The fitting of the model to either map lost one to three of these interactions (Table 2.1), although the map may represent a transient closed state of CFTR (223). In the crystallographic-fit model, S341, a pore-lining residue near the gate/selectivity filter of CFTR (152), is in close proximity to TM12 residues L1135 and N1138, which is characteristic of the closed state (see Figure 2.1). It should be noted that the 2D protein crystals used to determine the cryo-EM map were composed of nonphosphorylated CFTR in the absence of ATP (157), yet both phosphorylation and ATP binding are necessary for the opening of the channel (106, 112, 236-238). Therefore, it is not surprising that fitting an open-state homology model of CFTR to the cryo-EM map effectively "closed" the channel in the absence of ATP. In this pose, the NBDs are dimerized despite the lack of ATP, possibly a consequence of the 2D crystal packing in the cryo-EM experiments (157). However, this pose of CFTR may represent a physiological state of CFTR wherein the NBDs transiently interact, but the interaction of the NBDs without ATP is not sufficiently stable to open the CFTR pore $(239,240)$; this state may be equivalent to the "strained transitional" closed conformation described by Rahman et al., which is permissive to opening but not yet open (130). The idea of an intermediate closed state has also been recently proposed by Simhaev et al. (223). In that study, two homology models of CFTR, those from Corradi et al. (162) and from Dalton et al. (164), were flexibly fitted into the Rosenberg et al. cryo-EM map (157) and simulated in the apo-ATP state. Analysis of the MD simulations of these new models also demonstrated a lack of pore formation in the absence of ATP. This suggests that

ATP binding to the NBDs stimulates significant conformational changes to enable pore formation.

Table 2.1: Experimentally validated interactions in the original homology model and fitted structures. Numbers in brackets are references for the listed interactions.

| Residues | Interaction | Homology | Averaged | Crystallographic |
| :--- | :--- | :---: | :---: | :---: |
| S605-A1374 | [1] Cross-link $\leq 8 \AA$ | $\checkmark$ | $\checkmark$ | $\checkmark$ |
| S549-S1248 | [1] Cross-link $\leq 8 \AA$ | $\checkmark$ | $\checkmark$ | $\checkmark$ |
| S434-D1336 | [1] Cross-link 8A $\leq \mathrm{d} \leq 16 \AA$ | $\checkmark$ | $\checkmark$ | $\checkmark$ |
| S549-A1374 | [1] Cross-link $8 \AA \leq \mathrm{d} \leq 16 \AA$ | $\checkmark$ | $\checkmark$ | $\checkmark$ |
| E267-K1060 | [2] Salt Bridge $\leq 4 \mathrm{~A}$ | $\checkmark$ | - | - |
| R347-D924 | [3] Salt Bridge $\leq 4 \mathrm{~A}$ | $\checkmark$ | - | - |
| R352-D993 | [4] Salt Bridge $\leq 4 \mathrm{~A}$ | $\checkmark$ | $\checkmark$ | - |
| M348-T1142 | [5] Cross-link $\leq 13 \AA$ | $\checkmark$ | $\checkmark$ | $\checkmark$ |
| T351-T1142 | [5] Cross-link $\leq 13 \AA$ | - | $\checkmark$ | $\checkmark$ |

[1] M. Mense, P. Vergani, D. M. White, G. Altberg, A. C. Nairn, and D. C. Gadsby. In vivo phosphorylation of CFTR promotes formation of a nucleotide-binding domain heterodimer. EMBO J., 25:4728-4739, 2006.
[2] A. Billet, J. P. Mornon, M. Jollivet, P. Lehn, I. Callebaut, and F. Becq. CFTR: effect of ICL2 and ICL4 amino acids in close spatial proximity on the current properties of the channel. J. Cyst. Fibros., 12:737-745, 2013.
[3] J. F. Cotten and M. J. Welsh. Cystic fibrosis-associated mutations at arginine 347 alter the pore architecture of CFTR: Evidence for disruption of a salt bridge. J. Biol. Chem., 274:5429-5435, 1999.
[4] G. Cui, Z.-R. Zhang, A. R. W. O'Brien, B. Song, and N. A. McCarty. Mutations at arginine 352 alter the pore architecture of CFTR. J. Membr. Biol., 222:91-106, 2008.
[5] E. Y. Chen, M. C. Bartlett, T. W. Loo, and D. M. Clarke. The 508 mutation disrupts packing of the transmembrane segments of the cystic fibrosis transmembrane conductance regulator. J. Biol. Chem., 279(38):39620-39627, 2004.


Figure 2.1: Cartoon depictions of our two MDFF-fitted structures ("crystallographic" on the left and "averaged" on the right) and the Rahman et al. homology model that served as the starting point for MDFF. The domains are colored as follows: NBD1, pink; NBD2, blue; TMD1, gray; TMD2, green. A slight twist of the NBDs relative to the original model is indicated by the gray rectangles in the refined models. The additional curvature of TMs 7 and 8 , as compared to the homology model, is highlighted by the purple rectangles. The pink circle magnifies the proximity of residue S341 (pink) on TM6 and L1135 (blue) and N1138 (yellow) on TM12.

Reference: K. S. Rahman, G. Cui, S. C. Harvey, and N. A. McCarty. Modeling the conformational changes underlying channel opening in CFTR. PLoS One, 8(9):1-13, 2013).

### 2.3.2. ATP-stabilized dimerization of NBDs is improved in fitted models as compared to the original homology model.

A wealth of evidence indicates that CFTR channel opening is preceded by ATP-stabilized dimerization of the NBDs $(241,242)$. This was supported by targeted molecular dynamics simulations of the Rahman et al. homology model (130), which described a conformational wave starting with dimerization of the NBDs and leading to pore dilation. Our initial models generated from MDFF feature loosely dimerized NBDs, while the TMDs present a closed channel. We reasoned that simulating these models in the presence or absence of ATP may allow us to observe conformational changes relevant to channel gating of CFTR. To identify novel fitting-induced behavior, we simulated three distinct initial models, namely, the original Rahman et al. homology model (130) as well as our two MDFF-derived models. For each of these models, we generated the following three states: "bound" (two ATP docked between the NBDs; see Methods), "semi" (one ATP at the noncanonical binding site), and apo (no ATP). Thus, a total of nine states were each simulated for at least 100 ns . The dimerization of the NBDs has been quantified as the distance between the centers of masses of the NBDs and has been plotted for the bound simulations in Figure 2.2. Docking of ATP at both sites led to tighter NBD dimerization in both the averaged- and crystallographic-fit models when compared to the original homology model. Simulations of P-glycoprotein have led to the hypothesis that the adenine moiety of each ATP forms stabilizing hydrophobic interactions with the Xloop of an NBD (243). We see similar interactions between the X-loop of NBD1 and the ATP in the consensus site in the simulation of the crystallographic-fit model but not the
averaged-fit model; such an interaction is also seen in the cryo-EM structure of ATPbound hCFTR (128). In neither case were interactions between the X-loop of NBD2 and the ATP in the degenerate site observed.


Figure 2.2: Plot of NBD-NBD distance for the three different CFTR homology models simulated with ATP bound. The separation was calculated by taking the difference in centers of mass of the $\alpha$-carbons in each NBD. Both refined models, averaged and crystallographic, display tighter NBDs dimerization than the original Rahman et al. homology model. The dashed line and the solid line each represent a different trial.

Reference: K. S. Rahman, G. Cui, S. C. Harvey, and N. A. McCarty. Modeling the conformational changes underlying channel opening in CFTR. PLoS One, 8(9):1-13, 2013).

### 2.3.3. Analysis of simulations shows the development of a partial pore in the

 crystallographic-fit model.It is expected that ATP binding at both sites will induce the opening of a pore in CFTR $(244,245)$. We searched for such a pore in the three models with the program HOLE applied every 1 ns to our simulation trajectories (233). Even though a fully conducting pore (radius larger than $1.8 \AA$ across the entire length of CFTR) could not be seen in any of the nine systems within 100 ns , partial pore opening was observed for the crystallographic-fit model when compared to the original model but not for the averagedfit model. To facilitate observing possible differences between the models, the pore radius near the residue F337 at the extracellular vestibule, which is one helical turn beyond S341 and noted as a bottleneck previously (157), was used for comparison (Figure 2.3). Upon simulating the original Rahman et al. homology model (130) with the addition of ATP, the originally reported pore quickly collapsed near F337 with a radius below $2 \AA$; however, a consistent increase in pore radius in the ATP-bound state of the crystallographic-fit model was observed during the simulation. This increase in pore radius is due to a coupled motion of TMs 9 and 12. In the simulation of the averaged-fit model, TM9 starts farther from the protein center, which allows TM12 to collapse inward, preventing the formation of a pore (see Figure 2.5). Repeated 100 ns runs of the bound and apo states for each model produced similar results (see Figure 2.4). The pore analysis also revealed alternative pathways through the extracellular region of CFTR. For example, the pathway described in Rahman et al. (130) was between residue S341 and T1134 on TMs 6 and 12, whereas, in our simulation of the crystallographic-fit model, a distinct pathway between TMs 1 and 12 is observed. These pathways are consistent with


Figure 2.3: Pore analysis of the three different CFTR homology models simulated in ATP-apo (black), ATP semibound (green), and ATP-bound states (blue). The pore radius plotted for each model was evaluated near F337. The dashed line indicates the radius of a chloride ion ( $1.8 \AA$ ). Only the crystallographic-fit model shows widening in both bound and semibound states. See Figure 2.4 for repeated runs of the bound and apo states of each model.


Figure 2.4: Pore analysis of the second runs of the three different CFTR homology models in ATP-apo (black) and ATP-bound states (blue). The pore radius plotted for each model was evaluated near F337. The dashed line indicates the radius of a chloride ion ( $1.8 \AA$ ). Only the crystallographic-fit model shows widening in both bound and semi-bound states.


Figure 2.5: Comparison of the averaged-fit (red) and crystallographic-fit (green) models for the first run of each. (A,B) Comparison at 0 (A) and 100 ns (B) viewed from the membrane plane (the intracellular side is on the bottom). TM9 is indicated. (C,D) Comparison at $0(\mathrm{C})$ and $100 \mathrm{~ns}(\mathrm{D})$ viewed from the extracellular side. TM9 and TM12 are indicated.
the findings based upon both the Mornon et al. (165) and Corradi et al. (162) homology models. Additionally, the Corradi study reported two lateral tunnel openings forming at the NBD and ICL cytoplasmic clefts. Multiple water-accessible pathways are also consistent with results of $0.1-1.2 \mu \mathrm{~s}$-long simulations of both secondary and primary active transporters, which are found to be generally leaky for water (246). In the simulation analysis described above, the radius of the partial pore formed depends greatly on the positions of side chains, and thus, the precision of the pore reported may exceed the accuracy of the CFTR homology model. Therefore, an alternate metric was developed to focus on the outer radius of the channel. This metric, akin to a two-dimensional radius of gyration, $\mathrm{R}_{\mathrm{G}}$ (see Methods), is plotted in Figure 2.6. A higher $\mathrm{R}_{\mathrm{G}}$ value is indicative of more splayed TMDs, which may correlate with a more open pore in CFTR $(247,248)$.

We partitioned the TMDs along the channel axis into three slices, each including two to three turns of the TM helices, and measured $\mathrm{R}_{\mathrm{G}}$ for each over all of the 100 ns simulations (data points taken every 0.2 ns ). We then asked whether any of the simulations exhibited time-dependent changes in $\mathrm{R}_{\mathrm{G}}$ that would be consistent with channel opening as the pore domain of CFTR shifts from inward-facing to outward-facing. Only $\mathrm{R}_{\mathrm{G}}$ for the simulation of the crystallographic-fit model showed substantial dependence on the ATP occupancy state in two independent runs. This dependence is most pronounced for the slice most distant from the membrane on the extracellular side, shown in Figure 2.6 and Figure 2.7, as may be expected $\left(\mathrm{R}_{\mathrm{G}}\right.$ for the other two slices are given in Figure 2.8).


Figure 2.6: Radius of gyration ( $\mathbf{R}_{\mathbf{G}}$ ) analysis for the three CFTR homology models simulated in ATP-apo, ATP-semibound, and ATP-bound states. (upper left) Cartoon representation of the TMDs of the crystallographic-fit CFTR (extracellular side at the top). The TMDs have been divided on the basis of their position along the pore axis into three sections. $\mathrm{R}_{\mathrm{G}}$ for the upper section (yellow) is plotted here for the indicated structures, and the middle (gray) and bottom (blue) sections are plotted in Figure 2.7 and 2.8. The crystallographic-fit model shows significant widening for the uppermost section in the ATP-bound state.


Figure 2.7: Radius of gyration $\left(\mathbf{R}_{\mathbf{G}}\right)$ vs. time for slice 1 from the second runs of the Rahman et al. homology (A), averaged-fit model (B), and crystallographic-fit model (C).


Figure 2.8: Radius of gyration $\left(\mathbf{R}_{\mathbf{G}}\right)$ vs. time for slices 2 and 3 from the first runs of the Rahman et al. homology model ( $\mathbf{A}, \mathrm{B}$ ) and averaged-fit model ( $\mathrm{C}, \mathrm{D}$ ).

Reference: Rahman, K. S., Cui, G., Harvey, S. C., and McCarty, N. A. (2013) Modeling the Conformational Changes Underlying Channel Opening in CFTR. 8, e74574.


Figure 2.9: Radius of gyration $\left(\mathbf{R}_{\mathbf{G}}\right)$ vs. time for the first crystallographic-fit run, extended to 300 ns . The graphs labeled Slice 1-3 correspond to the colored sections of the figure in the top left.

### 2.3.4. Extended simulations of the crystallographic-fit model display a complete pore

## in the ATP-bound state.

Given that only the crystallographic-fit model shows any ATP dependence, both in partial pore formation and in adopting a putative outward-facing conformation within 100 ns , simulations of all three ATP occupancies of this model were extended to 300 ns (second runs for the bound and apo states were also extended to 300 ns ). The difference in $\mathrm{R}_{\mathrm{G}}$ between the bound state and apo/semi states grew continuously over the entire 300 ns simulation (see Figure 2.9). Examination of the pore evolution in CFTR over this


Figure 2.10: Pore analysis of the crystallographic-fit model in (A) ATP-bound and (B) ATP-apo states after 280 ns of simulation each. TMD1 is shown in gray, transparent and TMD2 is in green; NBDs are not shown. In parts A and B, the pore in CFTR is shown according to the following color scheme: radius $>2.3 \AA$ is blue, $1.15-2.3 \AA$ is yellow, and $<1.15 \AA$ is red. The dashed lines indicate the position of the membrane. (C) Plot of pore radius as a function of position along the channel axis (normal to the membrane) for both bound (blue) and apo (black) states at 280 ns . The shaded area indicates the position of the membrane, and the dashed line at $1.8 \AA$ is the radius of a chloride ion. Second runs of the bound and apo states are shown in Figure 2.11 .


Figure 2.11: Pore analysis of the second $300-n s$ runs of the crystallographic-fit model in (A) ATP-bound and (B) ATP-apo states. TMD1 is shown in grey, transparent and TMD2 is in green; NBDs are not shown. In (A) and (B), the pore in CFTR is shown according to the following color scheme: radius > $2.3 \AA$ is blue, 1.15$2.3 \AA$ is yellow, and $<1.15 \AA$ is red. The dashed lines indicate the position of the membrane. (C) Plot of pore radius as a function of position along the channel axis (normal to the membrane) for both bound (blue) and apo (black) states at 300 ns . The shaded area indicates the position of the membrane, and the dashed line at $1.8 \AA$ is the radius of a chloride ion.
longer time scale reveals a complete pore in only the first run of the bound-state model at around 280 ns (Figure 2.11), albeit one that is still watertight on the intracellular side at the level of the tetrahelix bundle (235). At the same 280 ns time point, the apo state shows a different, mostly closed pathway (radius of $1-1.5 \AA$; Figure 2.10 ), which diverges laterally at the intracellular side of the membrane. The physiological relevance of this lateral pathway for exiting ions, if any, is uncertain. The second run of the bound state also displays an expanded pore in the transmembrane region, although not a complete one (see Figure 2.11). The pore is lined by TMs 4-9 and 12 at various points along its path through CFTR; structurally, it forms due to a radially outward shift of TMs 7-9 and 12 (Figure 2.12). The pore is continuously solvated, but we never observe an ion


Figure 2.12: Differences between ATP-bound (green) and ATP-apo (orange) states of CFTR. Structures are taken after 280 ns of the first run starting from the crystallographic-fit model (see also Fig. 2.10). (A) NBDs viewed from the cytoplasm. ATP molecules in the bound state are shown in purple. (B) ICLs viewed from the cytoplasm in the same orientation as the NBDs in (A). The bottom of TM9, connected to ICL3, is also indicated. (C) Side-view of ICLs (bottom) and TMDs with one of the discovered salt bridges highlighted. (D) TMDs viewed from the extracellular side. The red x marks the position of the putative initial pore.
inside of it. Arginines, such as R303, R933, R347, and R1128, are present in the pore, which could provide a favorable electrostatic environment for chloride ions. However, the radius is only slightly above the $1.8 \AA$ threshold for a desolvated chloride ion for much of its length, and therefore, we do not expect it to be conductive yet. On the basis of a comparison of the ATP-apo and ATP bound states, we hypothesize a causal chain of events leading to channel opening: (1) binding of ATP induces a tighter association of the NBDs (Figure 2.12), (2) the ATP-bound NBDs stabilize the ICLs (Figure 2.12), (3) the close association of NBDs and ICLs permits additional interactions, e.g., the observed
salt bridge between E543 (NBD1) and K968 (ICL3), which shifts the position of TM9, among others (Figure 2.12), and (4) this shift of TMs at the cytoplasmic side induces a corresponding one at the extracellular side, opening a pore (Figure 2.12).

### 2.3.5. Comparison of the Crystallographic-Fit Model with a Recent 3.2 Å Resolution

## Outward-Facing Human CFTR Structure.

The recent advancements in the field of single particle cryo-EM have led to multiple structures of CFTR in the resolution range 3-4 Å in different conformations. We compare our crystallographic-fit model to the phosphorylated, ATP-bound outward-facing conformation of hCFTR, which surprisingly did not possess an open pore as expected (128). We found an overall root-mean-square deviation for the backbone of $5.8 \AA$. In equilibrium MD simulations, fluctuations of 2-4 Å from a crystal structure are regularly observed, e.g., as seen for ABC transporters $\operatorname{Sav} 1866$ and $\operatorname{MsbA}(249,250)$; while $5.8 \AA$ is beyond these observations, it should be noted that both structures may represent distinct physiological states. Many features of the ATP-bound outward-facing structure of hCFTR (128) align with our crystallographic-fit model of human CFTR, such as the bending of TM6 at residue V350. While the positions of most of the TMs in the crystallographic-fit model match the $3.2 \AA$ resolution structure closely, TM 6 is noticeably shifted in the crystallographic-fit model (RMSD $6.5 \AA$; see Figure 2.13). This is most likely due to the arrangement of TMs 7 and 8 . TM8 in the hCFTR structure is broken into three short helices, a feature only seen in the recently published structures of CFTR (48, 126-128) and not found in structures of related ABC transporters. The helical portion of TM8 located at the extracellular side occupies a more central position within CFTR than in the crystallographic-fit model, displacing TMs 6 and 7. The functional


Figure 2.13: Structural comparison of the outward-facing hCFTR structure (PDB ID 6MSM) in orange and the hCFTR outward-facing crystallographic-fit model in blue. (A) Aligned structures. The root-mean-square deviation between the structures is 5.8 Å. (B) The alignments of TM6, TM7, and TM8 are highlighted to show major differences.


Figure 2.14: Comparison between the Rahman et. al. homology model (blue) and closed-state cryo-EM structure of human CFTR (orange; PDB 5UAK). The full structures are shown in (A) and TMs 6, 7, and 8 are highlighted in (B).

Reference: K. S. Rahman, G. Cui, S. C. Harvey, and N. A. McCarty. Modeling the conformational changes underlying channel opening in CFTR. PLoS One, 8(9):1-13, 2013).
relevance of this broken TM8 is still being investigated, especially through MD simulations (167). Similar differences are seen in comparing the closed-state homology model of Rahman et al. (130) with the 3.9 Å resolution structure of inward-facing hCFTR as well (Figure 2.14) (126). Despite these positional differences in the TMDs, the agreement between the ICLs and NBDs after alignment of the whole structure and model is better, with the ICLs having an RMSD of $4.2 \AA$ and the NBDs $3.7 \AA$ for the outwardfacing structures. To further validate the crystallographic-fit model, three key open-state salt bridges were examined, namely, R347-D924 (147), R352-D993 (146, 251), and E267-K1060 (47). All three pairs form salt bridges in the outward-facing hCFTR structure (128). In simulations of the bound state of the crystallographic-fit model, a salt bridge between R347 and D924 is only seen once in 300 ns in one run, one between R352 and D993 forms for the first 30 ns in one run and is stable over 300 ns in the other, and, finally, one between E267 and K1060 is present over nearly the entire 300 ns of one run and the first 110 ns in the other. In contrast, in Simhaev et al., all pairs of residues are within 2.5-6 Å over the course of 20 ns MDFF runs (223). These interactions, identified in many CFTR homology models (130, 159-162, 164, 252), have been validated through rigorous electrophysiology studies (146-148). Specifically, the first two interactions, R347-D924 and R352-D993, have been characterized, especially in our work (146, 148). Interestingly, the last of these interactions (E267 and K1060) was found via homology modeling and was subsequently verified experimentally (161, 235). Chargereversal mutation of either residue lowers the opening rate of CFTR in response to ATP but not the stability of the open state, suggesting that the interaction plays an important role in maintaining the architecture of the ATP binding site in the apo state (235). In
addition, K1060 is the site of a disease-associated mutation (K1060T) (253). Although this interaction was initially discovered on the basis of homologous residues in the prokaryotic transporter MsbA, a multiple sequence alignment of these regions shows that these residues are unique to CFTR among ABCC proteins (see Figure 2.15).

| ICL2 E267 in red |  |
| :---: | :---: |
| ABCC7 | nnlnkfdeglalahfvwiaplqvallmgliwellqasafcglgflivlalfqaglgrmmm |
| ABCC4 | ndvnkfdqvtvflhflwagplqaiavtallwmeigisclagmavliillplqscfgklfs |
| ABCC5 | ndgqrmfeaaavgsllaggpvvailgmiynviilgptgflgsavfilfypammfasrlta |
| ABCC12 | sdsyslfeaalfcplpatipilmvfcaayaffilgptaligisvyvifipvqmfmaklns |
| ABCC11 | gdvnylfegvcygplvlitcaslvicsissyfiigytafiailcyllvfplavfmtrmav |
| ABCC7 | kyrdqragkiserlvitsemieniqsvkaycweeamekmienlrqtelkltrkaayvryf |
| ABCC4 | slrsktatftdarirtmnevitgiriikmyaweksfsnlitnlrkkeiskilrssclrgm |
| ABCC5 | yfrrkcvaatdervqkmnevltyikfikmyawvkafsqsvqkireeerrilekagyfqsi |
| ABCC12 | afrrsailvtdkrvqtmnefltcirlikmyaweksftntiqdirrrerkllekagfvqsg |
| ABCC11 | kaqhhtsevsdqrirvtsevltciklikmytwekpfakiiedlrrkerkllekcglvqsl <br> : . *: .*.: *: :* * * : : : : :*. * :.. .: |
| ABCC7 | nssafffsgffvvflsvlpyalikg-iilrkifttisfcivlrmavtrqfpwavqtwyds |
| ABCC4 | nlasffsaskiivfvtfttyvllgsvitasrvfvavtlygavrltvtlffpsaiervsea |
| ABCC5 | tvgvapivvviasvvtfsvhmtlgfdltaaqaftvvtvfnsmtfalk-vtpfsvkslsea |
| ABCC12 | nsalapivstiaivltlschillrrkltapvafsviamfnvmkfsia-ilpfsikamaea |
| ABCC11 | tsitlfiiptvatavwvlihtslklkltasmafsmlaslnllrlsvf-fvpiavkgltns |
|  |  |

ICL4 K1060 in red

| ABCC7 | kdiailddllpltifdfiqlllivigaiavvavlqpyifvatvpvivafimlrayflqts |
| :---: | :---: |
| ABCC4 | kdighlddllpltfldfiqtllqvvgvvsvavavipwiaiplvplgiififlrryflets |
| ABCC5 | kdmdevdvrlpfqaemfignvilvffcvgmiagvfpwflvavgplvilfsvlhivsrvli |
| ABCC12 | kdmdeldvrlpfhaenflqqffmvvfilvilaavfpavllvvaslavgffillrifhrgv |
| ABCC11 | gdleqldqllpifseqflvlslmviavllivsvlspyillmgaiimvicfiyymmfkkai |
|  |  |
| ABCC7 | qqlkqlesegrspifthlvtslkglwtlrafgrqpyfetlfhkalnlhtanwflylstlr |
| ABCC4 | rdvkrlesttrspvfshlssslqglwtiraykaeercqelfdahqdihseawflflttsr |
| ABCC5 | relkrldnitqspflshitssiqglatihaynkgqeflhryqellddnqapfflftcamr |
| ABCC12 | qelkkvenvsrspwfthitssmqglgiihaygkkescity---------hllyfncalr |
| ABCC11 | gvfkrlenysrsplfshilnslqglssihvygktedfisqfkrltdaqnnylliflsstr |
|  |  |
| ABCC7 | wfqmriemifviffiavtfisiltt-gegegrvgiiltlamnimstlqwavnssidvdsl |
| ABCC4 | wfavrldaicamfviivafgslilaktldagqvglalsyaltlmgmfqwcvrqsaevenm |
| ABCC5 | wlavrldlisialitttglmivlmhgqippayaglaisyavqltglfqftvrlasetear |
| ABCC12 | wfalrmdvlmniltftvallvtlsfssistsskglslsyiiqlsgllqvcvrtgtetqak |
| ABCC11 | wmalrleimtnlvtlavalfvafgisstpysfkvmavnivlqlassfqatarigleteaq |
|  | * : *: : . . : : . : . : : : . . . . . |

Figure 2.15: Sequence alignment of CFTR and related proteins. The sequence segments in the alignment correspond to ICL2 (top) and ICL4 (bottom). Residues E267 and K1060, which appear to contribute to a salt bridge, are highlighted in red.

### 2.3.6. Identification and Experimental Validation of a Salt Bridge between ICL3 and

 NBD1. ABC transporters use flexible loop motifs to couple their domains, two of which are the Q- and X-loops. The Q-loop is adjacent to the ATP binding site and is known to facilitate NBD-NBD dimerization upon ATP binding as well as NBD-ICL coupling (254). It has also been suggested that one byproduct of the $\Delta \mathrm{F} 508$ mutation is a conformation of the Q-loop that inhibits NBD dimerization (255). The X-loop is a flexible motif present at the interface between the NBDs and the ICLs, the latter of which are each composed of two long helices and one short helix arranged in a horseshoe shape (Figure 2.12) (256). The flexible Q- and X-loops are contact points to the ICLs and likely play an important role in conferring motion from the NBDs to the TMDs. In simulations

Figure 2.16. Snapshot of the bound crystallographic-fit trajectory after 200 ns (top), focusing on the interface between NBDs and ICLs (bottom). The domains of CFTR are labeled accordingly, and E543, K968, and K1292 are shown as sticks and colored by residue type (acidic in red and basic in blue).
of the crystallographic-fit model, E543 of NBD1 (X-loop) forms alternating salt bridges with K968 (ICL3) and K1292 of NBD2 (Q-loop); all three residues are shown in Figure 2.16. The former interaction has been observed in other homology models $(130,163)$ but not the latter. Over the 300 ns simulations of the bound state, E543 formed a salt bridge with K968 36\% of the time ( $73 \%$ in the second run) and with K1292 $26 \%$ of the time ( $0 \%$ in the second run; Figure 2.17). In one of the ATP-bound simulations, E543 appeared to alternate between interacting with K968 and K1292. The E543-K968 salt bridge was also present in the semi-bound simulation $(80 \%)$ and for part of one of the apo simulations (37\%), prior to the separation of the NBDs. The E543-K1292 salt bridge was only observed near the end of one of the apo simulations and was not observed at all in the semi-bound simulation. To determine the functional relevance of the E543-K968 and E543-K1292 salt bridges, the behaviors of CFTR channels bearing mutations at these sites were recorded in electrophysiology experiments. The single mutants E543Kand K968A-CFTR exhibited a significantly longer (E543K) or slightly shorter (K968A) mean activation time-defined as the time required for currents to reach a plateau in response to ATP + PKA—as compared to WT-CFTR (Figure 2.18). The mean activation time for the charge swapped double mutant (E543K/K968E-CFTR) was similar to WT-CFTR channels, exhibiting rescue. Even though the single mutant K1292E-CFTR had a mean activation time similar to WT-CFTR, the K1292E mutation in conjunction with the E543K mutation, as a charge swapped double mutant, partially rescued the long mean activation time seen in the E543K-CFTR mutant (Figure 2.18). While both charge-swapped double mutants E543K/ K1292E- and E543K/K968ECFTR can at least partially rescue the mean activation time of the E543K mutant, the


Figure 2.17: Salt-bridge distances over time for the crystallographic-fit ATPbound simulation. Three experimentally verified salt bridges are tracked over time in (A) run 1 and (B) run 2. (C) Two salt bridges newly discovered and experimentally confirmed here for both runs.
latter has a greater effect (Figure 2.18). These data suggest that E543 interacts with both K968 and K1292. It should be noted that, for CFTR to transition from the closed to the open state, the R-domain must be phosphorylated. Although the homology model in our simulation does not contain the R-domain, there are many other steps necessary for the transition that could be observed. To investigate the effects of these residues on the opening of CFTR after phosphorylation, we explored the reactivation of CFTR channels with ATP alone. For this experiment, we used the following protocol: WT-CFTR and


Figure 2.18: Mean activation time changed in mutants compared to wt-CFTR. Sample traces of inside-out macropatch currents of (A) WT-, (B) E543K-, (C) K968A, (D) E543K/K968E-, (E) K1292E-, and (F) E543K/K1292E-CFTR recorded under the experimental conditions listed in the panels. Control, $150 \mathrm{mM} \mathrm{Cl}^{-}$intracellular solution; INH172, $10 \mu$ M CFTRinh172. (G) Summary data for mean activation time for WT and mutants. Statistical data are as follows: $\mathrm{n}=30$ for WT; $\mathrm{n}=11$ for E543K; $\mathrm{n}=7$ for K1292E; $\mathrm{n}=18$ for K968A; $\mathrm{n}=11$ for E543K/K968E; $\mathrm{n}=10$ for E543K/K1292E. ***, P < 0.001 compared to WT; **, $\mathrm{P}<0.01$ compared to WT-CFTR.
mutated channels the by $127.6 \mathrm{U} / \mathrm{mL}$ PKA and 1 mM MgATP ; channels were allowed to close briefly by washout of ATP and PKA; channels were then reactivated by addition of 1 mM MgATP alone; channels were then deactivated again by washout of ATP (Figure 2.19). We attempted to fit both the reactivation and deactivation rates of the WTCFTR channel, the single E543K- mutant, the single K968A- mutant channel, and the E543K/K968E-CFTR double mutant channel. However, mutation at these residues caused the macroscopic opening and closing transitions, upon applying or washing out


Figure 2.19: 1 mM MgATP reactivated WT and mutant CFTR after channels were fully activated by ATP + PKA. (A) WT-CFTR was fully activated with 1 mM MgATP and $127.6 \mathrm{U} / \mathrm{ml}$ PKA, deactivated by removal of ATP and PKA using control solution, and then reactivated by 1 mM MgATP alone. Representative current traces for E543K (B), K968A (C), and E543K/K968A-CFTR (D) were recorded with the same experimental conditions as WT-CFTR. Summary data are shown in E. Y axis indicate the ratio of maximum current in ATP alone ( $\mathrm{I}_{(\mathrm{ATP})}$ ) divided by maximum current in ATP and PKA $\left(\mathrm{I}_{(\mathrm{ATP}+\mathrm{PKA})}\right)$. Statistical data are follows: $\mathrm{n}=4$ for WT; $\mathrm{n}=6$ for E 543 K ; $\mathrm{n}=8$ for K968A; n=6 for E543K/K968E. **, P < 0.01 compared to WT.

ATP, to be quite irregular, compared to the behavior of WT-CFTR channels with the same protocol, making quantitative fits impossible (Figure 2.20). In spite of this inability to quantify, it is nonetheless evident that disrupting the interaction between E543 and K968 greatly perturbs the macroscopic channel behavior such that neither single nor double exponentials efficiently fit the reactivation data; however, the double E543K/K968E mutant began to restore WT macroscopic behavior. The combined electrophysiology data lead us to conclude that the K968-E543-K1292 triad contributes to the transition from the closed state to the open state. The charge-swapping double mutations were unable to completely rescue WT-CFTR channel behavior, suggesting that all three residues interact during gating. Another possibility is that, due to instability of the loop, any mutation may alter its structure. This same phenomenon was previously seen for electrostatic interactions in extracellular loop 1 (251). The final remaining question we addressed was whether these interactions also contribute to the steady-state channel function after CFTR is fully activated. Comparing the steady-state behavior to WT-CFTR channels, K968A-CFTR channels behaved very similarly, with regular closed and open states, a very rare subconductance state, and similar mean burst durations (Figure 2.21). Moreover, K968A-CFTR exhibited a significantly lower open probability as compared to WT-CFTR, which is supported by a previous study (235). These data suggest that the above electrostatic interactions contribute very little in modulating the steady-state behavior of CFTR channels and may contribute mostly to opening and/or closing transitions, but more experiments are needed to confirm.


Figure 2.20: Representative fits of the ATP-induced activation of phosphorylated CFTR and deactivation after washout of ATP. All activation and deactivation data were fit in Igor using a double exponential (without an X-offset), as follows: (A) WTCFTR activation, (B) WT-CFTR deactivation, (C) K968A-CFTR activation, (D) K968A-CFTR deactivation, (E) E543K-CFTR activation, (F) E543K-CFTR deactivation, (G) E543K/K968E-CFTR activation, and (H) E543K/K968E-CFTR deactivation. The differences between the raw data and the double exponential fit were calculated and plotted above each fit. Goodness of fit was also analyzed by Chi-square value. The activation traces for each single mutant (K968A-CFTR or E543K-CFTR) were impossible to fit using a double exponential function; however, the double mutant (E543K/K968E-CFTR) seems to partially restore to WT-CFTR channel behavior, although not completely, thus enabling the data to be fit.


Figure 2.21: K968A exhibited similar single-channel behavior to WT-CFTR. (A) Representative Single channel current traces of WT- and K968A-CFTR were recorded using inside-out patch with 150 mM Cl - intracellular solution in the presence of 1 mM MgATP with $127.6 \mathrm{U} / \mathrm{ml}$ PKA at membrane potential -100 mV . (B) Open probability of K968A is significantly lower than WT-CFTR. (C) K968A exhibits similar mean burst duration as WT-CFTR (WT-CFTR data cited from previous publication Cui, G., Rahman, K. S., Infield, D. T., Kuang, C., Prince, C. Z., and McCarty, N. A. (2014) Three charged amino acids in extracellular loop 1 are involved in maintaining the outer pore architecture of CFTR. The Journal of General Physiology 144, 159-179 . N=5 for K968A-CFTR. ${ }^{* * *}$, $\mathrm{P}<0.001$ compared to WT.

### 2.4. DISCUSSION.

Recent advancements in the field of cryo-EM have led to an influx of new structures at higher resolutions than previously attainable without relying on crystallization. Within the last three years, four structures of CFTR have been published using single-particle cryo-EM techniques (48, 126-128). These structures have provided valuable information on the closed state and the conformational changes induced by phosphorylation and ATP binding; however, none of them, including the outward-facing structures, displays a complete conducting pore. It is possible that the ATP-bound zebrafish and human CFTR structures both represent a state similar to the aforementioned "strained transitional" state of CFTR (130), and additional signals or steps are required before a pore will form on a much longer time scale than simulated here. Such putative transitional states of CFTR can be explored with MD simulations, combined with experimental confirmation of key interactions observed. Before the release of the four 3-4 Å resolution cryo-EM structures of CFTR, several homology models were built to ameliorate the dearth of structural information. Here, we refined one of those models from Rahman et al. (130) by flexibly fitting it to two versions of a low-resolution cryo-EM map (157), one with the full 12fold crystallographic symmetry of the map and one averaged to a single copy. We found that fitting to the crystallographic map produced a more functionally relevant model than fitting to the averaged map, likely due to the maintenance of the crystal contacts, which further restrict fluctuations at a resolution below that of the map itself. Our study complements that of Simhaev et al. (223), who used the same map to refine two homology models of CFTR from Corradi et al. (162) and from Dalton et al. (164). Fitting was followed by simulations of each model for at least 100 ns in different ATP-
occupancy states. Similar to Simhaev et al. (223), we observed that even without ATP the NBDs collapse. When comparing the ATP-bound states simulated here, we found that the crystallographic-fit model exhibits increased NBD dimerization when compared to the original homology model as well as the opening of a partial pore at F337. The radius of gyration also shows a significant widening of the extracellular side of the protein in the crystallographic-fit model in the ATP-bound state compared to the apo state. Upon extension of the simulations from 100 to 300 ns , the crystallographic-fit model revealed the formation of a complete pore at 280 ns of one run (Figure 2.10) and an expanded partial pore in the other run (Figure 2.11), similar to the pore identified in other homology models (165). We note that, although the existence of a pore is a promising sign, the simulations are still far from converged, which would require a time scale orders of magnitude larger to fully describe CFTR's gating cycle. We also compared our crystallographic-fit model to the outward-facing hCFTR structure (128). We found that some elements of CFTR aligned moderately well between our crystallographic-fit model and the hCFTR structure, such as the ICLs (RMSD $4.2 \AA$ ) and NBDs (RMSD $3.7 \AA$ ). However, the structural differences in the TMDs are greater. These differences most likely stem primarily from a kink in TM8 seen only in the recently published structures of CFTR but not represented in CFTR structures resolved under different conditions (171). However, as mentioned previously, the outward-facing structure of hCFTR could represent a "strained transitional" state and, thus, has possibly not yet signaled for pore formation. These transitional states can be further characterized through MD simulations and confirmed through experimentation. In addition to the transition from a strained state to one with a pore over the 300 ns simulation of the
crystallographic-fit model, salt bridges were observed between E543 in the X-loop of NBD1 and K968 in ICL3 as well as between E543 and K1292 in the Q-loop of NBD2. These interactions, although previously suggested by other homology models (130, 163), have not been experimentally tested until now. Mutagenesis and electrophysiology show that disrupting the E543-K968-K1292 electrostatic triad significantly alters the macroscopic rate of channel activation, with E543K having the largest effect (see Figure 2.18). Therefore, we suggest that this triad is part of a structural relay from the NBDs to the TMDs signaling ATP occupancy and leading to pore formation, as observed in the simulations. Preliminary experiments suggest that, once signaling has occurred, the steady-state behavior is not strictly dependent on the triad. In the outward-facing hCFTR structure, neither the E543-K968 nor the E543-K1292 salt bridge is seen, although only slight movements of a loop would be required for them to form (side chain distances of 8.2 and $10.0 \AA$, respectively). Future simulations and experiments will be used to further elucidate the signaling mechanisms in CFTR, especially under different phosphorylation conditions.

## CHAPTER III

 CFTR EXPRESSION AND PURIFICATION
### 3.1. INTRODUCTION.

CFTR, only expressed in vertebrates, has a complex biogenesis requiring multiple proteins that aid in folding, proper insertion into the membrane, and post-translational processing of CFTR $(58,63,257)$. Because of the complexity of CFTR biogenesis, the cell type chosen for CFTR expression for purification and location of the affinity tag is critical for a high yield of highly homogenous CFTR. Currently, several cell types are being used for CFTR expression and can be dependent upon the CFTR ortholog. Due to the complexity and instability of human CFTR, only eukaryotic cells have been used successfully in expression for purification. Purification of membrane proteins, especially ABC transporters, is highly dependent on the detergent solubilization step, including the choice of detergent and method of solubilization (258-260). CFTR is no different. CFTR ATPase function appears to be highly dependent on the detergent used for solubilization and stabilization, which cannot be rescued by reconstitution into lipids (133). In this chapter, we describe attempts and successes at expression and purification of human CFTR in three different cells types—Sf9 (ovary cells of Spodoptera frugiperda), BHK (Baby Hamster Kidney cells), and CHO (Chinese Hamster Ovary cells) - evaluating the overall quality of protein expression and purification. In the following chapters, CFTR function, both ATPase activity and channel function are evaluated.

### 3.1.1. Individual contributions.

3.1.1.1. Sf9 EXPRESSION SYSTEM.

The initial CFTR construct for protein expression in the Sf9 cell system was designed by Dr. Canhui Li and Dr. Mohabir Ramjeesingh of the Dr. Christine Bear Lab at the School of Medicine, University of Toronto, Canada and gifted to Dr. Brandon Stauffer of the McCarty Lab at the School of Medicine at Emory University in Atlanta, GA. I was initially taught cell culture and viral expression techniques for Sf 9 cells by Dr. Youngman Kwon in the Kang Lab at Georgia State University in Atlanta, GA, and Dr. Nidhi Williams of Atlanta, GA. I performed the final bacmid transfection, viral infection, and CFTR protein expression from the Sf 9 cells.

### 3.1.1.2. BHK EXPRESSION SYSTEM.

Stably transfected BHK-CFTR-10xHis cell line was gifted to McCarty Lab by Dr. John Hanrahan of the Department of Physiology at McGill University in Montreal, Canada. I maintained and designed cell culture protocols for transitioning to suspension culture and preformed and optimized protein purification.

### 3.1.1.3. CHO EXPRESSION SYSTEM.

CFTR-3xFLAG-tag construct gifted to Dr. Guiying Cui of McCarty Lab by Dr. Hong Joeng of the lab of Dr. Eric Sorscher in the School of Medicine at Emory University. Cloning of CFTR-3xFLAG insert into T-Rex ${ }^{\text {TM }} \mathrm{pcDNA} 5 / \mathrm{TO}$ plus an IRES-CFP vector performed by the Custom Cloning Division within the Emory Integrated Genomics Core. I developed the stably transfected CHO-CFTR-3xFLAG-ECL4 line, with help from the Winship Flow Cytometry Core within the Pediatrics Department at Emory University and from Mr. Brian Dobosh (Tirouvanziam lab). Further optimization and protein purification was completed by me.

### 3.1.2. Publications resulting from this chapter.

Optimization of CFTR protein purification will be published in downstream publications, as CFTR purification is a new technique to both the McCarty and Schmidt-Krey labs.

### 3.2. METHODS.

### 3.2.1. Sf9 expression system.

### 3.2.1.1. MOLECULAR CLONING FOR hCFTR EXPRESSION IN SF9 CELLS.

Original plasmid (hCFTR with a c-terminal 10xHis-tag in pFastBacDual) (Figure 3.1) was provided by the Bear lab, as noted above. Amplification of plasmid was completed by transformation into XL 10-Gold E. coli cells on $75 \mu \mathrm{~g} / \mathrm{mL}$ LB agar plates. Plasmid (given number pCF340 in the McCarty lab) was purified by miniprep (ZymoPure MiniPrep Kit) and CFTR sequence confirmed by full-length sequencing of hCFTR (Genewiz ${ }^{\oplus}$, https://www.genewiz.com/en). Two stabilizing mutations, D110C and


Figure 3.1: Plasmid map of WT-hCFTR in pFastBacDual vector. This plasmid was used for wt-hCFTR expression in Sf9 cells, but also for the generation of mutant hCFTR constructs and expression in Sf9 cells.

K892C, were introduced into WT-hCFTR (McCarty pCF546) using the Emory Integrated Genomics Core (EIGC). Full-length sequencing of hCFTR constructs were completed before the generation of bacmid.

### 3.2.1.2. MAINTENANCE OF SF9 CELLS.

Gibco ${ }^{\circledR}$ Sf9 cells from Invitrogen were thawed quickly in $37^{\circ} \mathrm{C}$ water bath and resuspended in 5 mL of SF-900 ${ }^{\mathrm{TM}}$ II SFM media. To expand and infect cells, DMSO must be removed immediately upon resuspension. To remove DMSO, cells were pelleted at 800 g for 5 minutes at RT, and the supernatant removed. Cells were resuspended in 5 mL of new warmed SF-900 ${ }^{\mathrm{TM}}$ II SFM media and transferred to 50 mL of media in a sterile 250 mL Corning media bottle. Cells were grown in a non-humidified, air-regulated incubator at $27^{\circ} \mathrm{C}$ with a loosened cap, shaking at 150 RPM . Cells were counted using a hemocytometer every two days and split at a density of $1 \times 10^{7}$ cells $/ \mathrm{mL}$. To make frozen cell stocks, cells were pelleted at 800 g for 5 minutes at RT and then resuspended in freezing solution ( $30 \%$ FBS, $10 \%$ DMSO, and $60 \%$ SF- $900^{\text {TM }}$ II SFM media) and frozen at a density of $3 \times 10^{6}$ cells $/ \mathrm{mL}$ to $-80^{\circ} \mathrm{C}$. Frozen cells were stored in liquid nitrogen.

### 3.2.1.3. BACULOVIRUS PRODUCTION.

A general outline can be seen in Figure 3.2. In accordance with instructions for the Bac-to-Bac Baculovirus Expression system (Invitrogen ${ }^{\mathrm{TM}}$ ), purified plasmid was transformed into DH10Bac E.coli for bacmid production and colonies were screened on LB-agar plates with $50 \mu \mathrm{~g} / \mathrm{mL}$ kanamycin, $7 \mu \mathrm{~g} / \mathrm{mL}$ gentamicin, $10 \mu \mathrm{~g} / \mathrm{mL}$ tetracycline, and 100 $\mu \mathrm{g} / \mathrm{mL}$ Bluo-gal and $40 \mu \mathrm{~g} / \mathrm{mL}$ IPTG (Blue-white Screening). Colonies were selected based on positive blue/white screening, amplified, and purified in accordance with the ZR BAC DNA ${ }^{\text {TM }}$ Miniprep Kit protocol $\left(\right.$ Zymo $\left.^{\circledR}\right)$. Purified bacmid was screened first by

PCR amplification of inserted gene followed by full-length sequencing of the WT and mutant hCFTR construct (Genewiz®, https://www.genewiz.com/en). Promising constructs were used for baculovirus production. Sf9 cells were plated at $\sim 50 \%$ confluency in Grace's Insect Media, Unsupplemented (ThermoFischer ${ }^{\text {TM }}$ ), and incubated for 1 hour before transfection. Sf9 cells were transfected for 5 hours at $27^{\circ} \mathrm{C}$ in Grace's Insect Media, Unsupplemented, using a Bacmid:Cellfectin ratio of $1(\mu \mathrm{~g})$ DNA: $8(\mu \mathrm{~L})$ Cellfectin ${ }^{\circledR}$ II, which was preincubated for 30 minutes at RT. Cells were allowed to recover and produce virus for 72 hours in $\mathrm{Sf}-900^{\mathrm{TM}} \mathrm{II}$ media. Virus-containing media was removed, supplemented with $2 \%$ FBS (Fetal Bovine Serum), and stored at $4^{\circ} \mathrm{C}$ protected from light (for short-term storage). Viral colonies were selected and purified via plaque assay, and then the viral titer was determined also using plaque assay. Briefly, cells were plated at $\sim 25 \%$ confluency in a 6 -well plate and incubated overnight at $27^{\circ} \mathrm{C}$ before treatment with virus for 1 hour at RT. Virus-containing media was removed from infected cells, and cells were covered in $1 \%$ agarose in $1 \mathrm{X} \mathrm{Sf}-900^{\mathrm{TM}} \mathrm{II}$ media solution. The plates were incubated at $27^{\circ} \mathrm{C}$, humidified until the number of plaque colonies did not change over 48 hours; then, viral colonies were either purified or titered. When purifying a viral colony, a sterile glass pipette was used to stab the agarose, and the agarose plug was transferred to a sterile microcentrifuge tube containing 0.5 mL of SF $900^{\mathrm{TM}}$ II SFM media supplemented with $2 \%$ FBS. This was mixed by vortexing, before 0.1 mL of plaque purified virus was plated into each well of a 6 -well plate containing adherent Sf9 cells at $75-80 \%$ confluency and incubated for 72 hours. The media was collected, and the cell debris was pelleted by centrifugation at 500 g for 5 minutes at RT. The supernatant was transferred to a sterile 15 mL conical tube supplemented with $2 \%$

FBS and was stored at $4^{\circ} \mathrm{C}$ away from light. During titering, plaque colonies were stained in 0.5 mL Neutral Red solution for 2 hours at RT and solution removed before counting colonies. To calculate the titer, the number of plaques per dilution was counted, multiplied by the dilution factor and divided by the volume of inoculation virus. Amplification of a plaque-purified p1 viral colony started with cells in a 6-well plate (2 x $10^{6}$ cells $/ \mathrm{mL}$ ) which were infected at an MOI (multiplicity of infection) of 0.1 before being harvested at 48 hours. The cells were pelleted at 500 g for 5 minutes at RT and the supernatant was collected ( p 2 viral stock). The p 2 viral stock was stored at $4^{\circ} \mathrm{C}$ supplemented with $2 \%$ FBS. The titer of p 2 viral stock was determined using the plaque assay. For long term-storage, any viral stock was stored at $-80^{\circ} \mathrm{C}$ protected from light.


Figure 3.2: Depiction for the overall flow of baculovirus production. The purified donor plasmid is transformed into DH 10 Bac E. coli. Bacteria containing the recombined CFTR-containing bacmid will survive antibiotic selection and can be further screened using Blue-White screening. CFTR-containing bacmid is transfected into Sf9 cells to generate Baculovirus (within media). Baculovirus can be used to infect Sf9 cells for CFTR protein production and purification.

### 3.2.1.4. INFECTION OF SF9 CELL SUSPENSION CULTURE.

Sf9 cells were plated in a 10 cm dish at $1.8 \times 10^{7}$ cells at RT for 30 minutes. The media was removed and replaced with SF-900 ${ }^{\mathrm{TM}}$ II SFM media supplemented with $1 \%$ FBS before adherent cells were infected at a multiplicity of infection (MOI) of 20 for 48 hours.

### 3.2.1.5. PROTEIN EXPRESSION SCREENING VIA WESTERN BLOT ANALYSIS.

Infected Sf9 cells were pelleted at 1000 g for 10 minutes at $4^{\circ} \mathrm{C}$ and the cell pellet was resuspended in RIPA buffer containing 1x protease inhibitor cocktail (cOmplete EDTAfree PIC Roche ${ }^{\ominus}$ ). Infected cells were lysed on ice for 10 minutes at $4^{\circ} \mathrm{C}$, and the cellular debris was pelleted at 1000 g for 10 minutes at $4^{\circ} \mathrm{C}$. The total protein concentration was measured using Pierce ${ }^{\mathrm{TM}}$ Bicinchoninic Acid (BCA) microplate assay in accordance with the manufacturer's protocol. Equivalent total amounts of protein $(50-150 \mu \mathrm{~g})$ for each sample were mixed with 1x Laemmli sample buffer (prepared in house) supplemented with 50 mM DTT (Dithiothreitol) and then incubated at $37^{\circ} \mathrm{C}$ for 30 minutes. All samples and the ladder (Precision Plus Protein ${ }^{\mathrm{TM}}$ Dual Color Standards Marker Bio-Rad) were loaded into a Mini-PROTEAN® TGX ${ }^{\text {TM }}$ precast $4-15 \%$ acrylamide: bisacrylamide SDSPAGE. The gel was run at 150 V for 45 minutes and then transferred overnight at $4^{\circ} \mathrm{C}$ at 60 mA onto a nitrocellulose membrane. All blots were blocked in $5 \%$ milk in TBST (Tris-buffered saline and Tween ${ }^{\circledR}$ 20) for 1 hour at RT, and then stained with 1:1,500 mouse anti-CFTR 596 antibody in TBST with $5 \%$ BSA overnight at $4^{\circ} \mathrm{C}$, followed by 1:1,000 goat anti-mouse antibody conjugated to HRP (Sigma) in TBST with 5\% BSA for 1 hour at RT with three 15 minute washing steps after each antibody stain with TBST. Western blotting detection was determined using Amersham ${ }^{\text {TM }}$ ECL $^{\text {TM }}$ Western Blotting Detection reagents, and blots were imaged on a Bio-Rad ChemiDoc ${ }^{\text {TM }}$ XRS+ system.

### 3.2.1.6. HIS-TAG ACCESSIBILITY DETERMINATION.

Infected Sf9 cells were collected by titration and pelleted at 1000 g for 10 minutes at $4^{\circ} \mathrm{C}$. Cells were resuspended in 0.5 mL Roche Buffer A ( $50 \mathrm{mM} \mathrm{NaH}_{2} \mathrm{PO}_{4}, \mathrm{pH} 8.0,0.3 \mathrm{M}$ NaCl ) and lysed using a Dounce Homogenizer. Large cellular debris was pelleted by centrifugation at 1000 g for 10 minutes at $4^{\circ} \mathrm{C}$. The supernatant was prepared for resinbinding by the addition of DDM and imidazole to make a final concentration of $0.1 \%$ DDM and 0.5 mM imidazole in Roche A buffer solution. The prepared supernatant was mixed with $50 \mu \mathrm{~L}$ Roche ${ }^{\odot}$ His-resin overnight at $4^{\circ} \mathrm{C}$. The resin was "packed" in Ultrafree ${ }^{\circledR}$ PVDF $0.5 \mu \mathrm{~m}$ centrifuge filter (Millipore-Sigma ${ }^{\circledR}$ ) at 100 g for 1 minute at $4^{\circ} \mathrm{C}$ and the flow-through was collected. The resin was washed in $150 \mu \mathrm{~L}$ Roche A supplemented with $0.1 \% \mathrm{DDM}$ and 0.5 mM imidazole. CFTR was eluted from the resin with $50 \mu \mathrm{~L}$ Roche $\mathrm{B}\left(50 \mathrm{mM} \mathrm{NaH}_{2} \mathrm{PO}_{4}, \mathrm{pH} 8.0,0.3 \mathrm{M} \mathrm{NaCl}\right.$, and 0.25 M imidazole) by centrifugation at 100 g for 1 minute at $4^{\circ} \mathrm{C}$.

### 3.2.2. BHK-CFTR-10xHis Expression System.

### 3.2.2.1. MAINTENANCE OF BHK-CFTR-10xHIS CELLS.

BHK cells were stably transfected with recombinant hCFTR containing a 10x His-tag on the C-terminal end, as previously described (102). BHK cells were maintained adherently by splitting in the range of $1: 5$ to $1: 20$ at $100 \%$ confluency into DMEM/F12 50:50 (Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12) plus 10\% FBS with 1\% Penicillin/Streptomycin and 0.5 mM Methotrexate (BHK-CFTR complete media). Frozen cell stocks were prepared in 10\% DMSO, 30\% FBS, and 60\% DMEM/F12 50:50 at a density of $3 \times 10^{6}$ cells/ mL and cooled to $-80^{\circ} \mathrm{C}$, and then transferred to liquid nitrogen for long term storage.

### 3.2.2.2. HIS-TAG ACCESSIBILITY DETERMINATION.

Cells plated on $10 \mathrm{~cm}^{2}$ plates were collected by trypsinization and pelleted at 1000 g for 10 minutes at $4^{\circ} \mathrm{C}$. The cells were resuspended in 0.5 mL Roche Buffer A ( 50 mM $\left.\mathrm{NaH}_{2} \mathrm{PO}_{4}, \mathrm{pH} 8.0,0.3 \mathrm{M} \mathrm{NaCl}\right)$ and lysed using a Dounce Homogenizer. Large cellular debris was pelleted by centrifugation at 1000 g for 10 minutes at $4^{\circ} \mathrm{C}$. Then the supernatant was prepared for resin-binding by the addition of DDM and imidazole to make a final concentration of $0.1 \% \mathrm{DDM}$ and 0.5 mM imidazole in Roche A buffer solution. The prepared supernatant was mixed with $50 \mu \mathrm{~L}$ Roche ${ }^{\oplus}$ His-resin overnight at $4^{\circ} \mathrm{C}$. The resin was packed in an Ultrafree ${ }^{(1)}$ PVDF $0.5 \mu \mathrm{~m}$ centrifuge filter (MilliporeSigma ${ }^{\mathrm{TM}}$ ) at 100 g for 1 minute at $4^{\circ} \mathrm{C}$ and the flow-through was collected. The resin was washed in $150 \mu \mathrm{~L}$ Roche A supplemented with $0.1 \% \mathrm{DDM}$ and 0.5 mM imidazole. CFTR was eluted from the resin with $50 \mu \mathrm{~L}$ Roche $\mathrm{B}\left(50 \mathrm{mM} \mathrm{NaH} \mathrm{PO}_{4}, \mathrm{pH}\right.$ $8.0,0.3 \mathrm{M} \mathrm{NaCl}$, and 0.25 M imidazole) by centrifugation at 100 g for 1 minute at $4^{\circ} \mathrm{C}$.

### 3.2.2.3. TRANSITION OF ADHERENT BHK-CFTR-10xHIS CELLS TO SUSPENSION

## CULTURE.

Cells plated on two T75 flasks were grown to confluency. Once confluent, cells were washed in PBS and incubated in $0.25 \%$ trypsin-EDTA for 90 seconds before being removed. The cells were incubated for another 90 seconds before being resuspended in 12 mL of BHK-CFTR complete media in the same plastic T75 flask. This method was repeated over 4 days, or until cells began forming 3 dimensional (3D) structures. Once the cells began forming 3D structures, the cells were transitioned into suspension flasks. The adherent cells were washed in the T75 flasks with PBS before incubation in 0.25\% trypsin for 30 seconds. The cells were washed again in PBS and rested without solution
for another 30 seconds before being resuspended in BHK-CFTR complete media. Cells from two T75 flasks were transferred to a 1 L suspension culture flask filled with 500 mL of BHK-CFTR complete media supplemented with $0.1 \%$ Pluronic ${ }^{\circledR}$ F68 (Gibco ${ }^{\circledR}$ ). The suspended cells were fed within 24 hours of transition with 550 mL of complete media supplemented with $0.1 \%$ Pluronic $^{\circledR}$ F68 and spiked with 0.5 mM Methotrexate (final concentration) 12 hours before purification.

### 3.2.2.4. CFTR PURIFICATION FROM BHK-CFTR-10xHIS CELLS.

BHK cells were pelleted either in 50 mL conical tubes at 1000 g for 5 minutes at $4^{\circ} \mathrm{C}$ or in 750 mL bottles at 4000 g for 30 minutes with slow braking at $4^{\circ} \mathrm{C}$. The cell pellet mass was measured, and all volumes described are for 1 g total mass. The cell pellet was resuspended in 10 mL of 8 mM HEPES-Na, $\mathrm{pH} 7.2,0.8 \mathrm{mM}$ EDTA, 1 mM DTT and PIC ( 1 mM PMSF, $20 \mu \mathrm{M}$ Leupeptin, $3 \mu \mathrm{M}$ Chymostatin, 3 mM Benzamidine, 0.2 mM AEBSF, $10 \mu \mathrm{M} \mathrm{E-65} ,10 \mu \mathrm{M}$ Bestatin, and $10 \mu \mathrm{M}$ Pepstatin). The cells were lysed using a Dounce Homogenizer with 20 strokes from the loose pestle and then from the tight pestle. The cell lysate was mixed with $1 / 7^{\text {th }}$ volume of 2 M sucrose in 8 mM HEPES-Na, $\mathrm{pH} 7.2,0.8 \mathrm{mM}$ EDTA, and 1 mM DTT and incubated on ice for 10 minutes. Large cellular debris was pelleted twice by centrifugation at 1000 g for 10 minutes, $4^{\circ} \mathrm{C}$. The supernatant was ultracentrifuged at $100,000 \mathrm{~g}$ for 1 hour at $4^{\circ} \mathrm{C}$ with slow braking. The membrane pellet was washed in 5 mL of 50 mM Tris- $\mathrm{HCl}, \mathrm{pH} 7.5,0.5 \mathrm{M} \mathrm{NaCl}$, and $10 \%$ glycerol by resuspension using a Dounce Homogenizer-three strokes with the loose pestle and then three strokes with the tight pestle. The resuspended pellet was ultracentrifuged again at $100,000 \mathrm{~g}$ for 1 hour at $4^{\circ} \mathrm{C}$ with slow braking. The membrane pellet was washed in 1 mL of 50 mM Tris- $\mathrm{HCl}, \mathrm{pH} 8.0,0.2 \mathrm{M} \mathrm{NaCl}$, and $10 \%$ glycerol
and resuspended using a Dounce Homogenizer. The resuspended membranes were moved to an ice-cold beaker in a cold room, and enough 50 mM Tris- $\mathrm{HCl}, \mathrm{pH} 8.0,0.2$ $\mathrm{M} \mathrm{NaCl}, 2.5 \mathrm{mM} \mathrm{MgCl} 2,10 \%$ glycerol, and 1 mM ATP was added dropwise to make a final volume of 10 mL . CFTR was solubilized by adding $10 \%$ DDM/ $2 \%$ CHS ( $10 \% \mathrm{n}-$ dodecyl- $\beta$-D-maltoside/ $2 \%$ cholesterol hemisuccinate) to make a final concentration of $0.1 \% \mathrm{DDM} / 0.02 \%$ CHS dropwise over 30 minutes with gentle mixing using a 5 mm stir bar, while still on ice. Solubilized CFTR was separated from insoluble material by ultracentrifugation at $100,000 \mathrm{~g}$ for 30 minutes at $4^{\circ} \mathrm{C}$ with slow braking. Only native, solubilized CFTR was extracted from the supernatant and incubated with equilibrated HisPure ${ }^{\mathrm{TM}} \mathrm{Ni}-\mathrm{NTA}$ (nitrilotriacetic acid) resin $(0.5 \mathrm{~mL})$ (Thermo Fischer Scientific) for 1 hour at $4^{\circ} \mathrm{C}$ with rotating. The resin was packed in a gravity flow column and washed in increasing amounts of imidazole ( $10 \mathrm{mM}, 25 \mathrm{mM}, 75 \mathrm{mM}$ and 125 mM ) in 50 mM Tris- $\mathrm{HCl}, \mathrm{pH} 7.5,0.15 \mathrm{M} \mathrm{NaCl}, 2.5 \mathrm{mM} \mathrm{MgCl} 2$, and $10 \%$ glycerol. CFTR was phosphorylated on the column with $10 \mathrm{U} / \mathrm{mL}$ Promega ${ }^{\circledR}$ PKA in 10 mM ATP in the first wash for 10 minutes at $4^{\circ} \mathrm{C}$. CFTR was eluted from the column using 0.45 M imidazole in 5 x resin volume in 1 mL fractions, and selected elution fractions were pooled and concentrated using Amicon ${ }^{\circledR}$ 100,000 MWCO (molecular weight cut-off) filters at 1000 g for 20 minutes at $4^{\circ} \mathrm{C}$. The concentrated elution fractions were injected onto the ÄKTA ${ }^{\text {TM }}$ Purifier (GE Healthcare Life Sciences) with a Superdex ${ }^{\text {TM }} 200$ 10/300 GL column (GE Healthcare Life Sciences), and CFTR was isolated by size exclusion. CFTR was expected to elute at approximately 11 mL , in agreement with chromatography standards (Figure 3.3), and did successfully.


Figure 3.3: Size Exclusion Chromatography (SEC) Standards on Superdex ${ }^{\text {TM }} 200$ 10/300 GL column. Molecular Weight standards for SEC were loaded onto Superdex ${ }^{\mathrm{TM}}$ $20010 / 300$ GL column and run at a flow rate of $0.25 \mathrm{mg} / \mathrm{mL}$. Based on these standards and the molecular weight of CFTR $(\sim 170 \mathrm{kDa})$, CFTR and is anticipated to elute at 11 mL . CFTR-nanodiscs would be much larger, eluting at $<11 \mathrm{~mL}$ but $>9 \mathrm{~mL}$.

### 3.2.2.5. ANALYSIS OF CFTR PURIFICATION.

Each sample was mixed with 6x Laemmli Sample Buffer (prepared in house) to a final of 1 x and 50 mM DTT and immediately loaded, with a heated ladder, into either a MINIPROTEAN® TGX ${ }^{\text {TM }}$ precast 4-15\% acrylamide: bisacrylamide SDS-PAGE or a handcast $8 \%$ acrylamide: bisacrylamide discontinuous SDS-PAGE. The gel was run at 150 V for 45 minutes or 1 hour, depending on the gel type. Precast SDS-PAGE gel was transferred overnight at $4^{\circ} \mathrm{C}$ at 60 mA onto a nitrocellulose membrane. To improve the

CFTR signal on the nitrocellulose membrane, the membrane was fixed in $50 \%$ methanol at $4^{\circ} \mathrm{C}$ for 30 minutes and dried at $37^{\circ} \mathrm{C}$ for 30 minutes (261). The membrane was blocked in LI-COR Intercept blocking buffer for 1 hour at RT, stained in $1: 1,500$ mouse antiCFTR 596 antibody in Intercept blocking buffer plus $0.1 \%$ Tween ${ }^{\circledR} 20$ (Bio-Rad) overnight at $4^{\circ}$ and in 1:10,000 LI-COR IRDye ${ }^{\circledR} 680$ IR goat anti-mouse antibody in Intercept blocking buffer and $0.1 \%$ Tween ${ }^{\circledR} 20$ for 1 hour at RT with three 15 minute washing steps with PBST after each antibody. The membranes were imaged on a LICOR Odyssey ${ }^{\circledR} 9120$ Infrared Imaging system. For the hand-cast discontinuous SDSPAGE, gels were silver stained in accordance with Pierce Silver Stain manufacturer's protocol. All protein concentrations were determined using the Pierce ${ }^{\mathrm{TM}}$ BCA protein concentration assay.

### 3.2.3. T -Rex ${ }^{\mathrm{TM}} \mathrm{CHO}$ expression system.

### 3.2.3.1. MOLECULAR CLONING.

The insert (construct nucleotide 905 to 5461 ) was cloned from the provided construct of WT-hCFTR in pCDNA3 which contains a glycine linker (3x) C-terminally and Nterminally to the $3 x$ FLAG-tag within the extracellular loop 4 (ECL4), between construct nucleotides 3,598 and 3,712 (CFTR nucleotide 2,694 and 2,695 or CFTR amino acids S898 and R899). The addition of the tag increased the molecular weight by an additional 114 nucleotides ( 38 amino acids), making the final CFTR construct 4,557 nucleotides, or 1518 amino acids, in length. The vector was cloned from the provided T-Rex ${ }^{\text {TM }}$ pcDNA5/TO construct containing WT-hCFTR plus an IRES-eCFP reporter system (construct nucleotide 1 to 1,040 and 5,484 to 11,420). The final construct, McCarty lab construct name pCF595, is 11,534 nucleotides and contains a CMV promoter with

Tetracycline operator, the WT-hCFTR construct with 3xFLAG-tag in ECL4, an IRESeCFP reporter system, a hygromycin resistance gene, the BGH polyA tail, the SV40 promoter and origin, the pUC origin, and an ampicillin resistance gene (Figure 3.4). This construct was transformed into XL 10-Gold ${ }^{\circledR}$ Ultracompetent cells in accordance with the manufacturer's protocol. Several bacterial colonies were selected and grown in 5 mL of LB-Miller (Difco ${ }^{\mathrm{TM}}$ ) broth with $75 \mu \mathrm{~g} / \mathrm{mL}$ ampicillin. Bacteria were pelleted and plasmid was purified using ZymoPURE ${ }^{\text {TM }}$ Miniprep Kit. The purified plasmids were


Figure 3.4: Plasmid map of WT-hCFTR with a 3x-FLAG-tag in ECL4 for stable transfection of T-Rex ${ }^{\text {TM }} \mathbf{C H O}$ cells. WT-hCFTR with a $3 x$ FLAG-tag in extracellular loop 4 (ECL4) cloned from this construct and inserted into pcDNA5/TO containing an internal ribosomal entry site (IRES) and cyan fluorescent protein (CFP) for transfection and protein production reporting in T-Rex ${ }^{\mathrm{TM}} \mathrm{CHO}$ cells.
screened via restriction digestion (Figure 3.5). Briefly, $5 \mu \mathrm{~g}$ of pCF595 was digested with 2 units of PvuI (New England BioLabs ${ }^{\circledR}$ (NEB)) in NEB buffer 3.1 for 1 hour at $37^{\circ} \mathrm{C}$. Restriction digests were analyzed on a $1 \%$ agarose gel stained with $0.5 \mu \mathrm{~g} / \mathrm{mL}$ ethidium bromide ( EtBr ) and imaged on a Bio-Rad ChemiDoc ${ }^{\mathrm{TM}}$ XRS+ system. Results of the restriction digest informed the decision of a single bacterial colony for large-scale amplification and plasmid purification using Maxiprep (ZymoPURE ${ }^{\text {TM }}$ ). The CFTR construct in the final purified plasmid was confirmed by full-length sequencing through GeneWiz ${ }^{\oplus}$.


Figure 3.5: Restriction digestion of pCF595 (McCarty Lab). Results of restriction digestion, using PvuI, of pCF595 purified from three different bacterial colonies (c1, c 2 , c3) on a $1 \%$ agarose gel stained with $0.5 \mu \mathrm{~g} / \mathrm{mL}$ ethidium bromide. Theoretical gel (left) was produced for ease of interpretation of experimental gel (right). Proper insertion and digestion will display two bands, one at just under 10 kbp and one between 3 kbp and 2 kbp . All three colonies (c1, c2, and c3) show expected digestion bands.

### 3.2.3.2. MAINTENANCE OF T-REX ${ }^{\mathrm{TM}}$ CHO CELLS.

T-Rex ${ }^{\text {TM }}$ CHO cells (Thermo Fischer Scientific) were thawed and plated in a T25 flask in Ham's F12, $10 \%$ FBS, 2 mM L-glutamine, $1 \% \mathrm{P} / \mathrm{S}$ and $10 \mu \mathrm{~g} / \mathrm{mL}$ blasticidin (CHO complete media) and allowed to grow to confluency. At confluency, cells were split at a range of 1:5 to 1:20 into a new T25 flask containing CHO complete media. Frozen cells were prepared in $10 \%$ DMSO, $45 \%$ conditioned CHO complete media (media exposed to growing cells), and $45 \%$ new CHO complete media at a density of $3 \times 10^{6}$ cells/ mL and cooled to $-80^{\circ} \mathrm{C}$ and then transferred to liquid nitrogen for long term storage. Stably transfected CHO-CFTR-3xFLAG cells were maintained using the same general methods as T-Rex ${ }^{\text {TM }} \mathrm{CHO}$ cells, except CHO-CFTR-3xFLAG cells, which were grown in CHO complete media plus $0.45 \mathrm{mg} / \mathrm{mL}$ hygromycin (CHO-CFTR complete media).

### 3.2.3.3. GENERATION OF STABLY TRANSFECTED T-REX ${ }^{\text {TM }}$ CHO CFTR

## EXPRESSION SYSTEM.

To confirm that a $3 x$-FLAG-tag in ECL4 would not interfere with CFTR biogenesis, the generated CFTR-pCDNA3 construct was transfected into BHK cells (data not shown). Optimal conditions for transfection of T-Rex ${ }^{\mathrm{TM}} \mathrm{CHO}$ cells with pCF595 were determined to be 1:2 ratio with a 12-hour transfection in a T25 flask. A hygromycin kill curve of TRex ${ }^{\mathrm{TM}} \mathrm{CHO}$ cells showed that after 4 days in $450 \mu \mathrm{~g} / \mathrm{mL}$ hygromycin, approximately $50 \%$ of cells were dead (Figure 3.6). Transfected cells were induced with $1 \mu \mathrm{~g} / \mathrm{mL}$ tetracycline, and flow cytometric parameters were optimized using the Emory Flow Cytometry Core (Figure 3.7). With optimized parameters, induced cells were separated, singly, into two 96-well plates and allowed to grow for 3 days without selection. Once growth was observed for most wells, the selection agent, hygromycin, was added at 450
$\mu \mathrm{g} / \mathrm{mL}$ for 5 days (Figure 3.7). Over several weeks, confluent wells were transferred to a T25 flask and allowed to grow to confluency before the evaluation of protein expression and determination of induction conditions.


Figure 3.6: Microscopy of a T-Rex CHO cell kill curve at $450 \mu \mathrm{~g} / \mathrm{mL}$ hygromycin. The concentration of selection agent that will show some cell death at 4 days and complete cell death after 8 days must be determined before the generation of a stable cell line by selection agent. A range of hygromycin concentrations was tested $(0 \mu \mathrm{~g} / \mathrm{mL}$ to $1.5 \mathrm{mg} / \mathrm{mL}$ ) and a concentration of $450 \mu \mathrm{~g} / \mathrm{mL}$ hygromycin fits this profile. Depicted in this figure is the concentration of $450 \mu \mathrm{~g} / \mathrm{mL}$, which displays cell death on Day 4, but the most on Day 8.




|  | Sample Name |
| :---: | :---: |
| $\square$ | Specimen_001_NoCFP.fcs |
| $\square$ | Specimen_001_CFP.fcs | Colony B2




Figure 3.7: Generation of stably transfected T-Rex ${ }^{\text {TM }} \mathbf{C H O}$ cells with inducible CFTR-3xFLAG. The pcDNA5/TO containing an inducible WT-hCFTR cloned with a 3x-FLAG-tag in ECL4 and a CFP-reporting system was transiently transfected into TRex ${ }^{\mathrm{TM}} \mathrm{CHO}$ cells. (A) T-Rex CHO cells were induced and were single-cell sorted by flow cytometry using the CFP reporting-system. The first plot of untransfected cells and the second of transfected cells show increased cell debris and death reported by the large side-scatter signal (SSC-A). The third plot shows the fluorescent channel separation of transfected cells from untransfected cells. (B) Representative individual colonies several days after sorting shows growth. (C) Images of two colonies that express CFTR, as well as the CFP-reporting system. (D) Western blot shows CFTR expression in colony B2, but not in several other colonies screened (D12 and F4). The first negative control is parental T-Rex ${ }^{\mathrm{TM}} \mathrm{CHO}$ cells, and the second negative control is uninduced B2 colony. Immunoblotting for CFTR: Primary - mouse anti-CFTR 596 antibody, 1:1,500 and Secondary - IRDye ${ }^{\circledR}$ 680RD goat anti-mouse antibody, 1:10,000 (LICOR).

### 3.2.3.4. ANALYSIS OF CFTR EXPRESSION AND PURIFICATION.

Induced stably transfected T-Rex ${ }^{\mathrm{TM}} \mathrm{CHO}$ cells were pelleted at 1000 g for 10 minutes at $4^{\circ} \mathrm{C}$ and resuspended in RIPA buffer with protease 1 x inhibitor cocktail (cOmplete EDTA-free PIC Roche ${ }^{\ominus}$ ). Cells were incubated for 10 minutes at $4^{\circ} \mathrm{C}$ and cellular debris was pelleted at 1000 g for 10 minutes at $4^{\circ} \mathrm{C}$. Total protein was measured using Pierce ${ }^{\mathrm{TM}}$ BCA microplate assay in accordance with the manufacturer's protocol. Equivalent amounts of protein $(50-150 \mu \mathrm{~g})$ were mixed with 1x Laemmli sample buffer (prepared in house) with 50 mM DTT and incubated at $37^{\circ} \mathrm{C}$ for 30 minutes. Samples and ladder, preheated (Precision Plus Protein ${ }^{\mathrm{TM}}$ Dual Color Standards Marker, Bio-Rad), were loaded into Mini-PROTEAN ${ }^{\circledR}$ TGX ${ }^{\mathrm{TM}}$ precast $4-15 \%$ acrylamide: bisacrylamide SDS-PAGE gels. Alternatively, an equivalent volume of each sample was mixed with 6x Laemmli Sample Buffer (prepared in house) to a final concentration of 1 x and 50 mM DTT and immediately loaded, along with a pre-heated ladder, into Mini-PROTEAN ${ }^{\circledR}$ TGX $^{\mathrm{TM}}$ precast $4-15 \%$ acrylamide: bisacrylamide SDS-PAGE or hand-cast $8 \%$ acrylamide: bisacrylamide discontinuous SDS-PAGE gels. The gel was run at 150 V for 45 minutes or 1 hour, respectively. Precast SDS-PAGE was transferred overnight at $4^{\circ} \mathrm{C}$ at 60 mA onto a nitrocellulose membrane. To improve the overall CFTR signal on a nitrocellulose membrane, the membrane was fixed in $50 \%$ methanol at $4^{\circ} \mathrm{C}$ for 30 minutes and dried at $37^{\circ} \mathrm{C}$ for 30 minutes (261). The membrane was blocked in LI-COR Intercept blocking buffer for 1 hour at RT, stained in 1:1,500 mouse anti-CFTR 596 antibody in Intercept blocking buffer plus $0.1 \%$ Tween ${ }^{\circledR} 20$ overnight at $4^{\circ}$ and in 1:10,000 IRDye ${ }^{\circledR}$ 680RD goat anti-mouse antibody in Intercept blocking buffer and $0.1 \%$ Tween ${ }^{\circledR} 20$ for 1 hour at RT with three 15-minute washing steps with PBST after each antibody. The membranes
were imaged on a LI-COR Odyssey ${ }^{\circledR} 9120$ Infrared Imaging system. For the hand-cast discontinuous SDS-PAGE, gels were silver stained in accordance with Pierce Silver Stain manufacturer's protocol. All protein concentrations were determined using the Pierce ${ }^{\mathrm{TM}}$ BCA protein concentration assay.

### 3.2.3.5.CFTR PURIFICATION FROM STABLY TRANSFECTED T-REX ${ }^{\text {TM }}$ CHO CELLS.

 Adherent stably transfected CHO-CFTR-3xFLAG cells were seeded into 1 L suspension culture flask at $0.5 \times 10^{6}$ cells $/ \mathrm{mL}$ in CHO-CFTR complete media plus $0.01 \%$ Pluronic $^{\circledR}$ F68. Cells were grown to $500 \times 10^{6}$ cells $/ \mathrm{mL}$ and induced with $10 \mathrm{ug} / \mathrm{mL}$ tetracycline for 12 hours. CHO cells were pelleted in 50 mL conical tubes at 1000 g for 5 minutes at $4^{\circ} \mathrm{C}$. The cell pellet mass was measured, and all volumes listed in reference to 1 g initial mass. The cell pellet was resuspended in 10 mL of 8 mM HEPES-Na, $\mathrm{pH} 7.2,0.8 \mathrm{mM}$ EDTA, and 1 mM DTT. The cells were lysed using a Dounce Homogenizer with 20 strokes using the loose pestle and then again with the tight pestle. The cell lysate was mixed with $1 / 7^{\text {th }}$ volume of 2 M sucrose in 8 mM HEPES-Na, $\mathrm{pH} 7.2,0.8 \mathrm{mM}$ EDTA and 1 mM DTT and incubated on ice for 10 minutes. Large cellular debris was pelleted by centrifugation twice at 1000 g for 10 minutes at $4^{\circ} \mathrm{C}$. The supernatant was ultracentrifuged at 100,000 g for 1 hour at $4^{\circ} \mathrm{C}$ with slow braking. The membrane pellet was washed in 5 mL of 50 mM Tris- $\mathrm{HCl}, \mathrm{pH} 7.5,0.5 \mathrm{M} \mathrm{NaCl}$, and $10 \%$ glycerol by resuspension using a Dounce Homogenizer (3 strokes with the loose pestle and three strokes with tight). The resuspended pellet was ultracentrifuged again at $100,000 \mathrm{~g}$ for 1 hour at $4^{\circ} \mathrm{C}$ with slow braking. The membrane pellet was washed in 1 mL of 50 mM Tris-HCl, $\mathrm{pH} 8.0,0.2 \mathrm{M}$ NaCl , and $10 \%$ glycerol and resuspended using a Dounce Homogenizer. The resuspended membranes were moved to an ice-cold beaker in the cold room, and enough50 mM Tris- $\mathrm{HCl}, \mathrm{pH} 8.0,0.2 \mathrm{M} \mathrm{NaCl}, 2.5 \mathrm{mM} \mathrm{MgCl} 2,10 \%$ glycerol, and 1 mM ATP was added dropwise to make a final volume of 10 mL per initial cell pellet gram. To solubilize CFTR, $10 \%$ DDM/ $2 \%$ CHS solution was added dropwise over 30 minutes, to make a final concentration of $0.1 \% \mathrm{DDM} / 0.02 \% \mathrm{CHS}$ with gentle mixing using a 5 mm stir bar. Solubilized CFTR was separated from insoluble material by ultracentrifugation at $100,000 \mathrm{~g}$ for 30 minutes at $4^{\circ} \mathrm{C}$ with slow braking. Only native, solubilized CFTR was extracted from the supernatant and incubated with Anti-FLAG ${ }^{\circledR}$ M2 Affinity Gel $(0.01 \mathrm{~mL})$ for 1 hour at $4^{\circ} \mathrm{C}$ with rotating. The resin was packed in a gravity flow column and washed in 50 mM Tris- $\mathrm{HCl}, \mathrm{pH} 7.5,0.15 \mathrm{M} \mathrm{NaCl}, 2.5 \mathrm{mM} \mathrm{MgCl}_{2}$, and $10 \%$ glycerol. CFTR was eluted from the column using 2 column volumes (CV) of $0.1 \mathrm{mg} / \mathrm{mL} 3 \mathrm{x}$ $\mathrm{FLAG}^{\circledR}$ peptide and selected elution fractions were pooled and concentrated using Amicon ${ }^{\circledR} 100,000$ MWCO filters by centrifugation at 1000 g for 20 minutes at $4^{\circ} \mathrm{C}$. Concentrated elution fractions were injected into the ÄKTA ${ }^{\text {TMTM }}$ Purifier and CFTR was isolated by size exclusion on a Superdex ${ }^{\text {TM }} 200$ 10/300 GL column. CFTR was anticipated to elute at about 12 mL , which also agrees with chromatography standards.

### 3.3. RESULTS.

### 3.3.1. Expression of CFTR by baculoviral infection of Sf9 cells.

### 3.3.1.1.PRODUCTION OF MUTANT AND WT-hCFTR CONTAINING BACMID.

Full length sequencing of hCFTR in pFastBacDual construct showed the correct sequence for expression in Sf 9 cells, albeit with a non-standard single codon repeat for the His-tag, instead of alternating codons. Bacmids purified after plasmid transformation into DH10Bac E. coli (Blue/White Screening) (Figure 3.8), and PCR amplification of the gene of interest region showed the correct size of WT and mutant hCFTR sequence
incorporation into Bacmid (Figure 3.9).


Figure 3.8: Images of representative agar plates utilizing Blue/White screening to confirm successful bacmid production after transformation. (A) Initial transformants plated on LB-agar plates with $50 \mu \mathrm{~g} / \mathrm{mL}$ kanamycin, $7 \mu \mathrm{~g} / \mathrm{mL}$ gentamicin, $10 \mu \mathrm{~g} / \mathrm{mL}$ tetracycline, and $100 \mu \mathrm{~g} / \mathrm{mL}$ Bluo-gal and $40 \mu \mathrm{~g} / \mathrm{mL}$ IPTG. Colonies that have been transformed with plasmid and have correctly produced recombinant bacmid are white. (B) Selected colonies from the first plate were restreaked on new LB-agar plates (containing previously mentioned additives) to confirm the homogeneity of each selected colony.


Figure 3.9: PCR amplification of a section of CFTR from purified WT-CFTR and mutant CFTR bacmid. Primers, designed in house, were used to amplify a specific region of CFTR from purified bacmid to confirm CFTR gene insertion into bacmid. The positive control is the WT-CFTR plasmid (pCF340, McCarty Lab) and the negative control is ABCC4 in pGEMHE construct. Both mutant and WT Bacmid show similar size bands to positive control suggesting the proper insertion of CFTR into the bacmid.

### 3.3.1.2. TRANSFECTION OF SF9 CELLS WITH BACMID TO PRODUCE

## BACULOVIRUS.

Positive infection of Sf9 cells was observed via an increase in cell size and the generation of many vesicles within the cells (Figure 3.10). The titer of both p1 and p2 plaquepurified viral colonies was determined via plaque assay and neutral red staining. The levels of CFTR expression per viral colony was determined by Western blot using a CFTR specific antibody; however, a His-tag antibody could not detect the same CFTR expressed protein on a Western Blot (Figure 3.11). The lack of detection of a Hist-tag by Western blot suggested difficulty in the purification of CFTR using His-tag affinity chromatography.


Figure 3.10: Images of transfected Sf 9 cells to confirm viral infection and baculovirus production. (A) Images are comparing Sf9 cells that were transfected with bacmid (WT) to produce baculovirus. After 7 days, transfected Sf9 cells will appear larger in size when compared to untransfected cells and will contain many intracellular vesicles. Infected Sf9 cells will eventually leave a region of no cell growth or a plaque under plaque assay conditions. Individual plaques are collected and can be used to infect more copious amounts of cells. (B) Visualization of Sf9 cells infected with plaquepurified p1 virus for WT-CFTR (Wt 8 and Wt 3 ) or mutant CFTR (mutant 2 or mutant 3, D110C/K892C). Again, cells infected by baculovirus are identified by swelling and the presence of small vacuoles.


Figure 3.11: Western blot analysis to determine high-expressing WT-CFTR p1 viral stock. High-expressing CFTR plaque purified p1 viral stocks, single 1 and single 2 , or mixed plaques, mixed 1 , mixed 2 , mixed 3 , and mixed 4 , were determined by western blot analysis using an anti-CFTR antibody (A), but were not detected by anti-His-tag antibody (B). Positive controls are CFTR expressed in BHK cells (A) and Histagged sphingomyelinase, purified (B). Immunoblotting for CFTR: Primary - mouse anti-CFTR 596 antibody, 1:1,500 and Secondary - goat anti-mouse antibody conjugated to HRP, 1:1,000. Immunoblotting for His-tag: Primary - rabbit anti-His-Tag antibody, 1:1,000 and Secondary - goat anti-rabbit antibody conjugated to HRP, 1:1,000.

### 3.3.1.3. HIS-TAG IS NOT ACCESSIBLE IN CFTR PRODUCED BY SF9 CELLS.

A crude purification testing the accessibility of the His-tag on baculoviral expressed CFTR showed no binding to Roche ${ }^{\oplus}$ cOmplete His-tag resin indicating the inability to purify CFTR expressed in the Baculovirus system via the incorporated His-tag (Figure 3.12).


Figure 3.12: Western blot analysis of crude CFTR purification from infected $\mathbf{S f} 9$ cells expressing WT-hCFTR. Sf9 cells were infected with a high CFTR expressing p1 virus (WT, mixed 3) at an MOI of 20. Infected cells were lysed in Roche A buffer and $0.1 \%$ DDM. CFTR could not be separated from the lysate using His-tag affinity resin, confirming the inaccessibility of His-tag. Immunoblotting for CFTR: Primary - mouse anti-CFTR 596 mouse antibody, 1:1,500 and Secondary - goat anti-mouse antibody conjugated to HRP, 1:1,000.

### 3.3.2. CFTR purification from the BHK-CFTR-10xHis expression system.

### 3.3.2.1. HIS-TAG OF RECOMBINANT CFTR IS ACCESSIBLE IN BHK-CFTR-10xHIS

 CELL LINE.Because CFTR expressed in Sf9 cells showed the inability to use the His-tag for separation of CFTR from endogenous proteins under crude purification conditions, a new cell expression system was tested. A crude purification of CFTR using Roche ${ }^{\odot}$ cOmplete His-Tag Resin from the stably transfected BHK cells showed that the His-tag was accessible (Figure 3.13). The accessibility of the His-tag on CFTR tested and confirmed in this cell expression system means the possibility of purifying CFTR for downstream applications.


Figure 3.13: Western blot analysis of crude CFTR purification from BHK cells stably transfected to express WT-hCFTR. Stably transfected BHK cells expressing WT-hCFTR were lysed in Roche A buffer and $0.1 \%$ DDM. CFTR was separated from the endogenous protein in the lysate using His-tag affinity resin. The ability to separate CFTR confirms the accessibility of the His-tag in this cell expression system. Immunoblotting for CFTR: Primary - mouse anti-CFTR 596 antibody, 1:1,500 and Secondary - goat anti-mouse antibody conjugated to HRP, 1:1,000.

### 3.3.2.2. TRANSITION OF ADHERENT BHK-CFTR-10xHIS CELLS TO

## SUSPENSION CULTURE DOES NOT AFFECT CFTR EXPRESSION.

Suspension cultures allowed for increased yield of cells and thus are optimal for protein purification. The stably transfected BHK-CFTR-10xHis cell line grows adherently, and so to transition these BHK cells to suspension culture, the cells must grow in clumps known as BHK pearls. It is imperative to confirm that the transition of the adherent BHK-CFTR-10xHis cell line to suspension culture does not affect CFTR expression. Western blot analysis of the expression profile of CFTR shows no change between adherent and suspension cultures (Figure 3.14).


Figure 3.14: CFTR expression is unchanged under suspension cell culture conditions. CFTR expressed in the stably transfected BHK cell line. Cells were transitioned to suspension culture, growing as "pearls" for purification. (A) BHK-CFTR-10xHis pearls after a few days under suspension culture conditions. (B) Western blot comparing CFTR expression under suspension and adherent cell culture conditions. Immunoblotting for CFTR: Primary - mouse anti-CFTR 596 antibody, 1:1,500 and Secondary - IRDye ${ }^{\circledR} 680$ RD goat anti-mouse antibody, 1:10,000. Immunoblotting for Actin: Primary - mouse anti-actin antibody, 1:5,000 and Secondary - IRDye ${ }^{\circledR}$ 800CW goat anti-mouse antibody, 1:10,000.

A typical 2.4 L BHK-CFTR-10xHis suspension culture yielded a total of 4-6 g wet cell mass. Cell lysis via Dounce homogenizing showed that >90\% of cells were lysed (Figure 3.15). A dramatic improvement in the CFTR yield was observed in changing the solubilization technique. Previously, CFTR was solubilized by the direct addition of $1 \%$ DDM followed by incubation over 30 minutes; however, by changing to the dropwise addition of $0.1 \%$ DDM/0.02\% CHS over 30 minutes the yield of solubilized CFTR was dramatically improved (Figure 3.16). Overall, CFTR purity was dramatically improved by changing from Roche ${ }^{\circledR}$ cOmplete resin to Pierce HisPure ${ }^{\mathrm{TM}}$ Ni-NTA resin and by increasing the amount of imidazole in the wash steps (Figure 3.17). Phosphorylation of CFTR on the column during the first wash step also improved overall yield. The current


Figure 3.15: Microscopic confirmation of at least $\mathbf{> 9 0 \%}$ lysed cells. BHK cells are lysed using a Dounce Homogenizer. Cells imaged before (A) and after (B) lysis.
purification protocol yielded the mostly CFTR, albeit with one strong copurified protein (Figure 3.18). Even after size exclusion chromatography, this copurified protein remained present (Figure 3.19). The final yield of total protein concentration varies but was typically $50-200 \mu \mathrm{~g}$ with CFTR being approximately $20 \%-50 \%$ analyzed by densitometry.


Figure 3.16: CFTR solubilization is improved by slow-dropwise addition of detergent. The method of solubilization for CFTR not only increases the amount of CFTR from the membrane fraction but also improves the overall yield. Immunoblotting for CFTR: Primary - 596 mouse anti-CFTR antibody, 1:1,500 and Secondary - LI-COR goat anti-mouse antibody, 1:10,000


Figure 3.17: CFTR purity improved by changing the His-tag affinity resin used in purification. Silver stained Mini-PROTEAN ${ }^{\circledR}$ TGX ${ }^{\mathrm{TM}}$ pre-cast $4-15 \%$ acrylamide: bisacrylamide gradient SDS-PAGE gel showing the improvement in purity by changing the resin type. The elution fraction between the Roche ${ }^{\circledR}$ His-resin (A) and the HisPur ${ }^{\mathrm{TM}}$ Ni-NTA resin (B), shows a dramatic improvement to the number of protein bands in the elution lane in the HisPur ${ }^{\mathrm{TM}} \mathrm{Ni}-\mathrm{NTA}$ resin.


Figure 3.18: SDS-PAGE analysis of CFTR purification. Each lane, and lane label, represents the sample at each stage of the purification process described. Silver stain of $8 \%$ acrylamide: bisacrylamide hand-cast SDS-PAGE gel showing the overall purification, especially improving the purity of CFTR. An unknown copurified protein was mostly eluted in wash 3 and wash 4 . However, this protein can still be seen in the final elution lane of CFTR ([Elution]).


Figure 3.19: Size Exclusion Chromatography (SEC) of CFTR purified from BHK cells. (A) Full UV-spectra chromatogram from SEC with a Superdex ${ }^{\text {TM }} 200$ 10/300 GL Column after injection with concentrated CFTR elution fractions. Void volume is marked by a black arrow and the monomeric CFTR peak is marked by a blue arrow. Several peaks present in the SEC chromatogram shows the presence of multiple proteins. (B) Silver stained $8 \%$ acrylamide: bisacrylamide hand-cast SDS-PAGE gel comparing the purity of CFTR from pooled elution fractions [Elution] to purity of CFTR after SEC fraction [SEC].

### 3.3.3. CHO-CFTR-3xFLAG expression system.

### 3.3.3.1. PRODUCTION OF A STABLY TRANSFECTED CHO-CFTR-3xFLAG CELL

LINE.

The confirmed construct bearing CFTR-3xFLAG (ECL4) in pcDNA5/TO was transfected into the T-Rex ${ }^{\mathrm{TM}} \mathrm{CHO}$ cell line with transfection monitored by the IRESCFP system. Individual cells were sorted by flow cytometry allowing for the development of uniform cell colonies during the selection of stably transfected cell lines.

From this method, 6 different cell lines were developed, with varying levels of CFTR expression and two, colony B2 and C1, are shown in Figure 3.7.

Purification of CFTR from the CHO line showed a variety of dramatic improvements, including in purity (Figure 3.20), shortening the overall purification time, and shortening the amount of time CFTR is in detergent, while maintaining yield; however, the yield could be improved by the removal of some of the glycosylation signal.


Figure 3.20: Analysis of purification of CFTR from CHO cells using Size Exclusion Chromatography (SEC) and Western blot. (A) Western blot analysis shows some CFTR binding to and eluting from resin, especially of Band B. Immunoblotting for CFTR: Primary - mouse anti-CFTR antibody 596, 1:1500, and Secondary - IRDye ${ }^{\circledR}$ 680RD goat anti-mouse antibody, 1:10,000. (B) Full UV-spectra chromatogram from SEC with a Superdex ${ }^{\text {TM }} 200$ 10/300 GL column after injection with concentrated CFTR elution fractions. Void volume is marked by a black arrow, monomeric CFTR peak is marked by a blue arrow, and the $\mathrm{FLAG}^{\circledR}$ peptide is marked by a green arrow.

### 3.4. DISCUSSION.

The inaccessibility of the His-tag on CFTR produced in the Sf9 expression system renders the purification of CFTR from this expression system impossible. As to why the His-tag is inaccessible, it could be that CFTR was not fully translated in Sf9 cells. Since the tag is on the C-terminus of CFTR, the last portion of the protein to be translated, if CFTR was trapped in the ribosome towards the end of synthesis, then the tag may not have been synthesized. However, the protein band on the Western Blot is of correct reported size for CFTR expressed in Sf9 cells, and the antigen for the CFTR-specific antibody used is in a region (a.a. 1204 to 1211) in NBD2, the C-terminus-containing domain (132) (CFTR Antibodies Distribution Program, Cystic Fibrosis Foundation). Thus, for this to be the reason, only a small portion of CFTR is not translated. If this is the case, moving the His-tag to another section of the protein could improve the use of this cell expression system for CFTR purification. Modifications and improvements in the purification steps of CFTR from the BHK-CFTR-10xHis cell expression system improved the overall protein yield (from $20 \mu \mathrm{~g}$ to almost $100 \mu \mathrm{~g}$ ) and can be used to inform CFTR purifications from any cell line. One of these modifications was in the detergent solubilization step of CFTR with the use of a cholesterol-derived detergent known as cholesteryl hemisuccinate (CHS). The use of this detergent has become popular in the purification of ABC transporters $(262,263)$, as well as shows improved thermal stability of other tricky membrane proteins (264, 265). It's possible that CHS has improved the thermal stability of CFTR in detergent, and thus provides a higher overall yield than CFTR purified without CHS. This hypothesis can be tested by a series of thermal melting curves of CFTR in different detergents, especially in the presence or
absence of CHS. The copurified proteins persistent with CFTR from the BHK-CFTR10xHis system remained challenging to remove, even after increased resin washing steps and SEC. This is not uncommon for His-tag affinity chromatography systems, whereas FLAG-tag affinity chromatography systems are much improved in purity (266). Thus, to improve CFTR purity, a system using FLAG-tag affinity chromatography was developed. The CHO-CFTR-3xFLAG improved the purity of CFTR as shown by SEC. The use of this system, as opposed to the stably transfected BHK-CFTR-10His system, will allow for the quick, $\sim 3$ weeks, production of multiple individual stable cell lines for a single mutation or multiple mutations. The ability to generate stably transfected cell lines, without the need for viral titering, means disease-relevant or thermostabilizing mutations can be introduced with relative ease. The clear separation of Band B CFTR from Band C CFTR, unlike in the BHK cells, will also provide a way to track the production of Band C or Band B CFTR with the introduction of each new mutation. The ease of transition between adherent and suspension culture conditions means CFTR can be purified from this culture or recorded using a variety of electrophysiological techniques. This allows for more comparative studies of CFTR channel activity both preand post- purification.

## CHAPTER IV

## CFTR RECONSTITUTION AND FUNCTION

### 4.1. INTRODUCTION.

Studying membrane proteins in a lipid bilayer provides a more physiologically relevant environment than detergent; however, the structures that lipid bilayer layers form have always made studying individual membrane proteins difficult. The recent development of individually packaged membrane proteins in lipid bilayers, meaning nanodiscs and native nanodiscs or SMALPS (or their derivatives), has revolutionized the study of membrane proteins (1, 181). In fact, structural and functional studies of even wellcharacterized membrane proteins have shown that the lipid environment of membrane proteins can dramatically alter the characteristics of the membrane protein-decreasing ATPase activity, but improved transport efficiency (267), rearrangement of transmembrane helices (268), identification of critical lipid binding positions (263), etc. These studies are supporting the hypothesis that lipids play a significant role in membrane protein function and structure. Recent structural studies of detergentsolubilized hCFTR have identified multiple electron-dense regions around the TMDspossibly copurified lipids; however, the identities of these lipids are unknown (128). Other functional studies of CFTR demonstrate the importance of certain types of lipids in the ATPase activity of CFTR (133). This chapter will briefly discuss the expression and purification of Membrane Scaffold Protein (MSP) and the formation of nanodiscs using two different types of lipids. Also, this chapter will focus on the function of CFTR in detergent versus lipids, and between different lipid environments by both an ATPase
assay and planar lipid bilayer electrophysiology. Reconstitution of WT-hCFTR in nanodiscs demonstrates different ATPase activities dependent on the environment. The channel function of detergent purified CFTR reconstituted into proteoliposomes demonstrates comparable channel characteristics of CFTR as seen in cellular membranes; however, traditional inhibitors of CFTR show reduced efficacy which might be dependent on the type of lipid environment.

### 4.1.1. Individual Contributions.

I performed the reconstitution of CFTR in nanodiscs and proteoliposomes experiments and the ATPase activity assays. I designed and performed the MSP1D1 expression and purification experiments with the help of Ms. Isabela Povkov (a Georgia Tech undergraduate student). The planar lipid bilayer (PLB) experiments were conducted by Mrs. Kirsten Cottrill (an Emory graduate student). The first model was built with the help of Mr. Gorman Stock (a former student), which was later refined by Dr. Curtis Balusek, both of Dr. JC Gumbart's Lab.

### 4.1.2. Publications resulting from this chapter.

Parts of this chapter will be published as a chapter in Methods in Molecular Biology on the use of BioBeads ${ }^{\mathrm{TM}}$ and the reconstitution of membrane proteins into nanodiscs and proteoliposomes. Other parts of this chapter will be published in downstream manuscripts.

### 4.2. METHODS.

### 4.2.1. Preparation of BioBeads ${ }^{\mathrm{TM}}$.

Bio-Beads ${ }^{\mathrm{TM}}$ (SM-2 Adsorbents cat\#1523920) were weighed ( $\sim 3 \mathrm{~g}$ ) to fill $1 \%$ of the volume of a 50 mL conical tube. The BioBeads ${ }^{\mathrm{TM}}$ were washed by filling the 50 mL
conical tube with $100 \%$ methanol and rotated for at least 24 hours at RT. The beads were allowed to settle, so methanol could be removed and then washed in 50 mL doubledistilled or milli- ${ }^{\circledR}$ (Millipore Sigma) water for 24 hours at RT, again with rotating. Water washes were repeated for at least four days before beads were stored in a new volume of water at $4^{\circ} \mathrm{C}$. The BioBeads ${ }^{\mathrm{TM}}$ were tested for quality by forming empty nanodiscs under the most optimal conditions-with one of the three lipids known to form nanodiscs (See below) readily.

### 4.2.2. MSP1D1 expression and purification.

There are several commercially available MSP plasmids. Using a model of the 9.7 nm diameter nanodisc formed by the MSP1D1 protein and structures of CFTR, it was determined that CFTR could be incorporated into nanodiscs of this diameter with little hindrance. pMSP1D1 construct (plasmid \#20061) was purchased from Addgene, originally gifted by Dr. Stephen Sligar, and shipped in DH5 $\alpha$ E. coli cells (184) (Figure 4.1). The cells were streaked on LB-agar plates with $50 \mu \mathrm{~g} / \mathrm{mL}$ kanamycin and incubated overnight at $37^{\circ} \mathrm{C}$. Several bacterial colonies were selected and grown in 5 mL of LBMiller (Difco ${ }^{\mathrm{TM}}$ ) broth with $50 \mu \mathrm{~g} / \mathrm{mL}$ kanamycin. Bacteria were pelleted and the plasmid was purified using ZymoPURE ${ }^{\text {TM }}$ Miniprep Kit. The purified plasmids were screened via restriction digestions (Figure 4.2). Briefly, $1 \mu \mathrm{~g}$ of pMSP1D1 was digested with 1 U of PvuI (New England BioLabs ${ }^{\circledR}$ (NEB)) in NEB buffer 3.1 for 1 hour at $37^{\circ} \mathrm{C}$ and double digested with 1 U of HindIII and HincII (New England BioLabs ${ }^{\circledR}($ NEB $)$ ) in NEB buffer 2.1 for 1 hour at $37^{\circ} \mathrm{C}$. Restriction digests were analyzed on a $1 \%$ agarose gel stained with $0.5 \mu \mathrm{~g} / \mathrm{mL}$ Ethidium Bromide (EtBr) and imaged on a Bio-Rad ChemiDoc ${ }^{\text {TM }}$ XRS+ system. Results of restriction digest informed the selection of a single bacterial colony


Figure 4.1: pMSP1D1 plasmid map. The pMSP1D1 construct is purified from DH5 $\alpha$ E. coli and transformed into BL21 (DE3) E. coli for production of MSP1D1 protein, which can be purified using His-tag affinity chromatography and used in the formation of nanodiscs.


Figure 4.2: Restriction digestions of pMSP1D1. Results of restriction digestions, using PvuI (A) or HincII and HindIII (B), of pMSP1D1 purified from three different DH5 $\alpha$ E. coli bacterial colonies (c1, c2, c3) on a $1 \%$ agarose gel stained with $0.5 \mu \mathrm{~g} / \mathrm{mL}$ ethidium bromide. Theoretical gel for restriction digestion (left) was produced for ease of interpretation of experimental gel (right). Colony c3 was chosen as the source of pMSP1D1because the results of both restriction digestion experiments displayed anticipated banding patterns.
for large-scale amplification and plasmid purification using Maxiprep (ZymoPURE ${ }^{\text {TM }}$ ). The final purified plasmid was confirmed by sequencing through GeneWiz ${ }^{\circledR}$. For protein expression, pMSP1D1 was transformed into BL21 (DE3) E. coli cells in accordance with manufacturer's protocol. For the transformation of BL21 (DE3) E. coli cells, a range of pMSP1D1 concentrations was used ( 0.5 to 100 ng ) and a large range of volumes of the transformed bacteria (10 to $250 \mu \mathrm{~L}$ ) was plated on LB-agar plates with $50 \mu \mathrm{~g} / \mathrm{mL}$ kanamycin. The best transformant was chosen for MSP1D1 expression and purification. Transformant starter culture, 5 mL of LB-broth and $50 \mu \mathrm{~g} / \mathrm{mL}$ kanamycin, was grown at $37^{\circ} \mathrm{C}$ at 250 RPM for several hours until cloudy. A 1 mL volume of the starter culture was added to 150 mL of LB-broth with $50 \mu \mathrm{~g} / \mathrm{mL}$ kanamycin and was grown at $37^{\circ} \mathrm{C}$ with shaking at 250 RPM until an $\mathrm{OD}_{600}$ of between 0.5 and 0.6 was reached. Protein production was induced with 0.1 mM IPTG overnight at $16^{\circ} \mathrm{C}$ with shaking at 250 RPM . Bacteria was pelleted at 4000 g for 20 minutes at $4^{\circ} \mathrm{C}$ and resuspended in 15 mL phosphate buffered saline (PBS) supplemented with protease inhibitor cocktail (PIC, Cell Signaling $\left.{ }^{\circledR}\right)$. The bacterial cells were lysed over 10 minutes by sonication, by alternating 1 second sonication and 1 second resting period, at a $35 \%$ output and on ice. The insoluble material was separated from the soluble material by centrifugation at $11,000 \mathrm{~g}$ for 20 minutes at $4^{\circ} \mathrm{C}$. The soluble fraction was incubated with $10 \mu \mathrm{~L}$ of equilibrated Roche ${ }^{\circledR}$ cOmplete His-Tag resin per each 1 mL of supernatant overnight at $4^{\circ} \mathrm{C}$. The insoluble fraction was screened for MSP1D1 by resuspension in PBS and loading onto an SDS-PAGE. His-tag resin was packed in a gravity flow column and the flow-through was collected. The packed resin was washed sequentially in 30 resin volumes of Roche A buffer ( $50 \mathrm{mM} \mathrm{NaH}{ }_{2} \mathrm{PO}_{4}, \mathrm{pH} 8.0$ and 0.3 M NaCl$)$ at least five times. MSP1D1 was
eluted in 6 resin volumes of Roche B buffer $\left(50 \mathrm{mM} \mathrm{NaH}_{2} \mathrm{PO}_{4}, \mathrm{pH} 8.0,0.3 \mathrm{M} \mathrm{NaCl}\right.$, and 250 mM imidazole) at least three times, and each elution fraction was collected in an individual tube. MSP1D1 for nanodiscs was further purified by SEC. The third elution fraction was injected into the ÄKTA ${ }^{\text {TM }}$ Purifier with Superdex ${ }^{\text {TM }} 200$ 10/300 GL column (GE Healthcare) using a flow rate of $0.5 \mathrm{~mL} / \mathrm{min}$ in Roche A buffer (Figure 4.3). Protein purity and chromatography efficiency were determined by SDS-PAGE (Figure 4.3).


Figure 4.3: Purification of MSP1D1 from BL21 (DE3) E. coli. (A) Hand-cast 12\% acrylamide: bisacrylamide SDS-PAGE stained with Coomassie to analyze MSP1D1 purity and efficiency of purification. Each lane represents a sample at each stage of the purification process. MSP1D1 begins eluting from the Roche ${ }^{\circledR}$ cOmplete His-Tag resin (resin packed in a gravity-flow column) at elution fraction E1 and continues until fraction E3. The most concentrated MSP1D1 fraction is E3, which was further purified using Size Exclusion Chromatography. (B) Full SEC UV-spectra chromatogram of affinity chromatography purified His-tagged MSP1D1 using a Superdex ${ }^{\text {TM }} 200$ 10/300 GL column. Void volume is marked by a black arrow and MSP peak is marked by an orange arrow.

Briefly, each sample was mixed with 6x Laemmli loading dye (prepared in-house) to a final concentration of 1 x and loaded in proportion into a hand-cast $12 \%$ acrylamide: bisacrylamide SDS-PAGE. The gel was run at 150 V for 1 hour and stained in $0.1 \%$ Coomassie blue (R-250, in $10 \%$ acetic acid, $30 \%$ ethanol, and $60 \%$ water) for 1 hour with rocking and destained overnight in $10 \%$ acetic acid, $30 \%$ ethanol, and $60 \%$ water with rocking (Figure 4.3). Finally, the protein concentration was determined by Pierce ${ }^{\mathrm{TM}} \mathrm{BCA}$ assay and MSP1D1 was stored at $4^{\circ} \mathrm{C}$.

### 4.2.3. Formation of empty nanodisc controls.

To test the BioBeads ${ }^{\mathrm{TM}}$, the following control protocol for forming empty nanodiscs was used. Membrane Scaffold Protein (MSP1D1; $1 \mathrm{mg} / \mathrm{mL}$; purified in-house or Sigma M7074-5MG) was thawed on ice and lipid stock, either DMPC or POPC ( $10 \mathrm{mg} / \mathrm{mL}$ in $3.5 \%$ NaDeoxycholate), was thawed at RT. MSP1D1 stock was gently mixed by flicking, and lipid stock was gently vortexed. MSP1D1 and the lipid of choice, DMPC or POPC, were added to nanodisc buffer ( 20 mM Tris $\mathrm{pH} 7.4,0.1 \mathrm{M} \mathrm{NaCl}, 0.5 \mathrm{mM}$ EDTA, $0.01 \%$ $\mathrm{NaN}_{3}$ ) in a specific ratio of $80: 1$ or 65:1. Approximately 8-15 medium-sized Bio-Beads ${ }^{\mathrm{TM}}$ were added to the MSP-Lipid-Buffer volume and incubated for 2 hours at $24^{\circ} \mathrm{C}$ for DMPC or incubated for 4 hours at $4^{\circ} \mathrm{C}$ for POPC. Empty nanodiscs were screened by SEC on an ÄKTA ${ }^{\text {TM }}$ Purifier using a Superdex ${ }^{\text {TM }} 200$ 10/300 GL column, SDS-PAGE, and by transmission electron microscopy (TEM) (see below). To test for empty nanodisc formation under conditions used for forming CFTR-nanodiscs, the following protocol was used. BioBeads ${ }^{\mathrm{TM}}$ were weighed to a final wet mass of 0.35 g in a 2 mL microcentrifuge tube. MSP1D1 and lipid stocks were thawed as previously described. In a final volume of 1 mL , MSP1D1 was added to 0.7 mL Buffer $\mathrm{G}(50 \mathrm{mM}$ Tris pH 7.5 ,
0.15 M NaCl , and 2.5 mM MgCl 2 ) and POPC was added to 0.3 mL of Buffer H .2 ( 50 mM Tris $\mathrm{pH} 7.5,0.15 \mathrm{M} \mathrm{NaCl}, 2.5 \mathrm{mM} \mathrm{MgCl} 2,10 \%$ glycerol, and $0.1 \% \mathrm{DDM} / 0.02 \%$ cholesteryl hemisuccinate (CHS)) to result in a final MSP1D1:POPC ratio of 1:65. The lipid-containing buffer was mixed with the MSP1D1-containing buffer by pipetting and added to BioBeads ${ }^{\mathrm{TM}}$ in the 2 mL tube. MSP1D1-POPC-BioBead ${ }^{\mathrm{TM}}$ mixture was incubated for 4 hours at $4^{\circ} \mathrm{C}$. Empty nanodiscs were screened by SEC on an ÄKTA ${ }^{\text {TM }}$ Purifier using a Superdex ${ }^{\text {TM }} 20010 / 300$ GL column with a flow rate of $0.5 \mathrm{~mL} / \mathrm{min}$. Empty nanodiscs also were screened using TEM on a JEM-1400 (JEOL) transmission electron microscope at 120 kV . Empty nanodiscs were diluted 10 to 20 -fold before incubating $2 \mu \mathrm{~L}$ on carbon-coated copper grids for 60 seconds at RT. The sample was blotted using Whatman ${ }^{\circledR}$ \#4 filter paper at the side of the grid and then the sample was stained in $2 \mu \mathrm{~L}$ of $2 \%$ uranyl acetate for 30 seconds at RT before being blotted. Empty nanodiscs were screened at a magnification of $15,000 x-20,000 x$, before imaging at a higher magnification (30,000x $-50,000 x)$. Electron micrographs were collected with Gatan Ultrascan ${ }^{\mathrm{TM}}$ CCD camera and viewed with Digital Micrograph ${ }^{\circledR}$ software.

### 4.2.4. Reconstitution of CFTR into nanodiscs.

To form CFTR-containing nanodiscs, total protein concentration was determined by Pierce ${ }^{\mathrm{TM}}$ BCA assay, in accordance with manufacturer's protocol. BioBeads ${ }^{\mathrm{TM}}$ were weighed to a final wet mass of 0.35 g in a 2 mL microcentrifuge tube. MSP1D1 and lipid stocks were thawed as previously described. In a final volume of 1 mL, POPC was added to 0.3 mL of purified CFTR from BHK cells in Buffer H. 2 ( 50 mM Tris $\mathrm{pH} 7.5,0.15 \mathrm{M}$ $\mathrm{NaCl}, 2.5 \mathrm{mM} \mathrm{MgCl} 2,10 \%$ glycerol, and $0.1 \% \mathrm{DDM} / 0.02 \%$ cholesteryl hemisuccinate (CHS)) to make a final CFTR:Lipid ratio of 1:330 for POPC. The CFTR-POPC mixture
was incubated on ice for 10 minutes with gentle flicking. MSP1D1 was added to 0.7 mL Buffer $\mathrm{G}\left(50 \mathrm{mM}\right.$ Tris $\mathrm{pH} 7.5,0.15 \mathrm{M} \mathrm{NaCl}$, and $2.5 \mathrm{mM} \mathrm{MgCl}_{2}$ ) and to the CFTR-POPC mixture to make a final CFTR:MSP1D1:POPC ratio of 1:11:330. The CFTR-POPC containing buffer was mixed with the MSP1D1-containing buffer by pipetting and was added to BioBeads in a 2 mL tube. The CFTR-MSP1D1-POPC-BioBead ${ }^{\text {TM }}$ mixture was incubated at $4^{\circ} \mathrm{C}$ overnight. The formation of CFTR-nanodiscs was screened by FPLC on an ÄKTA ${ }^{\text {TM }}$ Purifier using a Superdex ${ }^{\text {TM }} 200$ 10/300 GL column with a flow rate of $0.25 \mathrm{~mL} / \mathrm{min}$. The SEC fraction containing CFTR-nanodiscs was concentrated using 2 mL Amicon ${ }^{\circledR}$ centrifuge filters with a MWCO of 100,000 by centrifugation at 1000 g for 10 minutes at $4^{\circ} \mathrm{C}$ until the final volume was $1 / 10^{\mathrm{th}}$ of original.

### 4.2.5. ATPase Activity Assay.

CFTR in detergent or in nanodiscs was phosphorylated by the Promega ${ }^{\circledR}$ PKA $\alpha$-catalytic subunit ( $100 \mathrm{U} / \mathrm{mL}$ ) and 10 mM MgATP for 2 hours at $4^{\circ} \mathrm{C}$. PKA, excess MgATP , and ADP were separated from CFTR-containing samples using SEC as previously described (Section 4.2.4). Confirmation of phosphorylation was achieved by SDS-PAGE and Pro$\mathrm{Q}^{\mathrm{TM}}$ Diamond phosphorylation stain (Thermo Fischer Scientific) and phosphorylation immunostaining by Western blot analysis. Sample preparation and gel running conditions were previously described for SDS-PAGE and Western blots (Section 3.2.2.5). SDSPAGE, hand-cast $8 \%$ acrylamide: bisacrylamide hand-cast, was stained with Pro-Q ${ }^{\mathrm{TM}}$ Diamond phosphorylation stain in accordance with the manufacturer's protocol. The SDS-PAGE gel was fixed in $50 \%$ methanol, $10 \%$ acetic acid two times for 30 minutes, and was washed in deionized water three times for 10 minutes. Then, the SDS-PAGE gel was stained in Pro- $\mathrm{Q}^{\mathrm{TM}}$ stain for 90 minutes, destained in $20 \%$ acetonitrile in 50 mM
sodium acetate pH 4 for 30 minutes three times, and washed in water for 5 minutes two times, all at RT. The SDS-PAGE gel was imaged on Bio-Rad ChemiDoc ${ }^{\text {TM }}$ XRS+ system using UV transilluminator settings. Immunoblotting for phosphorylation on Western blots was performed as follows: blots were blocked in LI-COR Intercept ${ }^{\circledR}$ (PBS) buffer for 1 hour at RT before incubation in rabbit anti-phospho-(Ser/Thr) antibody (abcam17464) at 1:1000 in LI-COR Intercept ${ }^{\circledR}$ (PBS) blocking buffer and $0.1 \%$ Tween $^{\circledR}$ 20 at $4^{\circ} \mathrm{C}$ overnight. Blots were washed for 15 minutes at RT in PBST three times before and after incubation in IRDye ${ }^{\circledR} 800 \mathrm{CW}$ goat anti-rabbit antibody, 1:10,000 in LI-COR Intercept blocking buffer and $0.1 \%$ Tween ${ }^{\circledR}$ 20. Blots were imaged on a LI-COR Odyssey ${ }^{\circledR} 9120$ Infrared Imaging system (Figure 4.4). ATPase activity was measured using a Malachite Green ATPase assay kit from Sigma (MAK30) using a range of ATP concentrations from 10 mM to 0.1 pM in $100 \mu \mathrm{~L}$ reactions with CFTR in detergent or nanodiscs, for 1 hour at RT. Michaelis-Menten kinetics were determined by fitting ATPase assay data in IgorPro (Wavemetrics).

### 4.2.6. Reconstitution of CFTR into proteoliposomes.

The concentration of CFTR was determined by the Pierce ${ }^{\mathrm{TM}}$ BCA assay in accordance with the manufacturer's protocol. The dialysis tubing used was Spectra/Por ${ }^{\text {TM }} 2$ (Spectrum ${ }^{\mathrm{TM}}$ ) and had a MWCO of $12-14 \mathrm{kD}$ with a flat width of 25 mm . A 2-inch strip was cut and prepared by washed with deionized water before incubation in Buffer H. 2 (without detergent) for 10 minutes at RT. CFTR and POPC were mixed at 1:100 Protein:POPC molar ratio, placed into dialysis tubing and sealed with dialysis clips. The filled dialysis tubing was placed in 1 L of buffer H. 2 (without detergent) with stirring at $4^{\circ} \mathrm{C}$. Buffer H. 2 without detergent was exchanged every 12 hours for 4 days.


B


Figure 4.4: Phosphorylation of CFTR in detergent or in nanodiscs before ATPase activity measurements. CFTR in detergent and in nanodiscs was phosphorylated by Promega ${ }^{\circledR}$ PKA $\alpha$-catalytic subunit at $100 \mathrm{U} / \mathrm{mL}$ in 1 mM ATP for 2 hours at $4^{\circ} \mathrm{C}$. PKA, excess ATP, and ADP separated from CFTR in detergent or in nanodiscs using SEC. (A) Phosphorylation of CFTR in detergent confirmed by Western blot and hand-cast $8 \%$ acrylamide: bisacrylamide SDS-PAGE gel stained with Pro-Q ${ }^{\mathrm{TM}}$ Diamond phosphorylation stain. Immunoblotting for phosphorylation: Primary - rabbit anti-phospho-(Ser/Thr) antibody (abcam17464), 1:1000 and Secondary - IRDye ${ }^{\circledR}$ 800CW goat anti-rabbit antibody, $1: 10,000$. (B) Phosphorylation of CFTR in nanodiscs confirmed by hand-cast $8 \%$ acrylamide: bisacrylamide SDS-PAGE gel stained with Pro-Q ${ }^{\mathrm{TM}}$ Diamond phosphorylation stain.

Proteoliposomes were extracted from the dialysis bag and stored at $4^{\circ} \mathrm{C}$ until screening by TEM. Proteoliposomes, $2 \mu \mathrm{~L}$, were incubated on a carbon-coated 400 mesh copper grid for 60 seconds at RT, and then were blotted away with Whatman ${ }^{\circledR}$ \#4 filter paper. Samples were stained with $2 \mu \mathrm{~L}$ of $2 \%$ uranyl acetate for 30 seconds at RT before blotting. Proteoliposomes were screened on a JEM-1400 (JEOL) transmission electron microscope at an accelerating voltage of 120 kV .

### 4.2.7. Planar lipid bilayer measurement of CFTR channel activity.

Planar lipid bilayers were formed from a stock lipid solution of 7:3 POPE:POPS. For the preparation of the lipid stock, POPE and POPS in chloroform were mixed at a ratio of 7:3, and a final mass of 0.3 mg and the chloroform solvent was evaporated under a steady stream of nitrogen gas. The lipids were resuspended in $10 \mu \mathrm{~L}$ of decane and painted onto the aperture between the cis and trans wells which were filled with recording buffer (10 mM MOPS, $\mathrm{pH} 6.9,1 \mathrm{mM} \mathrm{MgCI}_{2}, 2 \mathrm{mM} \mathrm{CaCl} 2$, and 50 mM KCl . The formation of a stable bilayer was confirmed by the emergence of a square capacitive current wave under a voltage ramp protocol. Membrane proteins in BHK cellular membranes or CFTR proteoliposomes were phosphorylated by incubation of $20 \mu \mathrm{~L}$ of respective samples with $100 \mathrm{U} / \mathrm{mL}$ PKA (Promega ${ }^{\circledR} \alpha$-subunit) and 5 mM MgATP for 15 minutes at RT. Samples were stored on ice until use. BHK cellular membranes, $7 \mu \mathrm{~L}$ with a protein concentration of about $2 \mathrm{mg} / \mathrm{mL}$, or CFTR proteoliposomes, $7 \mu \mathrm{~L}$ with a protein concentration of about $1 \mathrm{mg} / \mathrm{mL}$, were added to the cis chamber containing recording buffer along with 0.5 mM MgATP and $50 \mathrm{U} / \mathrm{mL}$ PKA (Promega ${ }^{\circledR} \alpha$-subunit). A gradient across the cis and trans chambers was created by adding enough KCl to make a final concentration of 300 mM in the cis chamber while leaving an approximate 50 mM KCl in the trans chamber. Single
channel data were collected at 1 kHz and 0.1 kHz before digital filtering to 50 Hz and were recorded using Clampex $10.2^{\mathrm{TM}}$ (Axon ${ }^{\mathrm{TM}}$ ). Single channel data were processed as follows in Clampfit $10.2^{\mathrm{TM}}$ (Axon ${ }^{\mathrm{TM}}$ ): when necessary, the baseline current was manually adjusted to 0 , single channel properties were evaluated using single channel search, and histograms were generated and fitted.

### 4.2.8. Transmission Electron Microscopy (TEM) of CFTR-Nanodiscs.

A $2 \mu \mathrm{~L}$ volume of CFTR-nanodiscs was incubated on glow-discharged (15 seconds) carbon-coated copper grids for 60 seconds before blotting with Whatman ${ }^{\circledR}$ \#4 filter paper. Samples were stained in $2 \%$ uranyl acetate for 30 seconds at RT and again blotted. Grids were screened at magnifications of $10,000 x-20,000 x$, before imaging at magnifications of $30,000 x-50,000 x$. Micrographs used for image processing were collected at $50,000 x$ with a defocus range of 0.8 to $1.2 \mu \mathrm{~m}$. Electron micrographs were taken on 2 k by 2 k Gatan Ultrascan ${ }^{\mathrm{TM}}$ charge-coupled detector (CCD) camera and were viewed with the Digital Micrograph ${ }^{\circledR}$ software before analysis with EMAN 2.3 (269). Particles were manually picked from 76 initial micrographs with a particle size of 125 and a box size of 192 and extracted. After contrast transfer function (CTF) correction, performed in EMAN by CTFFIND (270), 990 extracted particles were used in initial class averaging studies. Particles of poor quality were manually excluded resulting in about 500 particles for class averaging.

### 4.3. RESULTS

### 4.3.1. The process of cleaning and storing BioBeads ${ }^{\mathrm{TM}}$ affects the efficiency of nanodisc formation.

We found that the storage conditions of BioBeads ${ }^{\text {TM }}$ greatly affected the ability of the resin to form nanodiscs. BioBeads ${ }^{\mathrm{TM}}$ stored on the benchtop at room temperature after a year developed a yellowish huge, clumped, and moisture within the storage bottle. This is different in appearance to new BioBeads ${ }^{\mathrm{TM}}$ (Figure 4.5). However, BioBeads ${ }^{\mathrm{TM}}$ that have been washed well in methanol and stored in water at $4^{\circ} \mathrm{C}$ can be used a year after washing without a significant decrease in their ability to remove detergent. To improve the length of use, BioBeads ${ }^{\mathrm{TM}}$ are either stored washed or stored in the original bottle sealed with parafilm and stored in a desiccator at room temperature.


Figure 4.5: Comparison of old Bio-Beads ${ }^{\text {TM }}$ to new Bio-Beads ${ }^{\text {TM }}$. Old BioBeads ${ }^{\mathrm{TM}}$ (left), appeared to be clumped, yellowish in color, and had moisture along all walls of the bottle. New Bio-Beads ${ }^{\text {TM }}$ moved freely, appeared white, and had no moisture in the bottle.

### 4.3.2. Empty nanodiscs were formed using two different types of lipids.

Nanodiscs devoid of membrane protein, called empty nanodiscs, formed with the MSP1D1 protein of any single lipid composition, DMPC or POPC, were confirmed by SEC and SDS-PAGE. If empty nanodiscs have formed, there will be the emergence of a peak at 12 mL on Superdex ${ }^{\mathrm{TM}} 200$ 10/300 GL column and the presence of MSP in the 12 mL SEC fraction when analyzed on an SDS-PAGE. In Figure 4.6, empty nanodiscs were formed with both DMPC and POPC. Of note, even at the correct MSP:POPC ratio, POPC displayed a rather large void volume. When the void volume fraction was screened by TEM, there were small liposomes (Figure 4.7). Alteration of the MSP:POPC to prevent the presence of these liposomes, prevented the formation of the empty nanodiscs. Screening the 12 mL SEC fraction in which showed the presence of MSP on the SDSPAGE (Figure 4.6) Empty nanodiscs formed under control conditions and empty formed under the same buffer conditions that would be used to form CFTR-nanodiscs were also screened by transmission electron microscopy (Figure 4.8). Empty nanodiscs formed under both conditions, the control buffer conditions and the buffer conditions for forming CFTR-nanodiscs, displayed the anticipated dimensions of 5 nm by 10 nm for empty nanodiscs formed with MSP1D1 when screened via negative stain TEM (Figure 4.8). Under our TEM studies, empty nanodiscs seemed to prefer a side orientation or an orientation in which the nanodiscs are sitting on edge (Figure 4.8).


Figure 4.6: Confirmation of empty nanodiscs formed with two different lipidsDMPC and POPC. Empty nanodiscs formed under control buffer conditions with DMPC (A) and POPC (B) were evaluated using SEC and SDS-PAGE. Full UVspectra chromatogram from SEC with a Superdex ${ }^{\text {TM }} 200$ 10/300 GL Column after injection with empty nanodiscs on the left and key fractions analyzed for the presence of MSP on $12 \%$ acrylamide: bisacrylamide hand-cast SDS-PAGE gel stained by Coomassie on the right.


Figure 4.7: Transmission electron micrograph of liposomes present in the SEC void volume of POPC lipids. Even at the recommended Lipid-to-Protein (LPR) ratio for MSP and POPC, a void volume can be seen and contained what appears to be small liposomes. Samples were stained in $2 \%$ uranyl acetate. The scale bar corresponds to 50 nm .


Figure 4.8: Micrograph of negatively stained ( $2 \%$ uranyl acetate) empty POPC Nanodiscs. The POPC nanodiscs show a preferred "side-view" orientation, providing critical information on successful formation of nanodiscs with a thickness and diameter of approximately 8 nm by 10 nm , respectively. These nanodiscs devoid of CFTR also provide an important control for reconstitution of CFTR into CFTR-nanodisc. The scale bar corresponds to 20 nm .

### 4.3.3. CFTR was incorporated into POPC-based nanodiscs.

Initial attempts to form CFTR-nanodiscs used DMPC as the lipid of choice due to its prevalence in membrane protein reconstitution. However, the formation of nanodiscs was inconsistent. By changing the choice of lipid to POPC, a lipid with a much lower phase transition temperature (DMPC is $24^{\circ} \mathrm{C}$ and POPC is $4^{\circ} \mathrm{C}$ ) improved the consistency of nanodiscs formation. CFTR-nanodiscs were screened first by SEC, as CFTR-nanodiscs being of much larger molecular weight will elute earlier than both monomeric detergentsolubilized CFTR and empty nanodiscs. SEC results of CFTR-nanodiscs revealed the emergence of a peak shoulder at around 10 mL on Superdex ${ }^{\mathrm{TM}} 200$ 10/300 GL column, while monomeric detergent-solubilized CFTR alone eluted at 11 mL and empty nanodiscs eluted at 12 mL (Figure 4.9). Western blot analysis is one confirmation method of nanodiscs formation by the presence of CFTR and MSP in the same SEC elution fraction. We confirmed the presence of CFTR and MSP1D1 in the same SEC elution fraction using Western blot analysis (Figure 4.9). Another confirmation method of nanodisc formation and membrane protein confirmation is TEM. Before screening by TEM, a model of CFTR in a nanodisc was built for comparing particles seen in the proposed CFTR-nanodiscs SEC elution fraction to model. CFTR-nanodiscs are anticipated to be about 10 nm by 15 nm in size and demonstrate "mushroom" like features (described in more detail below). When the SEC elution fraction was screened by TEM, particles identified in micrographs displayed several characteristic features expected for CFTR in a nanodisc. The particles identified were 10 nm by 15 nm in size and demonstrated "mushroom" like features meaning an elongated "stalk" below a "cap", or the nanodisc as well as, several particles appear to have two separate densities at the base
of the "stalk," which could be separated NBDs (Figure 4.10).


Figure 4.9: CFTR-nanodiscs generated from CFTR purified from BHK cells screened SEC and western blot. (A) UV-spectra chromatogram from SEC with a Superdex ${ }^{\text {TM }} 200$ 10/300 GL Column after injection with CFTR-nanodiscs. Arrows indicate the following: void (black), CFTR-nanodiscs (purple), CFTR (blue), and empty nanodiscs (orange). (B) Western blot SEC fractions identifying CFTR ( 168 kDa ) and MSP ( 24 kDa ) in the same fractions. Immunoblotting for CFTR: Primary - mouse antiCFTR 596 antibody, 1:1,500 and Secondary - IRDye ${ }^{\circledR}$ 680RD goat anti-mouse antibody, $1: 10,000$. Immunoblotting for MSP: Primary - rabbit anti-His-tag antibody, 1:1,000 and Secondary IRDye ${ }^{\circledR} 800 C W$ goat anti-rabbit antibody, 1:10,000.

## A



## B <br> ~10 nm



Figure 4.10: CFTR-nanodiscs generated from CFTR purified from BHK cells screened by TEM. (A) Micrograph of negatively stained CFTR-nanodiscs. A few examples of particles are boxed in blue. The micrograph shows a good distribution of particles and no aggregation. Scale bar represents 50 nm . (B) A CFTR-nanodiscs model was built of hCFTR (PDB ID: 5UAK) in a nanodisc (PDB ID: 4V6M), in Visual Molecular Dynamics (VMD). The lipids in front of CFTR in a nanodisc have been cut away to show TMDs.

### 4.3.4. ATPase activity of CFTR is improved in a lipid environment over a detergent

 environment.CFTR phosphorylation, whether in nanodiscs or in detergent, was determined by SDSPAGE and phosphorylation stain (Figure 4.4). CFTR concentration, whether in nanodiscs or detergent, was determined by densitometry (data not shown). The production of inorganic phosphate by the ATPase activity of CFTR was determined by the malachite green assay using an ATP concentration range 10 mM to 0.1 pM and each reaction was run in $100 \mu \mathrm{~L}$ volumes (Figure 4.11). ATPase kinetic data showed that CFTR in a single


Figure 4.11: ATPase activity of CFTR-nanodiscs or CFTR in detergent (DDM) measured by Malachite Green Assay. After phosphorylation (Figure 4.4), PKA, excess ATP, and ADP were separated from phosphorylated CFTR using SEC. Inorganic phosphate produced by ATPase activity of CFTR was measured by Malachite green complexation for the following range of ATP concentrations in $100 \mu \mathrm{~L}$ volumes: 10 mM to 0.1 pM . Michaelis-Menten kinetics were determined in IgorPro and plotted as "fit". CFTR-nanodiscs exhibit a higher ATPase activity than CFTR in detergent. Error bars are SEM for three trials.
lipid, POPC, environment has an increased rate of ATPase activity rate of $63.5 \pm 9.75$ $\mathrm{nmol} / \mathrm{min} / \mu \mathrm{g}$ as compared CFTR in detergent with an ATPase activity rate of $7.9 \pm 0.36$ $\mathrm{nmol} / \mathrm{min} / \mu \mathrm{g}$ (Figure 4.11). There is also an increased Michaelis-Menten constant ( $\mathrm{K}_{\mathrm{M}}$ ) of CFTR in a POPC lipid environment $(0.172 \pm 0.117 \mathrm{mM})$ compared to CFTR in detergent $(0.00692 \pm 0.00176 \mathrm{mM})$. An increased $\mathrm{K}_{\mathrm{M}}$ usually signifies a reduction in the binding affinity of the substrate to the enzyme, but the increased $\mathrm{V}_{\text {max }}$ is proportional to the catalytic rate of the enzyme. These parameters indicate that ATP binding to CFTR in a lipid environment is reduced, but the enzymatic rate of ATP to ADP conversion has increased compared to that of CFTR in detergent.

### 4.3.5. Purified CFTR has the same channel function as CFTR in BHK cellular membranes.

CFTR was reconstituted into POPC-based proteoliposomes, and the membrane formation was screened by TEM (Figure 4.12). CFTR currents were recorded for CFTR from the BHK cellular membrane fraction, and from CFTR that was detergentsolubilized, purified, and reconstituted into proteoliposomes. Once fusion of either cellular membranes of proteoliposomes to planar lipid bilayer was observed, CFTR currents were recorded over several seconds. CFTR currents recorded from BHK cellular membrane fraction showed the expected -0.61 pA current (average for each channel) with an expected open probability, the percentage of time the channel was open divided by the entire recording time $\left(\mathrm{P}_{\mathrm{o}}\right)$, of approximately $37 \%$ under a functional voltage of -90 mV (composed of an applied -45 mV and $\mathrm{aCl}^{-}$gradient voltage of -45 mV ) (Figure 4.13). To confirm this channel is CFTR, the CFTR specific inhibitor INH172 was added to the cis chamber and showed a 94 \% inhibition of the CFTR current from BHK cellular
membranes (Figure 4.13). Currents from CFTR proteoliposomes were measured to be 0.68 pA with an open probability of approximately $32 \%$ (and up to $50 \%$ in some recordings) (Figure 4.14). Again, to confirm this channel was CFTR, the use of INH172 was used. Incubation with CFTR inhibitor only showed approximately $25 \%$ inhibition (Figure 4.14). The difference in efficacy of INH172 on CFTR from proteoliposomes compared to CFTR from the cellular membranes could be due to two possibilities. The first could be the difference of lipid environment between the cellular membrane, which provides a multitude of lipid types. The second is that CFTR in POPC proteoliposomes was detergent-solubilized, purified and reconstituted. The detergent solubilization step could have introduced structural defects to the purified CFTR that are unable to be rescued by the reconstitution lipid environment.


Figure 4.12: Micrograph of negatively stained (2\% uranyl acetate) CFTR proteoliposomes. Purified detergent-solubilized CFTR was reconstituted into POPCbased proteoliposomes and screened by TEM. The scale bar corresponds to 100 nm .

Planar Lipid Bilayer: BHK Membranes Pre-INH172


Planar Lipids Bilayer: BHK Membranes Pre-INH172


| Channel | Current (pA) |
| :--- | :--- |
| Channel 1 | -0.70 |
| Channel 2 | -0.61 |
| Channel 3 | -0.53 |

Planar Lipids Bilayer: BHK Membranes Post-INH172



\section*{| Channel | Current (pA) |
| :--- | :--- |
| Channel 1 | -0.52 |}

$\mathrm{PO}=0.041$

Figure 4.13: Planar lipid bilayer (7:3 POPE: POPS ratio) single-channel recordings of CFTR from BHK cellular membranes. Recordings of CFTR under an applied driving force of -90 mV for $\mathrm{Cl}^{-}$. PKA and ATP ( $50 \mathrm{U} / \mathrm{mL}$ and 0.5 mM final) were added to the cis chamber. Top graphs are of the planar lipid bilayer recordings pre-treatment with INH172 (A) and post-treatment with INH172 (B). A histogram for both preINH172 (A) and post-INH172 (B) treatments were plotted for each state-3 open channels, 2 open channels, 1 open channel or closed channels. Before the addition of INH172 (A), three CFTR channels can be seen in a single recording, each with a current amplitude of $-0.70 \mathrm{pA},-0.61 \mathrm{pA},-0.53 \mathrm{pA}$ and an average amplitude of -0.61 pA . The open probability for CFTR in this recording was $37 \%$, as expected for CFTR. After the addition of INH172 (B), only a single CFTR channel can be seen in a single recording, a current amplitude of -0.52 pA . The open probability for CFTR in this recording was $4 \%$. This represents $94 \%$ inhibition of CFTR by $10 \mu \mathrm{M}$ INH172.


Figure 4.14: Planar lipid bilayer (7:3 POPE:POPS ratio) single-channel recordings of CFTR from proteoliposomes. Recordings of CFTR under an applied driving force of -90 mV for $\mathrm{Cl}^{-}$. PKA and ATP ( $50 \mathrm{U} / \mathrm{mL}$ and 0.5 mM final) were added to the cis chamber. Top graphs are of the planar lipid bilayer recordings pre-treatment with INH172 (A) and post-treatment with INH172 (B). A histogram for both pre-INH172 (A) and post-INH172 (B) treatments were plotted for each state-1 open channel or closed channels. Before the addition of INH172 (A), a single CFTR channel can be seen in a single recording displaying a current amplitude of -0.68 pA with an open probability of $32 \%$ for CFTR in this recording, as expected. After the addition of INH172 (B), a single CFTR channel can be seen in a single recording displaying a current amplitude of -0.72 pA and an open probability of $24 \%$ for CFTR in this recording. This represents $25 \%$ inhibition of CFTR by $10 \mu \mathrm{M}$ INH172.
4.3.6. Preliminary class averages for CFTR-nanodiscs display expected characteristics of successful reconstitution of CFTR into nanodises.

Particles from images of negatively stained samples were manually picked using EMAN 2.3 (269). Initial class averages used standard EMAN 2.3 settings. Several classes contained particles of smaller sizes than expected for CFTR-nanodiscs, with dimensions of $\sim 5 \mathrm{~nm}$ by 10 nm (thickness and diameters, respectively), closely corresponding to nanodiscs devoid of CFTR. Approximately $80 \%$ of particles had dimensions of $\sim 15 \mathrm{~nm}$ by 10 nm corresponding to the expected dimensions of height and diameter for CFTRnanodiscs. Following classification (Figure 4.15) of these larger particles, structural characteristics were observed that are consistent with the expected overall size and a density consistent with NBDs of CFTR protruding from an elongated density expected for a nanodisc in a "side view" orientation. Next, a 3D model will be calculated, which will be followed by cryo-EM studies. The large percentage of successfully reconstituted CFTR into nanodiscs, the homogeneity of the sample, and the good particle distribution without aggregation, are important steps towards cryo-EM as well as biochemical studies of CFTR.


Figure 4.15: Preliminary class averages of CFTR-nanodiscs. Initial 2D class averages were generated with EMAN2.3 from a total of 918 particles.

### 4.4. DISCUSSION.

The nanodisc bilayer system has revolutionized the study of membrane proteins both structurally and functionally by providing a method for the individual packaging of membrane proteins in a variety of lipid environments, and this includes the studies presented here. In these studies, we report the emergence of a large void volume during SEC of empty nanodiscs formed using POPC, but not DMPC. And screening the void volume on a transmission electron microscope identified the presence of small lipid vesicles. The formation of these small vesicles is most likely a result of the lipid tails and can be confirmed by forming nanodiscs with other single lipid combinations with the same lipid tail, but different head groups, and TEM screening of the void volume. As for the studies on CFTR ATPase activity and the contributions of the lipid or detergent environment, these are the first studies in which both the orientation of CFTR is unrestricted to buffer conditions, unlike CFTR in proteoliposomes, and no detergent is present, unlike destabilized proteoliposomes. Other similar studies measuring the ATPase activity of CFTR in different lipids have utilized destabilized proteoliposomes, which still require the presence of detergent (133). The determined Michaelis-Menten constants of the ATPase activity for CFTR in detergent was a lower $K_{M}, 0.00692 \pm$ 0.00176 mM compared to CFTR-nanodiscs $(0.172 \pm 0.117 \mathrm{mM})$, and a lower $\mathrm{V}_{\max }, 7.9$ $\pm 0.36 \mathrm{nmol} / \mathrm{min} / \mu \mathrm{g}$ compared to CFTR-nanodiscs $(63.5 \pm 9.75 \mathrm{nmol} / \mathrm{min} / \mu \mathrm{g})$. These results make for difficult interpretations. First, as $K_{M}$ is an indicator of substrate binding, the lower the $\mathrm{K}_{\mathrm{M}}$ the tighter the substrate binding to the enzyme. This suggests that ATP binds tighter to CFTR in detergent than CFTR in nanodiscs. In addition, the ATPase rate of CFTR is much higher for CFTR in nanodiscs than in detergent but can be expected
for the high $\mathrm{K}_{\mathrm{M}}$ values of CFTR in nanodiscs. The increased ATPase rate for CFTRnanodiscs does show a higher catalytic rate for CFTR, which could signify the ease of CFTR transitioning through the NDB-gating cycle. However, the variation in the values for the ATPase activity for CFTR-nanodiscs leaves room for improvement and optimization. Currently, only a single lipid nanodiscs system for CFTR has been tested. More complex lipid environments in the nanodiscs could result in dramatically improved the kinetic parameters for the ATPase activity of CFTR. The theory that a more complex, physiologically similar lipid environment affects the function of CFTR could be true for the differences in the efficacy of a specific CFTR inhibitor. For the first time, the difference in inhibition of CFTR by a common CFTR inhibitor (INH172) based on the lipid environment, or preparation state using a detergent for solubilization and purification, was observed. And while it is still unknown if the difference in INH172 efficacy is due to the detergent solubilization or the lipid environment, there are experiments that can elucidate the answer. The first of these experiments will be the incorporation of more complex lipids in the formation of the CFTR-proteoliposomes. The efficacy of inhibition by INH172 on CFTR from these complex lipid CFTRproteoliposomes can then be screened again using planar lipid bilayer channel recordings. This work only further suggests the importance of the lipid environment on CFTR function—both as measured by ATPase activity and $\mathrm{Cl}^{-}$channel activity.

## CHAPTER V

## DETERMINATION OF THE LIPID ENVIRONMENT OF CFTR

### 5.1. INTRODUCTION.

Nanodisc technology, including SMALPs, has revealed that altering the lipid environment of a membrane protein can dramatically affect the function of and also the structure of the membrane protein $(267,271)$. Initial mass spectrometry (MS) of detergent-solubilized V-type ATPases revealed the identities of several copurified lipids (272). Native MS has additionally revealed that oligomeric states of membrane proteins are stabilized by the presence of specific endogenous lipids (273). This provides substantial evidence that lipids can play a critical role in the structure of membrane proteins, including CFTR. The most recent detergent-solubilized structures of CFTR reveal areas of electron density that could be several copurified lipids (128, 172); however, the only investigations into the identities of these lipids or the native lipid environment of CFTR are fluorescent microscopy studies. These studies show that CFTR localizes to cholesterol-enriched microdomains in the plasma membrane under certain conditions, but CFTR does exist outside of these microdomains (274). Determining the identity of the copurified lipids of detergent-solubilized CFTR by lipidomics MS can illuminate the importance of lipids structurally. Determination of the annular lipid environment by SMALP-purified CFTR will reveal the types of lipids critical for function and structure. Here, I show the first, critical steps towards SMALPsolubilization of CFTR. In addition, I discuss the lipidomics analysis of detergent-
solubilized CFTR and of SMALP-purified CFTR.

### 5.1.1. Individual contributions.

SMA preparation and purification of SMALP-CFTR was performed by myself. Lipidomics experiments and analyses were performed with the help of Georgia Institute of Technology's Parker Petit Institute for Bioengineering and Bioscience including the Systems Mass Spectrometry Core Facility, which has been supported by the CF@LANTA RDP Center with funding from the Cystic Fibrosis Foundation. Dr. Josh Chandler (Emory University) provided useful critiques and quality control parameters to the lipidomics data processing.

### 5.1.2. Publications resulting from this work.

Parts of this chapter will be published as a manuscript on determining the lipids critical for CFTR function.

### 5.2. METHODS

### 5.2.1. BHK-CFTR-10xHis expression system.

5.2.1.1. CFTR PURIFICATION FROM BHK-CFTR-10xHIS CELL LINE.

See the previous section (3.2.2.4).

### 5.2.1.2. SMALP-SOLUBILIZATION AND PURIFICATION OF CFTR.

BHK cells were pelleted in 50 mL conical tubes at 1000 g for 5 mins at $4^{\circ} \mathrm{C}$, and the cell pellet mass was measured. All volumes listed are for 1 g cell pellet. The cell pellet was resuspended in 10 mL of 8 mM HEPES-Na, pH 7.2, 0.8 mM EDTA and 1 mM DTT. Cells were lysed using a Dounce Homogenizer for 20 strokes with the loose pestle followed by 20 strokes with the tight pestle. The cell lysate was then mixed with $1 / 7^{\text {th }}$ volume of 2 M sucrose in 8 mM HEPES-Na, $\mathrm{pH} 7.2,0.8 \mathrm{mM}$ EDTA and 1 mM DTT and
was incubated on ice for 10 minutes. Large cellular debris was pelleted twice at 1000 g for 10 minutes at $4^{\circ} \mathrm{C}$. The supernatant was ultracentrifuged at $100,000 \mathrm{~g}$ for 1 hour at $4^{\circ} \mathrm{C}$ with slow braking. The pellet was washed in 5 mL of 50 mM Tris- $\mathrm{HCl}, \mathrm{pH} 7.5,0.5$ M NaCl , and $10 \%$ glycerol by resuspension using a Dounce Homogenizer (3 strokes with the loose pestle and three strokes with the tight pestle). The resuspended pellet was ultracentrifuged again at $100,000 \mathrm{~g}$ for 1 hour at $4^{\circ} \mathrm{C}$ with slow braking. The membrane pellet was washed in 1 mL of 50 mM Tris- $\mathrm{HCl}, \mathrm{pH} 8.0$, and 0.2 M NaCl and resuspended using a Dounce Homogenizer. The resuspended membranes were transferred to a 5 mL tube. The total membrane mass (protein and lipid content) was measured by Pierce ${ }^{\mathrm{TM}}$ BCA assay in accordance with the manufacturer's protocol. To solubilize CFTR, enough $10 \%$ SMA was added to achieve a final concentration of $2.5 \%$ per $40 \mathrm{mg} / \mathrm{mL}$ lipid and protein mass. The SMA-membrane sample was incubated for 1 hour at RT. Solubilized CFTR was separated from insoluble material by ultracentrifugation at $100,000 \mathrm{~g}$ for 30 minutes at $4^{\circ} \mathrm{C}$ with slow braking. The supernatant was collected and incubated with equilibrated HisPur ${ }^{\mathrm{TM}} \mathrm{Ni}-\mathrm{NTA}$ resin $(50 \mu \mathrm{~L})$ for 1 hour at $4^{\circ} \mathrm{C}$ with rotation. The resin was packed in a gravity flow column and washed in increasing concentrations of imidazole ( $10 \mathrm{mM}, 25 \mathrm{mM}$, and 75 mM ) in 50 mM Tris- $\mathrm{HCl}, \mathrm{pH} 7.5$, and 0.15 M NaCl ). The purity and confirmation of CFTR was analyzed by SDS-PAGE and Western blot (see section 3.2.2.5).

### 5.2.2. Untargeted Lipidomics.

chloroform:methanol $\left(\mathrm{CHCl}_{3}: \mathrm{MeOH}\right)$ at 3000 RPM for 5 minutes (in pulse mode). An additional 0.4 mL of water was added, and the samples were vortexed again for 1 minute. The samples were centrifuged at $21,100 \mathrm{~g}$ for 5 minutes to enable phase separation. The organic layer was removed, and lipids were dried by vacuum. The lipids were further extracted by incubation of the aqueous layer with $0.4 \mathrm{~mL} \mathrm{2:1} \mathrm{chloroform:methanol} \mathrm{two}$ additional times and dried as previously described. All dried extracts were resuspended in 0.4 mL isopropyl alcohol (IPA) containing deuterated lipids as standards and controls $(3.3 \% \mathrm{v} / \mathrm{v}$ of the sample), sonicated for 5 minutes, vortexed for 5 minutes and centrifuged at $21,100 \mathrm{~g}$ for 5 minutes. The supernatant was extracted and stored at $4^{\circ} \mathrm{C}$ until injection into the mass spectrometer.
5.2.2.2. PREPARATION OF SMALP-CFTR SAMPLES FOR LIPIDOMICS MASS SPECTROMETRY.

The samples were vortexed in 1 mL IPA for 3 minutes at 3000 RPM. The samples were then sonicated in an ice bath for 3 minutes before 3 freeze-thaw cycles with liquid nitrogen. The samples were centrifuged at $21,200 \mathrm{~g}$ for 5 minutes, and the supernatant transferred and stored at $4^{\circ} \mathrm{C}$ until analysis.
5.2.2.3. ULTRA-PERFORMANCE LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (UPLC-MS).

Samples $(2 \mu \mathrm{~L})$ were injected into a Thermo Vanquish Ultra Performance Liquid Chromatography (UPLC) instrument equipped with an Accucore $\mathrm{C}_{30} 2.6 \mu \mathrm{~m}, 150 \times 2.1$ mm column. The mobile phase A ( $40 \%$ water / $60 \%$ acetonitrile, 10 mM ammonium formate, $0.1 \%$ formic acid) was exchanged to mobile phase B ( $90 \%$ IPA/ $10 \%$ acetonitrile, 10 mM ammonium formate, and $0.1 \%$ formic acid) at a flow rate of 0.4
$\mathrm{mL} / \mathrm{minute}$ using the following gradient protocol: 20 to $60 \%$ in 1 minute, $60 \%$ to $70 \%$ in 4 minutes, $70 \%$ to $85 \%$ in 0.5 minute, $85 \%$ to $90 \%$ in 0.5 minutes, $90 \%$ to $100 \%$ in 0.2 minutes, and ran at $100 \%$ B for 2.3 minutes before dropping to $20 \%$ in 0.2 minutes. The flow rate and temperature were held constant at $0.4 \mathrm{~mL} /$ minute and $50^{\circ} \mathrm{C}$. The fractionated sample was then injected into a Thermo Orbitrap ID-X Mass Spectrometer using a scan range $(\mathrm{m} / \mathrm{z})$ of 150-2000 with a resolution of 240,000 FWHM. The datadependent acquisition was collected under the following conditions using high-energy collisional dissociation (HCD) at collision energies of 15,30 , and 45 with an isolation window of $0.8 \mathrm{~m} / \mathrm{z}$ and a resolution of 300,000 .

### 5.2.2.4. DATA ANALYSIS FOR DETERGENT-SOLUBILIZED CFTR SAMPLES.

Lipidomics features were extracted from chromatograms ( $\mathrm{m} / \mathrm{z}$ and retention time) and identified through Compound Discoverer 2.X. using the following databases: mzVault, compound discover, mzCloud, and in-house mass list library (determined by theoretical masses of lipids of interest). For the detergent-solubilized samples, a total of 35,088 features were detected (28,482 features in positive mode and 6,607 features in negative mode). After the removal of background features and any features with a quality control score of greater than $30 \%, 1859$ features were identified in positive mode and 267 features in negative mode. Each biological replicate sample was run in triplicate and normalized peak area was averaged. Features enriched in the three biological replicates as compared to the blank were determined by calculating the $\log _{2}$ (fold change) of the averaged peak areas for the sample blank to the same feature peak area in the sample. Only features enriched by more than one $\log _{2}$ (fold change) in the sample over the blank were analyzed further. The coefficient of variation (CV) was determined for each feature
across the biological triplicates, and features of less than $50 \% \mathrm{CV}$ were analyzed. Confidence in the annotation of the final 383 lipid identities was determined based on the five confidence levels described by Schymanski et al. (275), listed in Table 5.1.

### 5.2.2.5. DATA ANALYSIS FOR SMALP-CFTR SAMPLES.

Lipidomics features were detected in an unbiased fashion, as described above. A total of 13,784 features were found across positive mode and negative mode acquisitions. Features that were enriched in the three biological replicates of the elution fraction containing CFTR were analyzed by $\log _{2}$ (fold change) as compared to the blanks and with a CV score of less than $50 \%$, as reported above. A total of 1,520 lipids were identified at a confidence level of 4 or 5, in accordance with the Schymanski confidence levels (275).

Table 5.1: Schymanski level of confidence for MS identification.

| Level | Confidence | Data Requirement |
| :--- | :--- | :--- |
| Level 1 | Confirmed structure | MS, MS <br> , retention time matching, <br> and reference standard match |
| Level 2 | Probable structure | MS, MS <br> experimental data. |
| Level 3 | Tentative candidate | MS, MS ${ }^{2}$ |
| Level 4 | Unequivocal molecular <br> formula | MS isotope |
| Level 5 | Exact mass | MS |

### 5.3. RESULTS.

### 5.3.1. SMALP-CFTR purification requires further optimization.

Both SDS-PAGE and Western blot analysis showed that CFTR can be solubilized by SMA but requires optimization to improve the solubility of CFTR. Another option to improve the overall solubility might be the use of one of the other available polymers (see section 1.4.3.2). There is CFTR present in the elution fractions, but the overall purification needs to be optimized as the majority of solubilized CFTR remains in the column FT fraction and is a result of weak binding of CFTR-SMALPs to the resin (Figure 5.1). There are many copurified proteins in the elution fraction, indicating the need for optimization (Figure 5.2).



-250 kD-
-250 kD-

Figure 5.1: Western blot analysis of SMALP-CFTR. CFTR is present in the soluble fraction, but the majority of CFTR remains mostly in the insoluble fraction. CFTRSMALPs also were present in the elution fraction, which indicates minimal binding of SMALP-CFTR to the resin. Immunoblotting for CFTR: Primary - mouse anti-CFTR 596 antibody, $1: 1,500$ and Secondary - IRDye ${ }^{\circledR}$ 680RD goat anti-mouse antibody, 1:10,000.


Figure 5.2: SDS-PAGE analysis of CFTR-SMALPs. Hand-cast $8 \%$ acrylamide: bisacrylamide SDS-PAGE gel, silver stained. CFTR-SMALPs can be seen in the elution fraction, along with several other copurified proteins.

### 5.3.2. Lipidomics Mass Spectrometry (MS) of detergent-solubilized CFTR.

Three biological replicates of detergent-solubilized CFTR samples were run in triplicate. A partial match in the mzCloud software, with a confidence level of 3 , was $5 \alpha$-cholesta-8,24-dien-3ß-ol or zymosterol (276) (Table 5.2). Zymosterol is a precursor of cholesterol found in the plasma membrane and is structurally different from both cholesterol and cholesteryl hemisuccinate (a detergent used to solubilize CFTR) (Figure 5.3). This match along with the structural identification of cholesterol, or a cholesterol derivative, from a recently determined hCFTR detergent-solubilized structure, indicates the possible structural importance of cholesterol for CFTR (128). The cluster of other lipid identities falls under level 4 identity confidence. For 382 lipid features, these were
identified by their chemical formulas linked to a possible name through several databases. Of these compounds with possible identities, approximately half (15 of 25) are of odd chain lipids, which only compose a small portion of cellular membranes (277); however, these lipids were enriched in the detergent-solubilized CFTR samples (Table A.1). The other 277 features can only be identified by the chemical formula (Table A.2), and the last 80 features are at a confidence level of 5 and can only be identified by molecular weight (Table A.3).

Table 5.2: Lipidomics results of detergent-solubilized CFTR and analysis results. The abbreviation FC is the fold change, and CV is the coefficient of variation.

| Name | Formula | Molecular <br> Weight | RT <br> $[\mathbf{m i n}]$ | RSD <br> QC <br> Areas <br> $[\%]$ | Average <br> FC | Median <br> FC | CV <br> of <br> FC |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| Zymosterol | $\mathrm{C}_{27} \mathrm{H}_{44} \mathrm{O}$ | 384.33935 | 3.929 |  | 1 | 5.20 | 5.19 |

### 5.3.3. Lipidomics Mass Spectrometry of SMALP-CFTR.

Of the initial 2,097 lipid features identified, 1,520 lipids have linked chemical formulas, making for a level 4 confidence (Table A.4), and 577 lipids received a level 5 confidence with only a molecular weight determined (Table A.5). The copurified proteins taking up the majority of the SMALPs, however, complicates further interpretation of this data.




Figure 5.3: Structures of cholesterol, zymosterol, and cholesteryl hemisuccinate (CHS). There are apparent structural differences between the three sterol derivativescholesterol (A), zymosterol (B), and CHS (C). These structural differences include the double bond between C-5 and C-6 of the B ring in cholesterol and CHS, but only a single bond in zymosterol. Zymosterol has a double bond present between C-8 and C-9 of the B ring, which is a single bond in cholesterol and CHS. Zymosterol also includes another double bond present between $\mathrm{C}-24$ and $\mathrm{C}-25$, which is a single bond in both cholesterol and CHS.

### 5.4. DISCUSSION.

The current work shows a preliminary search into the lipid identities of the annular lipid environment of CFTR; however, this data, in conjunction with the many copurified SMALPs, complicates the confidence for an interpretation. Also, as the majority of CFTR remained in an insoluble fraction, the lipid profile of the SMALP-CFTR in this fraction most likely represents the non-majority of CFTR. Work to investigate the annular lipid profile for the majority of CFTR might require a different strategy, including using one of the aforementioned polymers or the use of MSP (189). As for the copurified lipids in the detergent-solubilized CFTR, a precursor of cholesterol called zymosterol was identified, which is also supported by several other studies. The first and most crucial study shows electron density similar to cholesterol, or a cholesterol derivative, bound to detergent-solubilized hCFTR (128). Studies of other ABC transporters in nanodiscs show that cholesterol clusters around the TMDs (262). Further analysis and replicates with reference standards for the lipidomics data of the detergentsolubilized CFTR samples will increase the number of and confidence in the lipids identified.

## CHAPTER VI

## CONCLUSIONS

### 6.1. INTRODUCTION.

Nanodisc technology has revolutionized membrane protein research, leading to the ability to study individual membrane proteins in different lipid environments and to determine how the changes in these environments lead to functional or structural consequences. In order to utilize this technology in these types of studies, first, the membrane protein of interest must be purified in an active form.

### 6.2. REVIEW OF WORK.

### 6.2.1. CFTR homology models and understanding transition states.

In lieu of CFTR structures, homology models of CFTR were built to investigate the complex transitions of conformations in this protein (130, 160-165). This work compares a homology model by Rahman et al. (130), to two of the recently released structures of CFTR $(126,128)$ and investigates the optimization of a homology model by flexible fitting into electron density maps of the initial structures of CFTR (157). Through this work, the interaction of three residues (E543-K968-K1292) between the ICLs and NBDs that might play a role in translating the consequences of ATP binding at the NBDs to the conformation of the TMDs was experimentally investigated by molecular modeling and electrophysiology. Thus, this initial work shows this interaction is likely, but not without complications. These simulations do not include the R-domain, and thus details of its role or the role phosphorylation of the R-domain on this region was not explored; even though this region of CFTR does play an important role in both (278).

As more structures of CFTR orthologs are released, simulations of these structures can provide valuable insight into the mechanism of CFTR's conformational transitions as well as the interactions of CFTR with the lipid bilayer (167). As all of the structures of CFTR released in the last three years have been of detergent-solubilized CFTR, the use of molecular dynamics (MD) will replace the detergent micelle with the more physiologically relevant lipid bilayer environment; however, as these structures of CFTR were solved in detergent, the likelihood of detergent-induced artifacts is high. The strategies we employed for the improvement of the homology models could be employed to these newly released structures in detergent. The initial electron density maps of CFTR were solved by 2D crystallography, meaning CFTR was in the more physiologically relevant environment of a lipid bilayer, and not detergent. By allowing these new structures to relax within the constraints of a low-resolution map through the use of molecular dynamics flexible fitting (MDFF), it is possible that detergent-induced artifacts could be reduced. In fact, one study has explored this idea through the MDFF of two inward-facing structures of CFTR recently released (223) into these released 2D crystallography maps of CFTR. The states of all of these structures were closed, and so an open, fully conducting pore was not expected, nor was it seen (223). Thus, further MDFF studies of the outward-facing structures of CFTR, which is expected to be open within these maps of CFTR in a lipid bilayer, could reveal key interactions of the CFTR open state. Simulations of these modified structures could unveil the necessary interactions CFTR must undergo to transition from the variety of closed states to a conducting, fully open state for CFTR. The fact that none of the release structures or refined structures has displayed a fully conducting pore of CFTR begs the need for more
structures, especially structures of CFTR in a lipid bilayer.

### 6.2.2. CFTR expression and purification.

The complexity of CFTR biogenesis results in overexpression difficulties and places a high level of importance on the cell type, as is true for many other membrane proteins with complex biogenesis (279). We investigated three different cell types for the overexpression of WT-hCFTR and two different tagging systems for affinity chromatography to improve the yield of WT-hCFTR; importantly, we did not introduce solubilizing or stability mutations into our protein-a common strategy in the field. From these studies, we developed a reproducible protocol for the purification of decently pure and functional WT-hCFTR from BHK cells. Many of the optimizations methods learned in this system can be translated to other CFTR expressing cell lines, especially the optimization in the detergent solubilization step of the CFTR purification. The use of cholesteryl hemisuccinate (CHS) and dodecyl-maltoside (DDM) to solubilize CFTR improved the overall yield of CFTR from each purification. The use of this detergent, CHS, has shown to improve the thermal stability of other membrane proteins in detergent micelles $(264,265)$. Thus, the improvement in yield of monomeric CFTR could be contributed to the improved thermal stability of CFTR in a detergent micelle containing CHS. This hypothesis can be tested by measuring any shifts in the melting temperature of CFTR in different detergent micelles, including micelles containing CHS. And while many attempts to improve the purity of CFTR from a His-tag affinity chromatography system were somewhat successful, the complete removal of several co-purified proteins proved to be problematic. His-tag systems are notorious for having strict buffer incompatibilities, reduced selectivity for proteins from specific expression systems, and
high amounts of leached metal content in purified protein samples (280). The establishment of many other affinity chromatography systems, like the $\mathrm{FLAG}^{\circledR}$-tag system, have dramatically improved the buffer compatibilities, purification of proteins from a variety of expression systems, and the overall purity (281). To improve the overall purity of CFTR, a modified T-Rex ${ }^{\mathrm{TM}}$ CHO cell line utilizing the $\mathrm{FLAG}^{\circledR}$-tag affinity system was developed. This modified T-Rex ${ }^{\mathrm{TM}} \mathrm{CHO}$ system utilized a CFP-reporting system and flow cytometry to single cell sort transfected cells for the generation of a homogeneous population of cells stably expressing CFTR. This newly developed system allows for the generation of new stably transfected cell lines in a few weeks, allowing for the production of many cell lines expressing different mutant versions of CFTR quickly. The purification of CFTR from this system still requires optimization, especially in the yield. One theory to the low yield could be occlusion of the tag by the glycosylation of CFTR, especially as the majority of solubilized CFTR remained in the column FT or unbound to the resin. There are a few options to improve the binding including: increasing the amount of resin, using deglycosylation enzymes to remove some of the glycosylation, or increasing the time of binding. If these strategies do not improve the overall yield, the FLAG-tag can be easily moved and several new cell lines development in a matter of weeks. The improvements and optimization of CFTR expression and purification allow a host of new questions to be answered, especially regarding the preferred lipid environment of CFTR.

### 6.2.3. CFTR reconstitution and functional studies.

The ability to purify CFTR has set the stage for the investigation into the functional consequences of changing the environment of CFTR. Previous work has begun to
investigate the consequences of the choice of detergent on ATPase activity and how the reconstitution of CFTR into the lipids of destabilized proteoliposomes, destabilized by detergent, may not be able to rescue the effects of detergent (133). The work presented here on CFTR-nanodiscs is the first study of CFTR ATPase activity in a lipid bilayer system without restricting access of the NBDs to ATP (i.e., proteoliposomes) or in the presence of detergent (i.e., destabilized proteoliposomes) and compares the activity to that measured in detergent. While only one lipid system (POPC) has been tested, the results clearly demonstrated differences in the ATPase activity of CFTR in POPC than in detergent alone. Additional single-lipid systems and complex lipid systems, including the presence of cholesterol, will provide further information on the importance of lipids and the critical type of lipids for the ATP function of CFTR. Pairing these ATPase functional studies of CFTR with the thermal stability studies of CFTR in different detergent micelles can correlate the changes to thermal stability with the changes to enzyme kinetic parameters measured by the ATPase assay. Not only in detergent micelles but these same studies, the thermal stability assays and kinetic enzyme assays, can be measured for CFTR in nanodiscs of varying lipid composition. While ATPase activity is commonly used to confirm functional purified protein, ATPase activity speaks indirectly to the channel activity of CFTR. Thus, we began investigating the effects of lipids on the channel function of CFTR, although the initial test was to confirm that our purified protein retained channel activity. Here we have shown that reconstitution of the purified protein into single lipid proteoliposomes, POPC only, and then measuring channel function by fusion of proteoliposomes into planar lipid bilayers confirms the channel function of purified CFTR. Not only does our purified protein retain channel activity, but
the effect of a common CFTR inhibitor, INH172, is reduced in studies of purified protein versus protein from cellular membranes. The cause of this difference, whether due to the presence of cholesterol or from detergent-induced structural changes unable to be rescued by lipids, has yet to be determined. Experiments to determine the cause of the reduced inhibition by INH172, first, would be to reconstitute the purified CFTR protein into increasingly more complex proteoliposomes and measure the efficacy of INH172 on CFTR from these different proteoliposomes. The next experiments would be to remove cholesterol from the cellular membrane fractions by treatment with methyl- $\beta$ cyclodextrin (MBCD) and recording the efficacy of INH172. The differences of efficacy for this specific CFTR inhibitor could ring true for other CFTR-specific inhibitors or even some of the approved modulators of CFTR. The mechanism of action for these modulator therapies is still being investigated, but the highly hydrophobic nature of these compounds hints towards possible binding to the TMDs. In fact, two recently released structures of CFTR show two bound modulators, one clinically approved and one not, in the TMDs (170). These results offer support for the importance of the lipid bilayer for the channel function of CFTR.

### 6.2.4. Determination of the lipid environment of CFTR.

The recent advances in the utilization of mass spectrometry to identify lipids and changes to the lipid environments of cells and membrane proteins have been fueled by the increased recognition that lipids are significant contributors to membrane protein structure and cellular function (282). This work utilizes the advancements of mass spectrometry lipidomics to investigate the annular lipid environment of CFTR by SMALPS and identify the copurified lipids of the detergent-solubilized CFTR. The lipids
identified from the SMALP-CFTR samples make for complex interpretations due to the many other copurified proteins in the samples. Currently, only one polymer, the commercially available SMA polymer, has been attempted in the solubilization and formation of native nanodiscs containing CFTR. As more polymers are released with various improvements, different polymers can be attempted, the first being polymers that have been shown to have similar capabilities of detergent (DDM) to solubilize membrane proteins. Moreover, the yield and purity of CFTR containing native nanodiscs can be improved by alteration of the affinity system used for purification. As previously discussed, His-tag affinity chromatography systems are not always the best choice due to buffer incompatibility, low purity, and challenges from a eukaryotic cell expression system. The development of the FLAG-tag affinity chromatography system in the CHO cells could provide increased purity of CFTR containing native nanodiscs. And while the purification of SMALP-CFTR and lipidomics of these SMALPs requires considerable improvement, the lipidomics results from the detergent-solubilized CFTR samples leads to two interesting conclusions. First, a cholesterol precursor known as zymosterol was identified at a level 3 confidence. This result, along with the identification of a cholesterol shaped electron density observed in one of the recently release CFTR structures (128), begs many questions about the importance of cholesterol for CFTR structure and function; this is an area of great interest to the McCarty lab as functional studies to investigate the importance of cholesterol has been much discussed in the previous sections. The second significant result is the large population of odd chain lipids present, which comprise a small portion of the lipid environment of cells. These results were both identified by untargeted lipidomics mass spectrometry with a relatively low confidence
level, level 3 and 4 respectively; however, confidence levels can be improved with the use of more targeted lipidomics studies. The introduction of reference standards with the detergent-solubilized CFTR samples can confirm the lipid identities currently hypothesized, at the lower confidence levels, to be bound to CFTR and will improve the overall confidence in the lipid identities. The lipids identified in the lipidomic results will inform our understanding of the structurally important lipids of CFTR and will inform our functional experiments of CFTR in a lipid environment.

### 6.3. FINAL REMARKS.

This work highlights the importance of the cell expression system and affinity tagging method for producing pure and active WT-hCFTR. This work established the development and use of new techniques for studying the lipid environment of CFTR and the need for more investigations into the functional and structural consequences of the environment of CFTR, as well as the need for more structures of CFTR, especially in a lipid environment. This work also highlights the need for computational simulations, both structures already published and hopefully of more structures within the lipid bilayer, to investigate the complex transitions CFTR undergoes.

## APPENDIX A

Table A.1: Lipidomics results of detergent-solubilized CFTR and analysis results. The abbreviation FC is the fold change. The listed features were identified by the mass list developed by members of systems MS lipidomics core, giving a confidence level of 4.

| Name | Formula | Molecular <br> Weight | RT [min] | RSD <br> QC <br> Areas <br> [\%] | Ave. <br> FC | Med. <br> FC | CV of <br> FC |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| Cer 37:1;1 | C37 H73 N O2 | 563.56446 | 7.962 | 18 | $\mathbf{1 . 6 0}$ | 2.33 | 8.01 |
| Cer 45:0;2 | C45 H91 N O3 | 693.70045 | 9.397 | 16 | $\mathbf{1 . 5 4}$ | 2.43 | 12.65 |
| Cer 45:0;1 | C45 H91 N O2 | 677.70545 | 9.597 | 17 | $\mathbf{2 . 7 3}$ | 3.78 | 16.77 |
| Tridemorph | C19 H39 N O | 297.30327 | 2.766 | 12 | $\mathbf{2 . 3 1}$ | 3.23 | 17.54 |
| LPA 25:0 | C28 H57 O7 P | 536.38452 | 5.895 | 18 | $\mathbf{3 . 4 4}$ | 3.41 | 18.10 |
| N-Acetyl-D- <br> sphingosine | C20 H39 N O3 | 341.29312 | 2.598 | 8 | $\mathbf{1 . 5 9}$ | 2.62 | 18.50 |
| 6-(alpha-D- <br> Glucosaminyl)- <br> 1D-myo-inositol | C12 H23 N O10 | 341.1323 | 1.426 | 16 | $\mathbf{1 . 5 8}$ | 1.52 | 19.50 |
| Cer 39:1;1 | C39 H77 N O2 | 591.59601 | 8.396 | 24 | $\mathbf{1 . 6 5}$ | 2.7 | 19.60 |
| Cer 45:0;1 | C45 H91 N O2 | 677.70545 | 7.785 | 19 | $\mathbf{1 . 9 8}$ | 3.11 | 19.62 |
| AcCa 18:0 | C25 H49 N O4 | 427.3664 | 3.544 | 11 | $\mathbf{2 . 2 2}$ | 2.92 | 21.87 |
| LPG 23:4 | C29 H51 O9 P | 574.32681 | 3.099 | 22 | $\mathbf{2 . 2 6}$ | 2.32 | 21.95 |
| AcCa 24:5 | C31 H51 N O4 | 501.3821 | 3.906 | 9 | $\mathbf{5 . 7 1}$ | 5.76 | 23.47 |
| 6-Hexanoyl-D- <br> erythro- <br> sphingosine | C24 H47 N O3 | 397.35575 | 3.37 | 22 | $\mathbf{1 . 1 5}$ | 1.76 | 23.48 |
| PA 29:2 | C32 H59 O8 P | 602.39638 | 1.876 | 7 | $\mathbf{1 . 1 7}$ | 1.6 | 25.26 |
| Cer 46:0;1 | C46 H93 N O2 | 691.72116 | 6.44 | 26 | $\mathbf{1 . 2 0}$ | 1.62 | 26.10 |
| Cer 47:0;2 | C47 H95 N O3 | 721.73178 | 9.586 | 22 | $\mathbf{1 . 9 0}$ | 2.86 | 26.42 |
| PC 29:1 | C37 H72 N O8 P | 689.50015 | 4.437 | 20 | $\mathbf{2 . 3 8}$ | 1.28 | 29.51 |
| 6-Hexanoyl-D- <br> erythro- <br> sphingosine | C24 H47 N O3 | 397.35574 | 3.493 | 8 | $\mathbf{1 . 5 8}$ | 2.63 | 30.27 |
| Cer 42:1;2 | C42 H83 N O3 | 649.63781 | 8.458 | 24 | $\mathbf{2 . 5 0}$ | 3.62 | 33.32 |
| LPA 23:1 | C26 H51 O7 P | 506.33745 | 3.905 | 10 | $\mathbf{2 . 3 5}$ | 2.38 | 34.53 |
| Cer 31:1;2 | C31 H61 N O3 | 495.46547 | 5.971 | 11 | $\mathbf{1 . 0 1}$ | 1.56 | 37.94 |
| [ST(2:0)]5alpha- <br>  <br> Cholesta-8_24- <br> dien-3beta-ol | C27 H44 O | 384.33935 | 3.929 | 1 | $\mathbf{5 . 2 0}$ | 5.19 | 41.82 |
| Cer 43:1;1 | C43 H85 N O2 | 647.65855 | 9.307 | 29 | $\mathbf{1 . 6 9}$ | 2.92 | 44.59 |
| LPA 17:2 | C20 H37 O7 P | 420.22795 | 1.802 | 15 | $\mathbf{2 . 4 0}$ | 2.43 | 48.14 |
| [ST(3:0)]cholest- <br> 5Z_7Z_24-trien- <br> 3beta-ol | C27 H42 O | 382.32371 | 3.011 | 13 | $\mathbf{3 . 0 3}$ | 3.14 | 49.88 |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |

Table A.2: Lipidomics results of detergent-solubilized CFTR and analysis results. The abbreviation FC is the fold change. As only a formula can be determined for these features, this gives a level 4 confidence.

| Name | Formula | Molecular Weight | $\begin{aligned} & \hline \text { RT } \\ & {[\mathrm{min}]} \end{aligned}$ | RSD QC Areas [\%] | Ave. FC | Med. FC | $\begin{aligned} & \text { CV of } \\ & \text { FC } \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | C57 H119 N9 P2 S2 | 1055.852 | 9.476 | 25 | 3.53 | 3.53 | 0.00 |
|  | C H3 N7 O3 P2 | 222.9776 | 4.523 | 13 | 3.39 | 3.39 | 0.17 |
|  | C26 H47 N8 O P | 518.3617 | 3.009 | 25 | 4.29 | 4.29 | 0.36 |
|  | C23 H45 N O3 | 383.3401 | 3.219 | 7 | 2.46 | 2.45 | 0.47 |
|  | C55 H115 N3 O12 | 1009.847 | 9.187 | 12 | 3.81 | 3.81 | 0.79 |
|  | C67 H107 N5 O | 997.8467 | 9.445 | 21 | 3.39 | 3.4 | 1.06 |
|  | C56 H104 O18 P2 | 1126.669 | 3.897 | 30 | 3.68 | 3.7 | 1.28 |
|  | C32 H44 N10 O17 | 840.2878 | 2.88 | 13 | 2.70 | 2.71 | 1.54 |
|  | C27 H53 N O3 | 439.4027 | 4.643 | 6 | 3.20 | 3.19 | 1.57 |
|  | C50 H112 N7 O4 P3 | 967.7996 | 8.486 | 10 | 4.38 | 4.35 | 1.94 |
|  | C80 H88 S | 1080.659 | 10.005 | 18 | 2.19 | 2.21 | 1.99 |
|  | C44 H99 N9 O9 | 897.7581 | 10.006 | 4 | 2.65 | 2.62 | 2.08 |
|  | C64 H112 N9 O2 P | 1069.868 | 9.475 | 24 | 3.26 | 3.29 | 2.15 |
|  | C49 H109 N9 O10 | 983.8312 | 9.546 | 25 | 3.56 | 3.59 | 2.34 |
|  | C31 H50 O6 | 518.3613 | 2.84 | 24 | 3.92 | 3.94 | 2.73 |
|  | C43 H49 O11 P | 772.3004 | 2.88 | 11 | 2.84 | 2.81 | 3.13 |
|  | C90 H134 N8 O12 | 1519.012 | 3.907 | 10 | 4.60 | 4.68 | 3.20 |
|  | C68 H109 N5 O | 1011.862 | 9.447 | 17 | 3.24 | 3.28 | 3.27 |
|  | C88 H144 N9 O7 P | 1470.093 | 3.904 | 3 | 7.49 | 7.47 | 3.28 |
|  | C22 H41 N 07 | 431.2885 | 1.564 | 16 | 2.82 | 2.85 | 3.29 |
|  | C25 H56 N6 O18 P2 | 790.3112 | 2.835 | 18 | 3.12 | 3.16 | 3.39 |
|  | C18 H26 | 242.2035 | 10.006 | 16 | 2.67 | 2.68 | 3.40 |
|  | C 23 H 26 N 2 | 330.2097 | 1.262 | 4 | 6.73 | 6.79 | 3.44 |
|  | C60 H121 N3 O5 P2 | 1025.878 | 9.448 | 18 | 3.98 | 3.9 | 3.48 |
|  | C63 H99 O4 P3 | 1012.675 | 3.906 | 7 | 3.16 | 3.15 | 3.49 |
|  | C2 H7 O10 P | 221.978 | 4.515 | 11 | 2.95 | 2.97 | 3.63 |
|  | C25 H49 N O3 | 411.3714 | 3.876 | 9 | 3.88 | 3.87 | 3.74 |
|  | C23 H52 N10 O12 P2 | 722.3234 | 2.839 | 21 | 3.43 | 3.38 | 3.75 |
|  | C34 H47 N10 O P3 | 704.3127 | 2.876 | 14 | 2.84 | 2.82 | 3.76 |
|  | C62 H99 N O8 | 985.7375 | 3.906 | 4 | 6.42 | 6.42 | 3.82 |
|  | C30 H57 N O7 | 543.4138 | 1.784 | 25 | 2.07 | 2.1 | 3.83 |
|  | C27 H44 | 368.3445 | 10.008 | 4 | 2.55 | 2.52 | 3.86 |
|  | C27 H42 | 366.3288 | 3.905 | 1 | 5.25 | 5.23 | 3.92 |
|  | C61 H98 O5 | 910.7419 | 9.448 | 7 | 3.00 | 3 | 4.00 |
|  | C54 H103 N7 O P2 | 927.7686 | 9.459 | 7 | 2.98 | 2.94 | 4.01 |


|  | C66 H98 O P2 | 968.711 | 3.903 | 4 | 6.03 | 6.03 | 4.06 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | C29 H55 N O6 | 513.4033 | 1.792 | 23 | 2.53 | 2.51 | 4.22 |
|  | C56 H111 N3 O4 P2 | 951.805 | 9.667 | 22 | 3.96 | 4.05 | 4.23 |
|  | C31 H50 O4 | 486.3712 | 4.516 | 25 | 3.79 | 3.8 | 4.24 |
|  | C49 H110 N7 O4 P3 | 953.7842 | 8.49 | 18 | 4.35 | 4.33 | 4.27 |
|  | C58 H94 O4 | 854.7156 | 10.008 | 5 | 2.82 | 2.75 | 4.30 |
|  | C16 H35 N O | 257.272 | 1.666 | 4 | 3.14 | 3.15 | 4.31 |
|  | C22 H41 N O7 | 431.2885 | 1.687 | 4 | 2.11 | 2.06 | 4.37 |
|  | C22 H51 N10 O2 P | 518.3935 | 1.562 | 5 | 3.57 | 3.55 | 4.37 |
|  | C89 H143 N4 O11 P | 1475.048 | 3.903 | 10 | 5.98 | 5.9 | 4.43 |
|  | C52 H105 N2 O13 P3 | 1058.681 | 3.895 | 28 | 4.58 | 4.53 | 4.48 |
|  | C24 H51 N O8 | 481.3618 | 1.942 | 9 | 4.81 | 4.77 | 4.53 |
|  | C17 H33 N O3 | 299.246 | 2.087 | 8 | 3.25 | 3.21 | 4.60 |
|  | C67 H113 N S2 | 995.8313 | 9.187 | 17 | 3.11 | 3.04 | 4.65 |
|  | C16 H34 O4 S | 322.2177 | 2.152 | 24 | 2.17 | 2.12 | 4.65 |
|  | C5 H12 N9 O P | 245.09 | 1.688 | 15 | 2.88 | 2.94 | 4.66 |
|  | C20 H52 N10 O10 P2 | 654.3357 | 2.838 | 18 | 3.98 | 4.07 | 4.67 |
|  | C27 H42 | 366.3288 | 9.838 | 2 | 3.00 | 2.99 | 4.68 |
|  | C53 H99 N6 P3 S | 944.6852 | 10.01 | 8 | 2.70 | 2.63 | 4.70 |
|  | C40 H60 N2 O3 | 616.4607 | 3.006 | 3 | 8.14 | 8.14 | 4.79 |
|  | C7 H10 N2 O2 | 154.0743 | 0.911 | 19 | 6.18 | 6.19 | 4.85 |
|  | C57 H93 N2 O P | 852.7001 | 9.838 | 7 | 3.03 | 2.98 | 4.86 |
|  | C33 H63 O11 P | 666.4097 | 2.03 | 9 | 4.05 | 3.95 | 4.93 |
|  | C42 H54 O2 S | 622.3834 | 2.046 | 7 | 5.15 | 5.06 | 4.99 |
|  | C14 H31 N O | 229.2407 | 1.25 | 5 | 2.71 | 2.66 | 5.03 |
|  | C32 H60 N9 P | 601.471 | 3.011 | 12 | 3.27 | 3.18 | 5.03 |
|  | C61 H101 O4 P3 | 990.6928 | 3.905 | 7 | 4.73 | 4.7 | 5.11 |
|  | C52 H105 N3 O6 S | 899.7735 | 10.008 | 8 | 2.45 | 2.44 | 5.11 |
|  | C21 H32 | 284.2505 | 3.907 | 7 | 3.64 | 3.54 | 5.15 |
|  | C33 H53 N2 O7 P3 | 682.3051 | 3.31 | 12 | 3.20 | 3.13 | 5.20 |
|  | C29 H51 N2 O11 P S | 666.2947 | 1.951 | 12 | 2.66 | 2.62 | 5.22 |
|  | C39 H86 N9 O8 P | 839.634 | 2.98 | 8 | 3.46 | 3.54 | 5.40 |
|  | C20 H47 N4 O7 P | 486.3173 | 1.944 | 23 | 2.71 | 2.7 | 5.54 |
|  | C3 H8 N2 O7 S2 | 247.9775 | 4.514 | 12 | 5.78 | 5.84 | 5.68 |
|  | C18 H40 N5 O7 P | 469.2654 | 1.486 | 11 | 4.19 | 4.24 | 5.70 |
|  | C63 H103 N 07 | 985.7741 | 9.477 | 10 | 3.04 | 3.05 | 5.94 |
|  | C32 H51 O3 P S | 546.3303 | 3.315 | 10 | 4.27 | 4.31 | 6.14 |
|  | C23 H54 N10 O10 P2 | 692.3512 | 2.415 | 22 | 3.17 | 3.17 | 6.16 |
|  | C41 H52 O3 S | 624.3637 | 2.408 | 24 | 3.44 | 3.43 | 6.26 |
|  | C27 H45 N5 O2 S | 503.3304 | 1.816 | 6 | 5.29 | 5.19 | 6.27 |
|  | C27 H47 N | 385.371 | 10.006 | 17 | 2.87 | 2.77 | 6.34 |


|  | C62 H103 N O4 | 925.7895 | 9.838 | 15 | 3.65 | 3.74 | 6.36 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | C18 H39 N O | 285.3033 | 2.075 | 2 | 2.31 | 2.34 | 6.62 |
|  | C39 H49 O2 P S | 612.3203 | 2.173 | 9 | 1.90 | 1.97 | 6.84 |
|  | C35 H54 O8 | 602.3817 | 2.408 | 27 | 3.77 | 3.71 | 6.91 |
|  | C90 H153 O7 P | 1377.134 | 7.145 | 20 | 5.13 | 5.2 | 6.94 |
|  | C56 H100 N2 O8 P2 | 990.6933 | 3.894 | 26 | 4.99 | 5.05 | 6.98 |
|  | C37 H76 N2 O3 | 596.5861 | 6.372 | 21 | 3.51 | 3.64 | 7.00 |
|  | C27 H42 | 366.3288 | 3.025 | 4 | 2.61 | 2.63 | 7.14 |
|  | C72 H144 N O11 P S | 1262.019 | 10.007 | 3 | 3.74 | 3.83 | 7.29 |
|  | C41 H90 N9 O8 P | 867.6653 | 3.399 | 24 | 3.25 | 3.2 | 7.35 |
|  | C14 H29 N | 211.23 | 1.259 | 14 | 2.65 | 2.6 | 7.37 |
|  | C11 H25 N10 O P | 344.1948 | 0.899 | 16 | 3.80 | 3.81 | 7.38 |
|  | C59 H88 N10 O2 | 968.7116 | 3.896 | 29 | 4.30 | 4.36 | 7.64 |
|  | C60 H99 N O5 | 913.7529 | 9.545 | 10 | 3.05 | 3.12 | 7.64 |
|  | C19 H38 O8 | 394.2566 | 1.566 | 20 | 2.60 | 2.53 | 7.65 |
|  | C16 H29 N O3 | 283.2149 | 1.59 | 19 | 2.76 | 2.84 | 7.67 |
|  | C34 H54 O2 | 494.4131 | 3.868 | 20 | 7.17 | 7.44 | 7.68 |
|  | C22 H48 N9 P | 469.377 | 1.797 | 16 | 2.01 | 2.03 | 7.73 |
|  | C32 H64 N3 O4 P S2 | 649.4076 | 2.019 | 10 | 2.12 | 2.14 | 7.80 |
|  | C35 H53 N4 O2 P S | 624.3643 | 2.404 | 6 | 3.77 | 3.7 | 7.85 |
|  | C27 H45 N6 O8 P | 612.3018 | 2.88 | 21 | 2.16 | 2.13 | 7.95 |
|  | C46 H107 N10 O5 P3 | 972.7618 | 8.931 | 11 | 4.10 | 4.1 | 8.05 |
|  | C21 H44 N10 O6 P2 | 594.2913 | 3.43 | 27 | 3.09 | 3.1 | 8.08 |
|  | C19 H28 | 256.2192 | 10.007 | 3 | 3.45 | 3.33 | 8.12 |
|  | C64 H105 N5 | 943.8361 | 10.112 | 4 | 4.37 | 4.5 | 8.17 |
|  | C34 H57 N O5 | 559.424 | 4.249 | 8 | 3.17 | 3.31 | 8.20 |
|  | C35 H53 N O2 | 519.408 | 5.8 | 15 | 3.35 | 3.31 | 8.27 |
|  | C35 H57 N O8 | 619.4089 | 2.405 | 3 | 3.21 | 3.18 | 8.30 |
|  | C35 H70 N5 O7 P | 703.503 | 2.403 | 8 | 3.12 | 3.03 | 8.38 |
|  | C35 H51 O5 P S | 614.3177 | 3.314 | 11 | 3.74 | 3.79 | 8.50 |
|  | C61 H99 N O5 | 925.753 | 9.192 | 15 | 3.76 | 3.83 | 8.53 |
|  | C25 H54 N5 O6 P | 551.3826 | 2.694 | 9 | 3.39 | 3.27 | 8.53 |
|  | C17 H44 N9 O2 P | 437.3355 | 1.949 | 10 | 3.47 | 3.48 | 8.66 |
|  | C31 H53 N O5 | 519.3927 | 3.415 | 6 | 3.01 | 3.12 | 8.73 |
|  | C17 H41 N7 O S | 391.3088 | 2.486 | 14 | 3.18 | 3.22 | 8.87 |
|  | C63 H105 N O4 | 939.805 | 9.838 | 10 | 3.33 | 3.49 | 9.20 |
|  | C74 H155 N9 O9 S2 | 1378.139 | 7.144 | 18 | 4.35 | 4.45 | 9.28 |
|  | C37 H82 N9 O7 P | 795.6079 | 3.044 | 6 | 2.35 | 2.44 | 9.33 |
|  | C38 H47 O2 P S | 598.3047 | 2.172 | 14 | 2.77 | 2.63 | 9.39 |
|  | C13 H28 O4 S | 280.1712 | 1.552 | 14 | 2.94 | 2.95 | 9.54 |
|  | C28 H70 N9 O7 P3 | 737.4602 | 2.023 | 23 | 2.43 | 2.52 | 9.55 |


|  | C4 H7 O5 P3 | 227.9507 | 4.497 | 18 | 2.03 | 1.98 | 9.62 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | C61 H93 N6 O2 P3 | 1034.657 | 3.925 | 15 | 2.77 | 2.82 | 9.69 |
|  | C27 H66 Cl N9 O5 P2 | 693.4339 | 2.022 | 17 | 2.49 | 2.55 | 9.70 |
|  | C57 H108 N5 P3 S | 987.7534 | 8.061 | 27 | 3.41 | 3.54 | 9.71 |
|  | C58 H92 O5 | 868.6952 | 8.708 | 19 | 3.52 | 3.66 | 9.72 |
|  | C27 H42 | 366.3288 | 2.87 | 5 | 3.56 | 3.66 | 9.75 |
|  | C62 H101 N O7 | 971.7583 | 8.94 | 13 | 4.22 | 4.3 | 9.76 |
|  | C30 H62 N5 P3 S | 617.3931 | 2.352 | 11 | 2.69 | 2.78 | 9.78 |
|  | C31 H48 O5 | 500.3505 | 3.012 | 4 | 2.92 | 3.03 | 9.85 |
|  | C25 H61 N7 P2 S | 553.4193 | 2.233 | 8 | 2.99 | 3.05 | 9.85 |
|  | C27 H53 N5 O7 S | 591.3657 | 1.831 | 14 | 1.56 | 1.52 | 10.16 |
|  | C65 H103 N5 | 953.8205 | 9.838 | 10 | 3.13 | 3.31 | 10.52 |
|  | C38 H49 O4 P | 600.3383 | 4.839 | 7 | 3.11 | 3.19 | 10.53 |
|  | C33 H63 N O8 | 601.4558 | 1.774 | 13 | 2.41 | 2.48 | 10.63 |
|  | C32 H47 O2 P S | 526.3038 | 3.432 | 19 | 2.56 | 2.59 | 10.79 |
|  | C35 H59 N5 S | 581.4506 | 2.48 | 6 | 3.13 | 3.32 | 10.88 |
|  | C26 H48 N9 P | 517.377 | 3.01 | 4 | 2.86 | 2.97 | 10.96 |
|  | C24 H42 O6 | 426.2984 | 1.79 | 10 | 2.26 | 2.36 | 11.02 |
|  | C29 H57 N3 O13 | 655.3878 | 2.172 | 17 | 2.44 | 2.34 | 11.06 |
|  | C64 H111 N O4 | 957.8519 | 10.112 | 2 | 3.82 | 4.06 | 11.18 |
|  | C28 H47 N5 O3 | 501.3669 | 1.784 | 25 | 1.84 | 1.91 | 11.29 |
|  | C26 H56 N9 O2 P | 557.4295 | 1.785 | 15 | 2.12 | 2.13 | 11.31 |
|  | C41 H55 N O S2 | 641.3722 | 2.174 | 2 | 2.50 | 2.4 | 11.34 |
|  | C42 H99 N10 O11 P3 | 1012.672 | 10.01 | 9 | 2.23 | 2.33 | 11.44 |
|  | C18 H28 N6 O2 | 360.2278 | 1.801 | 8 | 2.00 | 2.11 | 11.45 |
|  | C26 H45 N4 O P S | 492.3065 | 1.785 | 23 | 2.71 | 2.85 | 11.60 |
|  | C25 H54 N5 P S2 | 519.3563 | 2.505 | 23 | 3.76 | 3.72 | 11.60 |
|  | C21 H38 N2 O | 334.2986 | 3.171 | 7 | 4.31 | 4.03 | 11.86 |
|  | C62 H105 N O4 | 927.8052 | 10.008 | 6 | 2.65 | 2.74 | 12.02 |
|  | C26 H46 O7 | 470.3246 | 1.784 | 6 | 2.18 | 2.28 | 12.14 |
|  | C29 H49 N5 O | 483.3927 | 1.796 | 8 | 2.13 | 2.21 | 12.18 |
|  | C26 H49 N O7 | 487.3512 | 1.783 | 4 | 2.14 | 2.24 | 12.21 |
|  | C19 H52 N9 O3 P3 | 547.3394 | 1.816 | 14 | 1.58 | 1.65 | 12.32 |
|  | C28 H53 N O8 | 531.3774 | 1.775 | 3 | 2.09 | 2.17 | 12.41 |
|  | C28 H50 O8 | 514.3509 | 1.775 | 4 | 2.11 | 2.19 | 12.58 |
|  | C32 H67 N O10 | 625.4769 | 2.462 | 8 | 2.65 | 2.61 | 12.70 |
|  | C38 H35 N10 P | 662.2789 | 3.426 | 21 | 2.91 | 3.01 | 12.72 |
|  | C75 H155 N9 O14 | 1406.169 | 7.317 | 23 | 3.74 | 3.85 | 12.80 |
|  | C32 H47 N9 O3 | 605.3814 | 2.013 | 13 | 2.47 | 2.55 | 13.10 |
|  | C37 H59 N O3 | 565.4498 | 4.394 | 11 | 5.86 | 6.01 | 13.14 |
|  | C36 H54 O2 P2 | 580.3589 | 1.765 | 12 | 2.40 | 2.42 | 13.17 |


|  | C36 H52 N P S | 561.355 | 2.004 | 26 | 2.46 | 2.54 | 14.35 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | C24 H49 N4 O7 P | 536.3328 | 1.776 | 15 | 2.59 | 2.65 | 14.43 |
|  | C56 H99 N4 O8 P | 986.722 | 7.164 | 24 | 4.31 | 4.2 | 14.44 |
|  | C16 H22 | 214.1722 | 10.008 | 17 | 2.50 | 2.63 | 14.52 |
|  | C22 H38 O5 | 382.2721 | 1.795 | 7 | 2.21 | 2.33 | 14.64 |
|  | C63 H107 N O4 | 941.8205 | 10.007 | 5 | 2.57 | 2.71 | 14.65 |
|  | C34 H56 N10 S2 | 668.4115 | 1.75 | 12 | 2.15 | 2.17 | 14.70 |
|  | C23 H50 N9 O P | 499.3876 | 1.792 | 17 | 2.17 | 2.17 | 14.75 |
|  | C 23 H 44 O 2 | 352.3343 | 2.372 | 13 | 1.32 | 1.3 | 14.85 |
|  | C33 H51 N4 P3 | 596.3331 | 1.762 | 8 | 2.52 | 2.53 | 15.28 |
|  | C90 H154 N4 O13 S | 1531.122 | 4.626 | 8 | 7.13 | 7.25 | 15.30 |
|  | C63 H103 N O4 | 937.7895 | 9.669 | 15 | 3.16 | 3.2 | 15.41 |
|  | C 27 H 49 Cl 09 | 552.3068 | 1.772 | 9 | 2.38 | 2.49 | 15.44 |
|  | C51 H100 N3 O4 P3 | 911.6917 | 3.322 | 10 | 3.73 | 4.03 | 15.51 |
|  | C65 H111 N S2 | 969.8156 | 8.705 | 12 | 3.72 | 3.89 | 15.53 |
|  | C23 H56 N9 O5 P | 569.4145 | 1.921 | 7 | 4.11 | 4.09 | 15.58 |
|  | C31 H60 N3 P S | 537.4244 | 2.501 | 22 | 2.54 | 2.57 | 15.58 |
|  | C31 H69 N3 O3 P2 | 593.4812 | 4.394 | 24 | 3.59 | 3.88 | 15.64 |
|  | C28 H55 N5 O2 | 493.4346 | 2.168 | 22 | 2.51 | 2.56 | 15.67 |
|  | C64 H109 N O4 | 955.8358 | 10.007 | 6 | 2.48 | 2.62 | 15.83 |
|  | C15 H42 N9 P | 379.33 | 2.181 | 29 | 1.58 | 1.52 | 15.86 |
|  | C27 H54 N6 S | 494.4131 | 2.994 | 18 | 3.13 | 3.24 | 15.98 |
|  | C63 H105 N 05 | 955.8 | 8.704 | 17 | 3.93 | 3.99 | 16.23 |
|  | C26 H57 N10 O7 P S | 684.3856 | 1.749 | 17 | 2.34 | 2.32 | 16.45 |
|  | C28 H61 N10 O9 P | 712.4378 | 1.742 | 12 | 2.22 | 2.32 | 16.52 |
|  | C18 H32 N4 O2 | 336.2526 | 0.918 | 29 | 3.29 | 3.22 | 16.67 |
|  | C22 H40 N4 O2 | 392.3153 | 0.917 | 4 | 3.39 | 3.41 | 16.69 |
|  | C90 H153 N6 O10 P | 1509.14 | 4.622 | 7 | 6.06 | 6.21 | 16.98 |
|  | C31 H58 N6 O P2 S | 624.3852 | 1.758 | 8 | 2.27 | 2.38 | 17.20 |
|  | C18 H34 N4 O2 S | 370.2411 | 1.556 | 8 | 3.98 | 3.68 | 17.25 |
|  | C19 H34 N2 O | 306.2672 | 2.711 | 7 | 2.97 | 2.73 | 17.44 |
|  | C21 H38 N4 O2 | 378.2996 | 0.917 | 3 | 3.35 | 3.36 | 17.89 |
|  | C7 H8 N2 O4 | 184.0484 | 0.866 | 13 | 5.24 | 5.36 | 18.05 |
|  | C15 H18 O5 | 278.1157 | 0.892 | 5 | 3.77 | 3.86 | 18.71 |
|  | C16 H40 N10 O6 P2 S | 562.2335 | 1.962 | 14 | 3.04 | 3.15 | 18.72 |
|  | C29 H68 N9 O7 P | 685.4981 | 2.197 | 8 | 3.47 | 3.09 | 18.97 |
|  | C27 H65 N7 O P2 S | 597.4456 | 2.22 | 15 | 2.62 | 2.35 | 18.99 |
|  | C27 H51 N5 O4 | 509.393 | 2.243 | 26 | 2.18 | 2.38 | 19.03 |
|  | C30 H65 N10 O10 P | 756.4641 | 1.734 | 14 | 2.05 | 1.9 | 19.36 |
|  | C37 H39 O P3 | 592.2231 | 2.172 | 6 | 2.12 | 2.05 | 19.78 |
|  | C38 H86 N9 O3 P S2 | 811.6028 | 2.682 | 11 | 2.96 | 3.26 | 19.86 |


|  | C23 H42 N2 | 346.3349 | 2.202 | 12 | 3.54 | 3.61 | 19.87 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | C16 H25 N3 O2 | 291.1948 | 0.918 | 4 | 2.28 | 2.21 | 19.93 |
|  | C25 H60 N8 O16 | 728.4119 | 1.74 | 5 | 2.34 | 2.35 | 20.06 |
|  | C32 H57 O4 P | 536.3981 | 4.622 | 15 | 4.15 | 4.45 | 20.35 |
|  | C39 H86 N9 O9 P | 855.6289 | 2.644 | 9 | 3.34 | 3.64 | 20.49 |
|  | C35 H79 N7 O2 P2 S | 723.5502 | 2.775 | 7 | 1.95 | 2.05 | 20.67 |
|  | C35 H41 N O6 | 571.2939 | 2.173 | 14 | 2.41 | 2.33 | 20.73 |
|  | C16 H32 N6 O2 | 340.2591 | 2.19 | 22 | 1.60 | 1.66 | 20.88 |
|  | C45 H79 N5 O P2 | 767.5764 | 2.725 | 19 | 2.91 | 3.07 | 21.38 |
|  | C31 H53 N O7 | 551.3826 | 2.419 | 21 | 3.09 | 2.85 | 21.47 |
|  | C37 H65 N5 P2 | 641.472 | 2.205 | 16 | 3.04 | 2.83 | 21.57 |
|  | C20 H51 N9 O12 S | 641.3359 | 1.896 | 5 | 4.04 | 4.53 | 21.60 |
|  | C20 H52 N9 P | 449.4083 | 2.182 | 9 | 1.54 | 1.36 | 21.95 |
|  | C63 H107 O8 P | 1022.769 | 4.617 | 11 | 4.82 | 4.94 | 22.02 |
|  | C 22 H 45 N 03 | 371.3401 | 2.712 | 22 | 1.45 | 1.3 | 22.23 |
|  | C31 H72 N9 O7 P | 713.5296 | 2.428 | 16 | 2.00 | 1.82 | 22.65 |
|  | $\begin{array}{\|l} \hline \text { C48 H109 N10 O12 P3 } \\ \text { S } \\ \hline \end{array}$ | 1142.717 | 2.119 | 8 | 4.83 | 4.41 | 23.11 |
|  | C65 H111 N O4 | 969.8516 | 10.007 | 6 | 2.82 | 3.05 | 23.15 |
|  | C48 H106 N9 O12 P3 S | 1125.69 | 2.118 | 4 | 4.75 | 4.35 | 23.58 |
|  | C30 H63 N O11 | 613.4406 | 1.911 | 10 | 3.38 | 3.27 | 23.69 |
|  | C27 H43 N6 P3 S | 576.2492 | 2.173 | 2 | 2.02 | 1.81 | 24.01 |
|  | C87 H142 N6 O11 P2 S | 1540.994 | 3.934 | 22 | 5.10 | 4.86 | 24.27 |
|  | C32 H46 N4 O2 | 518.361 | 2.726 | 17 | 2.46 | 2.33 | 24.43 |
|  | C30 H48 N2 | 436.3819 | 4.621 | 11 | 4.42 | 4.56 | 24.73 |
|  | C31 H73 N7 O2 P2 S | 669.5033 | 2.446 | 8 | 2.34 | 2.26 | 24.77 |
|  | C37 H50 P2 | 556.338 | 2.695 | 22 | 2.30 | 2.27 | 25.21 |
|  | C34 H50 N2 O3 | 534.3824 | 3.946 | 11 | 5.08 | 5.13 | 25.31 |
|  | C45 H90 N2 O2 | 690.7007 | 3.907 | 29 | 3.53 | 3.83 | 26.08 |
|  | C20 H36 N4 O2 | 364.2838 | 0.925 | 6 | 3.29 | 3.55 | 26.82 |
|  | C22 H47 N | 325.3711 | 2.962 | 20 | 2.54 | 2.16 | 26.94 |
|  | C17 H44 N8 O10 | 520.3168 | 2.707 | 14 | 2.43 | 2.27 | 27.14 |
|  | C62 H117 N5 O | 947.9247 | 9.608 | 15 | 1.47 | 1.47 | 27.49 |
|  | C17 H46 N9 O P | 423.3562 | 2.17 | 15 | 1.38 | 1.31 | 27.92 |
|  | C48 H101 N7 O P2 | 853.7532 | 2.899 | 9 | 1.36 | 1.55 | 29.27 |
|  | C45 H61 N2 O P | 676.4511 | 2.211 | 19 | 1.26 | 1.31 | 30.25 |
|  | C29 H66 N5 O6 P S | 643.4454 | 1.213 | 26 | 3.05 | 3.32 | 30.43 |
|  | C32 H66 N2 O | 494.5178 | 4.347 | 16 | 2.04 | 2.03 | 31.82 |
|  | C20 H40 N6 O4 | 428.3116 | 2.171 | 26 | 1.52 | 1.45 | 31.88 |
|  | C36 H75 N O11 | 697.5345 | 2.745 | 21 | 2.20 | 1.96 | 32.09 |
|  | C20 H42 O5 | 362.3034 | 2.226 | 22 | 1.45 | 1.27 | 32.51 |
|  | C20 H44 N3 O14 P S | 613.2269 | 1.43 | 29 | 2.55 | 2.56 | 33.29 |


|  | C5 H12 N6 O12 P2 | 409.9988 | 0.779 | 22 | 1.37 | 1.21 | 33.31 |
| :--- | :--- | ---: | ---: | ---: | ---: | ---: | ---: |
|  | C19 H27 N9 O2 | 413.2293 | 1.384 | 10 | 4.10 | 4.84 | 33.66 |
|  | C23 H51 O7 P3 | 532.2858 | 1.475 | 3 | 8.16 | 7.61 | 34.33 |
|  | C22 H52 N4 P2 | 434.3663 | 3.944 | 16 | 3.95 | 3.96 | 34.56 |
|  | C27 H64 N9 O7 P | 657.4668 | 1.902 | 9 | 2.28 | 2.16 | 36.25 |
|  | C22 H43 N | 321.3397 | 2.643 | 11 | 2.71 | 3.02 | 37.07 |
|  | C3 H4 N2 O6 P2 | 225.955 | 4.531 | 15 | 1.58 | 1.56 | 37.11 |
|  | C55 H99 N7 O6 S2 | 1017.711 | 2.863 | 14 | 3.25 | 3.63 | 37.40 |
|  | C44 H62 N9 O6 P | 843.4564 | 1.98 | 29 | 2.14 | 2.53 | 37.47 |
|  | C34 H57 O18 P | 784.3284 | 1.381 | 24 | 2.31 | 1.84 | 37.71 |
|  | C16 H33 N O3 | 287.2461 | 1.517 | 20 | 2.79 | 2.69 | 38.34 |
|  | C30 H59 N O P2 | 511.4087 | 2.147 | 7 | 1.32 | 1.03 | 39.03 |
|  | C41 H81 N O | 603.6323 | 4.926 | 10 | 2.62 | 2.49 | 39.36 |
|  | C35 H70 N5 O4 P | 655.5156 | 1.696 | 12 | 3.71 | 3.02 | 41.28 |
|  | C53 H103 N9 O18 S | 1185.712 | 2.122 | 20 | 4.19 | 3.65 | 41.75 |
|  | C42 H83 N5 O10 | 817.6135 | 2.441 | 22 | 1.71 | 1.41 | 41.77 |
|  | C26 H36 N5 P | 449.2697 | 2.106 | 13 | 2.36 | 2.64 | 42.89 |
|  | C54 H103 N | 765.8098 | 7.542 | 17 | 2.07 | 2.51 | 42.90 |
|  | C38 H75 N5 O8 | 729.5608 | 2.471 | 8 | 1.44 | 1.12 | 43.07 |
|  | C32 H52 P2 S | 530.3275 | 1.881 | 16 | 2.31 | 2.3 | 43.79 |
|  | C34 H80 N9 O8 P | 773.5871 | 2.458 | 6 | 1.33 | 1.03 | 44.03 |
|  | C56 H100 N7 O9 P3 | 1107.68 | 2.2 | 21 | 3.43 | 2.6 | 44.46 |
|  | C30 H72 N9 O6 P | 685.5345 | 2.487 | 9 | 1.36 | 1.19 | 44.77 |
|  | C19 H41 N | 283.324 | 2.297 | 7 | 2.50 | 2.71 | 44.79 |
|  | C49 H111 N10 O12 P3 | 1156.733 | 2.117 | 5 | 3.81 | 3.32 | 45.10 |
|  | C |  |  |  |  |  |  |
|  | C23 H49 N | 339.3866 | 2.948 | 8 | 2.12 | 2.25 | 45.68 |
|  | C26 H51 N O | 393.3973 | 4.362 | 16 | 1.86 | 1.85 | 46.16 |
|  | C55 H104 N3 O13 P3 | 1107.68 | 2.194 | 7 | 3.21 | 2.52 | 46.27 |
|  | C61 H106 N O14 P S | 1139.706 | 2.117 | 6 | 3.68 | 3.18 | 47.25 |
|  | C21 H45 N | 311.3553 | 2.574 | 18 | 1.90 | 1.97 | 47.57 |
|  | C41 H90 N9 09 P | 883.66 | 2.889 | 25 | 2.97 | 3.16 | 47.63 |
|  | C44 H97 N8 O6 P3 | 926.6754 | 4.642 | 15 | 3.30 | 3.41 | 47.91 |
|  | C30 H72 N9 O7 P | 701.5294 | 2.231 | 16 | 1.68 | 1.65 | 48.15 |
|  | C47 H97 N7 O P2 | 837.7216 | 3.905 | 20 | 3.73 | 4.56 | 48.33 |
|  | C33 H71 N8 O2 P S | 674.5141 | 3.008 | 16 | 2.27 | 2.83 | 48.64 |
|  | C45 H92 N2 O2 | 692.7163 | 3.927 | 15 | 3.93 | 4.6 | 49.27 |
|  | C41 H86 N5 O4 P | 743.6435 | 3.91 | 20 | 2.54 | 2.97 | 49.57 |
|  | C18 H32 O | 264.2454 | 2.218 | 13 | 1.95 | 2.06 | 49.73 |
|  |  |  |  |  |  |  |  |

Table A.3: Lipidomics results of detergent-solubilized CFTR and analysis results. The abbreviation FC is the fold change. For these listed features, only molecular weight and retention time (RT) can be determined, and thus determined at a level 5 confidence.

| Name | Formula | Molecular <br> Weight | RT <br> [min] | RSD <br> QC <br> Areas <br> [\%] | Ave. <br> FC | Med. <br> FC | CV of <br> FC |
| :---: | :---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  |  | 1103.648 | 3.912 | 18 | 3.37 | 3.37 | 0.17 |
|  |  | 169.9792 | 4.421 | 25 | 5.92 | 5.90 | 0.49 |
|  |  | 913.7894 | 10.006 | 8 | 2.98 | 2.97 | 1.69 |
|  |  | 1723.43 | 9.836 | 10 | 4.27 | 4.26 | 1.89 |
|  |  | 1990.451 | 4.609 | 8 | 4.18 | 4.16 | 2.19 |
|  |  | 1022.683 | 2.87 | 20 | 3.37 | 3.32 | 3.20 |
|  |  | 457.3406 | 1.79 | 24 | 2.09 | 2.06 | 3.80 |
|  |  | 1810.552 | 10.007 | 14 | 6.13 | 6.05 | 3.85 |
|  |  | 1727.461 | 10.009 | 7 | 4.74 | 4.75 | 3.91 |
|  |  | 258.2692 | 1.665 | 17 | 3.19 | 3.25 | 4.21 |
|  |  | 1956.455 | 3.905 | 8 | 5.97 | 5.83 | 4.65 |
|  |  | 1811.555 | 10.002 | 13 | 5.14 | 5.10 | 4.82 |
|  |  | 1989.448 | 4.612 | 12 | 3.84 | 3.74 | 4.82 |
|  |  | 1955.452 | 3.904 | 4 | 6.21 | 6.20 | 4.83 |
|  |  | 645.4821 | 1.765 | 26 | 2.82 | 2.76 | 4.83 |
|  |  | 969.7141 | 3.909 | 8 | 5.42 | 5.34 | 4.89 |
|  |  | 279.2539 | 1.676 | 18 | 1.72 | 1.71 | 4.97 |
|  |  | 1520.015 | 3.9 | 10 | 3.33 | 3.42 | 5.03 |
|  |  | 220.9817 | 4.513 | 6 | 3.10 | 3.18 | 5.14 |
|  |  | 1796.536 | 10.006 | 17 | 5.34 | 5.32 | 5.35 |
|  |  | 1797.54 | 10.003 | 7 | 5.24 | 5.21 | 5.37 |
|  |  | 1957.458 | 3.903 | 7 | 5.19 | 5.26 | 5.61 |
|  |  |  | 1799.546 | 9.997 | 9 | 4.68 | 4.60 |
|  |  | 1812.558 | 10.004 | 8 | 4.45 | 4.41 | 5.63 |
|  |  | 485.372 | 1.791 | 19 | 2.07 | 2.09 | 6.13 |
|  |  | 1090.67 | 2.881 | 26 | 3.82 | 3.92 | 6.19 |
|  |  | 611.3179 | 2.126 | 10 | 1.82 | 1.87 | 6.24 |
|  |  | 258.2349 | 10.005 | 7 | 2.54 | 2.50 | 7.40 |
|  |  | 1228.635 | 3.309 | 8 | 3.70 | 3.73 | 7.61 |
|  |  | 592.3357 | 3.019 | 16 | 2.44 | 2.48 | 7.75 |
|  |  | 1148.647 | 10.009 | 18 | 2.78 | 2.79 | 8.29 |
|  |  |  |  |  |  |  |  |



|  |  | 1742.721 | 9.97 | 14 | 3.29 | 4.02 | 46.83 |
| :--- | :--- | ---: | ---: | ---: | ---: | ---: | ---: |
|  |  | 639.3465 | 1.488 | 29 | 1.92 | 1.40 | 48.73 |
|  |  | 386.3591 | 4.614 | 21 | 2.99 | 3.41 | 49.11 |
|  |  | 517.3324 | 2.523 | 23 | 1.80 | 1.94 | 49.90 |

Table A.4: Lipidomics results of CFTR-SMALPs and analysis results. The abbreviation FC is the fold change. These features determined at a confidence level of 4 with the identification of the formulas only.

| Name | Formula <br> Molecular <br> Weight | RT <br> [min] | RSD <br> QC <br> Areas <br> [\%] | Ave. <br> E1 | Ave. <br> E2 | Ave. <br> E3 | Med. <br> E1 | Med. <br> E2 | Med. <br> E3 | CV of <br> FC E1 | CV of <br> FC E2 | CV of <br> FC E3 |  |
| :--- | :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | C19 H36 N7 O16 P3 S2 | 775.0873 | 5.622 | 13 | 7.17 | 6.88 | 7.24 | 7.12 | 6.86 | 7.21 | 0.24 | 10.56 | 8.42 |
|  | C60 H124 N5 P | 945.9598 | 12.377 | 9 | 2.58 | 2.60 | 2.37 | 2.51 | 2.53 | 2.47 | 0.37 | 26.40 | 12.68 |
|  | C38 H79 N O | 565.6154 | 5.173 | 9 | 2.22 | 2.17 | 2.25 | 2.21 | 2.20 | 2.23 | 0.49 | 9.39 | 8.57 |
|  | C18 H38 N2 O2 | 314.2926 | 0.896 | 17 | 2.36 | 0.37 | 2.37 | 2.40 | 0.73 | 2.35 | 0.49 | 45.47 | 13.14 |
|  | C27 H44 | 368.3435 | 11.256 | 2 | 9.95 | 9.96 | 9.92 | 9.95 | 10.08 | 9.94 | 0.64 | 15.66 | 2.03 |
|  | C29 H53 O2 P S | 496.3521 | 5.825 | 14 | 2.53 | 2.30 | 2.58 | 2.51 | 2.33 | 2.55 | 0.69 | 5.80 | 8.15 |
|  | C24 H56 N7 O9 P S | 649.3624 | 2.296 | 22 | 2.26 | 1.40 | 2.29 | 2.31 | 1.51 | 2.30 | 0.76 | 38.50 | 3.51 |
|  | C27 H39 N O6 | 473.2771 | 2.062 | 15 | 9.93 | 8.66 | 10.04 | 9.89 | 8.77 | 9.90 | 0.76 | 25.95 | 20.94 |
|  | C23 H53 N7 O2 | 459.4258 | 3.884 | 19 | 2.33 | 2.48 | 2.44 | 2.47 | 2.43 | 2.49 | 0.77 | 9.33 | 7.32 |
|  | C28 H46 | 382.3592 | 11.365 | 15 | 2.99 | 3.12 | 3.19 | 3.06 | 3.54 | 3.15 | 0.78 | 43.68 | 9.30 |
|  | C46 H92 Cl N2 O2 P3 | 832.6068 | 5.129 | 3 | 4.14 | 4.10 | 4.11 | 4.17 | 4.29 | 4.14 | 0.79 | 24.37 | 13.49 |
|  | C46 H75 O8 P | 786.5193 | 5.182 | 9 | 4.81 | 4.83 | 4.76 | 4.81 | 4.60 | 4.80 | 0.97 | 31.25 | 6.60 |
|  | C18 H43 N6 O5 P | 454.3054 | 3.974 | 7 | 1.72 | 1.52 | 1.59 | 1.76 | 1.52 | 1.63 | 1.05 | 10.35 | 8.56 |
|  | C43 H73 O10 P | 780.495 | 5.465 | 9 | 1.01 | 1.04 | 1.12 | 1.00 | 1.01 | 1.02 | 1.07 | 6.51 | 15.16 |
|  | C42 H83 N2 O8 P | 774.5857 | 5.619 | 6 | 11.29 | 11.35 | 11.28 | 11.30 | 11.39 | 11.27 | 1.12 | 6.27 | 1.86 |
|  | C53 H110 N2 O6 | 870.8362 | 9.624 | 22 | 6.07 | 5.88 | 6.04 | 6.07 | 5.74 | 6.05 | 1.13 | 27.90 | 2.46 |
|  | C33 H62 O4 | 522.4639 | 9.627 | 3 | 6.00 | 5.85 | 5.95 | 5.97 | 5.76 | 5.92 | 1.14 | 11.53 | 3.67 |
|  | C42 H83 N O4 | 665.6313 | 6.574 | 8 | 2.08 | 1.92 | 2.15 | 2.11 | 2.06 | 2.55 | 1.23 | 31.79 | 46.87 |
|  | C23 H54 N5 P3 | 493.3609 | 2.314 | 5 | 5.03 | 4.18 | 5.02 | 4.99 | 4.27 | 4.99 | 1.23 | 36.16 | 5.79 |
|  | C47 H80 O7 S | 788.5631 | 3.864 | 5 | 4.79 | 4.66 | 4.82 | 4.82 | 4.70 | 4.82 | 1.23 | 9.66 | 1.00 |


|  | C81 H166 N8 O12 P2 | 1505.21 | 5.615 | 4 | 10.45 | 10.42 | 10.49 | 10.46 | 10.62 | 10.47 | 1.29 | 22.88 |
| :--- | :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | C20 H47 N10 O3 P | 506.3579 | 3.401 | 14 | 3.19 | 2.77 | 3.20 | 3.24 | 2.71 | 3.23 | 1.52 | 15.60 |
|  | C35 H71 N O4 | 569.539 | 9.624 | 6 | 7.79 | 7.65 | 7.72 | 7.81 | 7.60 | 7.75 | 1.53 | 7.68 |
|  | C30 H47 N O4 | 485.3519 | 2.666 | 18 | 2.96 | 2.93 | 3.06 | 2.93 | 2.91 | 3.04 | 1.64 | 5.94 |
|  | C49 H73 N O6 | 771.5402 | 3.547 | 17 | 1.66 | 1.30 | 1.76 | 1.66 | 1.34 | 1.81 | 1.67 | 6.87 |
|  | C54 H101 N3 O3 P2 | 901.7321 | 9.624 | 8 | 6.72 | 6.72 | 6.74 | 6.75 | 6.74 | 6.72 | 1.71 | 2.50 |
|  | C20 H46 N5 O2 P | 419.337 | 3.061 | 7 | 2.63 | 2.33 | 2.79 | 2.70 | 2.10 | 2.86 | 1.76 | 35.82 |
|  | C48 H93 O8 P | 828.6569 | 5.206 | 10 | 4.08 | 4.18 | 4.25 | 4.13 | 4.17 | 4.18 | 1.76 | 15.03 |
|  | C29 H54 N O11 P S | 655.3176 | 2.36 | 7 | 1.59 | 0.84 | 1.68 | 1.67 | 1.01 | 1.68 | 1.79 | 25.79 |
|  | C34 H47 N O6 | 565.3413 | 3.471 | 19 | 2.37 | 1.90 | 2.53 | 2.41 | 1.98 | 2.58 | 1.80 | 14.82 |
|  | C31 H70 N8 | 554.5731 | 7.628 | 6 | 5.63 | 5.57 | 5.64 | 5.65 | 5.59 | 5.64 | 1.87 | 6.07 |
|  | C18 H35 N O4 | 329.2557 | 2.29 | 11 | 2.15 | 1.30 | 2.23 | 2.22 | 1.42 | 2.20 | 1.90 | 36.05 |
|  | C28 H36 N6 O2 S | 520.261 | 2.314 | 17 | 2.09 | 1.24 | 2.17 | 2.16 | 1.37 | 2.15 | 1.91 | 35.88 |
|  | C25 H53 N | 367.4171 | 3.458 | 3 | 2.61 | 2.58 | 2.67 | 2.62 | 2.65 | 2.68 | 1.94 | 9.84 |
|  | C53 H104 N O8 P | 913.7494 | 9.08 | 4 | 2.21 | 2.11 | 2.18 | 2.20 | 2.10 | 2.21 | 1.96 | 5.60 |
|  | 3.76 |  |  |  |  |  |  |  |  |  |  |  |
|  | C27 H56 N6 S | 496.4268 | 2.314 | 9 | 2.07 | 1.21 | 2.15 | 2.14 | 1.35 | 2.12 | 1.97 | 35.79 |
|  | C50 H104 N2 O6 | 828.7895 | 9.623 | 5 | 13.79 | 13.61 | 13.76 | 13.79 | 13.58 | 13.76 | 2.01 | 7.70 |
|  | 0.43 |  |  |  |  |  |  |  |  |  |  |  |
|  | C77 H159 N7 O16 P2 | 1500.132 | 5.203 | 22 | 2.86 | 2.70 | 3.04 | 2.96 | 2.55 | 3.03 | 2.02 | 20.74 |
|  | 15.30 |  |  |  |  |  |  |  |  |  |  |  |
|  | C40 H86 N5 O12 P | 859.6011 | 4.452 | 2 | 3.16 | 3.32 | 3.08 | 3.17 | 3.64 | 3.09 | 2.04 | 39.07 |
|  | 3.39 |  |  |  |  |  |  |  |  |  |  |  |
|  | C42 H83 N5 O5 | 737.6393 | 4.611 | 4 | 4.95 | 4.94 | 4.96 | 4.94 | 4.95 | 4.96 | 2.05 | 1.93 |
|  | 0.96 |  |  |  |  |  |  |  |  |  |  |  |
|  | C35 H71 N O4 | 569.539 | 5.208 | 3 | 7.74 | 7.69 | 7.73 | 7.77 | 7.75 | 7.78 | 2.05 | 6.50 |
| 6.09 |  |  |  |  |  |  |  |  |  |  |  |  |
|  | C37 H74 N4 O13 | 782.5252 | 8.07 | 15 | 6.50 | 6.23 | 6.46 | 6.42 | 6.06 | 6.45 | 2.07 | 37.41 |
| 7.55 |  |  |  |  |  |  |  |  |  |  |  |  |
|  | C47 H95 N4 P3 | 808.6767 | 4.669 | 3 | 2.77 | 2.60 | 2.69 | 2.79 | 2.61 | 2.70 | 2.08 | 4.80 |
|  | 1.90 |  |  |  |  |  |  |  |  |  |  |  |
|  | C15 H33 N4 O14 P | 524.1723 | 2.316 | 13 | 2.06 | 1.97 | 2.13 | 2.12 | 1.77 | 2.18 | 2.09 | 40.49 |
| 12.13 |  |  |  |  |  |  |  |  |  |  |  |  |
|  | C63 H97 N O6 | 963.731 | 9.622 | 9 | 4.78 | 4.83 | 4.84 | 4.77 | 4.79 | 4.82 | 2.16 | 7.17 |
| 3.92 |  |  |  |  |  |  |  |  |  |  |  |  |
|  | C20 H33 N7 O | 387.2763 | 2.32 | 22 | 1.55 | 0.67 | 1.62 | 1.60 | 0.83 | 1.59 | 2.18 | 35.64 |
| 4.09 |  |  |  |  |  |  |  |  |  |  |  |  |


|  | C23 H40 N O7 P | 473.2561 | 2.296 | 13 | 2.01 | 1.17 | 2.07 | 2.07 | 1.26 | 2.05 | 2.22 | 36.69 |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | C50 H75 N O6 | 785.5603 | 3.858 | 5 | 4.93 | 4.74 | 4.93 | 4.98 | 4.78 | 4.95 | 2.23 | 7.49 |
|  | C11 H19 N7 | 249.1702 | 3.137 | 12 | 4.46 | 4.25 | 4.54 | 4.50 | 4.28 | 4.51 | 2.23 | 12.48 |
|  | C42 H87 Cl N5 O2 P | 759.6287 | 10.55 | 3 | 7.75 | 7.65 | 7.72 | 7.64 | 7.56 | 7.72 | 2.24 | 12.14 |
|  | C21 H36 N O7 P | 445.2249 | 2.284 | 1 | 1.99 | 1.08 | 2.00 | 2.03 | 1.27 | 2.01 | 2.27 | 35.62 |
|  | C24 H55 N7 O S | 489.4177 | 6.482 | 16 | 2.76 | 2.70 | 2.81 | 2.89 | 2.67 | 2.80 | 2.31 | 11.26 |
|  | C42 H80 N O8 P | 757.5611 | 3.506 | 14 | 5.64 | 5.13 | 5.59 | 5.63 | 5.00 | 5.30 | 2.33 | 43.16 |
|  | C26 H53 N6 O3 P | 528.3913 | 2.642 | 3 | 11.29 | 11.25 | 11.24 | 11.37 | 11.23 | 11.27 | 2.35 | 3.11 |
|  | C46 H79 O10 P | 822.5421 | 5.227 | 13 | 6.65 | 6.66 | 6.57 | 6.66 | 6.85 | 6.52 | 2.41 | 24.38 |
|  | C44 H57 Cl N9 O P3 S2 | 919.3036 | 7.755 | 8 | 2.58 | 2.42 | 2.68 | 2.58 | 2.45 | 2.67 | 2.42 | 4.19 |
|  | C46 H90 N O2 P S2 | 783.616 | 4.775 | 12 | 1.52 | 1.25 | 1.66 | 1.55 | 1.05 | 1.62 | 2.45 | 31.26 |
|  | C27 H51 P3 | 468.3211 | 4.383 | 4 | 2.75 | 2.82 | 2.74 | 2.81 | 2.79 | 2.62 | 2.50 | 4.53 |
|  | C63 H133 N3 O2 P2 | 1025.987 | 11.249 | 2 | 8.95 | 8.94 | 8.96 | 8.95 | 8.98 | 9.01 | 2.50 | 6.46 |
|  | C39 H77 N2 O8 P | 732.54 | 5.886 | 9 | 4.42 | 4.34 | 4.53 | 4.44 | 4.34 | 4.48 | 2.50 | 2.52 |
|  | 8.09 |  |  |  |  |  |  |  |  |  |  |  |
|  | C39 H81 N3 O2 | 623.6323 | 6.651 | 4 | 1.88 | 1.29 | 1.71 | 1.89 | 1.31 | 1.66 | 2.51 | 13.63 |
|  | 22.07 |  |  |  |  |  |  |  |  |  |  |  |
|  | C25 H54 N2 O P2 S | 492.3422 | 3.928 | 11 | 2.91 | 2.65 | 2.91 | 2.93 | 2.66 | 2.91 | 2.53 | 0.81 |
|  | 2.24 |  |  |  |  |  |  |  |  |  |  |  |
|  | C49 H75 N O6 | 773.5563 | 3.532 | 12 | 1.50 | 1.24 | 1.62 | 1.50 | 1.26 | 1.72 | 2.65 | 3.21 | 19.32.


| C35 H77 N7 O7 P2 | 769.5364 | 5.594 | 23 | 7.24 | 7.12 | 7.09 | 7.34 | 7.18 | 7.02 | 2.88 | 16.18 | 20.15 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| C36 H84 N10 O S5 | 832.5444 | 5.626 | 23 | 6.44 | 6.33 | 6.29 | 6.54 | 6.38 | 6.22 | 2.88 | 16.05 | 20.26 |
| C15 H44 N10 O P2 | 442.3186 | 2.706 | 2 | 8.33 | 8.35 | 8.34 | 8.40 | 8.33 | 8.35 | 2.92 | 3.46 | 3.07 |
| C21 H37 N O3 | 351.2768 | 2.31 | 18 | 2.22 | 1.39 | 2.28 | 2.47 | 1.45 | 2.31 | 2.92 | 36.96 | 4.83 |
| C39 H82 N9 O6 P | 803.6118 | 3.557 | 15 | 0.99 | 0.68 | 0.98 | 1.01 | 0.70 | 1.03 | 2.93 | 5.71 | 14.77 |
| C33 H73 N10 O4 P | 704.5542 | 5.896 | 6 | 2.04 | 2.03 | 2.08 | 2.11 | 2.09 | 2.10 | 2.96 | 10.49 | 2.77 |
| C17 H37 N O | 271.2869 | 10.093 | 11 | 1.29 | 0.49 | 1.01 | 1.17 | 0.09 | 0.99 | 2.97 | 41.33 | 10.54 |
| C31 H68 N8 O | 568.554 | 4.156 | 6 | 3.12 | 3.15 | 3.16 | 3.19 | 3.13 | 3.16 | 3.05 | 3.23 | 1.63 |
| C22 H48 N2 O4 S2 | 468.3061 | 2.37 | 17 | 1.71 | 0.96 | 1.88 | 1.78 | 1.18 | 1.84 | 3.10 | 29.17 | 9.61 |
| C42 H82 N O8 P | 759.5815 | 5.206 | 3 | 8.16 | 8.11 | 8.20 | 8.19 | 8.12 | 8.17 | 3.10 | 4.22 | 6.96 |
| C25 H43 O6 P S | 502.2501 | 2.312 | 22 | 2.08 | 1.25 | 2.12 | 2.13 | 1.31 | 2.10 | 3.12 | 37.10 | 3.06 |
| C36 H72 N2 O2 | 564.5588 | 7.352 | 3 | 1.03 | 0.59 | 1.05 | 1.06 | 0.59 | 1.06 | 3.12 | 8.10 | 10.31 |
| C49 H52 O8 | 768.3654 | 2.304 | 7 | 1.96 | 1.03 | 2.00 | 1.98 | 1.23 | 1.98 | 3.15 | 35.38 | 4.62 |
| C29 H64 N10 O6 | 648.499 | 2.669 | 17 | 2.78 | 2.59 | 2.95 | 2.90 | 2.59 | 2.94 | 3.21 | 20.14 | 17.79 |
| C42 H75 N3 O3 P2 | 731.5277 | 8.064 | 13 | 4.96 | 4.87 | 5.33 | 4.84 | 4.59 | 5.33 | 3.23 | 36.91 | 19.64 |
| C38 H75 N6 O4 P | 710.5581 | 5.89 | 2 | 5.66 | 5.63 | 5.70 | 5.68 | 5.63 | 5.68 | 3.23 | 4.87 | 6.04 |
| C82 H97 N8 O18 P S4 | 1640.554 | 9.622 | 4 | 7.74 | 7.48 | 8.72 | 7.70 | 7.47 | 8.39 | 3.25 | 5.21 | 45.29 |
| C14 H27 O7 P | 338.1499 | 2.321 | 5 | 1.92 | 0.98 | 1.96 | 1.94 | 1.19 | 1.94 | 3.29 | 35.36 | 4.69 |
| C11 H33 N10 O P | 352.2584 | 3.076 | 4 | 7.23 | 6.61 | 7.33 | 7.27 | 6.45 | 7.42 | 3.33 | 27.31 | 13.38 |
| C23 H58 N9 O P | 507.4499 | 3.992 | 5 | 2.05 | 2.03 | 2.14 | 2.12 | 2.00 | 2.10 | 3.36 | 3.63 | 7.62 |
| C41 H47 N10 O5 P | 790.3481 | 2.288 | 10 | 2.19 | 1.36 | 2.22 | 2.24 | 1.41 | 2.21 | 3.37 | 37.26 | 3.00 |
| C19 H41 Br P2 | 410.1874 | 1.885 | 21 | 3.17 | 2.53 | 3.38 | 3.22 | 2.36 | 3.17 | 3.38 | 31.47 | 29.77 |
| C37 H80 N10 O9 S | 840.5824 | 5.671 | 12 | 7.53 | 7.45 | 7.66 | 7.53 | 7.45 | 7.65 | 3.39 | 6.15 | 2.30 |
| C36 H75 N5 O11 S | 785.5162 | 5.21 | 7 | 6.51 | 6.39 | 6.45 | 6.49 | 6.25 | 6.45 | 3.43 | 18.90 | 1.51 |
| C27 H55 N | 393.4331 | 3.329 | 9 | 3.28 | 1.74 | 2.95 | 3.29 | 1.80 | 2.97 | 3.46 | 29.02 | 21.52 |
| C28 H25 N6 O18 P | 764.0963 | 5.619 | 6 | 6.83 | 6.93 | 6.88 | 6.86 | 6.66 | 6.87 | 3.56 | 38.25 | 3.02 |


| C33 H38 S3 | 530.2154 | 2.311 | 19 | 2.00 | 1.17 | 2.03 | 2.05 | 1.22 | 2.02 | 3.57 | 37.41 | 2.96 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| C28 H52 N O7 P | 545.3499 | 2.316 | 15 | 2.26 | 1.31 | 2.29 | 2.27 | 1.53 | 2.27 | 3.59 | 35.34 | 4.83 |
| C24 H51 N O2 | 385.3914 | 2.827 | 12 | 1.64 | 0.14 | 1.34 | 1.56 | 0.17 | 1.21 | 3.60 | 37.64 | 29.81 |
| C53 H105 Cl N6 O3 | 908.7939 | 9.083 | 6 | 2.46 | 2.18 | 2.38 | 2.43 | 2.22 | 2.40 | 3.61 | 6.23 | 2.88 |
| C49 H82 N O8 P | 843.5767 | 5.631 | 19 | 5.62 | 5.71 | 5.82 | 5.66 | 5.60 | 5.80 | 3.61 | 17.94 | 7.34 |
| C40 H78 N O10 P | 763.5335 | 5.217 | 9 | 6.31 | 6.17 | 6.28 | 6.32 | 6.15 | 6.27 | 3.62 | 3.92 | 1.72 |
| C24 H42 N O9 P | 519.2599 | 2.309 | 24 | 2.41 | 1.59 | 2.44 | 2.46 | 1.63 | 2.43 | 3.67 | 37.49 | 2.95 |
| C46 H92 N2 O2 | 704.7157 | 7.844 | 11 | 1.72 | 1.81 | 1.67 | 1.73 | 1.81 | 1.73 | 3.70 | 9.50 | 7.97 |
| C40 H82 N5 O P | 679.6248 | 11.245 | 6 | 8.52 | 8.51 | 8.51 | 8.52 | 8.45 | 8.52 | 3.70 | 16.79 | 2.31 |
| C47 H79 O10 P | 834.5422 | 5.62 | 25 | 4.44 | 4.23 | 4.26 | 4.45 | 4.23 | 4.39 | 3.80 | 1.53 | 15.93 |
| C19 H37 N O | 295.2869 | 1.932 | 13 | 2.16 | 0.28 | 1.59 | 2.00 | 0.55 | 1.59 | 3.81 | 41.95 | 6.21 |
| C15 H41 N9 O P2 | 425.2921 | 2.706 | 6 | 6.27 | 6.17 | 6.25 | 6.32 | 6.19 | 6.26 | 3.84 | 6.31 | 4.96 |
| C22 H41 N4 O3 P | 440.2897 | 3.866 | 6 | 3.84 | 3.79 | 3.80 | 3.84 | 3.88 | 3.81 | 3.87 | 31.57 | 8.05 |
| C47 H89 Cl2 N O P2 | 815.5798 | 5.124 | 6 | 4.51 | 4.55 | 4.49 | 4.58 | 4.61 | 4.53 | 3.87 | 8.01 | 10.80 |
| C39 H81 N7 O7 | 759.6197 | 5.177 | 4 | 8.35 | 8.51 | 8.26 | 8.39 | 8.67 | 8.23 | 3.88 | 23.95 | 3.97 |
| C30 H66 N10 O6 | 662.5149 | 2.676 | 20 | 2.63 | 2.60 | 2.70 | 2.68 | 2.58 | 2.76 | 3.90 | 12.93 | 11.75 |
| C32 H52 N6 S | 552.3997 | 3.85 | 11 | 2.59 | 2.45 | 2.42 | 2.61 | 2.43 | 2.47 | 4.00 | 14.13 | 20.37 |
| C52 H83 N4 O2 P S | 858.5977 | 4.382 | 9 | 3.39 | 3.46 | 3.37 | 3.35 | 3.50 | 3.34 | 4.01 | 13.73 | 7.49 |
| C24 H38 O4 | 390.2761 | 3.453 | 3 | 1.61 | 1.58 | 1.57 | 1.60 | 1.57 | 1.56 | 4.04 | 2.75 | 2.43 |
| C41 H78 N O7 P | 727.5493 | 5.923 | 4 | 4.13 | 4.10 | 4.22 | 4.17 | 4.09 | 4.20 | 4.05 | 2.95 | 9.91 |
| C21 H33 O7 P | 428.1977 | 1.884 | 16 | 3.06 | 2.48 | 3.26 | 3.13 | 2.29 | 3.03 | 4.06 | 34.68 | 30.18 |
| C25 H52 N6 S | 468.3957 | 2.308 | 4 | 1.77 | 0.80 | 1.79 | 1.77 | 1.04 | 1.77 | 4.08 | 35.32 | 5.06 |
| C16 H41 N10 O P | 420.3209 | 3.869 | 4 | 2.49 | 2.56 | 2.54 | 2.54 | 2.56 | 2.54 | 4.09 | 5.88 | 1.02 |
| C27 H50 N O7 P | 531.3345 | 2.283 | 10 | 2.11 | 1.16 | 2.11 | 2.12 | 1.38 | 2.12 | 4.12 | 37.43 | 5.22 |
| C50 H101 N O6 | 811.7629 | 9.623 | 7 | 11.16 | 11.01 | 11.15 | 11.16 | 10.95 | 11.12 | 4.12 | 9.01 | 4.14 |
| C46 H84 Cl N7 O2 S | 833.6099 | 5.129 | 4 | 3.34 | 3.29 | 3.35 | 3.47 | 3.44 | 3.41 | 4.14 | 22.04 | 11.61 |


| C27 H55 N O8 | 521.3922 | 2.316 | 2 | 3.35 | 2.53 | 3.35 | 3.43 | 2.64 | 3.37 | 4.14 | 38.55 | 2.49 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| C16 H30 N O7 P | 379.1764 | 2.321 | 11 | 1.89 | 0.91 | 1.90 | 1.88 | 1.15 | 1.89 | 4.15 | 35.32 | 5.09 |
| C37 H75 N O | 549.5846 | 5.515 | 2 | 1.10 | 0.45 | 0.73 | 1.07 | 0.19 | 0.81 | 4.16 | 43.08 | 12.38 |
| C37 H71 N O5 | 609.532 | 7.314 | 5 | 8.32 | 8.40 | 8.30 | 8.36 | 8.46 | 8.30 | 4.18 | 16.07 | 0.96 |
| C26 H54 N6 S | 482.4113 | 2.323 | 4 | 1.98 | 1.01 | 1.99 | 1.98 | 1.24 | 1.98 | 4.18 | 35.33 | 5.11 |
| C42 H78 N O8 P | 755.5453 | 5.213 | 6 | 7.38 | 7.36 | 7.41 | 7.41 | 7.37 | 7.41 | 4.22 | 0.89 | 1.18 |
| C16 H35 N9 S | 385.2722 | 2.19 | 5 | 2.99 | 1.91 | 3.18 | 3.06 | 1.99 | 3.16 | 4.22 | 43.42 | 15.18 |
| C37 H81 N9 O5 S | 763.6088 | 5.131 | 12 | 5.59 | 5.60 | 5.57 | 5.64 | 5.62 | 5.57 | 4.24 | 5.24 | 2.44 |
| C29 H65 N7 O2 S | 575.4906 | 4.385 | 7 | 2.33 | 2.36 | 2.46 | 2.39 | 2.38 | 2.45 | 4.25 | 4.19 | 3.23 |
| C31 H65 N3 O | 495.5126 | 3.891 | 7 | 2.81 | 2.56 | 2.74 | 2.81 | 2.59 | 2.74 | 4.26 | 11.78 | 1.11 |
| C42 H89 N2 O8 P | 780.6356 | 5.135 | 12 | 6.74 | 6.75 | 6.71 | 6.79 | 6.77 | 6.71 | 4.29 | 5.59 | 2.13 |
| C44 H87 N O4 | 693.6629 | 8.279 | 16 | 1.02 | 0.91 | 1.27 | 1.04 | 0.88 | 1.26 | 4.30 | 11.55 | 2.70 |
| C33 H41 N O3 | 499.3082 | 2.281 | 10 | 2.10 | 1.15 | 2.15 | 2.13 | 1.40 | 2.13 | 4.31 | 35.53 | 5.37 |
| C45 H75 N O7 | 741.5516 | 5.204 | 8 | 7.86 | 7.80 | 7.88 | 7.90 | 7.81 | 7.88 | 4.35 | 0.52 | 4.08 |
| C34 H69 N O3 | 539.5268 | 5.598 | 9 | 2.60 | 2.58 | 2.57 | 2.62 | 2.66 | 2.56 | 4.36 | 10.63 | 3.38 |
| C41 H87 N3 S2 | 685.6347 | 8.27 | 15 | 1.00 | 1.14 | 0.90 | 1.04 | 1.48 | 0.90 | 4.36 | 40.25 | 5.83 |
| C53 H109 N2 O9 P | 948.7875 | 6.662 | 13 | 3.41 | 3.35 | 3.63 | 3.38 | 3.21 | 3.70 | 4.36 | 17.50 | 12.03 |
| C33 H63 N3 O | 517.4966 | 3.889 | 7 | 2.03 | 1.78 | 1.96 | 2.04 | 1.80 | 1.96 | 4.39 | 11.22 | 1.15 |
| C31 H46 N4 | 474.3703 | 5.813 | 6 | 2.72 | 2.30 | 2.93 | 2.74 | 2.34 | 2.93 | 4.45 | 10.22 | 31.87 |
| C21 H40 N2 | 320.3186 | 2.825 | 8 | 1.38 | 0.18 | 1.13 | 1.25 | 0.40 | 1.08 | 4.47 | 28.35 | 10.56 |
| C 23 H 44 O 5 | 400.3179 | 2.792 | 29 | 3.38 | 2.48 | 3.50 | 3.60 | 2.29 | 3.53 | 4.52 | 33.10 | 22.39 |
| C69 H86 O S | 962.6402 | 8.343 | 8 | 2.57 | 2.50 | 2.48 | 2.60 | 2.46 | 2.55 | 4.52 | 7.08 | 7.83 |
| C27 H53 N O5 | 471.3911 | 2.744 | 15 | 2.89 | 2.83 | 2.87 | 2.92 | 2.70 | 2.95 | 4.52 | 17.02 | 10.54 |
| C26 H50 N O7 P | 519.3323 | 2.36 | 15 | 1.78 | 1.53 | 1.96 | 1.84 | 1.44 | 1.90 | 4.53 | 30.75 | 9.97 |
| C 28 H 43 N | 393.339 | 4.778 | 8 | 1.77 | 1.28 | 1.86 | 1.78 | 1.37 | 1.89 | 4.53 | 28.52 | 4.23 |
| C41 H74 N8 O5 | 758.5778 | 5.199 | 3 | 9.93 | 9.89 | 9.97 | 9.97 | 9.88 | 9.96 | 4.53 | 2.46 | 4.36 |


| C43 H62 N O11 P | 799.407 | 2.321 | 15 | 2.06 | 1.08 | 2.08 | 2.06 | 1.33 | 2.06 | 4.62 | 35.35 | 5.30 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| C39 H69 N O6 | 647.5118 | 5.472 | 8 | 3.09 | 3.29 | 3.02 | 3.08 | 3.28 | 3.06 | 4.63 | 11.71 | 5.37 |
| C33 H73 N9 | 595.6009 | 6.65 | 8 | 2.56 | 2.27 | 2.49 | 2.65 | 2.25 | 2.55 | 4.63 | 18.93 | 14.69 |
| C26 H41 N7 O2 | 483.3342 | 2.601 | 14 | 1.44 | 0.37 | 1.34 | 1.42 | 0.33 | 1.53 | 4.66 | 21.38 | 37.24 |
| C33 H77 N9 O2 P2 S3 | 789.4866 | 8.11 | 19 | 3.84 | 3.67 | 3.82 | 3.88 | 3.67 | 3.67 | 4.66 | 6.41 | 21.32 |
| C36 H74 N2 | 534.5844 | 5.561 | 19 | 2.61 | 1.21 | 2.21 | 2.61 | 1.31 | 2.19 | 4.66 | 39.03 | 13.38 |
| C57 H115 N3 O4 P2 S | 999.8091 | 7.314 | 16 | 4.13 | 4.31 | 4.09 | 4.20 | 4.25 | 4.12 | 4.67 | 9.88 | 5.00 |
| C30 H50 N O7 P | 567.3319 | 2.318 | 12 | 1.92 | 0.94 | 1.93 | 1.92 | 1.19 | 1.92 | 4.69 | 35.35 | 5.33 |
| C15 H20 | 200.156 | 11.259 | 10 | 3.43 | 3.68 | 3.22 | 3.42 | 3.66 | 3.25 | 4.70 | 23.42 | 5.01 |
| C20 H32 N9 O P | 445.2454 | 1.341 | 20 | 6.88 | 6.44 | 7.02 | 7.00 | 6.59 | 6.98 | 4.73 | 35.36 | 49.26 |
| C21 H40 N8 O3 S | 484.2951 | 4.377 | 10 | 3.20 | 3.29 | 3.18 | 3.23 | 3.28 | 3.22 | 4.76 | 3.42 | 4.90 |
| C26 H53 N O8 | 507.3766 | 2.315 | 3 | 3.75 | 2.77 | 3.71 | 3.81 | 2.95 | 3.71 | 4.78 | 37.63 | 2.28 |
| C36 H72 N6 O | 604.5766 | 7.314 | 4 | 7.38 | 7.44 | 7.35 | 7.46 | 7.44 | 7.34 | 4.78 | 7.70 | 3.09 |
| C47 H71 N O6 | 745.5247 | 3.529 | 10 | 1.54 | 1.27 | 1.59 | 1.50 | 1.27 | 1.68 | 4.79 | 4.12 | 20.44 |
| C34 H74 N3 O2 P | 587.5502 | 7.315 | 3 | 6.68 | 6.75 | 6.66 | 6.73 | 6.79 | 6.65 | 4.80 | 13.39 | 1.92 |
| C35 H52 O S | 520.3737 | 4.508 | 5 | 2.96 | 2.79 | 2.92 | 3.02 | 2.97 | 2.91 | 4.82 | 21.50 | 6.28 |
| C39 H82 Cl N3 O10 | 787.5701 | 4.023 | 12 | 3.11 | 3.12 | 3.05 | 3.12 | 3.12 | 3.06 | 4.83 | 5.64 | 3.08 |
| C49 H83 N3 O S | 761.6256 | 10.55 | 4 | 5.65 | 5.55 | 5.60 | 5.68 | 5.57 | 5.60 | 4.83 | 2.22 | 6.15 |
| C60 H125 N6 P S | 992.9427 | 2.69 | 28 | 0.11 | 0.58 | 0.08 | 1.28 | 0.73 | 0.08 | 4.83 | 44.18 | 22.97 |
| C26 H49 N | 375.3874 | 5.571 | 15 | 6.27 | 6.28 | 6.24 | 6.28 | 6.20 | 6.26 | 4.84 | 18.49 | 2.47 |
| C 27 H 40 O 2 | 396.3021 | 2.337 | 25 | 2.16 | 1.78 | 2.25 | 2.23 | 1.58 | 2.24 | 4.91 | 42.41 | 3.04 |
| C19 H38 O4 | 330.2764 | 2.335 | 16 | 2.12 | 1.34 | 2.20 | 2.19 | 1.39 | 2.18 | 4.94 | 36.95 | 4.23 |
| C87 H143 N9 O12 | 1506.086 | 5.205 | 21 | 2.39 | 2.34 | 2.32 | 2.32 | 2.32 | 2.28 | 4.95 | 3.99 | 20.16 |
| C33 H59 N O2 | 501.4539 | 7.081 | 15 | 1.79 | 1.25 | 2.04 | 1.81 | 1.14 | 1.98 | 4.96 | 42.51 | 29.72 |
| C53 H89 P | 756.6699 | 10.55 | 7 | 5.78 | 5.51 | 5.82 | 5.77 | 5.41 | 5.84 | 4.96 | 19.15 | 4.48 |
| C18 H41 N4 O4 P S2 | 472.2289 | 2.305 | 16 | 2.33 | 1.54 | 2.34 | 2.39 | 1.53 | 2.35 | 4.96 | 38.41 | 2.82 |



| C27 H26 O3 | 398.1875 | 1.884 | 26 | 2.84 | 2.02 | 3.02 | 2.94 | 1.99 | 2.78 | 5.36 | 16.14 | 33.29 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| C30 H49 N O4 | 487.3675 | 2.749 | 15 | 3.68 | 3.65 | 3.58 | 3.81 | 3.59 | 3.67 | 5.42 | 11.21 | 14.65 |
| C29 H43 N O | 421.3337 | 3.918 | 10 | 1.72 | 1.70 | 1.81 | 1.82 | 1.71 | 1.75 | 5.42 | 5.27 | 8.74 |
| C24 H53 N7 O6 | 535.4078 | 2.316 | 3 | 3.56 | 2.72 | 3.50 | 3.60 | 2.80 | 3.49 | 5.45 | 37.96 | 1.74 |
| C34 H68 N2 O2 | 536.5276 | 6.648 | 3 | 2.43 | 1.86 | 2.32 | 2.42 | 1.91 | 2.38 | 5.47 | 10.90 | 9.08 |
| C36 H73 N | 519.5739 | 4.637 | 7 | 1.49 | 0.37 | 1.38 | 1.48 | 0.71 | 1.31 | 5.55 | 41.92 | 9.69 |
| C 22 H 46 N 07 P | 467.3006 | 1.856 | 6 | 3.20 | 2.97 | 3.38 | 3.17 | 3.21 | 3.21 | 5.63 | 30.59 | 29.15 |
| C27 H62 N9 O5 P | 623.4613 | 1.813 | 11 | 3.85 | 3.72 | 3.97 | 3.86 | 3.63 | 3.76 | 5.64 | 10.76 | 27.93 |
| C42 H88 N2 O | 636.6889 | 8.899 | 3 | 2.00 | 0.59 | 1.83 | 1.97 | 0.82 | 1.87 | 5.64 | 42.66 | 8.16 |
| C36 H70 N O10 P | 707.4724 | 3.552 | 20 | 1.11 | 0.88 | 1.18 | 1.16 | 0.79 | 1.21 | 5.67 | 13.57 | 10.28 |
| C20 H36 N O7 P | 433.2247 | 1.876 | 19 | 3.05 | 2.50 | 3.28 | 3.09 | 2.28 | 3.06 | 5.68 | 32.60 | 33.11 |
| C20 H43 N9 O2 S | 473.3278 | 1.949 | 12 | 2.47 | 1.74 | 2.59 | 2.49 | 1.65 | 2.46 | 5.73 | 18.28 | 29.09 |
| C12 H37 N10 O P | 368.2899 | 3.034 | 8 | 4.49 | 3.88 | 4.48 | 4.46 | 4.13 | 4.73 | 5.73 | 29.04 | 39.56 |
| C12 H37 N10 O P | 368.2899 | 3.097 | 8 | 4.29 | 3.69 | 4.28 | 4.26 | 3.93 | 4.54 | 5.73 | 28.95 | 39.56 |
| C 15 H 12 O | 208.0883 | 2.287 | 14 | 1.77 | 0.90 | 1.79 | 1.78 | 1.07 | 1.77 | 5.73 | 34.49 | 5.89 |
| C35 H75 N2 P S | 586.5407 | 7.34 | 4 | 3.85 | 3.36 | 3.89 | 3.92 | 3.39 | 3.90 | 5.74 | 8.95 | 9.79 |
| C37 H32 N4 | 532.2609 | 2.344 | 11 | 2.07 | 1.11 | 2.06 | 2.04 | 1.32 | 2.06 | 5.79 | 34.31 | 3.24 |
| C48 H77 O10 P | 844.5242 | 5.24 | 13 | 4.38 | 4.61 | 4.40 | 4.36 | 4.49 | 4.24 | 5.81 | 30.88 | 26.11 |
| C20 H27 N | 281.2138 | 3.078 | 14 | 1.72 | 1.10 | 1.98 | 1.79 | 1.01 | 2.01 | 5.82 | 48.10 | 3.66 |
| C22 H36 N4 | 356.2922 | 2.501 | 22 | 3.17 | 2.43 | 3.37 | 3.17 | 2.33 | 3.57 | 5.84 | 29.88 | 23.01 |
| C38 H79 N3 O2 | 609.6163 | 5.525 | 10 | 1.05 | 0.79 | 1.14 | 1.18 | 0.79 | 1.13 | 5.85 | 18.92 | 11.95 |
| C42 H79 O8 P | 742.555 | 5.205 | 5 | 4.43 | 4.50 | 4.46 | 4.47 | 4.53 | 4.51 | 5.85 | 7.42 | 6.28 |
| C46 H66 O8 | 746.4724 | 4.384 | 10 | 3.22 | 3.29 | 3.14 | 3.29 | 3.32 | 3.19 | 5.86 | 4.51 | 9.68 |
| C29 H51 N O4 | 477.3813 | 3.414 | 10 | 2.16 | 2.34 | 2.20 | 2.21 | 2.33 | 2.20 | 5.91 | 2.76 | 5.44 |
| $\begin{aligned} & \text { C80 H102 Br N10 O8 P3 } \\ & \text { S5 } \end{aligned}$ | 1662.487 | 9.629 | 9 | 5.29 | 5.25 | 5.34 | 5.32 | 5.22 | 5.35 | 5.92 | 4.92 | 1.15 |



| C28 H58 N 06 P | 535.3994 | 3.53 | 14 | 1.59 | 1.32 | 1.46 | 1.48 | 1.29 | 1.58 | 6.43 | 9.97 | 15.51 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| C22 H57 N10 O2 P3 S | 618.3608 | 2.644 | 16 | 4.61 | 4.55 | 4.73 | 4.59 | 4.52 | 4.75 | 6.46 | 9.87 | 4.04 |
| C41 H82 N4 O3 | 678.6379 | 3.482 | 29 | 2.37 | 1.80 | 2.56 | 2.45 | 1.96 | 2.59 | 6.49 | 21.96 | 25.55 |
| C38 H67 N 06 | 633.4961 | 5.469 | 9 | 4.13 | 4.20 | 4.04 | 4.12 | 4.23 | 4.05 | 6.53 | 18.90 | 2.38 |
| C23 H47 N O8 | 465.3296 | 2.311 | 6 | 1.93 | 1.09 | 2.04 | 1.89 | 1.36 | 2.04 | 6.53 | 43.95 | 3.02 |
| C46 H80 N 07 P | 789.5655 | 5.636 | 11 | 6.05 | 6.14 | 6.00 | 5.92 | 6.11 | 6.00 | 6.53 | 13.75 | 0.69 |
| C34 H71 N9 O8 | 733.5434 | 5.909 | 4 | 3.15 | 3.07 | 3.15 | 3.13 | 3.07 | 3.14 | 6.56 | 3.12 | 4.28 |
| C16 H34 O3 | 274.2502 | 2.801 | 11 | 2.64 | 2.04 | 2.49 | 2.45 | 2.02 | 2.46 | 6.56 | 22.34 | 6.81 |
| C39 H83 N3 O15 P2 | 895.5298 | 1.449 | 14 | 1.18 | 0.23 | 0.97 | 1.22 | 0.36 | 1.03 | 6.57 | 17.50 | 13.13 |
| C22 H51 N9 O16 | 697.3466 | 1.44 | 12 | 1.02 | 0.04 | 0.80 | 1.05 | 0.18 | 0.86 | 6.60 | 16.75 | 13.56 |
| C17 H35 O9 P | 414.2032 | 1.34 | 23 | 2.64 | 2.03 | 2.62 | 2.68 | 1.92 | 2.47 | 6.63 | 45.25 | 48.65 |
| C29 H61 N6 O3 | 572.4542 | 2.749 | 7 | 5.12 | 5.30 | 5.00 | 5.38 | 5.26 | 5.07 | 6.63 | 13.67 | 12.09 |
| C20 H53 Cl N10 O2 P2 | 562.3526 | 2.243 | 4 | 4.43 | 4.35 | 4.50 | 4.46 | 4.36 | 4.47 | 6.64 | 16.54 | 13.21 |
| C44 H92 N2 O | 664.7208 | 9.417 | 16 | 3.42 | 1.69 | 3.07 | 3.40 | 1.97 | 3.11 | 6.66 | 45.66 | 12.01 |
| C9 H21 N3 O4 | 235.1542 | 3.132 | 14 | 1.68 | 1.50 | 1.50 | 1.68 | 1.36 | 1.56 | 6.69 | 19.32 | 7.65 |
| C23 H52 N5 O2 P | 461.3836 | 3.547 | 23 | 5.03 | 4.64 | 4.65 | 5.14 | 4.70 | 4.69 | 6.72 | 11.06 | 5.08 |
| C24 H54 N9 O P | 515.4184 | 4.507 | 7 | 1.60 | 1.52 | 1.53 | 1.61 | 1.51 | 1.57 | 6.80 | 6.67 | 6.33 |
| C32 H70 N O12 P3 | 753.4092 | 2.3 | 21 | 2.20 | 1.46 | 2.21 | 2.28 | 1.40 | 2.23 | 6.80 | 39.86 | 2.94 |
| C53 H96 N O8 P | 905.6882 | 8.099 | 14 | 1.04 | 0.71 | 1.22 | 1.07 | 0.49 | 1.18 | 6.82 | 33.98 | 18.63 |
| C15 H26 N2 O2 P2 | 328.1455 | 2.287 | 14 | 2.20 | 1.45 | 2.27 | 2.26 | 1.53 | 2.28 | 6.88 | 37.59 | 3.38 |
| C35 H71 N O | 521.5532 | 8.467 | 12 | 3.85 | 2.51 | 3.71 | 3.87 | 2.75 | 3.67 | 6.88 | 34.98 | 9.23 |
| C21 H44 N6 O6 S | 508.3021 | 1.462 | 12 | 1.32 | 0.43 | 1.13 | 1.39 | 0.56 | 1.18 | 6.89 | 16.63 | 13.40 |
| C41 H86 Cl N4 P S4 | 828.5168 | 4.873 | 17 | 3.02 | 2.86 | 2.85 | 3.06 | 3.22 | 2.81 | 6.94 | 37.25 | 18.44 |
| C28 H57 N O2 | 439.4384 | 6.553 | 2 | 1.18 | 0.11 | 0.89 | 1.22 | 0.11 | 0.95 | 7.01 | 39.70 | 13.25 |
| C31 H67 N9 O7 | 677.5193 | 7.315 | 16 | 3.80 | 3.66 | 3.82 | 3.79 | 3.49 | 3.82 | 7.02 | 32.37 | 3.55 |
| C29 H62 N8 O2 S | 586.4702 | 3.278 | 14 | 2.32 | 2.29 | 2.23 | 2.42 | 2.24 | 2.25 | 7.03 | 6.93 | 6.15 |



| C23 H55 Cl N6 O6 P2 | 608.3321 | 2.643 | 12 | 5.76 | 5.70 | 5.85 | 5.80 | 5.62 | 5.91 | 7.53 | 15.68 | 7.59 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| C88 H166 N7 O17 P3 | 1686.154 | 2.976 | 23 | 1.24 | 1.24 | 1.77 | 1.44 | 1.23 | 1.87 | 7.56 | 3.53 | 34.19 |
| C15 H33 N3 O4 | 319.2479 | 2.249 | 17 | 0.97 | 1.01 | 0.97 | 1.05 | 0.74 | 1.04 | 7.58 | 36.20 | 10.15 |
| C28 H41 N3 O6 | 515.2978 | 2.753 | 11 | 5.57 | 5.32 | 5.66 | 5.59 | 5.32 | 5.64 | 7.59 | 10.15 | 6.46 |
| C25 H53 N3 O5 | 475.3997 | 3.892 | 22 | 2.17 | 2.01 | 2.23 | 2.39 | 2.05 | 2.17 | 7.62 | 12.28 | 12.09 |
| C32 H67 N | 465.5271 | 4.676 | 2 | 1.47 | 0.14 | 1.20 | 1.46 | 0.07 | 1.26 | 7.65 | 42.88 | 11.89 |
| C54 H44 N8 O2 | 836.3594 | 1.902 | 29 | 3.08 | 2.40 | 3.29 | 3.27 | 2.30 | 3.04 | 7.66 | 17.86 | 34.41 |
| C8 H12 O3 | 156.0784 | 2.314 | 7 | 5.47 | 4.29 | 5.52 | 5.56 | 4.52 | 5.48 | 7.69 | 48.56 | 4.57 |
| C29 H54 N O7 P | 559.3658 | 2.342 | 16 | 2.11 | 1.12 | 2.06 | 2.03 | 1.37 | 2.06 | 7.73 | 34.18 | 4.27 |
| C34 H71 N O | 509.5529 | 10.2 | 4 | 1.81 | 0.44 | 1.52 | 1.78 | 0.49 | 1.55 | 7.75 | 39.88 | 10.67 |
| C22 H33 O9 P | 472.1875 | 3.076 | 10 | 3.82 | 3.36 | 3.96 | 3.89 | 3.17 | 3.80 | 7.75 | 31.11 | 21.11 |
| C20 H40 N6 O | 380.3261 | 4.199 | 12 | 1.62 | 1.69 | 1.59 | 1.69 | 1.68 | 1.69 | 7.75 | 4.85 | 19.39 |
| C31 H55 N O S | 489.4025 | 2.83 | 1 | 1.36 | 0.38 | 1.52 | 1.38 | 0.61 | 1.49 | 7.77 | 45.18 | 7.45 |
| C22 H48 N8 O2 S | 488.3602 | 2.758 | 8 | 3.59 | 3.55 | 3.61 | 3.67 | 3.59 | 3.66 | 7.78 | 5.42 | 8.48 |
| C83 H174 N5 O P S2 | 1352.29 | 11.287 | 15 | 2.51 | 2.53 | 2.49 | 2.52 | 2.67 | 2.46 | 7.81 | 31.64 | 15.03 |
| C27 H35 N2 O2 P S | 482.2164 | 3.076 | 19 | 3.45 | 2.98 | 3.80 | 3.38 | 2.79 | 3.83 | 7.82 | 38.46 | 16.84 |
| C 22 H 41 N 7 | 403.3427 | 3.289 | 13 | 1.77 | 0.54 | 1.55 | 1.99 | 0.64 | 1.55 | 7.83 | 13.58 | 32.86 |
| C43 H85 N O | 631.6628 | 9.845 | 5 | 1.19 | 1.24 | 0.89 | 1.29 | 0.77 | 1.08 | 7.83 | 49.55 | 22.73 |
| C21 H34 | 286.2653 | 11.259 | 13 | 4.43 | 4.34 | 4.54 | 4.51 | 4.52 | 4.53 | 7.84 | 20.90 | 5.72 |
| C27 H45 N5 O2 | 471.3555 | 2.734 | 9 | 1.71 | 1.07 | 1.85 | 1.70 | 1.03 | 1.81 | 7.87 | 39.38 | 7.96 |
| C47 H75 O10 P | 830.5134 | 4.869 | 4 | 1.62 | 1.66 | 1.36 | 1.55 | 1.79 | 1.33 | 7.87 | 36.07 | 18.88 |
| C39 H82 N5 O13 P | 859.564 | 5.632 | 17 | 4.00 | 3.94 | 4.18 | 3.94 | 3.75 | 4.06 | 7.87 | 28.71 | 24.35 |
| C36 H74 N5 O16 P | 863.4858 | 2.784 | 29 | 1.10 | 0.43 | 1.32 | 1.68 | 0.59 | 1.40 | 7.89 | 19.72 | 41.54 |
| C83 H141 N2 P | 1197.083 | 7.314 | 19 | 5.05 | 5.06 | 5.02 | 5.11 | 5.08 | 4.98 | 7.91 | 21.67 | 4.88 |
| C24 H39 O7 P | 470.2454 | 2.308 | 6 | 4.17 | 3.25 | 4.20 | 4.15 | 3.34 | 4.18 | 7.93 | 42.44 | 3.06 |
| C26 H59 N7 O8 | 597.4443 | 2.803 | 9 | 1.16 | 0.90 | 1.75 | 1.53 | 1.12 | 1.74 | 7.93 | 43.80 | 40.74 |


| C23 H48 N6 S | 440.3641 | 1.985 | 19 | 1.92 | 1.38 | 2.08 | 1.98 | 1.21 | 1.98 | 7.93 | 27.54 | 26.45 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| C87 H178 N P S2 | 1332.314 | 11.244 | 7 | 12.96 | 13.05 | 13.03 | 12.99 | 12.89 | 13.02 | 7.95 | 22.94 | 2.46 |
| C12 H32 N8 O3 P2 | 398.2087 | 2.322 | 17 | 4.39 | 3.29 | 4.82 | 4.52 | 3.38 | 4.76 | 7.96 | 26.46 | 47.77 |
| C40 H83 N3 O2 | 637.6479 | 6.651 | 17 | 2.00 | 1.27 | 1.83 | 2.02 | 1.30 | 1.91 | 7.97 | 12.14 | 9.86 |
| C16 H33 N2 O P S3 | 396.15 | 1.845 | 8 | 3.18 | 2.98 | 3.45 | 3.21 | 3.04 | 3.22 | 8.01 | 12.83 | 34.30 |
| C26 H55 N O2 | 413.4226 | 6.402 | 6 | 1.44 | 0.19 | 1.16 | 1.44 | 0.20 | 1.16 | 8.02 | 40.08 | 17.19 |
| C32 H64 N2 O2 | 508.4961 | 5.543 | 8 | 2.41 | 1.94 | 2.58 | 2.53 | 1.99 | 2.53 | 8.02 | 10.12 | 11.25 |
| C4 H4 O7 P2 | 225.9438 | 6.74 | 22 | 5.03 | 4.81 | 5.07 | 4.85 | 4.82 | 5.04 | 8.04 | 13.52 | 3.38 |
| C77 H163 Br N7 O9 P S2 | 1504.087 | 5.211 | 3 | 2.88 | 2.88 | 2.92 | 2.97 | 2.85 | 2.95 | 8.06 | 4.88 | 3.08 |
| C 39 H 79 NO | 577.616 | 5.961 | 19 | 1.96 | 0.29 | 1.66 | 2.01 | 0.55 | 1.63 | 8.07 | 44.18 | 15.63 |
| C26 H51 N O3 | 425.3863 | 3.382 | 6 | 2.33 | 1.95 | 2.36 | 2.45 | 1.98 | 2.32 | 8.08 | 6.23 | 10.86 |
| C32 H53 O9 P | 612.3438 | 2.657 | 19 | 4.15 | 4.11 | 4.08 | 4.16 | 4.12 | 4.11 | 8.09 | 7.23 | 8.85 |
| C29 H65 N10 O3 P | 632.4983 | 5.468 | 9 | 4.11 | 4.08 | 4.07 | 4.08 | 4.10 | 4.11 | 8.10 | 7.86 | 8.87 |
| C19 H37 N O | 295.287 | 3.346 | 16 | 1.67 | 0.37 | 1.41 | 1.77 | 0.45 | 1.36 | 8.11 | 21.48 | 14.94 |
| C42 H93 N5 O10 P2 S2 | 953.5835 | 3.489 | 10 | 1.66 | 1.31 | 1.74 | 1.63 | 1.33 | 1.85 | 8.11 | 4.59 | 20.22 |
| C 10 H 18 O 2 | 170.1304 | 2.828 | 4 | 1.38 | 0.37 | 1.54 | 1.42 | 0.55 | 1.59 | 8.14 | 43.13 | 9.04 |
| C24 H47 N O3 | 397.3552 | 3.014 | 10 | 2.35 | 2.18 | 2.26 | 2.31 | 2.12 | 2.26 | 8.14 | 9.11 | 4.66 |
| C37 H73 N O5 | 611.5483 | 4.136 | 5 | 1.23 | 1.05 | 1.49 | 1.39 | 1.49 | 1.50 | 8.18 | 44.73 | 41.99 |
| C36 H77 N7 011 | 783.5693 | 3.442 | 10 | 4.55 | 4.98 | 4.30 | 4.58 | 5.04 | 4.20 | 8.18 | 13.37 | 31.56 |
| C42 H75 N10 O5 P | 830.5663 | 3.802 | 14 | 2.56 | 2.87 | 2.70 | 2.53 | 2.84 | 2.70 | 8.18 | 15.22 | 0.81 |
| C36 H80 Br N9 O2 | 749.5632 | 10.758 | 10 | 3.66 | 3.41 | 3.30 | 3.60 | 3.46 | 3.42 | 8.19 | 22.31 | 17.42 |
| C30 H44 N4 | 460.3547 | 5.321 | 10 | 2.95 | 2.85 | 2.80 | 2.95 | 2.91 | 2.81 | 8.22 | 10.02 | 3.88 |
| C38 H76 N3 O3 P S | 685.5342 | 3.126 | 13 | 1.72 | 1.78 | 2.00 | 1.94 | 1.75 | 2.03 | 8.23 | 9.02 | 15.76 |
| C62 H93 O12 P S | 1092.612 | 3.517 | 6 | 5.28 | 2.99 | 5.13 | 5.34 | 3.02 | 5.28 | 8.24 | 23.68 | 36.21 |
| C24 H47 O12 P | 558.2792 | 2.643 | 20 | 2.33 | 2.47 | 2.62 | 2.46 | 2.36 | 2.64 | 8.24 | 21.31 | 15.60 |
| C30 H39 N5 | 469.3192 | 2.593 | 19 | 3.28 | 1.86 | 3.45 | 3.30 | 2.03 | 3.57 | 8.25 | 20.10 | 45.41 |


| C18 H38 O3 | 302.2816 | 3.12 | 11 | 3.77 | 3.52 | 3.90 | 3.78 | 3.55 | 3.87 | 8.27 | 5.91 | 4.89 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| C19 H41 N3 O5 | 391.3055 | 2.753 | 15 | 3.03 | 2.59 | 2.95 | 3.07 | 2.51 | 3.06 | 8.27 | 29.56 | 19.41 |
| C30 H34 O4 | 458.2449 | 2.333 | 24 | 2.36 | 1.65 | 2.36 | 2.44 | 1.54 | 2.38 | 8.27 | 41.42 | 4.05 |
| C26 H51 N5 O3 | 481.3974 | 2.829 | 12 | 2.73 | 1.85 | 2.91 | 2.73 | 1.80 | 3.13 | 8.33 | 27.27 | 34.08 |
| C15 H43 N10 P | 394.3425 | 4.769 | 13 | 3.09 | 2.80 | 3.33 | 3.20 | 2.76 | 3.36 | 8.35 | 29.47 | 6.30 |
| C19 H38 O4 | 330.2765 | 3.075 | 10 | 5.83 | 5.05 | 5.91 | 5.86 | 4.84 | 6.03 | 8.36 | 28.19 | 17.81 |
| C36 H66 N2 O2 | 558.5096 | 6.661 | 4 | 2.64 | 2.10 | 2.58 | 2.64 | 2.14 | 2.63 | 8.40 | 12.43 | 8.43 |
| C39 H84 Cl N9 P2 | 775.6023 | 10.553 | 8 | 4.35 | 4.21 | 4.33 | 4.33 | 4.14 | 4.29 | 8.40 | 23.45 | 5.02 |
| C37 H75 N O | 549.5846 | 5.02 | 3 | 1.94 | 0.53 | 1.67 | 1.93 | 0.73 | 1.72 | 8.44 | 42.58 | 8.99 |
| C 13 H 27 NO | 213.2089 | 2.178 | 12 | 1.37 | 0.83 | 0.88 | 1.48 | 0.61 | 0.83 | 8.44 | 33.65 | 17.40 |
| C50 H106 N10 O2 P2 | 940.797 | 8.077 | 20 | 1.33 | 0.97 | 1.52 | 1.37 | 1.32 | 1.50 | 8.46 | 43.32 | 11.69 |
| C59 H103 N2 O5 P S2 | 1014.705 | 3.465 | 19 | 5.45 | 2.15 | 5.37 | 5.29 | 2.59 | 5.33 | 8.47 | 48.68 | 25.32 |
| C20 H43 N O3 | 345.3254 | 7.317 | 16 | 2.35 | 2.42 | 2.27 | 2.35 | 2.49 | 2.22 | 8.50 | 9.40 | 9.82 |
| C39 H76 O2 S2 | 640.5312 | 3.831 | 7 | 2.76 | 2.67 | 2.75 | 2.84 | 2.72 | 2.76 | 8.52 | 12.43 | 4.58 |
| C52 H95 O13 P | 958.6504 | 5.471 | 5 | 2.78 | 2.74 | 2.76 | 2.86 | 2.99 | 2.77 | 8.53 | 40.26 | 7.47 |
| C42 H87 N O6 | 701.6526 | 8.063 | 15 | 1.04 | 0.83 | 1.16 | 1.11 | 1.03 | 1.24 | 8.56 | 24.65 | 14.02 |
| C37 H82 N6 O7 P2 | 784.5717 | 3.442 | 9 | 3.92 | 4.51 | 3.77 | 4.05 | 4.56 | 3.62 | 8.57 | 10.01 | 47.75 |
| C35 H71 N O4 | 569.5387 | 7.315 | 7 | 5.54 | 5.62 | 5.50 | 5.58 | 5.59 | 5.53 | 8.58 | 5.65 | 4.20 |
| C23 H48 N O7 P | 481.3161 | 3.852 | 8 | 1.72 | 1.65 | 1.81 | 1.73 | 1.48 | 1.67 | 8.58 | 32.64 | 20.89 |
| C27 H66 N9 O4 P | 611.4966 | 3.362 | 7 | 3.12 | 3.16 | 3.37 | 3.24 | 3.24 | 3.37 | 8.58 | 12.23 | 21.94 |
| C31 H51 N4 P3 S | 604.3074 | 4.836 | 15 | 1.15 | 0.22 | 1.60 | 1.09 | 0.17 | 1.38 | 8.59 | 27.21 | 48.48 |
| $\begin{aligned} & \text { C82 H175 N10 O16 P3 } \\ & \text { S2 } \end{aligned}$ | 1713.183 | 3.271 | 7 | 3.56 | 3.75 | 4.10 | 3.87 | 3.72 | 4.06 | 8.59 | 3.62 | 8.42 |
| C40 H86 N5 O2 P | 699.6509 | 8.457 | 4 | 1.86 | 2.16 | 1.96 | 1.95 | 2.24 | 1.95 | 8.60 | 22.43 | 6.89 |
| C40 H79 N O6 | 669.59 | 8.091 | 15 | 4.48 | 3.17 | 4.32 | 4.38 | 3.35 | 4.61 | 8.61 | 23.63 | 40.56 |
| C57 H89 N O13 S | 1027.605 | 3.466 | 9 | 5.47 | 4.86 | 5.96 | 5.52 | 4.83 | 5.91 | 8.64 | 17.96 | 43.20 |


| C14 H24 O5 | 272.1618 | 2.312 | 5 | 3.90 | 2.98 | 4.18 | 3.91 | 3.16 | 4.20 | 8.64 | 47.16 | 3.17 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| C35 H73 N | 507.5733 | 6.2 | 17 | 3.88 | 1.59 | 3.71 | 3.81 | 1.97 | 3.49 | 8.67 | 45.30 | 29.37 |
| C85 H172 N2 O3 P2 S2 | 1395.228 | 11.251 | 12 | 5.51 | 5.58 | 5.51 | 5.60 | 5.27 | 5.55 | 8.71 | 40.09 | 11.67 |
| C16 H35 N O | 257.2715 | 2.341 | 5 | 3.09 | 2.94 | 3.21 | 3.40 | 2.86 | 3.70 | 8.72 | 9.60 | 49.35 |
| C63 H103 N O6 | 969.776 | 8.079 | 18 | 1.25 | 0.76 | 1.37 | 1.30 | 0.65 | 1.44 | 8.73 | 34.00 | 13.98 |
| C37 H77 N O | 551.5998 | 5.436 | 3 | 1.13 | 0.17 | 0.81 | 1.17 | 0.13 | 0.84 | 8.73 | 42.26 | 6.44 |
| C31 H55 N O4 | 505.4128 | 4.387 | 11 | 2.27 | 2.35 | 2.32 | 2.35 | 2.37 | 2.35 | 8.76 | 11.12 | 7.28 |
| C22 H46 N8 O S | 470.3502 | 3.214 | 8 | 3.78 | 3.76 | 3.90 | 3.77 | 3.76 | 3.83 | 8.76 | 4.04 | 12.88 |
| C19 H35 N3 | 305.2825 | 1.831 | 10 | 8.08 | 8.01 | 8.16 | 8.07 | 8.03 | 8.22 | 8.78 | 2.41 | 11.86 |
| C37 H73 N2 O8 P | 704.5089 | 8.057 | 28 | 8.06 | 7.34 | 7.70 | 8.10 | 7.30 | 7.89 | 8.80 | 9.15 | 22.61 |
| C27 H55 N O | 409.4277 | 5.924 | 6 | 2.05 | 0.60 | 1.76 | 1.97 | 0.88 | 1.74 | 8.82 | 37.21 | 18.97 |
| C44 H88 N9 O13 P S | 1013.596 | 3.529 | 6 | 6.99 | 6.79 | 7.23 | 7.14 | 6.81 | 7.25 | 8.83 | 44.82 | 39.08 |
| C51 H108 N5 O3 P | 869.8188 | 5.047 | 15 | 3.82 | 2.48 | 3.35 | 3.78 | 2.36 | 3.41 | 8.88 | 45.80 | 18.00 |
| C13 H25 O7 P | 324.1342 | 1.969 | 7 | 1.92 | 1.43 | 2.10 | 2.03 | 1.24 | 1.99 | 8.89 | 25.31 | 29.53 |
| C87 H150 N9 O5 P S3 | 1528.068 | 5.215 | 21 | 2.30 | 2.36 | 2.41 | 2.34 | 2.32 | 2.37 | 8.90 | 9.84 | 8.76 |
| C30 H73 N9 O2 P2 | 653.5389 | 7.313 | 8 | 2.18 | 2.47 | 2.18 | 2.28 | 2.29 | 2.16 | 8.90 | 22.18 | 15.01 |
| C27 H53 N O2 | 423.4069 | 7.321 | 4 | 1.91 | 0.37 | 1.62 | 1.88 | 0.58 | 1.66 | 8.97 | 39.90 | 15.92 |
| C25 H52 N O7 P | 509.3479 | 4.379 | 7 | 2.93 | 3.02 | 2.90 | 2.87 | 3.01 | 2.90 | 8.98 | 3.38 | 1.52 |
| C 22 H 47 N O 2 | 357.36 | 4.886 | 6 | 2.55 | 1.37 | 2.10 | 2.66 | 1.46 | 2.27 | 9.01 | 19.17 | 19.65 |
| C32 H41 N P2 | 501.2717 | 1.696 | 13 | 8.45 | 8.55 | 8.73 | 8.45 | 8.57 | 8.72 | 9.04 | 24.22 | 13.86 |
| C37 H87 N8 O5 P3 | 816.6025 | 3.59 | 14 | 1.95 | 2.06 | 2.25 | 2.08 | 2.08 | 2.24 | 9.05 | 9.55 | 11.51 |
| C39 H76 N6 O2 | 660.6048 | 8.064 | 12 | 1.11 | 0.92 | 1.22 | 1.17 | 0.85 | 1.28 | 9.07 | 9.17 | 13.96 |
| C40 H84 N2 O2 | 624.6521 | 5.978 | 16 | 1.75 | 0.28 | 1.76 | 1.77 | 0.29 | 1.45 | 9.12 | 44.14 | 41.12 |
| C23 H42 N 07 P | 475.2719 | 2.323 | 27 | 2.50 | 1.81 | 2.51 | 2.60 | 1.68 | 2.53 | 9.14 | 41.94 | 3.48 |
| C48 H80 N O8 P | 829.566 | 10.474 | 3 | 4.34 | 4.28 | 4.40 | 4.38 | 4.27 | 4.39 | 9.14 | 11.05 | 7.17 |
| C32 H66 N6 O | 550.5318 | 11.252 | 23 | 1.14 | 0.82 | 1.16 | 1.14 | 1.15 | 1.14 | 9.15 | 35.41 | 7.34 |


| C31 H51 N3 S | 497.3815 | 3.878 | 17 | 3.80 | 3.85 | 3.93 | 3.77 | 3.88 | 3.92 | 9.18 | 14.60 | 4.65 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| C27 H55 N O | 409.4277 | 7.678 | 7 | 1.40 | 0.08 | 1.07 | 1.38 | 0.01 | 1.13 | 9.22 | 33.64 | 29.20 |
| C35 H53 Cl N6 O | 608.3945 | 2.622 | 10 | 3.89 | 3.75 | 3.76 | 3.94 | 3.74 | 3.81 | 9.23 | 7.61 | 14.56 |
| C 13 H 20 O 2 | 208.146 | 3.129 | 18 | 1.83 | 1.41 | 1.65 | 1.67 | 1.42 | 1.61 | 9.24 | 7.82 | 12.45 |
| C38 H79 N O | 565.6156 | 4.917 | 7 | 4.38 | 4.62 | 4.37 | 4.34 | 4.61 | 4.45 | 9.24 | 11.78 | 11.46 |
| C20 H32 N2 O2 | 332.2458 | 2.186 | 2 | 2.13 | 0.83 | 1.77 | 2.05 | 0.77 | 1.80 | 9.25 | 44.76 | 8.07 |
| C27 H53 N O | 407.4121 | 5.5 | 5 | 2.64 | 1.48 | 2.46 | 2.61 | 1.55 | 2.38 | 9.26 | 41.64 | 18.88 |
| C40 H30 N9 O2 P | 699.226 | 4.73 | 8 | 2.11 | 2.12 | 2.17 | 2.04 | 2.15 | 2.17 | 9.29 | 12.16 | 3.13 |
| C58 H115 N O6 | 921.8715 | 11.632 | 4 | 2.30 | 1.41 | 2.25 | 2.31 | 1.67 | 2.43 | 9.30 | 36.82 | 35.93 |
| C65 H129 N O6 | 1019.982 | 11.757 | 7 | 2.70 | 1.79 | 2.85 | 2.67 | 2.18 | 3.10 | 9.33 | 47.34 | 38.61 |
| $\begin{aligned} & \text { C21 H32 Br3 Cl4 N6 O3 } \\ & \text { P3 S2 } \end{aligned}$ | 949.7501 | 8.078 | 14 | 1.13 | 0.95 | 1.23 | 1.14 | 1.30 | 1.28 | 9.34 | 49.32 | 13.97 |
| C25 H51 N O2 | 397.3914 | 6.959 | 16 | 1.84 | 0.67 | 1.69 | 1.92 | 0.66 | 1.63 | 9.34 | 34.73 | 12.24 |
| C39 H73 N O13 | 763.5063 | 1.961 | 11 | 2.07 | 1.69 | 2.24 | 2.14 | 1.83 | 2.15 | 9.35 | 20.68 | 25.44 |
| C51 H97 N10 P | 880.7636 | 8.185 | 16 | 2.12 | 2.25 | 2.28 | 2.37 | 2.27 | 2.29 | 9.35 | 6.24 | 10.60 |
| C86 H163 N O18 | 1498.189 | 8.073 | 12 | 0.99 | 0.84 | 1.28 | 1.05 | 0.90 | 1.16 | 9.39 | 15.56 | 16.97 |
| C24 H47 N O7 | 461.3344 | 2.427 | 12 | 1.81 | 1.81 | 1.89 | 1.81 | 1.72 | 1.88 | 9.40 | 16.08 | 15.76 |
| C38 H77 N O | 563.6002 | 4.248 | 22 | 1.28 | 1.70 | 1.39 | 1.19 | 1.56 | 1.36 | 9.45 | 30.27 | 10.20 |
| C37 H73 N5 O8 | 715.5437 | 2.909 | 10 | 5.09 | 4.17 | 5.26 | 5.15 | 4.12 | 5.39 | 9.47 | 14.90 | 43.22 |
| C17 H45 N9 O P2 | 453.3232 | 3.236 | 9 | 3.68 | 3.63 | 3.73 | 3.59 | 3.65 | 3.65 | 9.49 | 2.54 | 14.19 |
| $\mathrm{C} 12 \mathrm{H} 20 \mathrm{O6}$ | 260.1254 | 2.314 | 25 | 5.16 | 3.62 | 5.51 | 5.26 | 3.80 | 5.50 | 9.54 | 29.60 | 5.82 |
| C26 H51 N O2 | 409.3913 | 7.036 | 4 | 1.11 | 0.51 | 0.63 | 1.13 | 0.22 | 0.78 | 9.55 | 34.40 | 19.31 |
| C36 H35 N4 O6 P S | 682.202 | 2.659 | 11 | 3.48 | 3.54 | 3.46 | 3.73 | 3.54 | 3.43 | 9.58 | 2.37 | 8.36 |
| C35 H73 N O | 523.5687 | 4.875 | 5 | 1.10 | 0.21 | 0.92 | 1.22 | 0.21 | 0.96 | 9.60 | 40.54 | 16.70 |
| C36 H76 N2 O | 552.5951 | 7.319 | 7 | 1.26 | 0.21 | 0.98 | 1.19 | 0.08 | 0.99 | 9.63 | 35.49 | 9.75 |
| C16 H31 N O4 | 301.2247 | 1.961 | 21 | 2.45 | 1.98 | 2.62 | 2.55 | 1.78 | 2.55 | 9.63 | 30.73 | 27.68 |



| C35 H77 N4 O2 P | 616.5784 | 8.071 | 9 | 1.14 | 0.96 | 1.23 | 1.15 | 1.33 | 1.27 | 10.15 | 49.72 | 14.03 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| C29 H45 N O4 | 471.3339 | 2.748 | 2 | 6.54 | 6.52 | 6.62 | 6.53 | 6.51 | 6.62 | 10.19 | 1.57 | 5.18 |
| C31 H65 N O | 467.5061 | 9.652 | 4 | 2.97 | 1.54 | 2.71 | 2.98 | 1.69 | 2.71 | 10.21 | 40.66 | 11.96 |
| C25 H53 N O | 383.412 | 8.187 | 5 | 1.88 | 0.38 | 1.58 | 1.87 | 0.56 | 1.68 | 10.23 | 38.70 | 18.86 |
| C59 H99 N S | 853.7484 | 9.631 | 18 | 4.51 | 4.48 | 4.54 | 4.68 | 4.78 | 4.48 | 10.28 | 33.81 | 14.98 |
| C41 H58 Cl N7 P2 S5 | 905.2513 | 7.547 | 8 | 2.55 | 2.44 | 2.46 | 2.50 | 2.41 | 2.54 | 10.30 | 22.45 | 9.91 |
| C40 H84 N2 O | 608.6574 | 8.466 | 5 | 1.40 | 0.15 | 1.21 | 1.33 | 0.10 | 1.28 | 10.30 | 47.73 | 12.55 |
| C20 H45 N3 O5 S | 439.3056 | 2.752 | 9 | 3.15 | 3.23 | 3.30 | 3.30 | 3.32 | 3.34 | 10.33 | 11.70 | 6.76 |
| C21 H17 N5 O16 P2 S | 688.9863 | 3.052 | 15 | 3.48 | 3.56 | 4.04 | 3.94 | 3.55 | 4.13 | 10.37 | 9.79 | 21.87 |
| C28 H45 N O4 | 459.3349 | 2.283 | 6 | 4.81 | 4.78 | 4.85 | 4.85 | 4.73 | 4.82 | 10.42 | 6.49 | 6.97 |
| $\mathrm{C} 16 \mathrm{H} 28 \mathrm{O6}$ | 316.1881 | 2.314 | 2 | 2.07 | 1.11 | 2.13 | 2.07 | 1.25 | 2.16 | 10.45 | 45.85 | 4.63 |
| C37 H80 N4 O10 P2 | 802.5357 | 3.338 | 6 | 3.41 | 3.72 | 3.29 | 3.32 | 3.72 | 3.24 | 10.48 | 9.66 | 15.22 |
| C54 H74 O3 S | 802.5349 | 3.421 | 6 | 1.79 | 2.10 | 1.67 | 1.70 | 2.10 | 1.62 | 10.48 | 9.66 | 15.22 |
| C39 H77 N O5 | 639.5798 | 4.781 | 7 | 2.30 | 2.34 | 2.42 | 2.54 | 2.71 | 2.64 | 10.51 | 39.18 | 32.85 |
| C50 H104 N4 O3 S2 | 872.7552 | 3.385 | 27 | 5.75 | 5.12 | 5.96 | 6.03 | 5.13 | 5.81 | 10.51 | 12.35 | 20.35 |
| C24 H54 N5 O P | 459.407 | 6.628 | 7 | 1.58 | 0.29 | 1.32 | 1.61 | 0.33 | 1.32 | 10.52 | 38.49 | 12.26 |
| C21 H35 N | 301.2763 | 4.185 | 8 | 1.17 | 0.24 | 0.98 | 1.12 | 0.19 | 1.00 | 10.52 | 38.49 | 6.18 |
| C21 H38 N O7 P | 447.2403 | 1.919 | 17 | 2.50 | 1.94 | 2.68 | 2.59 | 1.74 | 2.50 | 10.54 | 32.94 | 28.21 |
| C28 H60 N2 O | 440.4702 | 4.11 | 7 | 2.52 | 0.40 | 1.85 | 2.39 | 0.75 | 1.92 | 10.54 | 40.13 | 20.53 |
| C24 H49 N O | 367.3813 | 2.616 | 14 | 1.59 | 0.41 | 1.47 | 1.54 | 0.47 | 1.47 | 10.55 | 42.69 | 15.46 |
| C5 H14 N O4 P | 183.0657 | 5.62 | 16 | 3.24 | 3.17 | 3.23 | 3.29 | 3.35 | 3.21 | 10.56 | 21.46 | 3.05 |
| C37 H67 O10 P | 702.4458 | 4.867 | 19 | 6.35 | 5.42 | 6.39 | 6.25 | 5.23 | 6.47 | 10.58 | 38.52 | 24.37 |
| C82 H164 N10 O9 P2 S | 1527.188 | 5.617 | 7 | 7.84 | 7.82 | 7.87 | 7.99 | 7.89 | 7.92 | 10.60 | 14.90 | 10.70 |
| C16 H45 N10 O4 P | 472.3372 | 2.751 | 4 | 5.83 | 5.53 | 5.82 | 5.70 | 5.53 | 5.83 | 10.61 | 2.12 | 12.47 |
| C21 H33 N3 O4 | 391.2466 | 2.08 | 8 | 1.19 | 0.43 | 0.55 | 1.19 | 0.58 | 0.58 | 10.69 | 44.64 | 26.56 |
| C31 H63 N O3 | 497.4799 | 3.497 | 13 | 1.97 | 1.63 | 2.03 | 1.91 | 1.66 | 2.15 | 10.69 | 7.35 | 19.45 |


| C44 H25 O9 P3 | 790.0713 | 5.652 | 17 | 2.32 | 2.22 | 2.33 | 2.36 | 1.95 | 2.35 | 10.70 | 46.60 | 1.78 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| C19 H31 N O4 | 337.2244 | 1.883 | 22 | 2.85 | 2.33 | 2.98 | 3.30 | 2.11 | 2.80 | 10.71 | 37.70 | 27.98 |
| C60 H120 N2 O15 S | 1140.841 | 3.499 | 16 | 3.07 | 3.07 | 3.30 | 3.31 | 3.16 | 3.30 | 10.71 | 13.38 | 20.76 |
| C27 H55 N O2 | 425.4227 | 6.492 | 2 | 1.03 | 0.09 | 0.76 | 1.01 | 0.03 | 0.81 | 10.74 | 30.81 | 13.40 |
| C23 H58 N10 O6 | 570.4528 | 2.717 | 3 | 3.20 | 2.42 | 3.36 | 3.22 | 2.44 | 3.45 | 10.74 | 9.85 | 36.70 |
| C21 H39 N O | 321.3025 | 5.033 | 15 | 1.81 | 0.56 | 1.57 | 1.82 | 0.69 | 1.51 | 10.76 | 17.62 | 10.94 |
| C19 H34 O4 | 326.2451 | 2.33 | 15 | 5.33 | 4.07 | 5.21 | 5.61 | 4.16 | 5.47 | 10.78 | 15.11 | 32.71 |
| C25 H45 N3 O2 | 419.3508 | 2.186 | 3 | 1.42 | 0.16 | 0.96 | 1.33 | 0.04 | 0.90 | 10.80 | 40.47 | 10.14 |
| C13 H18 | 174.1405 | 11.257 | 7 | 5.04 | 5.22 | 5.17 | 5.06 | 5.28 | 5.16 | 10.81 | 8.15 | 9.88 |
| C38 H76 N2 O2 | 592.5902 | 7.658 | 4 | 1.20 | 0.45 | 1.43 | 1.38 | 0.56 | 1.33 | 10.82 | 22.11 | 24.33 |
| C20 H46 N10 | 426.3897 | 4.814 | 23 | 1.66 | 1.32 | 1.43 | 1.67 | 1.37 | 1.47 | 10.82 | 10.10 | 8.05 |
| C37 H75 N O | 549.5847 | 8.894 | 6 | 3.05 | 1.54 | 2.76 | 2.99 | 1.80 | 2.78 | 10.83 | 37.66 | 10.10 |
| C21 H33 N3 O3 | 375.2511 | 1.54 | 9 | 2.28 | 1.26 | 2.06 | 2.34 | 1.35 | 2.09 | 10.87 | 16.57 | 5.38 |
| C15 H22 | 202.1717 | 11.258 | 22 | 4.10 | 4.36 | 4.29 | 4.18 | 4.33 | 4.28 | 10.94 | 20.23 | 8.61 |
| C23 H31 O7 P | 450.1806 | 2.28 | 6 | 1.96 | 1.05 | 2.00 | 1.92 | 1.24 | 2.01 | 10.96 | 37.58 | 1.24 |
| C23 H48 N O7 P | 481.3164 | 2.291 | 6 | 5.92 | 5.90 | 5.97 | 5.96 | 5.86 | 5.93 | 10.96 | 5.56 | 7.57 |
| C30 H61 O4 P | 516.4294 | 3.085 | 6 | 3.18 | 1.91 | 3.37 | 3.19 | 2.32 | 3.40 | 10.98 | 45.34 | 7.06 |
| C21 H49 N10 O6 P | 568.357 | 3.557 | 22 | 4.82 | 4.63 | 4.55 | 4.75 | 4.66 | 4.58 | 10.99 | 9.17 | 6.07 |
| C21 H49 N10 O6 P | 568.3569 | 3.54 | 22 | 4.90 | 4.88 | 4.76 | 4.83 | 4.89 | 4.73 | 10.99 | 12.07 | 9.68 |
| C27 H53 N O | 407.4121 | 5.892 | 4 | 1.91 | 0.59 | 1.49 | 1.87 | 0.76 | 1.45 | 11.00 | 31.92 | 8.16 |
| $\mathrm{C} 23 \mathrm{H} 43 \mathrm{~N} \mathrm{O2}$ | 365.329 | 3.752 | 19 | 1.08 | 0.83 | 0.67 | 1.11 | 0.53 | 0.69 | 11.02 | 43.06 | 15.08 |
| C29 H59 N O6 | 517.4341 | 3.113 | 7 | 3.04 | 1.76 | 3.23 | 3.05 | 2.18 | 3.25 | 11.06 | 45.39 | 7.18 |
| C58 H63 N8 O18 P3 S2 | 1316.291 | 11.245 | 5 | 7.12 | 7.16 | 7.26 | 7.14 | 7.09 | 7.25 | 11.06 | 19.54 | 2.04 |
| C22 H48 N9 O2 P | 501.3661 | 2.618 | 4 | 3.61 | 3.17 | 3.80 | 3.78 | 3.08 | 3.82 | 11.10 | 10.98 | 20.55 |
| C25 H52 N6 S | 468.3958 | 2.357 | 4 | 1.45 | 0.68 | 1.58 | 1.51 | 0.98 | 1.66 | 11.10 | 36.87 | 12.32 |
| C31 H60 N3 O P3 | 583.3929 | 2.261 | 8 | 4.16 | 2.80 | 4.38 | 4.01 | 3.17 | 4.41 | 11.14 | 42.63 | 5.52 |


|  | C54 H98 CI N3 O S2 | 903.6839 | 9.187 | 13 | 3.82 | 3.92 | 4.02 | 3.76 | 3.89 | 4.12 | 11.14 | 11.27 | 12.08 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | C23 H54 N9 O P | 503.4181 | 2.831 | 3 | 1.63 | 0.38 | 1.68 | 1.52 | 0.72 | 1.68 | 11.15 | 38.49 | 7.16 |
|  | C12 H27 N9 O4 | 361.2172 | 11.25 | 8 | 4.02 | 4.31 | 4.36 | 4.11 | 4.20 | 4.37 | 11.17 | 17.95 | 9.71 |
|  | C72 H144 N5 O2 P3 | 1204.053 | 9.629 | 13 | 4.37 | 4.48 | 4.57 | 4.38 | 4.52 | 4.51 | 11.17 | 10.27 | 9.29 |
|  | C18 H46 N8 O6 S | 502.3247 | 2.312 | 17 | 3.37 | 2.69 | 3.36 | 3.37 | 2.84 | 3.30 | 11.20 | 38.22 | 8.43 |
|  | C27 H44 O3 | 416.3283 | 3.472 | 23 | 2.37 | 2.05 | 2.42 | 2.31 | 2.06 | 2.58 | 11.22 | 8.90 | 17.31 |
|  | C25 H58 N9 O P S | 563.4217 | 4.621 | 12 | 1.51 | 1.46 | 1.66 | 1.62 | 1.47 | 1.69 | 11.23 | 5.24 | 11.62 |
|  | C30 H69 N10 O7 P | 712.5096 | 4.882 | 16 | 3.48 | 2.69 | 3.59 | 3.62 | 2.79 | 3.94 | 11.24 | 24.19 | 46.59 |
|  | C18 H48 N9 P3 | 483.3251 | 3.081 | 7 | 3.52 | 2.00 | 3.66 | 3.47 | 1.98 | 3.75 | 11.25 | 18.87 | 41.67 |
|  | C8 H19 N8 P | 258.1462 | 8.042 | 13 | 4.02 | 2.94 | 3.70 | 3.86 | 3.07 | 3.79 | 11.26 | 49.11 | 31.98 |
|  | C49 H98 Cl N3 O8 | 891.7034 | 9.625 | 20 | 6.09 | 6.06 | 6.13 | 6.29 | 6.34 | 6.08 | 11.26 | 31.98 | 15.48 |
|  | C23 H47 N3 O2 | 397.3661 | 1.889 | 11 | 2.49 | 1.98 | 2.62 | 2.53 | 1.95 | 2.44 | 11.28 | 13.88 | 27.67 |
|  | C25 H58 N9 O3 P | 563.4391 | 2.314 | 3 | 3.49 | 2.56 | 3.39 | 3.48 | 2.62 | 3.40 | 11.28 | 42.50 | 1.53 |
|  | C20 H46 N7 O P | 431.3507 | 2.048 | 23 | 1.63 | 0.40 | 1.30 | 1.48 | 0.01 | 1.36 | 11.30 | 48.94 | 10.69 |
|  | C23 H49 N | 339.3858 | 2.812 | 9 | 1.16 | 0.21 | 1.06 | 1.15 | 0.08 | 1.10 | 11.31 | 38.38 | 10.72 |
|  | C68 H75 Cl N 014 P S3 | 1291.378 | 7.748 | 18 | 2.80 | 2.33 | 2.89 | 2.75 | 2.45 | 2.90 | 11.35 | 17.17 | 9.78 |
|  | C80 H173 N10 O18 P3 S | 1687.186 | 3.288 | 13 | 1.91 | 1.68 | 2.04 | 2.16 | 1.53 | 2.10 | 11.36 | 18.41 | 16.53 |
|  | C26 H45 N O | 387.3494 | 4.729 | 5 | 1.29 | 0.54 | 1.01 | 1.39 | 0.10 | 0.99 | 11.38 | 44.74 | 22.14 |
|  | C39 H61 N9 O P2 S2 | 797.3912 | 2.321 | 30 | 2.54 | 1.91 | 2.58 | 2.66 | 1.72 | 2.58 | 11.39 | 44.10 | 4.27 |
|  | C37 H77 N O | 551.6002 | 5.055 | 5 | 1.60 | 0.08 | 1.18 | 1.50 | 0.13 | 1.16 | 11.43 | 47.85 | 17.51 |
|  | C12 H27 N9 O4 | 361.2173 | 7.747 | 8 | 1.56 | 1.03 | 1.96 | 1.48 | 0.89 | 1.93 | 11.46 | 25.72 | 37.22 |
|  | C33 H51 N O13 | 669.3334 | 2.363 | 27 | 2.11 | 1.63 | 2.11 | 2.13 | 1.34 | 2.15 | 11.48 | 45.93 | 7.68 |
|  | C39 H59 N5 O3 P2 | 707.4062 | 3.458 | 1 | 4.65 | 4.16 | 4.93 | 4.76 | 4.06 | 5.03 | 11.52 | 27.98 | 42.55 |
|  | C23 H51 N7 O | 441.4178 | 4.574 | 11 | 1.46 | 0.03 | 0.91 | 1.40 | 0.02 | 0.97 | 11.53 | 41.40 | 14.10 |
|  | C28 H59 N | 409.4643 | 3.632 | 4 | 2.12 | 0.46 | 1.63 | 2.04 | 0.68 | 1.76 | 11.55 | 33.68 | 17.56 |
|  | C35 H44 O23 | 832.231 | 7.39 | 16 | 2.94 | 2.65 | 3.01 | 2.74 | 2.63 | 2.94 | 11.59 | 12.80 | 10.52 |


| C28 H57 N | 407.4485 | 3.408 | 10 | 1.33 | 0.19 | 0.60 | 1.30 | 0.09 | 0.67 | 11.60 | 41.70 | 15.54 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| C51 H92 N O8 P | 877.6574 | 8.028 | 29 | 1.03 | 0.28 | 0.97 | 1.06 | 0.27 | 1.10 | 11.61 | 20.00 | 15.23 |
| C38 H77 N O | 563.5998 | 5.977 | 17 | 2.67 | 2.96 | 2.72 | 2.66 | 2.82 | 2.75 | 11.63 | 17.48 | 3.59 |
| C42 H86 N2 O4 | 682.6582 | 3.074 | 12 | 3.44 | 1.75 | 3.07 | 3.49 | 2.07 | 2.77 | 11.65 | 38.90 | 47.82 |
| C43 H81 O7 P | 740.5695 | 6.532 | 14 | 3.38 | 3.60 | 3.57 | 3.35 | 3.49 | 3.48 | 11.69 | 26.75 | 17.27 |
| C20 H45 O P3 | 394.2693 | 2.49 | 10 | 8.98 | 7.97 | 8.80 | 9.07 | 7.70 | 8.88 | 11.77 | 47.89 | 16.38 |
| C31 H36 O8 S | 568.2129 | 2.358 | 13 | 1.73 | 1.05 | 1.85 | 1.80 | 1.17 | 1.85 | 11.80 | 37.57 | 2.92 |
| C25 H43 N3 O2 | 417.3347 | 2.047 | 4 | 1.31 | 0.77 | 0.90 | 1.20 | 0.44 | 0.95 | 11.91 | 49.52 | 6.93 |
| C47 H39 Cl N7 O2 P S | 831.2317 | 7.396 | 5 | 2.93 | 2.67 | 2.86 | 2.77 | 2.66 | 2.82 | 11.92 | 15.61 | 5.57 |
| C23 H51 N7 O2 | 457.4123 | 5.812 | 18 | 2.13 | 1.01 | 2.57 | 2.22 | 1.29 | 2.48 | 11.92 | 43.38 | 42.11 |
| C14 H33 N4 O3 P S2 | 400.1734 | 1.902 | 15 | 2.56 | 2.13 | 2.71 | 2.66 | 1.86 | 2.55 | 11.93 | 41.16 | 25.94 |
| C82 H158 N8 O14 | 1479.191 | 5.194 | 16 | 3.54 | 3.62 | 3.66 | 3.66 | 3.46 | 3.62 | 11.93 | 21.51 | 7.18 |
| C26 H50 N4 | 418.4051 | 2.542 | 23 | 0.87 | 0.77 | 0.58 | 1.08 | 0.71 | 0.47 | 11.95 | 27.46 | 14.57 |
| C21 H43 N O | 325.3338 | 2.809 | 3 | 2.40 | 1.93 | 2.43 | 2.44 | 1.80 | 2.57 | 11.96 | 18.81 | 19.92 |
| C75 H137 N9 O S | 1212.066 | 6.075 | 5 | 1.21 | 0.94 | 0.97 | 1.09 | 0.95 | 0.99 | 11.97 | 30.51 | 7.17 |
| C27 H46 O10 | 530.3085 | 2.668 | 7 | 5.44 | 5.52 | 5.71 | 5.44 | 5.50 | 5.62 | 11.98 | 3.67 | 17.08 |
| C31 H63 N O3 | 497.4801 | 6.799 | 3 | 1.32 | 0.25 | 1.09 | 1.28 | 0.18 | 1.05 | 11.99 | 41.75 | 13.53 |
| C18 H44 N6 O S | 392.3283 | 8.069 | 8 | 1.06 | 0.64 | 1.14 | 1.02 | 0.42 | 1.15 | 12.00 | 45.95 | 14.24 |
| C90 H175 P S2 | 1351.285 | 11.277 | 26 | 3.39 | 3.55 | 3.29 | 3.42 | 3.46 | 3.32 | 12.04 | 19.41 | 15.73 |
| C35 H78 N9 O2 P | 687.6005 | 7.494 | 5 | 4.60 | 3.63 | 4.45 | 4.51 | 3.38 | 4.53 | 12.05 | 46.67 | 14.03 |
| C 28 H 57 N O 2 | 439.4384 | 7.06 | 5 | 1.61 | 0.40 | 1.30 | 1.57 | 0.45 | 1.33 | 12.06 | 32.01 | 12.04 |
| C17 H44 N9 O4 P | 469.3244 | 4.899 | 12 | 1.98 | 2.21 | 2.50 | 2.05 | 2.23 | 2.29 | 12.15 | 12.21 | 34.15 |
| C19 H45 N9 O4 | 463.3597 | 1.955 | 7 | 1.96 | 1.01 | 1.42 | 1.82 | 0.72 | 1.29 | 12.20 | 48.65 | 36.05 |
| C22 H45 N O4 | 387.3342 | 2.711 | 7 | 2.92 | 2.66 | 2.81 | 3.05 | 2.79 | 2.82 | 12.21 | 15.29 | 7.63 |
| C13 H34 N10 O7 | 442.2598 | 3.498 | 10 | 3.79 | 3.52 | 3.79 | 3.85 | 3.33 | 3.79 | 12.21 | 38.78 | 3.22 |
| C38 H54 N2 O3 | 586.4166 | 2.848 | 18 | 1.74 | 1.97 | 1.73 | 1.94 | 2.00 | 1.63 | 12.23 | 8.04 | 49.01 |


|  | C16 H24 O4 | 280.1671 | 2.291 | 17 | 2.12 | 2.04 | 2.14 | 2.26 | 2.31 | 2.17 | 12.24 | 38.51 |
| :--- | :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | C28 H51 N9 O S | 561.3943 | 2.667 | 9 | 2.09 | 1.93 | 2.30 | 2.15 | 2.00 | 2.22 | 12.24 | 18.84 |
|  | C48 H73 N O6 | 759.5454 | 5.793 | 9 | 1.43 | 0.19 | 1.05 | 1.39 | 0.09 | 0.98 | 12.26 | 45.45 |
|  | C87 H174 N5 O17 P3 S | 1686.184 | 3.28 | 19 | 2.20 | 1.77 | 2.16 | 2.06 | 1.75 | 2.28 | 12.27 | 4.77 |
|  | C22 H47 N O2 | 357.3601 | 2.81 | 3 | 2.42 | 1.95 | 2.44 | 2.45 | 1.81 | 2.59 | 12.28 | 19.63 |
|  | C22 H38 N4 O3 | 406.2935 | 1.498 | 11 | 2.91 | 2.49 | 2.75 | 2.67 | 2.42 | 2.75 | 12.29 | 18.28 |
|  | C12 H22 O4 | 230.1512 | 3.498 | 4 | 2.02 | 2.14 | 2.10 | 2.01 | 2.05 | 2.10 | 12.33 | 12.80 |
|  | C57 H75 N9 O2 | 917.6047 | 3.466 | 17 | 3.71 | 1.72 | 4.15 | 3.32 | 1.74 | 3.96 | 12.35 | 2.62 |
|  | C41 H80 CI N6 O4 P | 786.5659 | 4.943 | 9 | 2.96 | 2.88 | 2.84 | 2.82 | 2.88 | 2.80 | 12.36 | 2.36 |
|  | C16 H24 Cl N3 O2 | 325.1551 | 1.296 | 4 | 2.00 | 0.78 | 1.71 | 1.86 | 0.92 | 1.63 | 12.37 | 28.28 |
|  | C29 H61 N | 423.4798 | 3.835 | 2 | 1.19 | 0.28 | 0.84 | 1.11 | 0.04 | 0.92 | 12.42 | 33.73 |
|  | C20 H39 N | 293.3077 | 2.6 | 19 | 1.28 | 0.94 | 0.89 | 1.22 | 0.44 | 0.81 | 12.42 | 48.59 |
|  | C21 H50 N5 O P | 419.3757 | 3.751 | 7 | 2.31 | 0.88 | 1.99 | 2.34 | 1.19 | 2.06 | 12.43 | 38.40 |
|  | C23 H43 P3 | 412.2583 | 3.421 | 11 | 1.53 | 1.56 | 1.36 | 1.41 | 1.60 | 1.27 | 12.45 | 7.56 |
|  | C41 H80 Cl N6 O4 P | 786.5664 | 3.862 | 14 | 7.01 | 6.92 | 7.06 | 7.00 | 6.98 | 7.00 | 12.47 | 7.91 |
|  | 13.12 |  |  |  |  |  |  |  |  |  |  |  |
|  | C19 H28 | 256.2184 | 11.257 | 10 | 4.82 | 4.74 | 4.84 | 4.76 | 4.85 | 4.79 | 12.48 | 13.43 |
|  | C41 H65 N2 O8 P3 S | 838.3668 | 1.876 | 17 | 2.72 | 2.25 | 2.85 | 2.76 | 2.00 | 2.65 | 12.51 | 41.19 |
|  | 25.44 |  |  |  |  |  |  |  |  |  |  |  |
|  | C7 H17 N O5 | 195.1102 | 1.932 | 22 | 2.33 | 1.82 | 2.52 | 2.46 | 1.63 | 2.38 | 12.53 | 30.23 | 27.32.



|  | C11 H30 N9 O6 P | 415.2067 | 1.745 | 15 | 11.16 | 10.82 | 11.30 | 11.36 | 10.87 | 11.18 | 13.18 | 19.45 | 25.45 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | C29 H62 N O P S | 503.4308 | 4.532 | 25 | 2.84 | 2.84 | 2.77 | 2.91 | 2.94 | 2.81 | 13.20 | 16.06 | 14.11 |
|  | C20 H47 N7 | 385.3911 | 5.236 | 5 | 1.17 | 0.42 | 0.71 | 1.09 | 0.23 | 0.80 | 13.20 | 36.56 | 14.95 |
|  | C11 H19 N7 | 249.17 | 1.142 | 14 | 2.23 | 2.63 | 0.96 | 2.00 | 2.26 | 0.61 | 13.21 | 46.91 | 49.18 |
|  | C21 H43 N O2 | 341.329 | 4.684 | 8 | 1.52 | 0.07 | 0.99 | 1.55 | 0.08 | 1.08 | 13.24 | 36.28 | 13.38 |
|  | C24 H52 N9 O3 P | 545.3927 | 2.611 | 4 | 3.85 | 3.40 | 4.06 | 3.95 | 3.45 | 3.99 | 13.25 | 7.27 | 17.96 |
|  | C75 H151 N10 O17 P S | 1527.072 | 5.202 | 19 | 3.38 | 3.53 | 3.47 | 3.38 | 3.32 | 3.45 | 13.27 | 31.52 | 7.41 |
|  | C26 H56 N9 O14 P S3 | 845.2848 | 7.622 | 10 | 2.46 | 2.24 | 2.37 | 2.36 | 2.22 | 2.34 | 13.28 | 3.35 | 5.71 |
|  | C19 H43 N8 O P | 430.329 | 3.111 | 5 | 3.57 | 2.29 | 3.71 | 3.52 | 2.51 | 3.75 | 13.30 | 45.31 | 6.50 |
|  | C27 H55 N O | 409.4276 | 5.256 | 14 | 1.56 | 0.22 | 1.35 | 1.66 | 0.32 | 1.44 | 13.32 | 42.19 | 11.00 |
|  | C12 H26 O3 | 218.1879 | 2.179 | 4 | 6.72 | 6.34 | 6.00 | 6.71 | 6.16 | 6.01 | 13.36 | 28.48 | 2.96 |
|  | C28 H41 Br N6 O7 S | 684.1941 | 6.404 | 17 | 3.48 | 3.30 | 3.29 | 3.38 | 3.23 | 3.34 | 13.37 | 11.38 | 7.49 |
|  | C27 H48 N 07 P | 529.3164 | 2.688 | 8 | 5.86 | 5.93 | 6.16 | 5.83 | 5.93 | 6.09 | 13.39 | 0.82 | 9.44 |
|  | C48 H65 N6 O P | 772.4965 | 8.097 | 12 | 5.03 | 5.14 | 5.43 | 5.07 | 5.19 | 5.44 | 13.39 | 9.35 | 7.72 |
|  | C55 H81 N8 O8 P | 1012.592 | 3.451 | 16 | 10.82 | 10.81 | 11.27 | 11.08 | 10.92 | 11.26 | 13.40 | 47.77 | 39.05 |
|  | C14 H35 N10 O2 P | 406.2685 | 2.755 | 19 | 1.29 | 1.58 | 1.34 | 1.14 | 1.52 | 1.35 | 13.42 | 23.08 | 4.54 |
|  | C16 H41 N8 P | 376.3185 | 2.867 | 7 | 2.75 | 2.00 | 3.01 | 2.72 | 2.05 | 3.01 | 13.43 | 15.05 | 41.35 |
|  | C9 H14 O3 | 170.0939 | 3.5 | 8 | 2.12 | 2.10 | 2.18 | 1.96 | 2.08 | 2.18 | 13.43 | 7.11 | 2.07 |
|  | C21 H44 N 07 P | 453.2846 | 5.467 | 20 | 3.48 | 3.37 | 3.38 | 3.53 | 3.54 | 3.42 | 13.46 | 18.72 | 7.71 |
|  | C42 H76 N 07 P | 737.5325 | 4.873 | 13 | 5.12 | 4.23 | 5.23 | 5.12 | 4.20 | 5.44 | 13.49 | 43.80 | 46.24 |
|  | C44 H88 N5 P3 | 779.6261 | 5.926 | 13 | 1.30 | 1.55 | 1.52 | 1.31 | 1.60 | 1.50 | 13.50 | 7.51 | 3.52 |
|  | C29 H70 N9 O4 P | 639.528 | 3.838 | 13 | 2.37 | 2.14 | 2.42 | 2.45 | 2.22 | 2.36 | 13.52 | 12.56 | 8.39 |
|  | C 23 H 47 N O 2 | 369.3601 | 4.37 | 2 | 1.27 | 0.11 | 0.85 | 1.20 | 0.02 | 0.94 | 13.54 | 30.85 | 13.09 |
|  | C25 H49 N O | 379.3809 | 4.575 | 5 | 1.16 | 0.03 | 0.92 | 1.12 | 0.17 | 0.93 | 13.56 | 30.44 | 10.96 |
|  | C38 H77 N O12 | 739.5441 | 3.085 | 7 | 3.48 | 3.07 | 3.56 | 3.56 | 3.10 | 3.59 | 13.62 | 9.75 | 10.18 |
|  | C25 H52 O7 | 464.3708 | 2.834 | 8 | 2.54 | 1.77 | 2.68 | 2.50 | 1.65 | 2.92 | 13.64 | 21.86 | 32.47 |


|  | C43 H87 N O5 | 697.6581 | 8.071 | 17 | 2.23 | 2.37 | 1.94 | 2.07 | 2.38 | 2.03 | 13.66 | 3.12 | 20.34 |
| :--- | :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | C56 H102 N O6 P3 S5 | 1137.552 | 2.032 | 16 | 1.55 | 1.14 | 1.73 | 1.64 | 0.95 | 1.63 | 13.69 | 29.58 | 31.45 |
|  | C24 H51 N O | 369.3965 | 7.858 | 2 | 1.33 | 0.13 | 0.99 | 1.26 | 0.08 | 1.06 | 13.70 | 31.47 | 14.66 |
|  | C28 H50 N O7 P | 543.3339 | 2.348 | 25 | 1.72 | 0.88 | 1.85 | 1.68 | 1.20 | 1.80 | 13.74 | 36.17 | 13.69 |
|  | C43 H69 N O7 | 711.5062 | 4.878 | 18 | 5.27 | 4.77 | 5.43 | 5.42 | 4.68 | 5.66 | 13.74 | 18.23 | 49.10 |
|  | C12 H20 O | 180.1511 | 3.207 | 6 | 1.75 | 1.77 | 1.90 | 1.79 | 1.72 | 1.87 | 13.74 | 11.60 | 6.25 |
|  | C13 H36 N9 O4 P | 413.2616 | 3.41 | 9 | 3.54 | 3.61 | 3.44 | 3.46 | 3.68 | 3.41 | 13.76 | 9.12 | 17.06 |
|  | C27 H57 N | 395.4483 | 3.454 | 2 | 1.01 | 0.02 | 0.67 | 1.05 | 0.18 | 0.69 | 13.77 | 32.89 | 30.43 |
|  | C28 H55 N O2 | 437.4228 | 7.545 | 2 | 1.24 | 0.33 | 0.83 | 1.14 | 0.14 | 0.92 | 13.78 | 39.62 | 14.14 |
|  | C23 H49 N O | 355.3809 | 2.909 | 3 | 1.38 | 0.21 | 0.91 | 1.28 | 0.04 | 0.98 | 13.78 | 32.96 | 12.23 |
|  | C34 H46 N4 O4 P2 | 636.2969 | 2.789 | 11 | 5.15 | 4.52 | 5.40 | 5.18 | 4.59 | 5.62 | 13.79 | 34.98 | 45.32 |
|  | C33 H70 N3 O7 P | 651.4922 | 3.127 | 4 | 1.66 | 1.07 | 1.64 | 1.53 | 1.18 | 1.57 | 13.80 | 16.43 | 13.21 |
|  | C18 H38 N2 O | 298.2978 | 1.894 | 10 | 2.72 | 2.34 | 2.88 | 2.78 | 2.48 | 2.71 | 13.83 | 20.90 | 26.33 |
|  | C27 H46 | 370.3587 | 11.258 | 12 | 3.33 | 3.23 | 3.42 | 3.38 | 3.28 | 3.36 | 13.86 | 10.73 | 9.06 |
|  | C46 H38 O | 606.2935 | 1.915 | 24 | 2.82 | 2.23 | 3.07 | 2.99 | 2.26 | 2.93 | 13.87 | 9.80 | 27.07 |
|  | C18 H36 N2 | 280.2873 | 2.473 | 10 | 2.14 | 1.45 | 1.74 | 2.11 | 1.53 | 2.04 | 13.92 | 29.26 | 33.73 |
|  | C8 H28 N9 O2 P S | 345.182 | 1.292 | 6 | 1.12 | 0.01 | 0.95 | 1.07 | 0.11 | 0.85 | 13.93 | 36.11 | 14.77 |
|  | C36 H82 N9 O3 P | 719.6284 | 6.356 | 5 | 3.97 | 4.07 | 4.11 | 3.99 | 4.20 | 4.13 | 13.95 | 15.40 | 8.17 |
|  | C27 H57 N | 395.4483 | 3.869 | 13 | 1.15 | 0.01 | 0.75 | 1.07 | 0.04 | 0.80 | 13.97 | 30.31 | 10.02 |
|  | C8 H12 O4 | 172.0733 | 2.314 | 4 | 4.69 | 3.65 | 4.78 | 4.63 | 3.82 | 4.81 | 13.98 | 45.47 | 3.12 |
|  | C30 H59 N O3 | 481.4489 | 6.44 | 9 | 1.35 | 0.01 | 0.64 | 1.48 | 0.20 | 0.91 | 13.98 | 24.71 | 35.91 |
|  | C30 H61 N | 435.4799 | 3.848 | 7 | 2.75 | 1.09 | 2.35 | 2.57 | 1.39 | 2.37 | 14.01 | 37.19 | 8.25 |
|  | C18 H12 N6 | 312.1118 | 2.368 | 11 | 1.34 | 0.49 | 1.47 | 1.26 | 0.60 | 1.55 | 14.06 | 42.08 | 11.71 |
|  | C36 H71 N O P2 | 595.5017 | 3.882 | 15 | 2.07 | 2.04 | 2.08 | 2.14 | 2.02 | 2.12 | 14.15 | 9.53 | 6.99 |
|  | C24 H47 N O | 365.3654 | 4.199 | 3 | 1.70 | 0.62 | 1.83 | 1.66 | 0.58 | 1.93 | 14.18 | 5.96 | 33.09 |
|  | C37 H67 O10 P | 702.4466 | 4.608 | 6 | 4.64 | 3.87 | 4.63 | 4.69 | 3.74 | 4.92 | 14.18 | 41.87 | 46.92 |


| C24 H49 N O9 | 495.3402 | 2.289 | 3 | 3.93 | 2.86 | 3.94 | 3.88 | 3.03 | 3.99 | 14.18 | 46.44 | 6.11 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| C62 H119 O5 P3 | 1036.828 | 8.091 | 10 | 5.99 | 6.49 | 6.01 | 6.08 | 6.48 | 6.08 | 14.20 | 16.61 | 12.41 |
| C43 H83 N7 O2 | 729.6626 | 3.411 | 12 | 2.78 | 0.95 | 2.21 | 2.62 | 1.26 | 1.99 | 14.22 | 33.68 | 28.80 |
| C14 H17 O P | 232.1029 | 2.044 | 19 | 0.77 | 0.06 | 0.99 | 1.87 | 0.00 | 1.01 | 14.23 | 7.18 | 38.68 |
| C24 H47 N O2 | 381.36 | 5.724 | 4 | 2.19 | 0.73 | 1.85 | 2.16 | 0.86 | 1.90 | 14.24 | 35.43 | 11.42 |
| C33 H58 Cl N6 P | 604.4155 | 2.492 | 20 | 1.30 | 1.63 | 0.45 | 1.04 | 1.16 | 0.46 | 14.25 | 46.79 | 22.94 |
| C41 H90 N5 O2 P | 715.6838 | 3.249 | 16 | 0.99 | 0.12 | 1.05 | 1.19 | 0.07 | 1.03 | 14.28 | 39.13 | 11.71 |
| C38 H68 N8 O17 | 908.4714 | 8.094 | 26 | 2.98 | 2.82 | 2.60 | 3.07 | 2.75 | 2.68 | 14.28 | 37.07 | 11.24 |
| C38 H77 N O | 563.6002 | 4.978 | 21 | 2.02 | 1.90 | 1.98 | 1.94 | 1.94 | 1.99 | 14.32 | 14.53 | 2.02 |
| C37 H63 N O2 P2 S2 | 679.3752 | 3.456 | 12 | 7.52 | 7.07 | 7.85 | 7.55 | 7.00 | 7.85 | 14.33 | 15.32 | 49.95 |
| C27 H42 S | 398.3004 | 2.857 | 9 | 5.05 | 4.04 | 5.51 | 5.16 | 4.21 | 5.38 | 14.38 | 19.03 | 47.88 |
| C29 H61 N O S | 471.4479 | 2.734 | 10 | 1.70 | 1.67 | 1.70 | 1.83 | 1.68 | 1.68 | 14.39 | 3.05 | 2.95 |
| C23 H49 N O | 355.3808 | 11.268 | 3 | 2.14 | 0.54 | 1.68 | 2.04 | 0.63 | 1.75 | 14.40 | 40.70 | 8.87 |
| C45 H73 N O7 | 739.5377 | 4.883 | 9 | 5.12 | 4.16 | 5.16 | 5.13 | 4.26 | 5.42 | 14.43 | 28.90 | 45.23 |
| C19 H35 N O | 293.2713 | 2.988 | 11 | 1.60 | 1.26 | 1.37 | 1.48 | 1.05 | 1.42 | 14.44 | 28.19 | 18.28 |
| C55 H109 N O6 | 879.8243 | 11.226 | 1 | 4.83 | 3.59 | 4.92 | 4.78 | 3.73 | 5.13 | 14.51 | 19.19 | 44.72 |
| C25 H52 N2 O4 | 444.3924 | 3.15 | 20 | 2.85 | 3.04 | 2.82 | 2.84 | 2.77 | 2.81 | 14.52 | 43.04 | 8.04 |
| C22 H42 O5 | 386.3026 | 2.964 | 8 | 3.69 | 2.67 | 3.51 | 3.66 | 2.49 | 3.67 | 14.52 | 31.26 | 32.98 |
| C59 H127 N10 O9 P3 | 1212.9 | 2.759 | 13 | 2.24 | 2.16 | 2.45 | 2.68 | 2.26 | 2.34 | 14.54 | 16.29 | 14.65 |
| C25 H53 N2 O5 P | 492.3674 | 2.087 | 8 | 1.16 | 0.27 | 0.68 | 1.12 | 0.45 | 0.73 | 14.55 | 43.15 | 26.09 |
| C27 H62 N10 O S | 574.4811 | 1.503 | 10 | 3.03 | 2.24 | 2.75 | 3.18 | 2.14 | 2.92 | 14.56 | 49.64 | 21.92 |
| C13 H18 O | 190.1354 | 3.124 | 16 | 2.25 | 2.17 | 1.92 | 2.04 | 2.19 | 1.98 | 14.62 | 10.13 | 8.58 |
| C36 H71 N O7 | 629.5222 | 2.629 | 4 | 2.83 | 1.23 | 2.51 | 2.96 | 1.47 | 2.39 | 14.64 | 27.59 | 33.36 |
| C41 H82 N3 O3 P S | 727.58 | 3.752 | 5 | 3.30 | 2.96 | 3.33 | 3.43 | 2.98 | 3.31 | 14.67 | 4.28 | 13.71 |
| $\begin{aligned} & \text { C86 H183 N10 O18 P3 } \\ & \text { S2 } \end{aligned}$ | 1801.236 | 3.248 | 19 | 3.07 | 2.53 | 3.01 | 3.02 | 2.49 | 3.09 | 14.68 | 7.78 | 20.24 |


|  | C33 H68 N2 O | 508.5326 | 5.501 | 9 | 1.32 | 0.05 | 1.09 | 1.33 | 0.36 | 1.20 | 14.69 | 34.35 | 12.90 |
| :--- | :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | C64 H108 O11 | 1052.789 | 3.55 | 7 | 3.10 | 2.96 | 3.14 | 3.27 | 2.92 | 3.09 | 14.72 | 6.30 | 15.57 |
|  | C46 H92 N2 O2 | 704.7158 | 8.01 | 12 | 1.93 | 1.35 | 1.61 | 1.69 | 1.47 | 1.56 | 14.73 | 39.06 | 9.82 |
|  | C46 H87 N6 P | 754.6733 | 10.549 | 13 | 5.63 | 5.39 | 5.96 | 5.72 | 5.36 | 5.96 | 14.73 | 13.42 | 2.90 |
|  | C32 H68 N2 O | 496.5324 | 5.248 | 18 | 1.42 | 0.26 | 1.20 | 1.33 | 0.12 | 1.24 | 14.76 | 42.80 | 15.14 |
|  | C26 H54 N5 P3 | 529.3581 | 1.936 | 7 | 2.23 | 1.69 | 2.46 | 2.40 | 1.59 | 2.33 | 14.78 | 23.63 | 26.04 |
|  | C13 H34 N9 O P | 363.2615 | 2.352 | 10 | 2.62 | 1.26 | 2.37 | 2.53 | 1.58 | 2.38 | 14.79 | 37.21 | 6.50 |
|  | C41 H81 N O | 603.6309 | 9.268 | 27 | 1.45 | 0.36 | 1.54 | 1.90 | 0.43 | 1.54 | 14.83 | 16.62 | 23.16 |
|  | C44 H89 N O6 | 727.6682 | 8.043 | 20 | 1.16 | 0.86 | 1.19 | 1.02 | 0.70 | 1.17 | 14.86 | 31.81 | 15.22 |
|  | C70 H95 O P | 982.7117 | 2.701 | 9 | 2.87 | 2.54 | 2.87 | 3.04 | 2.57 | 2.92 | 14.89 | 10.47 | 12.14 |
|  | C21 H42 N2 O2 | 354.3242 | 2.009 | 9 | 1.61 | 0.98 | 1.86 | 1.82 | 1.28 | 1.81 | 14.89 | 34.67 | 33.51 |
|  | C26 H53 N O2 | 411.407 | 5.759 | 4 | 2.82 | 1.42 | 2.60 | 2.74 | 1.42 | 2.57 | 14.89 | 34.45 | 5.88 |
|  | C27 H53 N5 O4 | 511.4082 | 2.704 | 3 | 7.19 | 6.14 | 7.51 | 7.18 | 6.25 | 7.50 | 14.92 | 14.47 | 49.93 |
|  | C28 H55 N5 O4 | 525.4235 | 2.817 | 8 | 2.31 | 1.53 | 2.78 | 2.27 | 1.52 | 2.71 | 14.95 | 8.07 | 42.96 |
|  | C19 H39 N | 281.3078 | 4.838 | 4 | 1.78 | 0.05 | 1.15 | 1.64 | 0.23 | 1.29 | 14.97 | 33.09 | 17.61 |
|  | C35 H71 N O5 | 585.5326 | 7.471 | 4 | 3.24 | 2.55 | 3.23 | 3.17 | 2.70 | 3.38 | 14.97 | 37.95 | 31.61 |
|  | C16 H31 N | 237.2451 | 2.008 | 12 | 2.73 | 1.31 | 2.12 | 2.56 | 1.44 | 2.02 | 14.98 | 18.70 | 19.62 |
|  | C21 H50 N9 O P | 475.3869 | 2.831 | 7 | 2.54 | 1.83 | 2.77 | 2.68 | 1.87 | 2.67 | 15.01 | 39.62 | 13.50 |
|  | C22 H38 O2 | 334.2866 | 2.788 | 12 | 1.02 | 0.98 | 1.24 | 1.16 | 0.93 | 1.17 | 15.04 | 17.58 | 34.97 |
|  | C24 H45 N4 P S | 452.3109 | 3.118 | 13 | 4.22 | 3.25 | 4.63 | 4.20 | 3.38 | 4.59 | 15.16 | 43.72 | 12.73 |
|  | C22 H35 N O4 | 377.2579 | 1.48 | 3 | 2.31 | 1.54 | 2.00 | 2.26 | 1.57 | 2.06 | 15.17 | 17.64 | 18.50 |
|  | C29 H67 N7 O8 | 641.508 | 3.147 | 12 | 2.08 | 2.15 | 2.55 | 2.36 | 2.10 | 2.54 | 15.19 | 12.87 | 27.22 |
|  | C22 H46 N6 O5 P2 | 536.299 | 2.714 | 17 | 1.34 | 1.23 | 1.29 | 1.48 | 1.34 | 1.64 | 15.24 | 33.11 | 37.09 |
|  | C40 H85 N2 O8 P | 752.6044 | 5.616 | 18 | 12.56 | 12.02 | 12.55 | 12.55 | 12.40 | 12.49 | 15.27 | 40.46 | 22.45 |
|  | C32 H73 N10 O4 P | 692.556 | 7.499 | 8 | 4.73 | 4.02 | 4.66 | 4.61 | 3.81 | 4.82 | 15.28 | 30.96 | 26.21 |
|  | C21 H39 N O4 | 369.2873 | 2.64 | 12 | 0.83 | 0.48 | 1.22 | 1.15 | 0.46 | 1.24 | 15.30 | 10.81 | 26.28 |


|  | C22 H51 N7 O2 | 445.4121 | 5.194 | 20 | 2.99 | 1.67 | 3.11 | 3.00 | 1.83 | 3.13 | 15.34 | 46.73 | 15.27 |
| :--- | :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | C62 H123 N O6 | 977.9341 | 11.49 | 6 | 6.57 | 5.27 | 6.55 | 6.49 | 5.22 | 6.82 | 15.36 | 9.15 | 37.14 |
|  | C33 H65 N5 O7 | 643.4866 | 2.675 | 2 | 6.14 | 5.19 | 6.39 | 6.17 | 5.04 | 6.48 | 15.38 | 18.05 | 48.96 |
|  | C17 H35 N | 253.2766 | 2.2 | 6 | 2.74 | 0.35 | 2.20 | 2.60 | 0.65 | 2.11 | 15.43 | 43.77 | 21.12 |
|  | C39 H84 N9 O2 P3 | 803.5961 | 2.895 | 14 | 3.29 | 2.40 | 3.60 | 3.38 | 2.50 | 3.66 | 15.48 | 16.09 | 46.50 |
|  | C29 H61 O2 P S | 504.4147 | 5.504 | 28 | 3.21 | 3.17 | 3.30 | 3.27 | 3.15 | 3.35 | 15.52 | 18.62 | 8.83 |
|  | C40 H61 N5 O3 P2 | 721.4219 | 3.456 | 2 | 4.53 | 4.02 | 4.89 | 4.66 | 3.96 | 4.97 | 15.53 | 27.71 | 45.80 |
|  | C44 H85 N8 O9 P | 900.6177 | 3.244 | 8 | 2.43 | 1.99 | 2.26 | 2.47 | 2.01 | 2.47 | 15.54 | 4.68 | 23.93 |
|  | C40 H77 N O9 S | 747.5344 | 2.412 | 10 | 1.51 | 0.68 | 1.51 | 1.47 | 0.65 | 1.39 | 15.57 | 7.88 | 35.58 |
|  | C19 H33 O9 P | 436.1856 | 3.919 | 7 | 3.28 | 2.82 | 3.28 | 3.08 | 2.87 | 3.22 | 15.58 | 8.36 | 24.38 |
|  | C18 H45 N8 O P | 420.3447 | 2.852 | 6 | 2.47 | 1.78 | 2.63 | 2.44 | 1.70 | 2.90 | 15.58 | 12.05 | 35.36 |
|  | C23 H45 N O | 351.3496 | 4.101 | 4 | 1.92 | 0.06 | 1.24 | 1.88 | 0.34 | 1.35 | 15.61 | 45.57 | 18.29 |
|  | C5 H13 N8 P | 216.0994 | 2.313 | 5 | 3.70 | 2.71 | 3.71 | 3.51 | 2.78 | 3.70 | 15.61 | 48.58 | 8.53 |
|  | C17 H42 N9 P | 403.3295 | 2.501 | 13 | 5.20 | 4.08 | 5.44 | 5.50 | 4.01 | 5.42 | 15.62 | 41.33 | 36.04 |
|  | C46 H89 N O4 | 719.6781 | 8.064 | 9 | 1.60 | 1.80 | 2.23 | 1.65 | 1.62 | 2.10 | 15.62 | 46.37 | 32.95 |
|  | C31 H65 P S | 500.4544 | 3.547 | 23 | 1.21 | 0.75 | 1.11 | 1.14 | 0.74 | 1.13 | 15.63 | 9.22 | 17.47 |
|  | C29 H52 N O7 P | 557.3501 | 2.275 | 14 | 1.90 | 0.98 | 1.93 | 1.82 | 1.22 | 1.91 | 15.66 | 35.38 | 6.17 |
|  | C28 H49 N O2 S | 463.3503 | 2.781 | 10 | 1.38 | 0.70 | 1.40 | 1.33 | 0.79 | 1.63 | 15.67 | 15.19 | 32.33 |
|  | C51 H92 N5 O5 P S2 | 949.6277 | 3.334 | 19 | 1.99 | 1.22 | 2.40 | 2.10 | 1.28 | 2.42 | 15.68 | 7.53 | 43.10 |
|  | C55 H114 N9 O10 P S | 1123.815 | 3.493 | 12 | 3.36 | 3.37 | 3.62 | 3.59 | 3.41 | 3.56 | 15.69 | 9.41 | 22.53 |
|  | C16 H37 N8 P | 372.2874 | 2.501 | 13 | 7.68 | 6.61 | 7.53 | 7.69 | 6.44 | 7.71 | 15.71 | 40.14 | 20.83 |
|  | C19 H34 N4 O4 S | 414.2288 | 3.075 | 6 | 4.29 | 3.55 | 4.27 | 4.22 | 3.40 | 4.31 | 15.71 | 29.96 | 11.86 |
|  | C20 H41 N O | 311.3184 | 2.578 | 6 | 1.99 | 0.82 | 1.51 | 1.87 | 0.95 | 1.56 | 15.72 | 23.74 | 14.22 |
|  | C45 H89 O10 P | 820.619 | 3.396 | 22 | 5.32 | 5.30 | 5.33 | 5.17 | 5.29 | 5.37 | 15.75 | 4.59 | 5.19 |
|  | C63 H89 N O6 | 955.6683 | 7.956 | 20 | 3.17 | 2.74 | 3.06 | 3.08 | 2.79 | 3.06 | 15.77 | 14.81 | 10.10 |
|  | C8 H17 N4 O P | 216.1145 | 1.5 | 20 | 1.31 | 0.65 | 0.76 | 1.25 | 0.63 | 0.81 | 15.81 | 24.56 | 27.17 |



| C23 H43 N O | 349.3339 | 3.924 | 19 | 1.56 | 1.41 | 1.35 | 1.52 | 1.66 | 1.34 | 16.29 | 28.37 | 3.35 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| C25 H47 N O6 | 457.3398 | 2.627 | 4 | 3.77 | 3.22 | 3.89 | 3.79 | 3.16 | 3.92 | 16.30 | 15.32 | 17.38 |
| C 22 H 46 O 5 | 390.3342 | 3.067 | 12 | 5.50 | 4.34 | 5.81 | 5.49 | 4.45 | 5.82 | 16.30 | 21.29 | 47.68 |
| C36 H67 N O3 | 561.5113 | 4.855 | 5 | 1.44 | 1.04 | 1.30 | 1.33 | 1.03 | 1.26 | 16.40 | 8.97 | 16.82 |
| C35 H74 N9 P S | 683.5541 | 3.789 | 6 | 2.15 | 1.94 | 2.18 | 2.19 | 1.90 | 2.12 | 16.41 | 7.22 | 11.69 |
| C31 H49 N O4 | 499.3655 | 3.268 | 19 | 1.79 | 1.40 | 1.63 | 1.78 | 1.50 | 1.55 | 16.43 | 14.81 | 25.45 |
| C54 H100 N O8 P | 921.7142 | 3.624 | 14 | 3.06 | 3.01 | 3.24 | 3.46 | 3.02 | 3.28 | 16.44 | 4.98 | 14.84 |
| C17 H46 N9 P | 407.3608 | 3.03 | 16 | 3.45 | 2.27 | 3.77 | 3.42 | 2.36 | 3.78 | 16.53 | 22.03 | 47.64 |
| C29 H63 O12 P3 | 696.3545 | 2.789 | 4 | 7.30 | 6.70 | 7.54 | 7.28 | 6.69 | 7.79 | 16.55 | 31.05 | 46.78 |
| C36 H53 N3 O3 | 575.4099 | 2.668 | 15 | 1.49 | 1.00 | 1.38 | 1.46 | 0.94 | 1.35 | 16.57 | 30.97 | 23.04 |
| C43 H88 N4 O P2 | 738.6427 | 4.612 | 6 | 3.34 | 3.32 | 3.33 | 3.36 | 3.38 | 3.38 | 16.58 | 8.42 | 5.87 |
| C45 H78 N 010 P | 823.5331 | 5.236 | 21 | 1.71 | 1.98 | 1.66 | 1.89 | 1.96 | 1.64 | 16.61 | 17.57 | 6.21 |
| C23 H38 N9 O2 P | 503.2879 | 2.162 | 11 | 2.77 | 1.67 | 2.22 | 2.86 | 1.69 | 2.26 | 16.61 | 32.24 | 9.72 |
| C16 H33 N | 239.2608 | 2.477 | 9 | 1.89 | 0.95 | 1.57 | 1.65 | 1.18 | 1.59 | 16.62 | 36.93 | 31.82 |
| C14 H31 O12 P | 422.1555 | 1.917 | 15 | 2.21 | 1.93 | 2.45 | 2.39 | 1.63 | 2.34 | 16.64 | 40.93 | 24.17 |
| C29 H57 N5 O2 | 507.4497 | 2.852 | 17 | 2.90 | 1.77 | 3.05 | 2.84 | 2.01 | 3.15 | 16.70 | 37.00 | 45.51 |
| C57 H104 O6 | 884.7797 | 11.225 | 8 | 6.58 | 5.43 | 6.71 | 6.58 | 5.51 | 6.92 | 16.70 | 17.04 | 46.26 |
| C21 H46 N P S | 375.3105 | 3.77 | 16 | 2.20 | 2.12 | 2.09 | 2.16 | 2.04 | 2.11 | 16.71 | 12.28 | 9.25 |
| C41 H76 N7 P S | 729.5602 | 3.107 | 5 | 2.54 | 2.37 | 2.60 | 2.75 | 2.32 | 2.79 | 16.73 | 15.88 | 22.25 |
| C34 H79 N7 O6 P2 | 743.558 | 5.214 | 15 | 2.51 | 2.63 | 2.63 | 2.67 | 2.67 | 2.64 | 16.78 | 12.80 | 2.44 |
| C20 H45 N4 O4 P | 436.316 | 3.719 | 14 | 4.29 | 3.04 | 4.59 | 4.25 | 2.99 | 4.55 | 16.81 | 13.92 | 38.92 |
| C19 H44 N10 O | 428.3692 | 2.394 | 6 | 1.61 | 0.45 | 0.45 | 1.72 | 0.49 | 0.44 | 16.82 | 33.07 | 18.61 |
| C16 H24 N8 S | 360.1844 | 3.531 | 14 | 1.48 | 0.18 | 1.33 | 1.42 | 0.12 | 1.12 | 16.82 | 38.49 | 37.98 |
| C20 H37 N7 O2 | 407.3009 | 3.108 | 13 | 3.57 | 3.60 | 3.74 | 3.60 | 3.52 | 3.72 | 16.87 | 14.44 | 6.87 |
| C30 H59 N O3 | 481.449 | 2.775 | 18 | 1.07 | 0.34 | 1.33 | 1.31 | 0.12 | 0.98 | 16.89 | 47.91 | 47.70 |
| C39 H77 N5 O10 | 775.5651 | 2.649 | 2 | 6.17 | 5.21 | 6.45 | 6.22 | 5.29 | 6.50 | 16.90 | 16.49 | 42.35 |


| C22 H53 N10 O P | 504.4144 | 5.557 | 28 | 1.99 | 2.37 | 2.79 | 2.45 | 2.24 | 2.85 | 17.02 | 27.22 | 8.24 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| C41 H81 N 06 | 683.6056 | 7.75 | 5 | 5.08 | 4.20 | 5.07 | 4.94 | 4.05 | 5.21 | 17.03 | 22.58 | 29.92 |
| C56 H111 N O11 P2 | 1035.763 | 3.541 | 7 | 3.38 | 3.14 | 3.39 | 3.49 | 3.13 | 3.36 | 17.03 | 1.70 | 17.87 |
| C36 H72 N2 O8 | 660.5299 | 6.821 | 14 | 6.27 | 5.67 | 7.04 | 6.56 | 5.88 | 6.87 | 17.04 | 24.06 | 33.36 |
| C50 H99 N3 O2 | 773.7738 | 8.444 | 19 | 1.95 | 1.97 | 2.11 | 1.95 | 2.00 | 2.10 | 17.04 | 16.11 | 9.46 |
| C29 H51 Cl P2 | 496.3174 | 1.946 | 15 | 0.91 | 0.88 | 0.36 | 1.03 | 0.68 | 0.14 | 17.05 | 39.18 | 28.11 |
| C39 H68 N10 O4 | 740.5405 | 4.879 | 7 | 3.60 | 2.67 | 3.60 | 3.53 | 2.67 | 3.85 | 17.07 | 30.01 | 45.12 |
| C24 H51 N O | 369.3967 | 2.599 | 11 | 1.79 | 0.04 | 1.35 | 1.70 | 0.44 | 1.30 | 17.07 | 40.51 | 22.08 |
| C58 H115 N O6 | 921.8716 | 11.494 | 20 | 2.15 | 1.19 | 2.23 | 2.03 | 1.14 | 2.39 | 17.15 | 14.09 | 34.51 |
| C20 H45 O P3 | 394.2694 | 2.575 | 6 | 7.78 | 6.86 | 7.76 | 7.84 | 6.73 | 7.82 | 17.15 | 40.35 | 16.64 |
| C26 H53 N O3 | 427.4022 | 5.129 | 21 | 2.09 | 0.70 | 1.82 | 1.97 | 0.84 | 1.91 | 17.18 | 17.14 | 16.73 |
| C37 H85 N10 O8 P | 828.6291 | 2.001 | 8 | 1.82 | 1.34 | 2.00 | 1.94 | 1.41 | 1.93 | 17.22 | 11.87 | 33.15 |
| C23 H43 N O5 | 413.3135 | 2.634 | 18 | 3.67 | 2.71 | 3.80 | 3.53 | 2.74 | 3.79 | 17.23 | 5.24 | 25.04 |
| C27 H63 N7 O7 | 597.482 | 3.17 | 6 | 3.30 | 3.21 | 3.37 | 3.51 | 3.26 | 3.49 | 17.23 | 10.45 | 14.54 |
| C47 H80 N2 O3 P2 | 782.5651 | 3.442 | 23 | 4.68 | 5.37 | 4.64 | 4.62 | 5.34 | 4.38 | 17.24 | 21.35 | 43.37 |
| C42 H81 N O4 | 663.6158 | 8.025 | 2 | 3.35 | 2.83 | 3.64 | 3.36 | 3.14 | 3.59 | 17.25 | 37.80 | 30.62 |
| C61 H121 N O6 | 963.9183 | 11.225 | 7 | 3.28 | 1.98 | 3.32 | 3.20 | 2.07 | 3.53 | 17.25 | 19.36 | 47.10 |
| C17 H37 N O | 271.287 | 2.285 | 9 | 1.66 | 1.01 | 0.58 | 1.25 | 0.87 | 0.61 | 17.30 | 33.43 | 9.19 |
| C18 H42 N9 O2 P | 447.3188 | 7.067 | 15 | 4.45 | 4.48 | 4.50 | 4.31 | 4.69 | 4.58 | 17.31 | 28.23 | 19.32 |
| C16 H29 N O3 | 283.2144 | 2.005 | 7 | 1.85 | 1.35 | 2.10 | 2.09 | 1.28 | 2.05 | 17.34 | 14.19 | 33.65 |
| C22 H33 N O4 | 375.2407 | 2.429 | 11 | 2.60 | 2.59 | 2.64 | 2.74 | 2.63 | 2.73 | 17.35 | 4.97 | 16.26 |
| C38 H75 P3 | 624.5112 | 7.32 | 6 | 2.12 | 1.82 | 1.98 | 1.95 | 2.11 | 1.96 | 17.36 | 42.15 | 4.17 |
| C29 H69 Cl N9 O P | 625.5059 | 7.316 | 14 | 3.25 | 3.32 | 3.19 | 3.08 | 3.41 | 3.19 | 17.37 | 17.22 | 2.06 |
| C21 H45 N O | 327.3496 | 2.638 | 4 | 1.70 | 0.07 | 1.25 | 1.57 | 0.10 | 1.28 | 17.39 | 26.60 | 9.97 |
| C19 H36 N6 O2 | 380.2895 | 3.506 | 10 | 9.19 | 8.61 | 9.03 | 9.20 | 8.32 | 9.07 | 17.39 | 45.33 | 11.79 |
| C40 H79 N O2 | 605.6108 | 10.494 | 8 | 2.53 | 0.23 | 1.93 | 2.38 | 0.64 | 1.68 | 17.41 | 43.69 | 39.87 |



|  | C23 H45 N7 | 419.3757 | 4.688 | 7 | 1.41 | 0.44 | 1.07 | 1.39 | 0.13 | 1.08 | 18.11 | 43.49 | 12.95 |
| :--- | :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | C17 H41 N8 O P | 404.3133 | 2.968 | 5 | 4.15 | 3.46 | 4.33 | 4.45 | 3.23 | 4.38 | 18.12 | 39.44 | 29.63 |
|  | C63 H125 N O6 | 991.9498 | 11.49 | 5 | 6.07 | 4.80 | 6.02 | 5.97 | 4.77 | 6.34 | 18.14 | 8.97 | 37.64 |
|  | C48 H99 N6 O3 P | 838.7515 | 4.688 | 7 | 1.35 | 0.50 | 1.01 | 1.33 | 0.18 | 1.02 | 18.14 | 43.49 | 12.92 |
|  | C31 H61 N5 O6 | 599.4605 | 2.685 | 3 | 5.32 | 4.43 | 5.57 | 5.38 | 4.34 | 5.66 | 18.14 | 16.77 | 47.22 |
|  | C25 H53 N O2 | 399.407 | 7.102 | 3 | 1.24 | 0.39 | 1.04 | 1.27 | 0.05 | 1.04 | 18.16 | 36.98 | 13.64 |
|  | C28 H58 N8 | 506.4807 | 3.753 | 6 | 1.51 | 0.19 | 1.16 | 1.41 | 0.38 | 1.12 | 18.17 | 31.54 | 8.46 |
|  | C23 H47 N O | 353.3653 | 4.798 | 3 | 1.56 | 0.50 | 1.54 | 1.44 | 0.62 | 1.38 | 18.19 | 24.94 | 20.98 |
|  | C29 H62 N O13 P S | 695.3704 | 2.789 | 6 | 5.83 | 5.13 | 6.26 | 6.12 | 5.29 | 6.38 | 18.21 | 35.60 | 49.76 |
|  | C36 H71 N5 O8 | 701.5279 | 2.771 | 2 | 4.39 | 3.46 | 4.49 | 4.43 | 3.47 | 4.64 | 18.22 | 11.11 | 44.34 |
|  | C17 H44 N9 O P | 421.3398 | 2.963 | 5 | 3.72 | 3.17 | 3.67 | 3.84 | 2.88 | 3.88 | 18.23 | 44.73 | 24.11 |
|  | C34 H70 Br N S | 603.4409 | 3.926 | 9 | 1.88 | 1.69 | 1.91 | 1.98 | 1.89 | 1.98 | 18.25 | 23.13 | 16.49 |
|  | C36 H65 N9 O4 | 687.5128 | 2.666 | 3 | 5.96 | 4.94 | 6.18 | 5.98 | 4.90 | 6.25 | 18.26 | 14.20 | 47.52 |
|  | C35 H73 N4 O5 P | 660.5298 | 6.472 | 10 | 7.22 | 6.67 | 7.67 | 7.29 | 6.74 | 7.56 | 18.27 | 19.31 | 30.52 |
|  | C38 H75 N O2 | 577.5795 | 9.761 | 11 | 1.20 | 0.40 | 0.93 | 1.05 | 0.15 | 0.95 | 18.35 | 29.96 | 23.16 |
|  | C25 H43 N O4 | 421.3185 | 3.417 | 20 | 2.94 | 3.16 | 3.13 | 2.98 | 3.25 | 3.01 | 18.36 | 19.61 | 16.18 |
|  | C33 H65 N5 O6 | 627.4915 | 2.932 | 4 | 5.26 | 4.21 | 5.38 | 5.33 | 4.22 | 5.54 | 18.38 | 20.71 | 47.72 |
|  | C26 H59 N7 O5 P2 S5 | 771.2658 | 7.471 | 22 | 2.62 | 2.50 | 2.50 | 2.50 | 2.49 | 2.49 | 18.38 | 4.26 | 3.52 |
|  | C29 H51 N O2 S | 477.3662 | 3.073 | 13 | 3.46 | 1.25 | 3.52 | 3.47 | 1.54 | 3.78 | 18.42 | 46.21 | 40.84 |
|  | C76 H131 N4 O12 P3 | 1384.897 | 3.485 | 8 | 8.09 | 6.98 | 8.19 | 8.01 | 7.10 | 8.27 | 18.44 | 17.91 | 31.42 |
|  | C18 H30 | 246.2341 | 11.258 | 15 | 3.34 | 3.43 | 3.18 | 3.24 | 3.25 | 3.23 | 18.48 | 32.15 | 10.10 |
|  | C44 H94 N9 O5 P3 | 921.6601 | 2.717 | 15 | 2.69 | 2.77 | 3.02 | 2.84 | 2.66 | 3.17 | 18.52 | 15.21 | 17.94 |
|  | C25 H48 N2 | 376.381 | 3.58 | 11 | 1.43 | 0.21 | 0.72 | 1.33 | 0.00 | 0.94 | 18.54 | 36.67 | 31.87 |
|  | C30 H59 N O | 449.4593 | 3.883 | 17 | 0.99 | 0.63 | 1.39 | 1.14 | 0.53 | 1.44 | 18.55 | 13.33 | 29.14 |
|  | C35 H71 N O4 | 569.5392 | 5.891 | 13 | 1.32 | 1.15 | 1.43 | 1.29 | 1.17 | 1.38 | 18.57 | 5.67 | 6.74 |
|  | C23 H47 N O | 353.3653 | 5.001 | 7 | 2.38 | 0.87 | 2.04 | 2.28 | 1.06 | 2.18 | 18.58 | 37.18 | 17.10 |



| C17 H42 N8 O4 S | 454.3055 | 4.508 | 14 | 2.79 | 2.72 | 2.84 | 2.89 | 2.82 | 2.81 | 19.16 | 12.57 | 3.37 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| C31 H66 N9 O6 P | 691.4865 | 2.663 | 13 | 3.07 | 2.63 | 3.20 | 3.26 | 2.70 | 3.04 | 19.20 | 18.19 | 21.32 |
| C29 H60 N8 | 520.4964 | 3.753 | 17 | 1.71 | 0.54 | 1.70 | 1.95 | 0.51 | 1.60 | 19.22 | 38.85 | 17.81 |
| C66 H128 N8 O16 P2 | 1350.892 | 3.448 | 22 | 1.61 | 1.38 | 1.71 | 1.54 | 1.35 | 1.89 | 19.23 | 7.51 | 25.53 |
| C41 H81 N O5 | 667.6095 | 5.605 | 23 | 3.53 | 3.83 | 4.17 | 4.10 | 4.32 | 4.04 | 19.25 | 47.47 | 20.27 |
| C20 H32 | 272.2496 | 11.259 | 17 | 3.62 | 3.58 | 3.62 | 3.65 | 3.59 | 3.52 | 19.28 | 7.70 | 12.16 |
| C19 H38 O S2 | 346.2349 | 2.356 | 9 | 4.01 | 2.47 | 3.85 | 3.92 | 2.80 | 3.81 | 19.32 | 46.16 | 5.92 |
| C22 H45 N O | 339.3496 | 5.345 | 5 | 1.56 | 0.23 | 1.06 | 1.43 | 0.22 | 1.11 | 19.35 | 27.66 | 13.98 |
| C31 H74 N9 O6 P | 699.5493 | 3.303 | 5 | 3.21 | 2.90 | 3.28 | 3.28 | 2.97 | 3.30 | 19.37 | 16.51 | 14.17 |
| C24 H52 N8 O2 | 484.4234 | 4.4 | 18 | 2.92 | 2.62 | 2.93 | 2.75 | 2.48 | 2.92 | 19.41 | 49.88 | 6.01 |
| C40 H67 N O7 P2 | 735.4377 | 3.46 | 2 | 6.22 | 5.62 | 6.64 | 6.40 | 5.48 | 6.78 | 19.44 | 27.20 | 49.99 |
| C44 H50 N10 O3 P2 | 828.3525 | 9.627 | 20 | 3.13 | 2.82 | 2.63 | 2.88 | 2.46 | 2.64 | 19.46 | 47.56 | 8.08 |
| C22 H51 N10 O3 P | 534.3894 | 3.891 | 19 | 1.74 | 1.47 | 2.38 | 1.77 | 1.91 | 2.36 | 19.50 | 44.54 | 8.87 |
| C29 H61 N5 O2 P2 | 573.4301 | 3.697 | 3 | 5.58 | 4.24 | 5.22 | 5.48 | 4.37 | 5.26 | 19.51 | 39.40 | 5.58 |
| C 23 H 40 O 5 | 396.287 | 2.63 | 14 | 2.75 | 1.71 | 2.90 | 2.60 | 1.71 | 2.82 | 19.52 | 0.32 | 33.78 |
| C31 H67 N4 O4 P | 590.488 | 7.472 | 3 | 5.72 | 5.05 | 5.78 | 5.59 | 5.01 | 5.84 | 19.52 | 21.60 | 30.09 |
| C43 H77 O10 P | 784.5217 | 6.037 | 24 | 1.22 | 0.36 | 0.46 | 1.72 | 0.40 | 0.58 | 19.57 | 35.88 | 16.63 |
| C20 H24 N8 O4 S | 472.1626 | 2.279 | 8 | 1.92 | 0.82 | 1.89 | 1.73 | 1.07 | 1.84 | 19.62 | 45.69 | 7.03 |
| C20 H39 N O2 | 325.298 | 3.22 | 11 | 3.62 | 2.55 | 3.84 | 3.51 | 2.49 | 3.82 | 19.64 | 25.61 | 34.13 |
| C23 H55 N6 O5 P | 526.3951 | 3.556 | 4 | 2.77 | 2.77 | 2.94 | 3.06 | 2.80 | 2.91 | 19.64 | 4.00 | 17.41 |
| C30 H66 N6 O4 P2 | 636.4601 | 3.431 | 15 | 3.20 | 2.99 | 3.10 | 3.36 | 3.06 | 3.20 | 19.71 | 9.07 | 21.74 |
| C49 H95 O8 P | 842.6725 | 5.208 | 21 | 2.71 | 2.99 | 2.83 | 2.73 | 2.94 | 2.90 | 19.73 | 13.27 | 10.59 |
| C24 H48 O6 | 432.3446 | 3.357 | 2 | 7.82 | 6.96 | 8.11 | 8.13 | 6.70 | 8.15 | 19.75 | 36.20 | 31.83 |
| C38 H77 N O3 | 595.5897 | 9.761 | 11 | 1.39 | 0.22 | 1.12 | 1.24 | 0.04 | 1.14 | 19.76 | 29.50 | 22.05 |
| C24 H56 N5 P | 445.4276 | 3.563 | 17 | 1.84 | 0.27 | 0.86 | 1.65 | 0.44 | 1.05 | 19.77 | 20.19 | 31.80 |
| C84 H123 N2 O11 P | 1366.887 | 3.486 | 4 | 8.06 | 6.80 | 8.10 | 7.90 | 6.85 | 8.18 | 19.79 | 17.98 | 30.18 |


| C44 H89 N O15 | 871.6235 | 3.037 | 9 | 1.51 | 1.06 | 1.74 | 1.73 | 1.25 | 1.60 | 19.81 | 26.73 | 21.46 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| C25 H62 N9 O3 P | 567.4705 | 3.394 | 7 | 2.60 | 2.48 | 2.79 | 2.44 | 2.60 | 2.92 | 19.82 | 36.54 | 19.75 |
| C51 H74 O2 | 718.5714 | 7.974 | 12 | 1.68 | 0.62 | 1.34 | 1.71 | 0.39 | 1.72 | 19.86 | 46.98 | 38.45 |
| C16 H25 N3 O3 | 307.189 | 2.073 | 12 | 1.91 | 0.26 | 1.23 | 1.92 | 0.26 | 1.31 | 19.91 | 34.61 | 13.85 |
| C20 H45 N6 O3 P | 448.3291 | 11.259 | 17 | 3.33 | 3.79 | 3.48 | 3.45 | 3.91 | 3.45 | 19.92 | 13.94 | 3.84 |
| C29 H59 N O S2 | 501.4024 | 3.399 | 22 | 2.46 | 2.14 | 2.22 | 2.54 | 2.16 | 2.18 | 19.93 | 8.34 | 28.23 |
| C34 H75 N10 O6 P | 750.5601 | 4.159 | 7 | 6.23 | 5.48 | 6.26 | 6.23 | 5.49 | 6.53 | 19.94 | 26.46 | 45.77 |
| C41 H81 N O2 | 619.6263 | 10.23 | 12 | 1.71 | 0.48 | 1.29 | 1.83 | 0.05 | 1.23 | 19.95 | 48.07 | 12.56 |
| C15 H29 N O4 | 287.2089 | 1.926 | 7 | 5.23 | 3.72 | 5.09 | 4.93 | 4.14 | 5.18 | 19.96 | 43.92 | 12.29 |
| C19 H51 N10 O5 P | 530.3789 | 2.813 | 15 | 3.75 | 3.01 | 4.09 | 3.76 | 2.92 | 4.18 | 19.96 | 36.21 | 46.96 |
| C17 H33 N O3 | 299.2455 | 1.881 | 13 | 1.02 | 0.19 | 0.12 | 1.45 | 0.20 | 0.01 | 19.99 | 7.52 | 17.26 |
| C25 H49 N O5 | 443.3603 | 3.568 | 19 | 1.28 | 0.73 | 1.17 | 1.14 | 0.75 | 1.26 | 20.02 | 9.98 | 10.64 |
| C41 H81 N O6 | 683.6055 | 7.264 | 16 | 3.41 | 2.38 | 3.63 | 3.43 | 2.51 | 3.60 | 20.03 | 32.50 | 23.53 |
| C16 H40 N10 O | 388.3386 | 2.958 | 6 | 3.69 | 2.95 | 3.88 | 4.01 | 2.77 | 3.88 | 20.03 | 30.92 | 30.35 |
| C25 H53 N | 367.4172 | 3.038 | 2 | 2.31 | 0.54 | 1.93 | 2.25 | 0.85 | 2.06 | 20.04 | 40.13 | 16.45 |
| C38 H49 N O6 | 615.3554 | 2.772 | 22 | 3.20 | 2.58 | 3.48 | 3.40 | 2.55 | 3.31 | 20.07 | 15.63 | 34.58 |
| C34 H63 N | 485.4957 | 3.853 | 18 | 1.55 | 0.02 | 1.14 | 1.70 | 0.06 | 1.15 | 20.09 | 17.57 | 19.01 |
| C20 H38 N6 O4 | 426.2951 | 2.97 | 7 | 5.63 | 4.90 | 5.85 | 5.97 | 4.71 | 5.84 | 20.09 | 35.24 | 31.85 |
| C16 H35 N | 241.2766 | 2.291 | 4 | 2.21 | 0.70 | 1.78 | 2.06 | 0.85 | 1.77 | 20.10 | 32.13 | 11.58 |
| C41 H65 N O7 | 683.4757 | 4.163 | 18 | 4.23 | 3.03 | 4.21 | 4.11 | 3.00 | 4.44 | 20.14 | 38.83 | 44.97 |
| C33 H67 N7 O10 | 721.4977 | 2.582 | 5 | 2.87 | 2.58 | 2.85 | 3.09 | 2.54 | 2.93 | 20.21 | 5.65 | 12.21 |
| C38 H77 N O | 563.5997 | 7.275 | 10 | 2.75 | 2.68 | 2.98 | 2.90 | 2.94 | 2.84 | 20.22 | 32.27 | 18.40 |
| C8 H6 O4 | 166.0263 | 2.447 | 6 | 2.20 | 2.21 | 2.25 | 2.12 | 2.32 | 2.37 | 20.22 | 25.29 | 22.37 |
| C43 H83 N O5 | 693.6264 | 8.025 | 3 | 3.70 | 3.10 | 3.76 | 3.52 | 3.15 | 3.70 | 20.27 | 8.81 | 20.24 |
| C29 H52 N4 O3 | 504.4029 | 1.476 | 15 | 1.67 | 0.55 | 0.65 | 1.50 | 0.42 | 0.90 | 20.33 | 37.91 | 29.31 |
| C51 H62 Cl2 N O4 P3 S2 | 979.2704 | 7.677 | 12 | 2.59 | 2.46 | 2.50 | 2.43 | 2.45 | 2.41 | 20.33 | 17.78 | 11.35 |


|  | C18 H37 N O4 | 331.2719 | 2.019 | 26 | 2.09 | 1.08 | 2.12 | 2.21 | 1.11 | 2.10 | 20.33 | 12.26 | 45.05 |
| :--- | :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | C54 H77 Cl N9 O17 P S4 | 1317.375 | 8.128 | 28 | 2.60 | 2.29 | 3.02 | 2.70 | 2.15 | 2.82 | 20.35 | 26.87 | 37.01 |
|  | C34 H74 N6 O4 P2 | 692.5228 | 3.257 | 2 | 2.11 | 1.91 | 1.98 | 2.01 | 1.91 | 2.01 | 20.35 | 3.07 | 5.45 |
|  | C19 H33 N | 275.2608 | 2.614 | 12 | 1.05 | 0.27 | 0.76 | 1.22 | 0.30 | 0.65 | 20.39 | 38.91 | 14.74 |
|  | C46 H89 N O3 | 703.684 | 8.273 | 10 | 1.55 | 1.58 | 1.51 | 1.47 | 1.52 | 1.47 | 20.45 | 8.26 | 16.36 |
|  | C41 H83 N O3 | 637.6362 | 8.072 | 7 | 1.22 | 1.44 | 0.98 | 1.48 | 1.40 | 1.17 | 20.46 | 5.76 | 32.90 |
|  | C28 H58 N8 O S | 554.4442 | 3.214 | 21 | 4.45 | 4.38 | 4.43 | 4.18 | 4.37 | 4.43 | 20.47 | 6.90 | 3.39 |
|  | C14 H20 | 188.156 | 11.258 | 11 | 3.17 | 3.33 | 3.00 | 3.26 | 3.61 | 3.08 | 20.47 | 35.23 | 18.17 |
|  | C21 H40 O3 | 340.297 | 3.362 | 11 | 4.58 | 3.51 | 4.60 | 4.67 | 3.36 | 4.75 | 20.48 | 21.31 | 26.99 |
|  | C45 H70 N P | 655.5232 | 3.332 | 7 | 3.52 | 3.22 | 3.51 | 3.56 | 3.26 | 3.60 | 20.49 | 13.56 | 17.38 |
|  | C30 H65 N9 O7 | 663.5024 | 3.211 | 5 | 2.26 | 2.04 | 2.22 | 2.20 | 2.09 | 2.20 | 20.49 | 6.83 | 3.18 |
|  | C22 H49 O P3 | 422.3002 | 3.347 | 3 | 8.39 | 7.54 | 8.69 | 8.73 | 7.26 | 8.73 | 20.50 | 35.72 | 30.46 |
|  | C31 H66 N10 O8 | 706.5059 | 8.054 | 18 | 5.96 | 5.70 | 5.78 | 5.67 | 5.44 | 5.77 | 20.50 | 35.59 | 0.62 |
|  | C30 H69 N7 O11 | 703.508 | 2.423 | 10 | 1.04 | 0.59 | 1.42 | 1.25 | 0.35 | 1.39 | 20.55 | 39.49 | 18.50 |
|  | C26 H58 N O10 P3 | 637.3281 | 3.62 | 25 | 5.54 | 5.05 | 6.10 | 5.68 | 4.94 | 5.95 | 20.56 | 28.37 | 44.21 |
|  | C29 H59 N9 O6 | 629.4567 | 3.273 | 6 | 1.37 | 0.25 | 0.74 | 1.18 | 0.02 | 0.73 | 20.60 | 41.06 | 10.58 |
|  | C43 H75 O8 P | 750.517 | 4.884 | 12 | 3.54 | 3.00 | 3.67 | 3.77 | 3.20 | 3.84 | 20.60 | 38.52 | 37.63 |
|  | C47 H77 N O7 | 767.5685 | 4.883 | 5 | 8.84 | 8.08 | 8.88 | 8.86 | 8.12 | 9.13 | 20.63 | 23.72 | 43.72 |
|  | C25 H45 N5 O | 431.3613 | 2.573 | 20 | 2.96 | 2.10 | 2.38 | 2.98 | 2.17 | 2.16 | 20.67 | 27.66 | 29.48 |
|  | C43 H87 N O | 633.6784 | 10.759 | 18 | 1.65 | 0.34 | 1.01 | 1.42 | 0.02 | 1.17 | 20.67 | 43.02 | 21.52 |
|  | C42 H71 O14 P | 830.4554 | 8.105 | 24 | 4.15 | 4.15 | 4.22 | 4.03 | 4.27 | 4.11 | 20.71 | 17.52 | 21.60 |
|  | C29 H71 N10 O P | 606.5579 | 11.489 | 4 | 5.02 | 3.62 | 4.88 | 4.87 | 3.58 | 5.31 | 20.72 | 6.41 | 43.39 |
|  | C35 H78 N9 O P3 S | 765.5241 | 2.576 | 5 | 3.04 | 2.59 | 2.95 | 3.12 | 2.61 | 3.04 | 20.74 | 3.22 | 10.90 |
|  | C34 H75 N9 O3 P2 S | 751.5207 | 4.896 | 12 | 1.84 | 1.32 | 1.92 | 2.10 | 1.47 | 2.10 | 20.75 | 40.75 | 40.69 |
|  | C74 H144 N5 O17 P | 1406.028 | 6.043 | 24 | 0.94 | 0.65 | 0.89 | 1.06 | 0.51 | 0.83 | 20.77 | 34.45 | 12.73 |
|  | C20 H44 N2 O9 | 456.3037 | 1.312 | 8 | 2.39 | 0.54 | 1.38 | 2.62 | 0.69 | 1.55 | 20.79 | 37.43 | 28.95 |



| C32 H63 N5 O7 | 629.4714 | 2.573 | 7 | 3.27 | 2.53 | 3.46 | 3.49 | 2.49 | 3.54 | 21.63 | 15.98 | 40.33 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| C42 H83 N O6 | 697.6221 | 8.469 | 9 | 3.23 | 1.94 | 3.39 | 3.15 | 1.82 | 3.54 | 21.64 | 20.52 | 48.76 |
| C59 H118 O4 S | 922.875 | 11.493 | 19 | 2.22 | 1.01 | 2.17 | 1.99 | 1.00 | 2.37 | 21.66 | 4.75 | 32.68 |
| C44 H79 N3 O8 | 777.5868 | 4.886 | 3 | 8.72 | 7.92 | 8.69 | 8.67 | 7.94 | 8.95 | 21.68 | 26.76 | 43.32 |
| C48 H79 N O7 | 781.5839 | 4.882 | 4 | 7.03 | 6.26 | 7.07 | 7.02 | 6.26 | 7.34 | 21.68 | 28.61 | 43.08 |
| C28 H60 N9 O5 P | 633.4451 | 2.596 | 8 | 3.85 | 3.22 | 3.83 | 3.83 | 3.29 | 3.83 | 21.70 | 22.06 | 11.40 |
| C22 H43 N O2 | 353.3293 | 3.678 | 20 | 2.82 | 1.96 | 3.10 | 3.32 | 2.16 | 3.10 | 21.72 | 40.16 | 19.50 |
| C33 H65 O10 P | 652.4333 | 4.161 | 1 | 6.65 | 5.80 | 6.64 | 6.59 | 5.76 | 6.91 | 21.74 | 39.38 | 44.68 |
| C37 H80 N6 O5 P2 | 750.565 | 3.363 | 7 | 2.41 | 2.45 | 2.42 | 2.26 | 2.44 | 2.40 | 21.76 | 3.27 | 6.73 |
| C28 H57 N3 S | 467.427 | 3.39 | 17 | 1.65 | 1.85 | 1.94 | 1.93 | 1.70 | 1.93 | 21.76 | 19.98 | 6.96 |
| C31 H50 O2 S | 486.3527 | 2.829 | 6 | 3.99 | 3.41 | 4.27 | 4.07 | 3.83 | 4.42 | 21.88 | 45.62 | 47.07 |
| $\begin{aligned} & \text { C88 H179 N10 O12 P3 } \\ & \text { S3 } \end{aligned}$ | 1757.209 | 3.258 | 15 | 2.58 | 2.25 | 2.69 | 2.71 | 2.32 | 2.79 | 21.91 | 9.10 | 14.87 |
| C48 H79 N O7 | 781.584 | 4.602 | 6 | 4.80 | 4.05 | 4.79 | 4.80 | 3.94 | 5.09 | 21.92 | 45.10 | 45.54 |
| C73 H157 N10 O7 P3 S2 | 1443.089 | 3.308 | 5 | 1.43 | 1.28 | 1.27 | 1.32 | 1.25 | 1.30 | 21.93 | 4.14 | 4.32 |
| C36 H79 N6 P S2 | 690.5571 | 8.04 | 18 | 4.67 | 4.38 | 4.78 | 4.79 | 4.35 | 4.69 | 21.94 | 41.62 | 14.11 |
| C76 H165 N10 O16 P3 S | 1599.134 | 3.308 | 12 | 2.67 | 2.29 | 2.69 | 2.76 | 2.26 | 2.61 | 21.94 | 11.57 | 22.32 |
| C20 H46 N5 O2 P | 419.3371 | 2.974 | 7 | 2.76 | 2.69 | 3.23 | 2.92 | 2.69 | 3.18 | 21.95 | 14.72 | 20.49 |
| C49 H81 N O7 | 795.5991 | 4.886 | 3 | 7.77 | 7.03 | 7.82 | 7.78 | 7.07 | 8.09 | 21.95 | 25.94 | 43.17 |
| C18 H35 N | 265.2767 | 2.558 | 3 | 2.25 | 0.40 | 1.80 | 2.07 | 0.59 | 1.74 | 21.95 | 34.58 | 17.35 |
| C30 H53 N P2 | 489.3658 | 3.187 | 13 | 2.18 | 2.10 | 2.47 | 2.40 | 2.09 | 2.50 | 21.97 | 17.72 | 18.47 |
| C23 H40 N3 O2 P | 421.2865 | 3.914 | 11 | 2.66 | 2.73 | 2.83 | 2.75 | 2.79 | 2.79 | 22.03 | 13.33 | 7.29 |
| C61 H131 N10 O10 P S3 | 1290.895 | 2.627 | 8 | 2.18 | 1.70 | 2.09 | 2.49 | 1.84 | 2.11 | 22.04 | 28.30 | 18.77 |
| C37 H67 N O15 | 765.4487 | 2.792 | 3 | 3.74 | 3.03 | 3.82 | 3.67 | 3.10 | 4.23 | 22.10 | 42.64 | 46.77 |
| C86 H161 N8 O15 P S2 | 1641.127 | 2.978 | 20 | 2.86 | 2.69 | 3.13 | 3.25 | 2.60 | 3.36 | 22.15 | 11.92 | 27.14 |
| C27 H56 N6 O2 | 496.4483 | 5.942 | 19 | 3.02 | 3.51 | 2.65 | 3.11 | 3.36 | 2.95 | 22.16 | 25.72 | 34.87 |


| C38 H66 N4 | 578.5266 | 11.228 | 5 | 3.98 | 2.74 | 4.07 | 4.04 | 2.69 | 4.47 | 22.17 | 26.46 | 42.62 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| C35 H69 O10 P | 680.4639 | 4.6 | 4 | 6.50 | 5.77 | 6.52 | 6.53 | 5.61 | 6.80 | 22.17 | 49.69 | 44.10 |
| C40 H80 N O8 P | 733.561 | 3.478 | 16 | 2.03 | 1.59 | 2.40 | 1.83 | 1.60 | 2.31 | 22.25 | 10.43 | 23.86 |
| C19 H17 N3 O7 | 399.1069 | 1.933 | 20 | 2.06 | 1.47 | 2.08 | 2.20 | 1.21 | 1.94 | 22.26 | 40.48 | 27.78 |
| C22 H43 N O | 337.3339 | 3.907 | 7 | 1.78 | 1.52 | 1.73 | 1.79 | 1.81 | 1.73 | 22.28 | 31.85 | 4.32 |
| C33 H73 N9 | 595.6008 | 7.352 | 9 | 2.14 | 1.86 | 2.15 | 2.01 | 1.88 | 2.10 | 22.31 | 22.20 | 6.84 |
| C22 H45 N O | 339.3496 | 5.483 | 3 | 2.26 | 0.70 | 1.82 | 2.12 | 0.86 | 1.87 | 22.35 | 33.82 | 16.40 |
| C 29 H 41 Cl 2 N | 473.26 | 1.658 | 14 | 8.02 | 8.24 | 7.95 | 7.83 | 8.00 | 7.74 | 22.37 | 32.94 | 31.85 |
| $\mathrm{C} 37 \mathrm{H} 73 \mathrm{~N} \mathrm{O2}$ | 563.5633 | 7.488 | 3 | 3.36 | 3.11 | 3.69 | 3.23 | 3.00 | 3.50 | 22.40 | 22.45 | 30.89 |
| C28 H58 N2 O4 | 486.4398 | 3.153 | 29 | 2.40 | 2.07 | 2.14 | 2.35 | 2.24 | 2.15 | 22.44 | 27.58 | 11.09 |
| C40 H87 Cl N4 O2 P2 S2 | 816.5424 | 10.678 | 18 | 3.76 | 3.05 | 3.80 | 3.70 | 3.21 | 3.80 | 22.44 | 19.06 | 8.35 |
| C45 H60 N P | 645.4477 | 2.629 | 12 | 2.12 | 2.03 | 2.01 | 2.51 | 1.89 | 1.99 | 22.48 | 34.66 | 11.64 |
| C60 H112 N3 O2 P | 937.8477 | 3.074 | 28 | 2.71 | 0.25 | 2.64 | 3.11 | 0.00 | 2.65 | 22.48 | 43.52 | 2.27 |
| C45 H73 N O7 | 739.5381 | 4.16 | 11 | 8.68 | 7.85 | 8.74 | 8.67 | 7.80 | 8.95 | 22.49 | 36.24 | 46.93 |
| C42 H79 N O4 | 661.5999 | 5.379 | 3 | 4.52 | 4.50 | 4.53 | 4.38 | 4.41 | 4.36 | 22.52 | 40.96 | 24.84 |
| C24 H54 N6 O P2 | 504.3815 | 3.567 | 4 | 3.11 | 3.08 | 3.24 | 3.45 | 3.09 | 3.18 | 22.55 | 3.45 | 24.54 |
| C38 H61 N4 O2 P S2 | 700.4005 | 6.06 | 10 | 1.94 | 1.44 | 1.43 | 1.95 | 1.41 | 1.26 | 22.57 | 20.98 | 34.63 |
| C42 H85 N O3 | 651.6519 | 11.059 | 18 | 2.80 | 1.35 | 2.49 | 2.75 | 1.53 | 2.65 | 22.64 | 49.50 | 18.00 |
| C28 H50 N O7 P | 543.3345 | 2.268 | 9 | 1.33 | 0.31 | 1.27 | 1.08 | 0.61 | 1.23 | 22.68 | 40.49 | 8.11 |
| C50 H83 N O7 | 809.6157 | 4.882 | 4 | 4.40 | 3.70 | 4.51 | 4.39 | 3.71 | 4.68 | 22.77 | 29.38 | 43.17 |
| C43 H64 N P | 625.4766 | 3.09 | 17 | 1.63 | 1.50 | 1.78 | 1.49 | 1.55 | 1.80 | 22.79 | 9.76 | 18.14 |
| C18 H37 N O | 283.2869 | 3.767 | 10 | 2.65 | 1.17 | 2.11 | 2.57 | 1.35 | 2.11 | 22.79 | 22.15 | 19.82 |
| C14 H17 N | 199.1356 | 1.659 | 21 | 4.90 | 5.20 | 4.80 | 4.76 | 5.20 | 4.92 | 22.80 | 34.39 | 17.03 |
| C 22 H 43 N O 2 | 353.329 | 2.685 | 3 | 1.85 | 1.74 | 1.61 | 1.85 | 1.59 | 1.74 | 22.80 | 35.16 | 15.04 |
| C27 H56 N6 O4 S | 560.4108 | 3.123 | 8 | 1.79 | 0.48 | 1.32 | 1.51 | 0.70 | 1.35 | 22.83 | 38.28 | 6.14 |
| C50 H83 N O7 | 809.6166 | 4.95 | 4 | 7.70 | 7.00 | 7.81 | 7.69 | 7.00 | 7.98 | 22.83 | 29.49 | 43.22 |


| C39 H84 N9 O P3 | 787.6009 | 2.784 | 17 | 1.52 | 1.17 | 1.38 | 1.36 | 1.00 | 1.40 | 22.84 | 45.76 | 9.34 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| C24 H49 N O2 | 383.3759 | 3.051 | 4 | 3.22 | 1.56 | 3.10 | 3.03 | 1.57 | 3.27 | 22.85 | 12.10 | 35.52 |
| C30 H56 N6 O2 | 532.4465 | 6.38 | 13 | 7.09 | 7.38 | 7.23 | 7.19 | 7.08 | 7.20 | 22.86 | 39.45 | 12.74 |
| C19 H44 N5 O2 P | 405.3216 | 3.128 | 14 | 2.55 | 2.59 | 2.71 | 2.46 | 2.58 | 2.67 | 22.89 | 11.68 | 5.57 |
| C35 H78 N8 O4 P2 S | 768.5323 | 1.546 | 4 | 4.04 | 2.37 | 3.24 | 4.26 | 2.41 | 3.52 | 22.89 | 43.63 | 31.46 |
| C22 H37 N6 O2 P S | 480.2458 | 3.379 | 27 | 3.11 | 2.19 | 3.09 | 3.42 | 2.18 | 3.15 | 22.89 | 12.50 | 8.37 |
| C45 H81 N5 O6 S | 819.5912 | 2.643 | 8 | 5.36 | 4.41 | 5.58 | 5.40 | 4.46 | 5.64 | 22.92 | 19.14 | 43.69 |
| C64 H132 N2 O12 P2 S2 | 1246.869 | 2.633 | 5 | 4.79 | 4.52 | 4.79 | 5.23 | 4.62 | 4.87 | 22.92 | 21.43 | 15.84 |
| C42 H83 N O2 | 633.6415 | 11.062 | 18 | 3.01 | 1.58 | 2.71 | 2.97 | 1.76 | 2.86 | 22.93 | 49.16 | 18.20 |
| C38 H77 N O3 | 595.5897 | 7.486 | 3 | 3.42 | 3.15 | 3.76 | 3.29 | 3.05 | 3.57 | 22.94 | 22.96 | 31.98 |
| C75 H141 N8 O3 P3 S | 1327.005 | 3.216 | 4 | 2.03 | 1.76 | 1.98 | 1.92 | 1.85 | 1.96 | 22.96 | 10.30 | 3.51 |
| C34 H74 N9 O3 P | 687.564 | 7.288 | 22 | 3.19 | 2.41 | 3.88 | 3.41 | 2.46 | 3.81 | 22.96 | 42.14 | 25.50 |
| C20 H45 N4 O4 P | 436.316 | 3.842 | 12 | 5.85 | 4.54 | 6.24 | 6.09 | 4.73 | 6.33 | 23.01 | 26.87 | 46.38 |
| C24 H49 N7 O5 | 515.3815 | 2.703 | 11 | 2.34 | 2.16 | 2.46 | 2.33 | 2.17 | 2.49 | 23.03 | 18.05 | 11.69 |
| C85 H170 N5 O16 P3 S | 1642.158 | 3.297 | 14 | 3.59 | 3.39 | 3.77 | 3.90 | 3.42 | 3.61 | 23.04 | 9.20 | 36.27 |
| C75 H147 N4 O11 P3 S | 1405 | 3.375 | 2 | 2.87 | 2.75 | 3.05 | 3.15 | 2.79 | 3.09 | 23.10 | 5.28 | 19.55 |
| C77 H153 N7 O17 P2 | 1510.078 | 3.339 | 13 | 2.72 | 2.72 | 3.07 | 3.28 | 2.67 | 2.97 | 23.11 | 12.47 | 28.98 |
| C42 H83 N4 O2 P | 706.6256 | 8.087 | 16 | 2.83 | 2.55 | 2.85 | 2.54 | 2.77 | 2.70 | 23.21 | 34.97 | 27.55 |
| C87 H142 N4 O5 P2 | 1385.046 | 3.26 | 3 | 2.35 | 2.02 | 2.13 | 2.23 | 2.11 | 2.14 | 23.22 | 11.68 | 6.66 |
| C11 H26 N6 O2 S | 306.1824 | 4.385 | 16 | 2.29 | 2.28 | 2.09 | 2.10 | 2.19 | 2.09 | 23.23 | 18.18 | 1.06 |
| C25 H58 N9 O3 P | 563.44 | 3.176 | 8 | 1.48 | 1.12 | 1.46 | 1.42 | 1.13 | 1.47 | 23.24 | 18.96 | 4.15 |
| C81 H148 N7 O7 P S2 | 1426.062 | 3.306 | 4 | 1.40 | 1.24 | 1.26 | 1.27 | 1.21 | 1.25 | 23.26 | 3.90 | 4.11 |
| C23 H55 N7 O7 | 541.419 | 2.586 | 12 | 2.46 | 1.57 | 2.32 | 2.41 | 1.47 | 2.46 | 23.29 | 12.94 | 22.45 |
| C20 H45 N6 O P | 416.3373 | 3.771 | 18 | 2.24 | 2.18 | 2.22 | 2.16 | 2.07 | 2.17 | 23.30 | 18.36 | 10.26 |
| C33 H45 N6 P S | 588.319 | 2.772 | 20 | 5.35 | 4.78 | 5.59 | 5.65 | 4.68 | 5.63 | 23.34 | 18.12 | 35.12 |
| C30 H49 N P2 S | 517.3039 | 2.179 | 9 | 1.99 | 0.81 | 1.90 | 2.19 | 0.77 | 1.79 | 23.37 | 30.87 | 33.56 |


| C24 H60 N9 O3 P | 553.4557 | 3.202 | 10 | 2.55 | 2.58 | 2.95 | 2.74 | 2.63 | 2.96 | 23.47 | 13.73 | 13.91 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| C47 H77 N O7 | 767.5685 | 4.601 | 12 | 7.32 | 6.53 | 7.36 | 7.37 | 6.40 | 7.62 | 23.47 | 46.15 | 45.97 |
| C61 H101 N3 P2 S | 969.7195 | 9.624 | 15 | 4.22 | 4.11 | 4.46 | 4.21 | 4.19 | 4.43 | 23.49 | 17.42 | 8.38 |
| C15 H5 N5 O13 P2 S | 556.908 | 3.132 | 5 | 3.35 | 3.20 | 3.52 | 3.53 | 3.17 | 3.50 | 23.49 | 4.60 | 35.84 |
| C60 H92 N7 O2 P | 973.7042 | 3.704 | 7 | 5.36 | 3.59 | 5.33 | 5.39 | 3.67 | 5.47 | 23.65 | 17.44 | 33.64 |
| C 28 H 58 N 2 O | 438.4544 | 3.866 | 7 | 1.22 | 0.33 | 0.70 | 1.05 | 0.04 | 0.84 | 23.65 | 41.48 | 17.09 |
| C47 H95 N O2 P2 S2 | 831.6277 | 3.24 | 4 | 4.48 | 4.09 | 4.53 | 4.62 | 4.15 | 4.52 | 23.66 | 8.36 | 23.23 |
| C57 H121 N10 O11 P S | 1184.867 | 3.461 | 8 | 2.33 | 2.46 | 2.56 | 2.54 | 2.45 | 2.57 | 23.67 | 3.90 | 19.27 |
| C39 H84 N9 O P3 | 787.6013 | 3.256 | 6 | 3.44 | 3.13 | 3.39 | 3.66 | 3.17 | 3.47 | 23.69 | 9.40 | 30.61 |
| C43 H75 O10 P | 782.507 | 5.21 | 15 | 1.21 | 1.42 | 1.15 | 1.30 | 1.45 | 1.13 | 23.73 | 22.08 | 7.57 |
| C67 H140 N9 O14 P3 | 1387.973 | 3.375 | 2 | 2.89 | 2.77 | 3.07 | 3.18 | 2.80 | 3.12 | 23.78 | 4.89 | 19.66 |
| C49 H94 N3 O8 P S | 915.6505 | 3.023 | 15 | 1.31 | 1.29 | 1.74 | 1.85 | 1.28 | 1.78 | 23.79 | 1.23 | 20.58 |
| C32 H53 N10 P3 S | 702.3411 | 3.481 | 10 | 5.28 | 3.71 | 5.78 | 5.55 | 3.76 | 5.93 | 23.85 | 31.32 | 47.22 |
| C19 H47 N7 O2 | 405.3809 | 2.785 | 15 | 2.28 | 1.01 | 2.27 | 2.18 | 1.23 | 2.17 | 23.88 | 28.74 | 43.21 |
| C42 H68 S | 604.5038 | 7.607 | 7 | 1.36 | 0.51 | 1.56 | 1.22 | 0.42 | 1.44 | 23.88 | 30.21 | 30.75 |
| C84 H179 N9 O16 S5 | 1730.207 | 3.269 | 8 | 2.85 | 2.51 | 2.89 | 3.06 | 2.56 | 2.90 | 23.93 | 12.15 | 21.46 |
| C82 H146 O3 P2 | 1241.074 | 7.754 | 4 | 3.25 | 2.07 | 3.32 | 3.16 | 2.30 | 3.62 | 23.98 | 40.67 | 37.76 |
| C67 H142 N9 O5 P3 S2 | 1309.978 | 3.22 | 4 | 1.97 | 1.76 | 1.94 | 1.88 | 1.83 | 1.93 | 23.98 | 8.86 | 1.87 |
| C35 H78 N10 | 638.6402 | 8.072 | 16 | 1.26 | 1.38 | 1.34 | 1.24 | 1.41 | 1.23 | 23.99 | 49.58 | 15.46 |
| C37 H77 N3 O2 | 595.6008 | 5.532 | 15 | 2.07 | 1.76 | 2.31 | 2.09 | 1.61 | 2.21 | 24.01 | 22.94 | 12.55 |
| C28 H70 N9 P3 S | 657.4667 | 2.548 | 8 | 2.34 | 2.36 | 2.32 | 2.24 | 2.33 | 2.01 | 24.02 | 17.57 | 44.29 |
| C32 H68 N2 O | 496.5327 | 5.923 | 12 | 1.21 | 0.06 | 1.09 | 1.19 | 0.18 | 1.14 | 24.09 | 46.66 | 8.35 |
| C21 H43 N O | 325.3339 | 2.357 | 24 | 1.68 | 0.14 | 0.46 | 2.18 | 0.06 | 0.47 | 24.11 | 41.92 | 48.60 |
| C54 H108 N2 O8 | 912.8108 | 11.489 | 16 | 9.92 | 8.87 | 9.82 | 9.79 | 8.82 | 10.13 | 24.15 | 7.32 | 39.19 |
| C22 H39 N | 317.3075 | 5.131 | 9 | 1.33 | 0.16 | 1.15 | 1.16 | 0.04 | 1.11 | 24.19 | 23.65 | 9.15 |
| C42 H80 N5 O7 P | 797.5796 | 11.31 | 22 | 3.36 | 3.37 | 3.58 | 2.71 | 3.42 | 3.65 | 24.24 | 25.20 | 11.00 |


|  | C33 H61 N8 O P | 616.4728 | 4.977 | 18 | 1.51 | 0.41 | 1.04 | 1.40 | 0.47 | 1.04 | 24.24 | 45.41 |
| :--- | :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | C75 H159 N10 O18 P3 | 1581.106 | 3.313 | 21 | 3.52 | 3.42 | 3.67 | 3.76 | 3.36 | 3.73 | 24.27 | 8.32 |
|  | C36 H73 N | 519.5736 | 5.698 | 15 | 1.72 | 0.70 | 1.61 | 1.72 | 0.33 | 1.54 | 24.31 | 48.60 |
|  | C28 H60 N9 P S | 585.4451 | 2.58 | 7 | 2.92 | 2.08 | 3.01 | 3.19 | 2.04 | 3.20 | 24.34 | 14.41 |
|  | C15 H24 N2 | 232.1933 | 0.923 | 20 | 1.91 | 0.78 | 2.01 | 1.86 | 0.84 | 2.25 | 24.37 | 23.08 |
|  | C25 H51 N O | 381.3963 | 6.081 | 6 | 2.28 | 1.13 | 2.26 | 2.16 | 1.18 | 2.23 | 24.45 | 39.88 |
|  | C12 H32 N5 O P | 293.2351 | 2.056 | 28 | 1.60 | 1.67 | 1.04 | 1.71 | 1.40 | 0.97 | 24.49 | 40.27 |
|  | C33 H48 O S | 492.3426 | 3.304 | 10 | 1.08 | 0.63 | 0.91 | 1.26 | 0.56 | 1.01 | 24.51 | 18.42 |
|  | C32 H65 N | 463.5114 | 4.213 | 19 | 1.60 | 0.24 | 1.22 | 1.48 | 0.16 | 1.18 | 24.52 | 49.45 |
|  | C22 H40 O | 320.3073 | 3.908 | 9 | 1.24 | 1.10 | 1.25 | 1.18 | 1.41 | 1.29 | 24.54 | 34.58 |
|  | C18 H34 N2 | 278.2716 | 2.592 | 6 | 1.74 | 0.36 | 1.17 | 1.52 | 0.27 | 1.12 | 24.54 | 12.73 |
|  | C61 H79 N7 O2 | 941.629 | 2.554 | 6 | 2.77 | 2.51 | 2.69 | 3.01 | 2.54 | 2.83 | 24.56 | 6.78 |
|  | C51 H102 N3 O9 P S | 963.7076 | 3.181 | 6 | 3.82 | 3.61 | 3.96 | 3.94 | 3.61 | 3.93 | 24.57 | 0.51 |
|  | 27.06 |  |  |  |  |  |  |  |  |  |  |  |
|  | C40 H84 Cl N3 O11 | 817.5787 | 5.169 | 28 | 4.82 | 4.79 | 4.93 | 5.21 | 4.83 | 4.90 | 24.58 | 6.97 |
|  | C87 H139 N3 O5 P2 | 1368.02 | 3.258 | 3 | 2.36 | 2.07 | 2.16 | 2.24 | 2.15 | 2.17 | 24.61 | 10.72 |
|  | C52 H109 N6 O P S2 | 928.7848 | 11.49 | 19 | 6.09 | 4.93 | 6.00 | 5.92 | 4.88 | 6.32 | 24.67 | 14.72 |
|  | 42.89 |  |  |  |  |  |  |  |  |  |  |  |
|  | C36 H67 N | 513.5272 | 4.327 | 20 | 1.37 | 0.11 | 0.91 | 1.37 | 0.04 | 0.63 | 24.77 | 32.97 |
|  | 40.78 |  |  |  |  |  |  |  |  |  |  |  |
|  | C18 H48 N9 P | 421.3762 | 3.24 | 19 | 1.21 | 1.40 | 2.05 | 1.40 | 1.43 | 1.77 | 24.78 | 5.73 |
| 46.45 |  |  |  |  |  |  |  |  |  |  |  |  |
|  | C26 H51 N5 O3 S | 513.369 | 2.677 | 21 | 3.71 | 3.46 | 3.44 | 3.77 | 3.39 | 3.55 | 24.88 | 19.67 |
|  | 18.82 |  |  |  |  |  |  |  |  |  |  |  |
|  | C63 H130 N6 O11 S2 | 1210.922 | 3.116 | 14 | 1.80 | 1.64 | 1.69 | 1.75 | 1.71 | 1.70 | 24.88 | 10.89 |


|  | C8 H15 N O3 | 173.1047 | 1.946 | 18 | 1.62 | 0.63 | 1.21 | 1.55 | 0.72 | 1.42 | 25.20 | 15.80 | 33.17 |
| :--- | :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | C38 H70 N2 O P2 | 632.4984 | 5.394 | 13 | 1.42 | 0.85 | 1.63 | 1.36 | 0.82 | 1.64 | 25.21 | 21.07 | 36.14 |
|  | C15 H39 N8 P | 362.3026 | 2.767 | 7 | 4.27 | 3.24 | 4.75 | 4.23 | 3.33 | 4.54 | 25.23 | 14.76 | 48.79 |
|  | C46 H87 N10 O8 P3 | 1000.592 | 3.492 | 6 | 8.70 | 7.29 | 8.51 | 8.47 | 6.99 | 8.74 | 25.23 | 46.26 | 27.98 |
|  | C59 H121 N4 O13 P S | 1156.839 | 3.121 | 2 | 2.80 | 2.46 | 2.72 | 2.89 | 2.50 | 2.83 | 25.31 | 3.97 | 27.78 |
|  | C13 H37 N10 O P | 380.2897 | 2.744 | 20 | 1.17 | 0.55 | 1.93 | 1.59 | 0.73 | 1.86 | 25.35 | 35.62 | 9.92 |
|  | C31 H51 O9 P | 598.3293 | 2.627 | 3 | 5.74 | 5.69 | 6.35 | 6.00 | 5.87 | 6.14 | 25.38 | 27.81 | 31.75 |
|  | C16 H22 O4 | 278.1513 | 2.445 | 5 | 1.89 | 1.82 | 1.96 | 2.02 | 1.92 | 1.83 | 25.38 | 21.87 | 30.68 |
|  | C31 H59 N S | 477.4392 | 3.03 | 10 | 4.68 | 3.60 | 4.83 | 4.47 | 3.68 | 4.82 | 25.40 | 22.55 | 45.19 |
|  | C34 H76 N10 | 624.6246 | 7.894 | 7 | 3.99 | 3.12 | 4.40 | 3.94 | 3.10 | 4.26 | 25.41 | 48.65 | 32.29 |
|  | C27 H48 S | 404.3496 | 3.281 | 18 | 1.71 | 1.80 | 1.85 | 1.66 | 1.78 | 1.87 | 25.43 | 9.18 | 27.30 |
|  | C41 H87 N3 O6 | 717.66 | 8.265 | 22 | 1.77 | 1.67 | 1.87 | 2.11 | 1.58 | 1.84 | 25.45 | 38.36 | 7.40 |
|  | C68 H130 N6 O17 S | 1334.922 | 2.625 | 7 | 4.89 | 4.93 | 4.82 | 5.01 | 4.80 | 4.90 | 25.50 | 17.62 | 14.31 |
|  | C57 H101 N8 O5 P | 1008.763 | 3.571 | 3 | 2.97 | 2.97 | 3.15 | 3.29 | 3.00 | 3.10 | 25.54 | 3.39 | 21.12 |
|  | C22 H50 N6 O16 | 654.3269 | 3.065 | 9 | 4.74 | 3.20 | 4.72 | 4.58 | 3.26 | 4.96 | 25.56 | 20.70 | 45.60 |
|  | C49 H80 N O10 P | 873.5484 | 4.446 | 14 | 3.51 | 3.27 | 3.23 | 3.32 | 3.35 | 3.30 | 25.57 | 13.90 | 10.24 |
|  | C38 H82 N9 O2 P3 | 789.5806 | 2.756 | 8 | 2.91 | 2.16 | 3.18 | 3.15 | 2.17 | 3.27 | 25.57 | 2.64 | 36.43 |
|  | C13 H23 N O | 209.1776 | 3.103 | 10 | 2.34 | 2.23 | 2.58 | 2.41 | 2.03 | 2.60 | 25.64 | 40.49 | 3.23 |
|  | C41 H57 N O6 | 659.4175 | 2.772 | 4 | 7.99 | 7.44 | 8.31 | 8.21 | 7.39 | 8.36 | 25.64 | 19.38 | 43.85 |
|  | C10 H23 N O9 | 301.1365 | 2.452 | 26 | 2.68 | 3.02 | 2.64 | 2.84 | 3.02 | 2.71 | 25.66 | 3.91 | 18.31 |
|  | C20 H52 N9 O3 P | 497.3924 | 2.592 | 9 | 3.47 | 2.60 | 3.50 | 3.51 | 2.46 | 3.69 | 25.67 | 24.10 | 21.70 |
|  | C14 H27 N O3 | 257.1986 | 1.985 | 16 | 3.14 | 3.00 | 2.60 | 3.07 | 3.00 | 2.63 | 25.71 | 15.76 | 21.88 |
|  | C42 H75 O8 P | 738.5175 | 4.6 | 11 | 2.95 | 2.31 | 2.99 | 3.20 | 2.20 | 3.28 | 25.76 | 20.15 | 39.04 |
|  | C21 H40 O3 | 340.2975 | 2.5 | 22 | 2.12 | 0.85 | 2.30 | 2.40 | 0.91 | 2.32 | 25.77 | 10.77 | 41.59 |
|  | C22 H41 N O | 335.3181 | 3.504 | 13 | 3.09 | 3.01 | 3.03 | 3.02 | 3.22 | 3.05 | 25.77 | 24.91 | 17.11 |
|  | C59 H127 N10 O11 P3 | 1244.89 | 3.09 | 3 | 2.56 | 2.31 | 2.68 | 2.73 | 2.32 | 2.77 | 25.86 | 9.20 | 26.49 |


| C19 H48 N8 O4 S | 484.3503 | 0.768 | 18 | 3.28 | 2.50 | 3.10 | 3.42 | 2.66 | 3.03 | 25.88 | 35.33 | 10.51 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| C34 H71 N3 O S2 | 601.5038 | 4.854 | 6 | 1.36 | 0.80 | 1.03 | 1.13 | 0.87 | 0.96 | 25.89 | 10.48 | 10.41 |
| C38 H51 N O6 | 617.3705 | 2.772 | 4 | 11.37 | 10.74 | 11.60 | 11.54 | 10.69 | 11.69 | 25.91 | 14.94 | 46.71 |
| C57 H117 N4 O12 P S | 1112.813 | 3.13 | 5 | 3.49 | 3.19 | 3.54 | 3.58 | 3.20 | 3.56 | 25.91 | 1.63 | 34.86 |
| C43 H89 N O | 635.694 | 11.868 | 14 | 0.97 | 0.95 | 0.40 | 1.04 | 0.58 | 0.35 | 25.94 | 40.38 | 23.65 |
| C15 H20 O5 | 280.1304 | 1.701 | 9 | 12.10 | 12.05 | 12.32 | 12.27 | 11.78 | 12.21 | 25.95 | 46.82 | 26.65 |
| C73 H155 N10 O17 P3 | 1537.079 | 3.326 | 3 | 3.29 | 3.08 | 3.45 | 3.50 | 3.05 | 3.46 | 25.96 | 5.43 | 16.82 |
| C38 H51 P3 | 600.3191 | 2.772 | 16 | 4.41 | 3.68 | 4.73 | 4.51 | 3.63 | 4.72 | 25.96 | 7.62 | 44.81 |
| C15 H29 N O2 | 255.2192 | 3.57 | 8 | 2.31 | 2.12 | 2.15 | 2.15 | 2.12 | 2.14 | 26.01 | 6.72 | 6.97 |
| C13 H18 | 174.1406 | 3.119 | 12 | 1.65 | 1.48 | 1.65 | 1.33 | 1.48 | 1.56 | 26.02 | 12.73 | 24.20 |
| C46 H82 N O8 P | 807.5761 | 4.861 | 6 | 3.65 | 3.64 | 3.63 | 3.45 | 3.88 | 3.45 | 26.02 | 28.89 | 23.76 |
| C34 H72 N8 O P2 S | 702.4997 | 3.376 | 4 | 2.68 | 2.59 | 2.87 | 2.94 | 2.62 | 2.92 | 26.06 | 4.07 | 18.71 |
| C32 H76 N9 O8 P | 745.5542 | 2.763 | 3 | 3.60 | 2.81 | 3.93 | 3.77 | 2.84 | 4.01 | 26.06 | 4.98 | 38.81 |
| C59 H79 N4 O3 P S | 954.5615 | 3.583 | 12 | 1.65 | 0.42 | 1.82 | 1.74 | 0.50 | 2.14 | 26.12 | 22.89 | 48.22 |
| C36 H24 N3 O13 P3 | 799.0519 | 2.997 | 13 | 3.10 | 2.78 | 3.25 | 3.47 | 2.85 | 3.33 | 26.12 | 9.93 | 22.93 |
| C78 H166 N9 O17 P3 S | 1626.133 | 3.296 | 5 | 2.91 | 2.72 | 3.19 | 3.03 | 2.68 | 3.19 | 26.13 | 5.53 | 13.38 |
| C21 H46 N O P S2 | 423.2748 | 3.153 | 23 | 3.04 | 2.93 | 3.06 | 2.92 | 2.89 | 3.08 | 26.16 | 11.23 | 13.04 |
| C29 H68 N9 O6 P | 669.5021 | 3.076 | 15 | 1.89 | 1.65 | 1.98 | 1.88 | 1.67 | 1.86 | 26.18 | 5.51 | 20.24 |
| C69 H132 N6 O15 S | 1316.947 | 3.412 | 2 | 2.67 | 2.82 | 2.99 | 3.10 | 2.83 | 3.04 | 26.21 | 0.54 | 18.42 |
| C32 H72 N10 O S | 644.56 | 3.945 | 6 | 1.19 | 0.26 | 1.03 | 1.24 | 0.44 | 1.06 | 26.22 | 36.42 | 7.60 |
| C20 H37 N O4 | 355.2717 | 3.233 | 12 | 2.44 | 2.09 | 2.18 | 2.43 | 2.14 | 2.12 | 26.27 | 16.06 | 8.76 |
| C39 H53 N O6 | 631.3862 | 2.772 | 4 | 11.29 | 10.62 | 11.54 | 11.42 | 10.60 | 11.63 | 26.32 | 16.26 | 49.87 |
| C68 H135 N O17 P2 | 1299.921 | 3.414 | 2 | 2.76 | 2.87 | 3.05 | 3.18 | 2.88 | 3.10 | 26.32 | 0.55 | 18.81 |
| C49 H110 N9 O15 P | 1095.786 | 3.132 | 3 | 3.53 | 3.22 | 3.58 | 3.61 | 3.21 | 3.59 | 26.34 | 2.57 | 33.22 |
| C18 H38 O4 | 318.2764 | 2.787 | 7 | 2.75 | 2.00 | 3.22 | 2.89 | 2.00 | 3.12 | 26.37 | 5.53 | 33.81 |
| C67 H128 N6 O15 S | 1288.916 | 3.076 | 4 | 2.90 | 2.61 | 3.10 | 3.06 | 2.62 | 3.13 | 26.44 | 4.73 | 28.67 |


|  | C60 H117 N4 O6 P3 S | 1114.791 | 2.652 | 8 | 4.18 | 3.83 | 4.14 | 4.29 | 3.84 | 4.08 | 26.46 | 2.01 |
| :--- | :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | C59 H118 N3 O13 P S | 1139.812 | 3.117 | 2 | 2.98 | 2.63 | 2.91 | 3.07 | 2.65 | 3.02 | 26.48 | 4.66 |
|  | C42 H90 N9 O2 P3 | 845.6435 | 2.833 | 14 | 2.79 | 2.48 | 2.71 | 2.58 | 2.46 | 2.70 | 26.49 | 4.17 |
|  | C18 H39 N O | 285.3024 | 5.167 | 19 | 1.52 | 0.01 | 1.21 | 1.52 | 0.17 | 1.15 | 26.50 | 38.09 |
|  | C24 H43 CI N4 O2 | 454.3067 | 1.3 | 9 | 4.44 | 2.53 | 3.41 | 4.63 | 2.62 | 3.43 | 26.50 | 39.24 |
|  | C39 H78 N5 O3 P3 S2 | 821.4737 | 3.798 | 15 | 1.42 | 0.07 | 0.61 | 1.07 | 0.11 | 0.75 | 26.51 | 35.32 |
|  | C69 H126 N7 O P3 S | 1193.896 | 3.118 | 10 | 1.83 | 1.75 | 1.78 | 1.81 | 1.80 | 1.79 | 26.52 | 8.29 |
|  | C22 H52 N9 P | 473.4079 | 2.514 | 20 | 4.51 | 2.80 | 4.42 | 4.81 | 2.81 | 4.46 | 26.56 | 7.78 |
|  | C18 H40 N5 O3 P | 405.285 | 3.101 | 13 | 3.63 | 3.28 | 3.44 | 3.62 | 3.23 | 3.35 | 26.57 | 7.79 |
|  | C65 H123 N5 O12 P2 | 1227.864 | 3.09 | 3 | 2.66 | 2.41 | 2.80 | 2.84 | 2.42 | 2.88 | 26.63 | 9.93 |
|  | C27 H59 N9 O6 | 605.4607 | 3.12 | 2 | 1.45 | 1.34 | 1.48 | 1.35 | 1.36 | 1.46 | 26.64 | 7.73 |
|  | C59 H89 N3 O4 | 903.6854 | 3.617 | 4 | 3.02 | 2.78 | 3.03 | 3.23 | 2.83 | 3.09 | 26.65 | 6.43 |
|  | C20 H39 N O2 | 325.2979 | 2.959 | 14 | 1.98 | 0.87 | 2.03 | 1.84 | 0.88 | 1.92 | 26.71 | 31.38 |
|  | C34 H59 N7 O5 P2 S | 739.3799 | 3.045 | 5 | 1.59 | 1.49 | 1.87 | 1.50 | 1.88 | 1.94 | 26.71 | 41.84 |
|  | C69 H141 N4 O18 P S | 1376.969 | 3.051 | 4 | 3.22 | 3.10 | 3.47 | 3.47 | 3.09 | 3.57 | 26.74 | 3.02 |
|  | 25.21 |  |  |  |  |  |  |  |  |  |  |  |
|  | C41 H73 N4 O3 P S | 732.5106 | 3.062 | 4 | 2.62 | 2.28 | 2.77 | 2.81 | 2.33 | 2.84 | 26.75 | 6.52 |
|  | 29.75 |  |  |  |  |  |  |  |  |  |  |  |
|  | C81 H156 N3 O14 P3 S | 1520.052 | 3.327 | 2 | 3.16 | 2.93 | 3.31 | 3.37 | 2.92 | 3.33 | 26.80 | 5.25 | 16.96


| C47 H97 N3 O10 P2 S | 957.6371 | 3.905 | 18 | 4.07 | 3.29 | 3.93 | 3.84 | 3.31 | 4.11 | 27.04 | 25.40 | 40.18 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| C55 H111 N O5 P2 S2 | 991.737 | 3.563 | 3 | 3.07 | 3.03 | 3.26 | 3.36 | 3.03 | 3.22 | 27.05 | 0.57 | 21.34 |
| C36 H71 N O | 533.5532 | 7.95 | 21 | 0.89 | 0.28 | 1.06 | 1.22 | 0.31 | 1.06 | 27.06 | 48.78 | 7.00 |
| C83 H157 N9 O14 P2 S | 1598.104 | 3.003 | 15 | 2.63 | 2.28 | 2.83 | 2.94 | 2.33 | 2.92 | 27.08 | 9.23 | 20.21 |
| C29 H54 O6 S | 530.363 | 3.529 | 28 | 2.08 | 0.86 | 1.58 | 2.10 | 0.89 | 1.54 | 27.14 | 35.01 | 24.95 |
| C34 H76 N5 P | 585.5823 | 8.41 | 9 | 1.03 | 0.95 | 0.55 | 1.07 | 0.56 | 0.51 | 27.18 | 46.34 | 32.68 |
| C51 H79 N9 O3 S | 897.6031 | 2.562 | 8 | 3.76 | 3.48 | 3.71 | 3.83 | 3.40 | 3.66 | 27.20 | 10.92 | 14.60 |
| C55 H113 N4 O11 P S | 1068.786 | 3.15 | 3 | 2.68 | 2.53 | 2.91 | 2.90 | 2.54 | 2.90 | 27.25 | 1.63 | 28.65 |
| C11 H25 N8 O4 P S | 396.1457 | 1.852 | 24 | 3.32 | 2.80 | 3.46 | 3.49 | 2.84 | 3.29 | 27.29 | 4.64 | 26.79 |
| C18 H45 N10 O P | 448.3523 | 3.408 | 11 | 2.50 | 2.39 | 2.42 | 2.32 | 2.39 | 2.30 | 27.31 | 1.88 | 16.11 |
| C32 H72 N9 O P S | 661.5333 | 6.821 | 8 | 4.65 | 4.38 | 5.19 | 4.72 | 4.17 | 5.01 | 27.34 | 38.65 | 33.69 |
| C57 H120 N9 O10 P3 | 1183.838 | 3.103 | 2 | 3.12 | 2.90 | 3.19 | 3.32 | 2.93 | 3.28 | 27.44 | 4.38 | 29.64 |
| C24 H53 N9 O5 | 547.419 | 3.021 | 6 | 1.50 | 1.37 | 1.49 | 1.36 | 1.39 | 1.54 | 27.45 | 6.77 | 7.37 |
| C24 H49 N O | 367.3809 | 5.856 | 4 | 1.51 | 0.60 | 2.10 | 1.42 | 0.61 | 1.87 | 27.46 | 38.48 | 31.10 |
| C64 H107 N6 O13 P S | 1230.735 | 4.459 | 15 | 2.59 | 1.25 | 2.57 | 2.59 | 1.50 | 2.84 | 27.49 | 29.33 | 42.64 |
| C 28 H 26 O 3 | 410.1877 | 2.283 | 9 | 3.04 | 2.45 | 2.85 | 3.62 | 2.32 | 2.94 | 27.52 | 24.04 | 22.49 |
| C30 H59 N9 O P2 | 623.4342 | 2.633 | 7 | 5.08 | 4.99 | 4.95 | 5.35 | 4.92 | 4.94 | 27.53 | 24.83 | 18.56 |
| C40 H79 N5 O9 | 773.5862 | 3.088 | 10 | 2.64 | 2.02 | 2.69 | 2.69 | 1.90 | 2.71 | 27.56 | 22.18 | 26.03 |
| C40 H81 N O3 | 623.621 | 7.89 | 24 | 3.73 | 2.59 | 4.25 | 3.79 | 2.91 | 4.15 | 27.59 | 35.52 | 30.04 |
| C33 H78 N9 O7 P | 743.5752 | 3.278 | 5 | 2.83 | 2.53 | 2.65 | 2.81 | 2.54 | 2.74 | 27.59 | 10.50 | 14.27 |
| C38 H79 N3 O | 593.6219 | 8.065 | 19 | 2.39 | 0.71 | 1.79 | 2.50 | 1.05 | 1.74 | 27.60 | 42.80 | 43.75 |
| C21 H41 N | 307.3234 | 4.836 | 4 | 2.49 | 1.48 | 2.90 | 2.42 | 1.57 | 2.72 | 27.61 | 30.87 | 33.74 |
| C69 H124 N3 O P3 S2 | 1167.841 | 3.464 | 4 | 2.61 | 2.71 | 2.85 | 2.81 | 2.68 | 2.80 | 27.63 | 4.20 | 21.30 |
| C48 H79 N O7 | 781.5852 | 4.16 | 10 | 3.58 | 2.89 | 3.78 | 3.74 | 2.77 | 3.96 | 27.65 | 49.09 | 48.85 |
| C69 H147 N10 O15 P3 | 1449.026 | 3.358 | 3 | 3.27 | 3.05 | 3.38 | 3.40 | 3.07 | 3.43 | 27.76 | 2.56 | 21.21 |
| C19 H43 N7 O12 | 561.2956 | 2.604 | 8 | 2.38 | 1.35 | 2.40 | 2.41 | 1.61 | 2.68 | 27.80 | 34.14 | 46.14 |



|  | C69 H144 N9 O15 P3 | 1432 | 3.357 | 3 | 3.23 | 3.02 | 3.36 | 3.38 | 3.04 | 3.40 | 28.53 | 2.48 | 21.28 |
| :--- | :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | C71 H107 N3 O P2 | 1079.789 | 3.521 | 3 | 2.94 | 2.92 | 2.99 | 3.10 | 2.96 | 3.01 | 28.56 | 6.04 | 19.50 |
|  | C40 H80 N4 O12 | 808.5792 | 5.621 | 6 | 3.75 | 4.61 | 4.21 | 3.59 | 4.29 | 3.94 | 28.57 | 46.73 | 34.57 |
|  | C78 H144 N10 O15 S | 1493.053 | 3.342 | 20 | 3.75 | 3.47 | 3.71 | 3.86 | 3.49 | 3.88 | 28.58 | 6.86 | 21.89 |
|  | C13 H37 N9 O2 P2 | 413.2563 | 2.249 | 17 | 1.50 | 0.68 | 0.92 | 1.50 | 0.92 | 0.96 | 28.59 | 35.99 | 12.57 |
|  | C23 H36 | 312.281 | 11.259 | 20 | 2.95 | 3.24 | 3.01 | 2.73 | 3.28 | 3.03 | 28.63 | 10.56 | 20.17 |
|  | C35 H77 N10 O3 P | 716.5924 | 8.406 | 19 | 2.26 | 1.97 | 2.00 | 2.05 | 2.07 | 1.95 | 28.69 | 15.75 | 26.63 |
|  | C39 H84 N9 P3 | 771.6061 | 3.715 | 3 | 2.76 | 2.58 | 2.94 | 3.01 | 2.58 | 2.91 | 28.70 | 2.52 | 16.17 |
|  | C82 H147 N3 O15 P2 | 1476.028 | 3.343 | 19 | 3.66 | 3.38 | 3.62 | 3.77 | 3.39 | 3.79 | 28.73 | 6.75 | 22.02 |
|  | C48 H91 N P2 | 743.663 | 8.027 | 13 | 3.10 | 0.67 | 2.78 | 2.95 | 0.43 | 3.06 | 28.74 | 39.12 | 38.48 |
|  | C37 H74 N6 O3 | 650.5843 | 8.019 | 2 | 2.89 | 2.44 | 3.05 | 2.77 | 2.79 | 3.11 | 28.76 | 45.43 | 30.41 |
|  | C36 H73 N2 O9 P | 708.5028 | 3.074 | 6 | 3.65 | 3.06 | 3.73 | 3.61 | 3.01 | 3.87 | 28.77 | 11.96 | 26.11 |
|  | C18 H29 N | 259.2296 | 2.237 | 10 | 1.42 | 0.42 | 0.61 | 1.31 | 0.22 | 0.76 | 28.79 | 34.91 | 17.96 |
|  | C51 H101 N5 O14 | 1007.734 | 3.162 | 6 | 3.84 | 3.48 | 3.85 | 3.91 | 3.50 | 3.91 | 28.93 | 4.50 | 25.69 |
|  | C30 H72 N9 O7 P S | 733.4995 | 2.607 | 9 | 4.46 | 4.42 | 4.36 | 5.02 | 4.42 | 4.36 | 28.95 | 32.66 | 25.29 |
|  | C41 H94 N9 O11 P | 919.6814 | 3.202 | 7 | 3.79 | 3.42 | 3.85 | 3.87 | 3.47 | 3.81 | 29.00 | 6.51 | 27.92 |
|  | C22 H44 N2 O | 352.3448 | 2.53 | 22 | 1.70 | 1.24 | 1.83 | 1.60 | 1.24 | 1.86 | 29.01 | 35.10 | 7.98 |
|  | C41 H79 N O14 | 809.5503 | 2.571 | 4 | 2.35 | 1.88 | 2.22 | 2.46 | 1.92 | 2.28 | 29.04 | 6.19 | 13.71 |
|  | C40 H63 N O7 | 669.4598 | 3.946 | 6 | 4.15 | 3.27 | 4.19 | 4.14 | 3.23 | 4.43 | 29.08 | 44.60 | 48.80 |
|  | C59 H122 N9 O12 P S | 1211.867 | 3.447 | 5 | 2.93 | 2.83 | 3.03 | 3.16 | 2.85 | 2.99 | 29.08 | 7.97 | 19.83 |
|  | C16 H30 O4 | 286.2138 | 3.213 | 20 | 1.57 | 1.24 | 1.37 | 1.49 | 1.35 | 1.41 | 29.08 | 14.12 | 7.88 |
|  | C19 H39 Cl O6 | 398.2441 | 1.308 | 10 | 2.62 | 0.73 | 1.61 | 3.07 | 0.85 | 1.66 | 29.12 | 43.09 | 36.04 |
|  | C63 H119 N5 O8 P2 | 1135.854 | 3.069 | 3 | 1.52 | 1.40 | 1.56 | 1.43 | 1.40 | 1.53 | 29.15 | 11.87 | 3.86 |
|  | C12 H23 N O2 | 213.1724 | 3.219 | 22 | 1.50 | 0.87 | 1.58 | 1.59 | 0.72 | 1.57 | 29.17 | 39.74 | 12.06 |
|  | C18 H20 O3 | 284.1409 | 2.227 | 7 | 1.76 | 0.09 | 0.91 | 1.53 | 0.02 | 1.04 | 29.17 | 33.53 | 18.07 |
|  | C36 H84 N9 O10 P | 833.6072 | 2.747 | 5 | 3.18 | 2.12 | 3.06 | 3.14 | 2.13 | 3.23 | 29.20 | 1.49 | 41.66 |


| C51 H104 N6 O14 | 1024.761 | 3.157 | 7 | 3.83 | 3.46 | 3.85 | 3.92 | 3.49 | 3.92 | 29.34 | 4.20 | 27.21 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| C19 H40 O4 | 332.2921 | 2.884 | 11 | 3.10 | 2.02 | 3.29 | 3.13 | 2.12 | 3.45 | 29.42 | 28.86 | 22.83 |
| C37 H73 N O6 | 627.5431 | 7.541 | 17 | 1.55 | 1.42 | 0.81 | 1.57 | 1.25 | 0.79 | 29.43 | 24.93 | 42.18 |
| C6 H13 N4 O2 P | 204.0783 | 2.445 | 9 | 3.10 | 3.07 | 3.19 | 3.18 | 3.14 | 3.27 | 29.45 | 15.38 | 10.74 |
| C20 H45 N9 O5 | 491.3558 | 2.69 | 11 | 3.12 | 2.51 | 3.02 | 3.02 | 2.54 | 3.18 | 29.45 | 12.28 | 23.06 |
| C62 H104 N6 O S | 980.7991 | 11.49 | 21 | 4.05 | 2.83 | 4.09 | 3.92 | 2.75 | 4.49 | 29.54 | 29.75 | 41.65 |
| C20 H41 N O4 | 359.3031 | 2.27 | 12 | 1.89 | 0.70 | 1.06 | 2.14 | 0.58 | 1.06 | 29.56 | 26.08 | 3.23 |
| C31 H71 N10 O7 P | 726.5261 | 4.162 | 14 | 2.79 | 1.97 | 2.85 | 2.84 | 1.86 | 3.12 | 29.60 | 39.45 | 47.74 |
| C31 H48 N3 O11 P | 669.3013 | 3.062 | 6 | 2.58 | 2.45 | 3.13 | 2.39 | 2.65 | 3.09 | 29.65 | 34.83 | 30.57 |
| C32 H57 P S | 504.3919 | 4.399 | 22 | 2.02 | 2.53 | 2.26 | 2.39 | 2.61 | 2.18 | 29.68 | 21.48 | 22.32 |
| C21 H41 N4 O P S | 428.2741 | 1.326 | 12 | 4.66 | 2.56 | 3.47 | 4.73 | 2.76 | 3.47 | 29.72 | 36.10 | 41.35 |
| C9 H6 N6 O18 P2 | 547.9211 | 3.022 | 8 | 1.32 | 1.25 | 1.28 | 1.14 | 1.21 | 1.29 | 29.74 | 7.84 | 6.20 |
| C32 H46 N4 O2 | 518.3604 | 4.164 | 15 | 2.23 | 1.43 | 2.40 | 2.27 | 1.32 | 2.65 | 29.77 | 32.34 | 48.74 |
| C62 H126 N2 O12 P2 | 1152.879 | 3.069 | 5 | 2.95 | 2.93 | 3.06 | 2.88 | 2.93 | 3.05 | 29.83 | 12.18 | 3.62 |
| C67 H144 N10 O15 P2 S | 1423.001 | 3.039 | 14 | 3.29 | 2.99 | 3.14 | 3.34 | 2.96 | 3.31 | 29.83 | 11.42 | 27.24 |
| C71 H126 N7 O13 P | 1315.916 | 3.063 | 4 | 3.11 | 2.88 | 3.33 | 3.26 | 2.90 | 3.35 | 29.95 | 3.21 | 28.23 |
| C76 H139 Br N O7 P3 | 1349.896 | 3.445 | 14 | 1.63 | 0.94 | 1.36 | 1.34 | 0.88 | 1.46 | 29.99 | 12.12 | 32.68 |
| C75 H120 N4 P2 S2 | 1202.843 | 2.641 | 11 | 3.87 | 3.67 | 3.92 | 4.00 | 3.67 | 3.89 | 29.99 | 11.71 | 9.88 |
| C15 H22 O | 218.1666 | 2.316 | 15 | 1.80 | 0.09 | 0.84 | 1.46 | 0.13 | 0.81 | 30.00 | 44.25 | 6.43 |
| C79 H157 N7 O18 P2 | 1554.105 | 3.327 | 20 | 1.95 | 1.64 | 2.25 | 1.83 | 1.69 | 2.20 | 30.06 | 6.42 | 16.60 |
| C22 H46 N7 O P S | 487.3213 | 3.221 | 15 | 1.57 | 0.43 | 1.49 | 1.37 | 0.61 | 1.32 | 30.15 | 21.89 | 23.59 |
| C69 H147 N10 O14 P S3 | 1467.001 | 2.602 | 8 | 3.92 | 3.88 | 3.96 | 4.42 | 3.83 | 3.90 | 30.17 | 29.63 | 13.73 |
| C30 H72 N9 O8 P | 717.5238 | 2.563 | 8 | 3.20 | 2.09 | 2.89 | 3.15 | 2.14 | 3.14 | 30.20 | 6.61 | 33.73 |
| C26 H52 N8 O5 | 556.4061 | 3.134 | 3 | 3.43 | 3.29 | 3.58 | 3.60 | 3.26 | 3.62 | 30.21 | 4.61 | 30.68 |
| C50 H81 O10 P | 872.5528 | 5.599 | 19 | 3.36 | 3.27 | 3.83 | 3.64 | 3.47 | 3.83 | 30.22 | 32.97 | 7.26 |
| C22 H46 N2 O | 354.3603 | 3.896 | 8 | 1.63 | 1.46 | 1.58 | 1.55 | 1.69 | 1.60 | 30.23 | 29.03 | 5.76 |


| C45 H73 N 07 | 739.5381 | 3.949 | 6 | 5.22 | 4.54 | 5.45 | 5.44 | 4.43 | 5.66 | 30.26 | 48.54 | 48.74 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| C11 H21 N O2 | 199.1566 | 1.007 | 10 | 1.94 | 0.61 | 2.21 | 1.60 | 0.90 | 1.92 | 30.35 | 35.45 | 39.22 |
| C33 H65 O10 P | 652.4334 | 3.946 | 2 | 4.30 | 3.29 | 4.24 | 4.17 | 3.26 | 4.50 | 30.38 | 42.64 | 48.63 |
| C23 H48 N2 O2 | 384.371 | 2.533 | 17 | 2.32 | 1.57 | 2.40 | 2.20 | 1.67 | 2.44 | 30.41 | 29.58 | 4.64 |
| C67 H139 N5 O10 S3 | 1269.968 | 3.162 | 5 | 2.36 | 2.22 | 2.18 | 2.19 | 2.23 | 2.18 | 30.44 | 10.81 | 2.73 |
| C42 H83 N O7 | 713.616 | 8.011 | 25 | 2.61 | 2.12 | 2.71 | 2.40 | 2.32 | 2.75 | 30.47 | 44.92 | 44.72 |
| C47 H71 N O6 | 745.5245 | 3.341 | 2 | 3.29 | 3.00 | 3.36 | 3.44 | 3.05 | 3.48 | 30.48 | 7.83 | 20.17 |
| C18 H40 N3 O6 P | 425.267 | 2.053 | 4 | 2.39 | 1.33 | 2.25 | 2.24 | 1.39 | 2.26 | 30.49 | 46.66 | 6.46 |
| C22 H54 N10 P2 | 520.399 | 2.051 | 12 | 1.78 | 0.44 | 0.48 | 1.64 | 0.40 | 0.60 | 30.57 | 17.80 | 27.73 |
| C60 H115 N | 849.9027 | 13.769 | 2 | 2.16 | 0.50 | 1.67 | 1.99 | 0.80 | 1.63 | 30.57 | 43.90 | 6.42 |
| C83 H163 N4 O16 P3 | 1597.1 | 2.998 | 17 | 3.16 | 2.93 | 3.41 | 3.38 | 2.89 | 3.37 | 30.58 | 7.61 | 12.81 |
| C39 H90 N10 O14 | 922.6634 | 2.742 | 24 | 3.14 | 2.15 | 3.37 | 3.32 | 2.16 | 3.35 | 30.68 | 33.06 | 17.92 |
| C35 H71 N O2 | 537.548 | 8.098 | 17 | 2.16 | 0.42 | 2.27 | 2.09 | 0.90 | 2.30 | 30.71 | 49.10 | 13.13 |
| C 30 H 45 N 06 | 515.3244 | 2.128 | 18 | 7.94 | 5.64 | 7.74 | 7.60 | 5.65 | 7.65 | 30.72 | 45.27 | 26.64 |
| C18 H42 N6 O4 | 406.3288 | 2.755 | 17 | 4.74 | 3.88 | 5.03 | 4.61 | 3.88 | 4.99 | 30.81 | 2.07 | 46.76 |
| C24 H48 N2 O | 380.3761 | 2.483 | 12 | 1.04 | 0.58 | 0.72 | 1.00 | 0.16 | 0.73 | 30.84 | 44.80 | 16.68 |
| C18 H24 O2 | 272.1771 | 2.38 | 16 | 1.44 | 0.46 | 1.09 | 1.35 | 0.13 | 1.07 | 30.84 | 44.07 | 11.08 |
| C61 H95 N 06 | 937.712 | 3.206 | 11 | 2.12 | 1.83 | 2.25 | 2.05 | 1.78 | 2.09 | 30.85 | 6.97 | 47.00 |
| C38 H60 N9 P | 673.4742 | 3.382 | 7 | 2.47 | 2.13 | 2.59 | 2.83 | 2.17 | 2.78 | 31.08 | 8.84 | 21.56 |
| C28 H57 N3 O9 | 579.4085 | 2.645 | 14 | 3.09 | 2.87 | 2.79 | 3.22 | 2.73 | 2.82 | 31.08 | 18.33 | 25.86 |
| C47 H103 N10 O4 P3 | 964.7374 | 3.596 | 5 | 2.75 | 2.57 | 2.80 | 2.80 | 2.61 | 2.84 | 31.09 | 9.95 | 20.57 |
| C31 H74 N9 O8 P | 731.5389 | 2.267 | 13 | 1.61 | 1.32 | 2.17 | 2.19 | 1.20 | 2.35 | 31.12 | 16.09 | 30.30 |
| C22 H45 N3 O6 | 447.3294 | 2.738 | 13 | 2.77 | 2.32 | 3.71 | 3.42 | 2.28 | 3.85 | 31.15 | 19.18 | 28.29 |
| C23 H52 N6 O P2 | 490.3669 | 3.179 | 8 | 3.49 | 3.16 | 3.48 | 3.56 | 3.01 | 3.42 | 31.22 | 28.03 | 41.98 |
| C33 H77 N10 O P3 S | 754.5239 | 3.021 | 6 | 3.75 | 3.46 | 4.16 | 3.99 | 3.51 | 4.12 | 31.26 | 12.00 | 31.98 |
| C51 H109 N10 O7 P S | 1036.795 | 2.98 | 5 | 3.57 | 3.43 | 3.49 | 3.47 | 3.42 | 3.50 | 31.29 | 2.69 | 6.24 |


| C24 H47 N O | 365.3654 | 4.578 | 9 | 2.68 | 2.49 | 2.64 | 2.70 | 2.76 | 2.63 | 31.29 | 37.21 | 9.82 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| C40 H71 O8 P | 710.4867 | 4.163 | 7 | 3.93 | 3.24 | 4.01 | 4.17 | 3.35 | 4.11 | 31.50 | 19.36 | 38.58 |
| C58 H109 N O6 | 915.8215 | 11.486 | 19 | 4.35 | 3.29 | 4.24 | 4.11 | 3.20 | 4.58 | 31.64 | 17.74 | 38.03 |
| C31 H62 N3 O P S | 555.4344 | 2.47 | 7 | 1.02 | 0.48 | 1.40 | 1.41 | 0.62 | 1.66 | 31.75 | 45.71 | 46.32 |
| C34 H75 N10 O6 P | 750.5589 | 3.947 | 11 | 3.88 | 3.25 | 3.83 | 3.88 | 3.24 | 4.15 | 31.75 | 47.09 | 45.55 |
| C68 H144 N8 O14 P2 S2 | 1422.973 | 2.612 | 22 | 4.90 | 4.53 | 4.57 | 5.16 | 4.57 | 4.67 | 31.81 | 26.95 | 16.25 |
| C17 H36 N6 O4 | 388.2816 | 1.309 | 12 | 3.92 | 1.92 | 2.76 | 4.11 | 2.06 | 2.95 | 31.82 | 36.97 | 33.26 |
| C26 H57 N5 O5 | 519.4338 | 5.887 | 15 | 2.14 | 2.72 | 2.41 | 2.18 | 2.38 | 2.39 | 31.84 | 46.20 | 11.69 |
| C19 H37 N O2 | 311.2818 | 2.639 | 7 | 2.02 | 0.91 | 1.71 | 2.19 | 1.01 | 1.64 | 31.88 | 28.75 | 13.61 |
| C41 H71 O8 P | 722.4867 | 4.167 | 10 | 1.96 | 1.36 | 1.74 | 2.09 | 1.60 | 2.03 | 31.99 | 49.11 | 41.65 |
| C21 H42 O4 | 358.3077 | 7.753 | 7 | 3.71 | 2.38 | 3.86 | 3.47 | 2.30 | 3.90 | 32.11 | 48.03 | 36.42 |
| C36 H80 N5 P | 613.613 | 8.834 | 5 | 2.77 | 0.90 | 1.95 | 2.51 | 1.10 | 2.10 | 32.14 | 46.67 | 29.40 |
| C21 H37 Cl N4 O2 | 412.2598 | 1.295 | 12 | 5.19 | 3.17 | 4.08 | 5.37 | 3.32 | 4.21 | 32.24 | 45.36 | 39.27 |
| C51 H108 N5 O13 P | 1029.768 | 3.635 | 12 | 3.14 | 0.72 | 2.73 | 2.95 | 0.84 | 2.93 | 32.24 | 40.03 | 25.59 |
| C53 H113 N10 O9 P S | 1096.815 | 3.528 | 3 | 2.47 | 2.55 | 2.45 | 2.68 | 2.60 | 2.55 | 32.30 | 5.72 | 18.52 |
| C18 H38 N2 O8 | 410.2637 | 1.309 | 12 | 5.68 | 3.64 | 4.50 | 5.86 | 3.79 | 4.65 | 32.30 | 36.47 | 36.53 |
| C26 H58 N6 O3 P2 | 564.4028 | 2.861 | 17 | 2.13 | 1.97 | 2.66 | 2.27 | 2.29 | 2.62 | 32.36 | 34.15 | 44.56 |
| C27 H61 N8 O P S | 576.4396 | 3.069 | 3 | 2.79 | 3.04 | 3.08 | 2.79 | 2.95 | 3.06 | 32.37 | 14.42 | 7.14 |
| C16 H31 N | 237.245 | 1.294 | 7 | 1.43 | 1.39 | 0.43 | 1.13 | 0.92 | 0.24 | 32.42 | 49.85 | 27.27 |
| C32 H40 N8 O | 552.334 | 4.078 | 7 | 3.59 | 2.03 | 3.06 | 3.46 | 2.37 | 3.08 | 32.52 | 39.15 | 5.94 |
| C46 H97 N7 O9 P2 S | 985.6549 | 2.53 | 9 | 3.02 | 2.71 | 3.00 | 3.25 | 2.72 | 2.92 | 32.53 | 8.73 | 25.50 |
| C45 H77 O8 P | 776.5372 | 3.012 | 4 | 4.22 | 4.11 | 4.51 | 4.54 | 4.09 | 4.71 | 32.55 | 7.83 | 21.52 |
| C90 H162 N10 O13 P2 S | 1685.151 | 2.979 | 11 | 2.39 | 2.07 | 2.56 | 2.38 | 2.37 | 2.72 | 32.61 | 32.04 | 30.87 |
| C23 H56 N9 O5 P | 569.4143 | 2.563 | 17 | 0.91 | 0.91 | 0.83 | 1.27 | 0.85 | 0.77 | 32.68 | 9.64 | 24.17 |
| C19 H41 N O2 | 315.3133 | 2.308 | 20 | 2.58 | 1.37 | 2.44 | 2.36 | 1.44 | 2.70 | 32.75 | 29.98 | 32.37 |
| C29 H55 N S | 449.4074 | 2.752 | 9 | 4.90 | 3.76 | 5.14 | 4.79 | 3.79 | 4.98 | 32.84 | 2.80 | 33.62 |


| C10 H23 N3 O5 | 265.1649 | 3.119 | 10 | 3.46 | 3.09 | 3.34 | 3.17 | 3.06 | 3.22 | 32.87 | 7.59 | 21.45 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| C35 H61 N3 O S3 | 635.3975 | 2.749 | 22 | 0.84 | 0.12 | 1.33 | 1.15 | 0.16 | 1.08 | 32.98 | 7.05 | 33.32 |
| C59 H110 N5 O8 P | 1047.809 | 4.864 | 7 | 3.92 | 1.77 | 3.46 | 3.81 | 1.94 | 3.78 | 33.14 | 30.53 | 38.32 |
| C 28 H 56 Cl P 3 | 520.327 | 0.779 | 13 | 3.29 | 2.59 | 3.25 | 3.35 | 2.82 | 3.22 | 33.22 | 32.90 | 15.83 |
| C73 H155 N10 O18 P3 | 1553.074 | 3.009 | 4 | 2.92 | 2.60 | 3.06 | 3.08 | 2.59 | 3.21 | 33.24 | 7.92 | 19.29 |
| C43 H69 N O7 | 711.5071 | 3.627 | 7 | 1.82 | 1.26 | 1.97 | 1.97 | 1.29 | 2.21 | 33.53 | 36.68 | 41.14 |
| C20 H52 N9 O4 P | 513.3874 | 2.262 | 23 | 2.01 | 1.23 | 2.82 | 2.70 | 1.28 | 2.94 | 33.54 | 42.87 | 43.09 |
| C34 H49 N5 O4 P2 | 653.3233 | 3.061 | 10 | 5.44 | 4.00 | 5.35 | 5.12 | 4.05 | 5.73 | 33.55 | 10.28 | 47.57 |
| $\begin{aligned} & \text { C65 H138 N10 O10 P2 } \\ & \text { S2 } \end{aligned}$ | 1344.952 | 3.397 | 8 | 1.79 | 1.84 | 1.76 | 2.27 | 1.83 | 1.99 | 33.59 | 5.01 | 27.58 |
| C41 H78 N O10 P | 775.5367 | 2.995 | 4 | 2.79 | 2.47 | 3.10 | 3.01 | 2.48 | 3.18 | 33.68 | 7.32 | 20.08 |
| C13 H20 N2 O6 | 300.1334 | 2.44 | 19 | 3.11 | 3.05 | 2.90 | 3.07 | 3.02 | 3.00 | 33.73 | 20.35 | 11.23 |
| C16 H31 N O2 | 269.2349 | 3.113 | 13 | 2.39 | 1.94 | 2.01 | 2.31 | 1.95 | 1.92 | 33.75 | 19.51 | 26.38 |
| C39 H70 N O8 P | 711.4872 | 2.624 | 8 | 4.77 | 4.51 | 4.47 | 5.05 | 4.53 | 4.59 | 33.76 | 18.68 | 17.36 |
| C37 H75 N O5 | 613.5645 | 2.578 | 14 | 0.76 | 1.36 | 0.32 | 1.22 | 1.32 | 0.03 | 33.80 | 5.77 | 48.69 |
| C73 H143 N9 O18 S | 1466.027 | 3.036 | 4 | 3.59 | 3.22 | 3.72 | 3.67 | 3.20 | 3.74 | 33.92 | 4.23 | 26.80 |
| C70 H139 N O18 P2 | 1343.947 | 3.394 | 4 | 3.00 | 2.83 | 3.01 | 3.08 | 2.80 | 3.08 | 34.05 | 4.07 | 20.60 |
| C26 H53 N | 379.4173 | 3.199 | 11 | 1.51 | 0.17 | 1.18 | 1.42 | 0.34 | 1.27 | 34.21 | 39.17 | 12.92 |
| C47 H75 N 07 | 765.5531 | 4.884 | 28 | 1.04 | 0.69 | 1.46 | 1.37 | 0.45 | 1.65 | 34.22 | 46.53 | 37.71 |
| C57 H107 N5 O6 P2 | 1019.769 | 2.972 | 4 | 2.82 | 2.60 | 2.67 | 2.64 | 2.62 | 2.74 | 34.25 | 4.10 | 13.25 |
| C40 H79 N O6 | 669.5902 | 6.481 | 23 | 2.26 | 1.39 | 2.38 | 2.24 | 1.23 | 2.26 | 34.38 | 29.42 | 32.53 |
| C72 H110 N4 O12 | 1222.812 | 2.362 | 16 | 2.94 | 3.06 | 2.65 | 3.32 | 2.75 | 2.68 | 34.38 | 44.80 | 30.22 |
| C71 H151 N10 O17 P3 | 1509.049 | 3.019 | 3 | 3.58 | 3.49 | 3.93 | 3.92 | 3.30 | 4.03 | 34.51 | 29.24 | 32.42 |
| C42 H83 N O8 P2 | 791.5605 | 2.406 | 22 | 2.73 | 2.06 | 3.00 | 2.84 | 1.98 | 2.91 | 34.72 | 15.48 | 19.72 |
| C20 H48 N5 P | 389.3652 | 3.045 | 8 | 1.41 | 0.52 | 1.14 | 1.32 | 0.08 | 1.17 | 34.73 | 48.97 | 4.15 |
| C16 H34 N O7 P | 383.2081 | 1.282 | 10 | 0.78 | 0.97 | 0.35 | 1.16 | 1.13 | 0.25 | 34.81 | 49.32 | 42.98 |


| C47 H87 N4 P S | 770.6381 | 3.134 | 21 | 3.83 | 3.24 | 3.65 | 3.83 | 3.27 | 3.72 | 34.94 | 22.57 | 8.70 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| C18 H30 O2 | 278.224 | 2.328 | 12 | 1.48 | 0.78 | 0.95 | 1.30 | 0.75 | 1.07 | 34.96 | 7.10 | 33.64 |
| C73 H133 N8 O13 P | 1360.973 | 3.394 | 4 | 2.96 | 2.79 | 2.98 | 3.05 | 2.76 | 3.04 | 34.99 | 4.00 | 20.47 |
| C55 H100 N2 O7 | 900.7535 | 11.222 | 14 | 4.65 | 3.07 | 4.80 | 4.43 | 3.09 | 5.04 | 35.01 | 18.53 | 47.69 |
| C18 H35 N | 265.2767 | 2.289 | 13 | 2.42 | 0.57 | 2.03 | 2.15 | 0.73 | 1.93 | 35.14 | 46.70 | 19.57 |
| C45 H73 N O7 | 739.5381 | 4.599 | 19 | 2.11 | 1.77 | 1.89 | 2.13 | 1.70 | 2.15 | 35.17 | 33.85 | 37.29 |
| C28 H58 N2 O2 | 454.4494 | 2.977 | 18 | 1.40 | 1.81 | 0.55 | 1.43 | 1.71 | 0.92 | 35.18 | 29.18 | 38.82 |
| C36 H77 N10 O8 P | 808.5654 | 4.39 | 15 | 2.95 | 2.22 | 2.90 | 2.53 | 2.24 | 2.84 | 35.22 | 38.43 | 11.10 |
| C10 H7 N O3 | 189.0422 | 2.444 | 12 | 2.10 | 2.11 | 2.18 | 2.07 | 2.24 | 2.17 | 35.28 | 28.45 | 17.33 |
| C30 H60 N9 O9 P S | 753.3957 | 3.045 | 2 | 2.21 | 2.07 | 2.37 | 1.96 | 2.40 | 2.48 | 35.36 | 36.21 | 29.83 |
| C21 H44 N2 O | 340.3447 | 3.945 | 6 | 1.35 | 1.40 | 1.31 | 1.39 | 1.41 | 1.37 | 35.42 | 9.35 | 20.10 |
| C12 H24 N5 P | 269.1773 | 2.355 | 7 | 2.70 | 1.84 | 2.46 | 2.31 | 2.10 | 2.48 | 35.48 | 33.94 | 20.58 |
| C27 H54 N6 O7 | 574.4049 | 2.803 | 12 | 3.59 | 2.60 | 3.86 | 3.23 | 2.41 | 3.81 | 35.49 | 24.60 | 43.99 |
| C32 H61 O3 P3 | 586.3842 | 3.933 | 15 | 3.60 | 2.52 | 3.37 | 3.86 | 2.47 | 3.57 | 35.49 | 22.00 | 27.98 |
| C17 H42 N10 O4 P2 | 512.2855 | 3.363 | 22 | 2.42 | 1.04 | 2.69 | 2.84 | 0.92 | 2.76 | 35.63 | 39.93 | 36.83 |
| C57 H108 N6 O4 | 940.8432 | 11.752 | 17 | 3.79 | 2.98 | 3.70 | 3.50 | 3.28 | 3.99 | 35.69 | 40.49 | 37.21 |
| C22 H58 N9 O P3 | 557.3956 | 2.652 | 20 | 4.71 | 4.48 | 4.59 | 4.90 | 4.51 | 4.65 | 35.72 | 8.99 | 19.91 |
| C60 H124 N10 O15 S | 1256.897 | 3.435 | 14 | 2.61 | 2.77 | 3.02 | 3.26 | 2.88 | 3.07 | 35.75 | 13.70 | 32.59 |
| C8 H21 N4 P | 204.1512 | 2.091 | 4 | 2.73 | 0.63 | 1.40 | 2.38 | 0.90 | 1.38 | 36.05 | 35.73 | 11.43 |
| C9 H21 N10 O9 P3 S | 538.0425 | 3.004 | 22 | 2.00 | 1.69 | 1.83 | 2.24 | 1.72 | 2.10 | 36.07 | 16.35 | 43.81 |
| C37 H73 N O5 P2 | 673.498 | 2.568 | 8 | 3.59 | 2.60 | 3.41 | 3.65 | 2.57 | 3.72 | 36.09 | 4.19 | 33.67 |
| C 21 H 40 O 4 | 356.2919 | 4.387 | 12 | 1.87 | 1.44 | 1.70 | 1.35 | 1.52 | 1.72 | 36.15 | 15.49 | 4.65 |
| C46 H67 N O8 | 761.4857 | 2.818 | 10 | 5.87 | 4.62 | 5.51 | 5.60 | 4.65 | 5.85 | 36.20 | 46.63 | 49.41 |
| C 23 H 42 Cl N 3 S | 427.2788 | 1.325 | 11 | 1.34 | 1.11 | 0.08 | 1.46 | 0.76 | 0.32 | 36.23 | 38.09 | 32.36 |
| C26 H61 N10 O2 P | 576.4727 | 7.31 | 24 | 1.47 | 1.54 | 1.38 | 1.30 | 1.70 | 1.41 | 36.28 | 28.56 | 8.17 |
| C20 H43 N3 O4 | 389.3262 | 3.096 | 18 | 1.21 | 0.24 | 1.82 | 1.12 | 0.04 | 1.70 | 36.28 | 34.50 | 21.04 |


|  | C29 H55 N O S | 465.4026 | 3.256 | 11 | 2.71 | 2.36 | 2.93 | 2.83 | 2.46 | 2.80 | 36.59 | 12.73 | 28.07 |
| :--- | :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | C37 H58 P2 | 564.4024 | 3.94 | 12 | 3.02 | 1.88 | 3.09 | 3.41 | 1.87 | 3.32 | 36.61 | 19.40 | 42.84 |
|  | C59 H120 N5 O P3 S2 | 1071.815 | 4.348 | 13 | 1.87 | 0.56 | 1.57 | 1.85 | 0.50 | 1.70 | 36.63 | 23.90 | 34.82 |
|  | C46 H75 N O7 | 753.5533 | 4.599 | 16 | 3.32 | 2.53 | 3.15 | 3.01 | 2.24 | 3.25 | 36.68 | 45.72 | 26.78 |
|  | C22 H52 N5 P | 417.3968 | 3.153 | 4 | 1.46 | 0.09 | 1.62 | 1.47 | 0.22 | 1.49 | 36.73 | 32.98 | 23.00 |
|  | C35 H63 O10 P | 674.4155 | 3.944 | 17 | 5.35 | 3.98 | 5.13 | 4.91 | 4.06 | 5.45 | 36.76 | 34.99 | 48.76 |
|  | C24 H47 O7 P | 478.3077 | 3.118 | 11 | 3.19 | 2.33 | 3.41 | 3.71 | 2.17 | 3.39 | 36.86 | 34.28 | 10.06 |
|  | C24 H42 N4 O3 | 434.3247 | 1.492 | 21 | 4.59 | 3.23 | 4.15 | 4.76 | 3.36 | 4.20 | 36.99 | 30.23 | 16.36 |
|  | C41 H57 N O6 | 659.4177 | 2.97 | 16 | 3.03 | 2.66 | 3.37 | 2.93 | 2.47 | 3.54 | 37.17 | 28.01 | 47.75 |
|  | C52 H110 N5 O13 P | 1043.783 | 3.823 | 11 | 2.04 | 0.87 | 2.51 | 2.55 | 0.87 | 2.59 | 37.22 | 7.08 | 20.87 |
|  | C36 H35 N5 | 537.2872 | 2.318 | 20 | 3.89 | 2.95 | 3.56 | 3.85 | 2.91 | 3.90 | 37.25 | 42.78 | 49.84 |
|  | C41 H81 N O5 | 667.6107 | 8.026 | 2 | 3.71 | 3.15 | 3.93 | 3.55 | 3.38 | 3.99 | 37.34 | 34.24 | 34.59 |
|  | C24 H48 O7 | 448.3403 | 1.474 | 20 | 5.03 | 4.66 | 4.95 | 5.75 | 4.57 | 4.94 | 37.43 | 15.82 | 34.22 |
|  | C18 H42 N5 O P | 375.3109 | 2.999 | 15 | 2.37 | 1.61 | 1.37 | 1.91 | 1.67 | 1.34 | 37.51 | 28.61 | 26.36 |
|  | C20 H32 N9 O2 P | 461.2401 | 1.681 | 23 | 8.50 | 8.05 | 8.49 | 8.27 | 8.44 | 8.40 | 37.57 | 40.74 | 19.09 |
|  | C59 H94 N3 O6 P | 971.6881 | 3.599 | 7 | 2.97 | 0.51 | 2.93 | 3.00 | 0.59 | 3.23 | 37.66 | 36.48 | 42.23 |
|  | C48 H69 N O6 | 755.5143 | 2.601 | 9 | 3.13 | 2.62 | 2.71 | 3.20 | 2.62 | 2.67 | 37.71 | 37.14 | 9.20 |
|  | C28 H61 N9 O9 | 667.4605 | 2.624 | 23 | 4.62 | 4.45 | 4.49 | 4.76 | 4.51 | 4.48 | 37.82 | 16.38 | 14.83 |
|  | C37 H73 O8 P | 676.5036 | 6.471 | 12 | 2.31 | 0.78 | 2.61 | 2.05 | 1.02 | 2.24 | 37.95 | 31.82 | 49.61 |
|  | C24 H57 N9 O8 P2 S | 693.3554 | 2.791 | 19 | 1.93 | 1.32 | 2.39 | 2.16 | 1.47 | 2.63 | 37.96 | 39.25 | 41.19 |
|  | C41 H54 N2 | 574.4264 | 3.124 | 8 | 2.70 | 1.00 | 1.99 | 2.31 | 1.30 | 2.05 | 38.05 | 35.42 | 7.21 |
|  | C39 H80 N2 O6 P2 | 734.5477 | 3.092 | 19 | 5.35 | 3.40 | 5.28 | 4.90 | 3.39 | 5.46 | 38.25 | 21.12 | 36.90 |
|  | C18 H43 N9 O4 | 449.3435 | 1.493 | 6 | 3.69 | 2.91 | 3.05 | 4.15 | 2.80 | 3.19 | 38.49 | 31.08 | 16.76 |
|  | C21 H32 Cl N3 O3 | 409.2123 | 1.922 | 19 | 2.17 | 1.45 | 2.09 | 2.35 | 1.50 | 2.02 | 38.59 | 29.25 | 20.82 |
|  | C12 H35 N10 O6 P | 446.2488 | 1.343 | 20 | 4.56 | 4.07 | 4.76 | 4.79 | 4.20 | 4.79 | 38.71 | 40.58 | 45.47 |
|  | C22 H53 N7 O5 | 495.4133 | 2.732 | 9 | 2.13 | 0.78 | 2.24 | 1.72 | 0.87 | 2.20 | 39.00 | 22.36 | 23.82 |


| C28 H59 N O S | 457.4316 | 2.755 | 13 | 1.71 | 1.88 | 1.84 | 1.80 | 1.74 | 1.79 | 39.03 | 36.11 | 10.83 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| C16 H33 N O3 | 287.2454 | 1.595 | 21 | 3.61 | 3.46 | 3.53 | 4.84 | 3.14 | 3.49 | 39.15 | 42.38 | 13.27 |
| C19 H36 O3 | 312.2659 | 7.752 | 3 | 2.87 | 1.77 | 3.05 | 2.58 | 1.63 | 2.97 | 39.17 | 38.54 | 43.48 |
| C16 H30 O3 | 270.2191 | 3.124 | 22 | 2.93 | 2.28 | 2.54 | 2.70 | 2.38 | 2.68 | 39.19 | 14.53 | 16.18 |
| C23 H13 N2 O18 P S | 667.9622 | 2.616 | 15 | 4.22 | 4.07 | 3.79 | 4.29 | 4.00 | 3.84 | 39.23 | 11.32 | 13.83 |
| C13 H36 N7 O2 P | 353.267 | 0.795 | 19 | 2.00 | 1.80 | 2.79 | 1.65 | 1.77 | 2.68 | 39.32 | 28.32 | 47.66 |
| C24 H49 N3 O2 | 411.3824 | 3.02 | 18 | 1.80 | 1.03 | 1.23 | 1.55 | 1.32 | 1.45 | 39.41 | 43.41 | 36.49 |
| C43 H52 O5 P2 | 710.328 | 3.043 | 5 | 2.76 | 2.48 | 2.79 | 2.85 | 2.54 | 2.98 | 39.43 | 8.69 | 26.72 |
| C14 H26 O2 | 226.1927 | 1.87 | 22 | 2.94 | 0.63 | 0.59 | 2.42 | 0.98 | 0.89 | 39.52 | 37.83 | 32.40 |
| C64 H100 N O P S | 961.7267 | 2.929 | 16 | 2.19 | 2.36 | 2.07 | 1.71 | 2.35 | 2.15 | 39.56 | 2.70 | 22.98 |
| C19 H48 N7 O4 P | 469.3503 | 3.369 | 13 | 5.81 | 3.84 | 5.90 | 6.21 | 4.00 | 5.80 | 39.85 | 21.59 | 34.08 |
| C19 H32 | 260.2497 | 11.261 | 23 | 2.19 | 2.30 | 2.38 | 2.03 | 2.23 | 2.32 | 40.01 | 12.97 | 28.13 |
| C50 H75 N O6 | 785.5586 | 2.764 | 16 | 0.53 | 0.10 | 0.27 | 1.50 | 0.12 | 0.44 | 40.04 | 10.29 | 34.17 |
| C18 H41 N9 O S | 431.3143 | 2.323 | 10 | 1.75 | 1.01 | 1.42 | 1.42 | 0.98 | 1.43 | 40.34 | 11.73 | 5.29 |
| $\begin{aligned} & \text { C80 H171 N10 O15 P3 } \\ & \text { S2 } \end{aligned}$ | 1669.158 | 3.284 | 15 | 3.56 | 3.25 | 3.69 | 3.50 | 3.22 | 3.71 | 40.61 | 5.32 | 15.58 |
| C13 H25 N O3 | 243.1832 | 3.203 | 18 | 2.25 | 1.84 | 1.99 | 2.11 | 1.90 | 1.94 | 40.64 | 23.65 | 6.97 |
| C31 H50 N8 O8 S | 694.35 | 2.791 | 17 | 2.38 | 1.74 | 2.76 | 2.76 | 1.91 | 3.11 | 40.71 | 41.19 | 42.64 |
| C48 H76 N5 O3 P | 801.5692 | 2.603 | 14 | 1.08 | 0.22 | 0.84 | 1.11 | 0.16 | 0.81 | 40.86 | 17.19 | 29.73 |
| C19 H40 N4 O13 | 532.257 | 1.985 | 22 | 2.93 | 1.51 | 2.50 | 3.24 | 1.52 | 2.37 | 40.95 | 0.77 | 33.48 |
| C22 H51 Cl N6 | 434.3844 | 2.599 | 9 | 2.53 | 1.17 | 2.22 | 2.36 | 1.16 | 2.47 | 41.05 | 25.76 | 30.77 |
| C11 H30 N10 O6 | 398.2365 | 1.459 | 11 | 3.84 | 3.01 | 3.61 | 4.76 | 2.99 | 3.87 | 41.06 | 34.02 | 29.11 |
| C17 H32 N2 O2 P2 | 358.1942 | 1.297 | 22 | 2.58 | 1.95 | 2.42 | 2.25 | 1.83 | 2.43 | 41.20 | 25.92 | 5.49 |
| C18 H17 N8 O3 P3 S | 518.0354 | 3.326 | 7 | 1.67 | 1.31 | 1.85 | 1.69 | 1.29 | 1.88 | 41.26 | 5.39 | 20.50 |
| C16 H44 N9 O P | 409.3398 | 2.611 | 4 | 1.56 | 0.67 | 1.49 | 1.58 | 0.69 | 1.82 | 41.39 | 14.24 | 35.18 |
| C19 H26 N9 O17 P3 S | 777.0382 | 3.007 | 7 | 3.00 | 2.62 | 3.22 | 3.13 | 2.64 | 3.30 | 41.45 | 8.95 | 17.87 |




|  | C78 H163 N10 O16 P S | 1559.171 | 3.42 | 20 | 1.86 | 1.63 | 1.81 | 1.50 | 1.66 | 2.01 | 49.21 | 21.99 | 42.95 |
| :--- | :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | C82 H132 N5 O5 P3 | 1359.945 | 3.059 | 8 | 2.24 | 1.86 | 2.33 | 2.45 | 1.87 | 2.46 | 49.40 | 9.80 | 46.16 |

Table A.5: Lipidomics results of CFTR-SMALPs and analysis results. The abbreviation FC is the fold change. These features determined at a confidence level of 5 with identification of the retention time (RT) only.

| Name | Formula | Molecular Weight | $\begin{gathered} \mathrm{RT} \\ {[\mathrm{~min}]} \end{gathered}$ | $\begin{array}{\|c\|} \hline \text { RSD } \\ \text { QC } \\ \text { Areas } \\ \text { [\%] } \\ \hline \end{array}$ | Ave. E1 | Ave. E2 | Ave. E3 | Med. E1 | Med. E2 | Med. E3 | CV of FC E1 | CV of FC E2 | $\begin{aligned} & \text { CV of } \\ & \text { FC E3 } \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | 774.0836 | 5.635 | 6 | 9.90 | 10.00 | 9.88 | 9.91 | 9.98 | 9.88 | 0.21 | 5.61 | 0.88 |
|  |  | 885.8559 | 9.625 | 6 | 4.85 | 4.69 | 4.76 | 4.83 | 4.67 | 4.75 | 0.35 | 5.76 | 1.48 |
|  |  | 3058.397 | 5.619 | 7 | 5.84 | 5.72 | 5.85 | 5.88 | 5.86 | 5.85 | 0.73 | 18.28 | 2.34 |
|  |  | 736.6315 | 5.176 | 4 | 9.81 | 9.83 | 9.79 | 9.76 | 9.72 | 9.79 | 0.78 | 15.99 | 9.16 |
|  |  | 563.5463 | 5.205 | 4 | 7.19 | 7.16 | 7.21 | 7.16 | 7.12 | 7.17 | 0.86 | 6.40 | 6.50 |
|  |  | 470.3271 | 2.754 | 10 | 3.49 | 3.44 | 3.53 | 3.54 | 3.53 | 3.54 | 0.88 | 14.03 | 8.94 |
|  |  | 872.8436 | 9.621 | 8 | 3.77 | 3.61 | 3.71 | 3.79 | 3.64 | 3.71 | 0.93 | 5.91 | 5.47 |
|  |  | 811.6595 | 5.626 | 22 | 4.69 | 4.72 | 4.65 | 4.61 | 4.66 | 4.67 | 1.22 | 8.35 | 4.48 |
|  |  | 1997.926 | 11.244 | 5 | 7.57 | 7.27 | 7.55 | 7.56 | 7.63 | 7.54 | 1.25 | 49.16 | 2.56 |
|  |  | 489.465 | 3.563 | 6 | 2.94 | 2.79 | 2.77 | 2.89 | 2.77 | 2.80 | 1.27 | 9.47 | 14.18 |
|  |  | 1523.179 | 5.679 | 8 | 3.94 | 3.93 | 4.03 | 3.96 | 4.09 | 4.00 | 1.32 | 25.36 | 8.03 |
|  |  | 638.6514 | 6.649 | 2 | 2.02 | 1.56 | 1.99 | 2.04 | 1.63 | 1.94 | 1.33 | 12.68 | 7.15 |
|  |  | 1528.195 | 5.62 | 4 | 6.77 | 6.69 | 6.77 | 6.79 | 6.75 | 6.75 | 1.36 | 11.68 | 3.51 |
|  |  | 871.8395 | 9.626 | 6 | 5.53 | 5.41 | 5.48 | 5.53 | 5.38 | 5.49 | 1.40 | 5.28 | 4.38 |
|  |  | 2301.778 | 5.619 | 10 | 7.11 | 7.10 | 6.95 | 7.12 | 7.16 | 7.06 | 1.43 | 18.01 | 22.40 |
|  |  | 812.7653 | 9.616 | 3 | 9.66 | 9.62 | 9.67 | 9.63 | 9.62 | 9.65 | 1.50 | 4.42 | 4.48 |
|  |  | 1635.517 | 9.629 | 3 | 6.65 | 6.63 | 6.66 | 6.64 | 6.63 | 6.64 | 1.52 | 6.23 | 2.91 |
|  |  | 1648.52 | 9.625 | 3 | 7.20 | 7.12 | 7.18 | 7.22 | 7.16 | 7.18 | 1.64 | 8.40 | 1.05 |
|  |  | 1647.517 | 9.625 | 3 | 8.65 | 8.57 | 8.60 | 8.66 | 8.59 | 8.60 | 1.64 | 8.27 | 0.97 |
|  |  | 187.5182 | 5.614 | 2 | 2.77 | 2.86 | 2.76 | 2.78 | 2.78 | 2.78 | 1.68 | 11.56 | 4.25 |


$\left.\begin{array}{|l|r|r|r|r|r|r|r|r|r|r|r|r|r|}\hline & & 826.7783 & 9.627 & 5 & 8.93 & 8.71 & 8.91 & 8.93 & 8.77 & 8.92 & 2.64 & 6.92 & 2.19 \\ \hline & & 898.8672 & 9.806 & 15 & 4.27 & 4.20 & 4.28 & 4.33 & 4.35 & 4.24 & 2.69 & 40.81 & 4.29 \\ \hline & & 739.6437 & 5.173 & 3 & 7.28 & 7.28 & 7.25 & 7.22 & 7.15 & 7.18 & 2.71 & 15.25 & 10.01 \\ \hline & & 746.5287 & 3.525 & 15 & 1.80 & 1.58 & 2.00 & 1.79 & 1.56 & 1.92 & 2.72 & 1.90 & 20.96 \\ \hline & & 913.8866 & 9.624 & 3 & 8.55 & 8.31 & 8.53 & 8.57 & 8.30 & 8.51 & 2.76 & 4.85 & 3.71 \\ \hline & & 854.8048 & 9.625 & 14 & 5.25 & 5.08 & 5.07 & 5.21 & 4.87 & 5.18 & 2.77 & 28.51 & 21.01 \\ \hline & & 525.3769 & 2.647 & 9 & 4.08 & 4.09 & 4.10 & 4.03 & 4.15 & 4.11 & 2.84 & 7.34 & 5.94 \\ \hline & & 839.7085 & 5.62 & 24 & 4.69 & 4.98 & 4.86 & 4.70 & 5.00 & 4.86 & 2.90 & 8.30 & 4.96 \\ \hline & & 624.6358 & 6.647 & 20 & 1.70 & 1.28 & 1.59 & 1.76 & 1.41 & 1.57 & 2.92 & 17.64 & 7.29 \\ \hline & & 717.7713 & 11.486 & 4 & 1.55 & 0.17 & 0.96 & 1.60 & 0.34 & 0.94 & 2.95 & 36.97 & 6.55 \\ \hline & & 251.2608 & 2.307 & 21 & 1.88 & 1.26 & 1.86 & 1.84 & 1.32 & 1.84 & 2.99 & 38.52 & 4.68 \\ \hline & & 884.8517 & 9.625 & 4 & 6.14 & 6.02 & 6.09 & 6.12 & 6.02 & 6.09 & 3.08 & 2.08 & 1.28 \\ \hline & & 805.8358 & 7.849 & 15 & 2.33 & 2.55 & 2.42 & 2.34 & 2.53 & 2.39 & 3.22 & 3.00 & 7.08 \\ \hline & & 1525.686 & 5.617 & 13 & 5.74 & 5.66 & 5.69 & 5.78 & 5.78 & 5.70 & 3.33 & 18.16 & 5.39 \\ \hline & & 652.6668 & 7.352 & 4 & 1.09 & 0.60 & 0.99 & 1.08 & 0.64 & 0.95 & 3.35 & 8.54 & 9.88 \\ \hline & & 1983.919 & 11.256 & 8 & 6.99 & 6.97 & 6.98 & 6.94 & 7.00 & 6.94 & 3.41 & 4.79 & 6.57 \\ \hline & & 832.801 & 9.623 & 3 & 5.83 & 5.60 & 5.77 & 5.83 & 5.58 & 5.74 & 3.48 & 3.69 & 3.65 \\ \hline & & 3054.383 & 5.62 & 9 & 7.13 & 6.99 & 7.15 & 7.19 & 7.14 & 7.15 & 3.50 & 22.18 & 0.88 \\ \hline & & & 1901.991 & 5.607 & 23 & 4.06 & 4.03 & 4.07 & 4.14 & 4.16 & 4.12 & 3.52 & 21.85\end{array}\right) 8.109$.

|  |  | 736.5578 | 5.208 | 4 | 4.72 | 4.76 | 4.75 | 4.67 | 4.70 | 4.72 | 3.81 | 10.02 | 6.03 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | 1900.988 | 5.612 | 18 | 4.40 | 4.55 | 3.95 | 4.48 | 4.57 | 3.78 | 3.81 | 9.50 | 23.46 |
|  |  | 1641.557 | 9.625 | 14 | 8.41 | 8.18 | 8.42 | 8.41 | 8.22 | 8.43 | 3.84 | 5.55 | 3.24 |
|  |  | 187.2688 | 5.615 | 8 | 1.45 | 1.47 | 1.31 | 1.37 | 1.25 | 1.32 | 3.96 | 25.00 | 4.05 |
|  |  | 1024.981 | 11.25 | 5 | 6.99 | 7.50 | 7.57 | 7.00 | 7.01 | 7.07 | 4.09 | 49.33 | 48.15 |
|  |  | 2304.787 | 5.612 | 9 | 5.08 | 5.09 | 5.10 | 5.17 | 5.21 | 5.07 | 4.11 | 19.22 | 3.76 |
|  |  | 1901.489 | 5.611 | 27 | 4.56 | 4.62 | 4.48 | 4.76 | 4.80 | 4.56 | 4.12 | 31.48 | 20.26 |
|  |  | 541.1992 | 2.316 | 17 | 2.34 | 1.69 | 2.45 | 2.29 | 1.78 | 2.34 | 4.14 | 31.71 | 17.29 |
|  |  | 374.3883 | 2.681 | 11 | 3.74 | 3.50 | 3.53 | 3.80 | 3.42 | 3.53 | 4.14 | 9.97 | 2.83 |
|  |  | 1529.198 | 5.622 | 4 | 5.76 | 5.79 | 5.73 | 5.78 | 5.75 | 5.76 | 4.17 | 5.74 | 3.64 |
|  |  | 1150.385 | 5.614 | 19 | 4.54 | 4.51 | 4.41 | 4.61 | 4.47 | 4.37 | 4.17 | 7.68 | 6.05 |
|  |  | 903.7369 | 9.551 | 8 | 2.84 | 3.08 | 2.94 | 2.87 | 2.85 | 2.95 | 4.21 | 33.73 | 2.85 |
|  |  | 791.8203 | 7.846 | 10 | 4.07 | 4.20 | 4.08 | 4.01 | 4.22 | 4.11 | 4.22 | 4.35 | 3.80 |
|  |  | 557.4136 | 2.265 | 9 | 1.29 | 0.24 | 1.17 | 1.42 | 0.26 | 1.10 | 4.22 | 23.22 | 39.33 |
|  |  | 573.4575 | 2.75 | 10 | 3.71 | 3.50 | 3.30 | 3.55 | 3.49 | 3.24 | 4.25 | 5.83 | 9.74 |
|  |  | 424.2851 | 2.7 | 6 | 3.13 | 2.84 | 3.10 | 3.07 | 2.86 | 3.12 | 4.30 | 3.67 | 7.09 |
|  |  | 484.3484 | 2.661 | 5 | 9.41 | 9.50 | 9.53 | 9.44 | 9.52 | 9.55 | 4.32 | 3.58 | 2.04 |
|  |  | 323.3181 | 2.751 | 22 | 1.52 | 1.63 | 1.23 | 1.52 | 1.58 | 1.23 | 4.37 | 49.43 | 32.36 |
|  |  | 552.479 | 3.935 | 8 | 3.16 | 2.95 | 3.15 | 3.12 | 2.93 | 3.08 | 4.40 | 8.76 | 10.46 |
|  |  | 1519.067 | 5.201 | 14 | 2.31 | 2.41 | 2.31 | 2.30 | 2.27 | 2.29 | 4.48 | 23.93 | 9.93 |
|  |  | 484.3392 | 2.661 | 8 | 5.12 | 5.10 | 5.19 | 5.15 | 5.06 | 5.22 | 4.51 | 8.25 | 10.42 |
|  |  | 630.4833 | 5.462 | 9 | 3.23 | 3.43 | 3.21 | 3.24 | 3.44 | 3.17 | 4.52 | 11.64 | 5.35 |
|  |  | 1338.273 | 11.249 | 6 | 10.84 | 10.63 | 10.80 | 10.82 | 10.84 | 10.80 | 4.54 | 32.16 | 3.17 |
|  |  | 560.3898 | 2.674 | 12 | 2.00 | 1.85 | 2.21 | 1.91 | 1.70 | 2.30 | 4.62 | 17.39 | 23.45 |
|  |  | 1472.193 | 5.196 | 14 | 3.00 | 2.89 | 3.03 | 2.98 | 2.70 | 3.02 | 4.68 | 29.77 | 18.11 |
|  |  | 587.5441 | 7.384 | 8 | 3.56 | 2.93 | 3.55 | 3.58 | 2.97 | 3.50 | 4.69 | 19.12 | 9.28 |


|  | 2302.781 | 5.62 | 16 | 6.76 | 6.78 | 6.75 | 6.82 | 6.87 | 6.75 | 4.72 | 16.56 | 1.09 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 832.738 | 9.64 | 4 | 5.83 | 6.15 | 5.75 | 5.88 | 5.88 | 5.77 | 4.82 | 33.90 | 10.91 |
|  | 711.5615 | 5.889 | 3 | 5.49 | 5.39 | 5.52 | 5.45 | 5.40 | 5.57 | 4.87 | 3.60 | 6.25 |
|  | 2281.803 | 5.616 | 18 | 4.83 | 4.81 | 4.76 | 4.89 | 4.97 | 4.77 | 4.96 | 25.65 | 1.17 |
|  | 1642.561 | 9.62 | 5 | 7.25 | 7.05 | 7.26 | 7.25 | 7.11 | 7.29 | 5.00 | 8.07 | 5.18 |
|  | 837.7548 | 9.631 | 7 | 3.30 | 3.29 | 3.16 | 3.31 | 3.30 | 3.22 | 5.00 | 3.37 | 38.66 |
|  | 1471.191 | 5.2 | 7 | 2.43 | 2.55 | 2.49 | 2.47 | 2.16 | 2.43 | 5.01 | 46.99 | 13.96 |
|  | 510.4423 | 2.323 | 15 | 1.72 | 1.00 | 1.73 | 1.73 | 0.74 | 1.74 | 5.05 | 35.39 | 5.50 |
|  | 920.3038 | 7.763 | 9 | 2.28 | 2.14 | 2.39 | 2.29 | 2.23 | 2.40 | 5.07 | 10.93 | 8.83 |
|  | 187.5196 | 5.618 | 3 | 2.06 | 2.03 | 1.92 | 2.00 | 1.90 | 1.92 | 5.17 | 19.22 | 0.14 |
|  | 993.3223 | 7.883 | 8 | 4.99 | 4.95 | 5.02 | 5.05 | 4.99 | 5.02 | 5.18 | 7.04 | 4.95 |
|  | 299.2455 | 1.467 | 25 | 2.03 | 0.69 | 1.26 | 1.68 | 0.56 | 1.21 | 5.27 | 21.56 | 14.94 |
|  | 366.3282 | 8.075 | 14 | 1.15 | 0.56 | 1.19 | 1.04 | 0.74 | 1.29 | 5.35 | 43.51 | 13.93 |
|  | 1054.29 | 7.79 | 12 | 1.04 | 0.99 | 1.13 | 1.01 | 0.93 | 1.03 | 5.40 | 14.08 | 14.61 |
|  | 1638.542 | 9.626 | 6 | 4.76 | 4.53 | 4.72 | 4.78 | 4.61 | 4.72 | 5.43 | 11.31 | 1.23 |
|  | 3060.404 | 5.62 | 6 | 4.26 | 4.02 | 4.25 | 4.33 | 4.07 | 4.25 | 5.46 | 12.39 | 10.02 |
|  | 868.809 | 9.62 | 6 | 4.63 | 4.42 | 4.59 | 4.60 | 4.48 | 4.60 | 5.53 | 20.62 | 0.69 |
|  | 838.5827 | 5.665 | 24 | 6.60 | 6.54 | 6.66 | 6.55 | 6.49 | 6.65 | 5.59 | 7.49 | 8.43 |
|  | 536.6063 | 7.127 | 3 | 1.46 | 0.07 | 1.16 | 1.55 | 0.11 | 1.39 | 5.60 | 45.57 | 29.75 |
|  | 410.4313 | 5.927 | 11 | 1.28 | 0.13 | 1.00 | 1.30 | 0.24 | 1.08 | 5.62 | 42.45 | 21.48 |
|  | 807.5669 | 4.831 | 4 | 2.56 | 2.76 | 2.44 | 2.52 | 2.53 | 2.44 | 5.62 | 28.54 | 0.80 |
|  | 284.2904 | 2.314 | 15 | 1.90 | 1.19 | 1.91 | 1.91 | 0.91 | 1.92 | 5.67 | 35.49 | 5.78 |
|  | 1027.678 | 9.627 | 22 | 4.30 | 4.40 | 4.36 | 4.24 | 4.43 | 4.41 | 5.72 | 7.94 | 11.33 |
|  | 1198.087 | 7.31 | 7 | 4.71 | 5.03 | 4.67 | 4.69 | 4.71 | 4.63 | 5.72 | 42.75 | 8.10 |
|  | 1510.227 | 5.611 | 17 | 3.84 | 3.52 | 3.74 | 3.69 | 3.43 | 3.81 | 5.75 | 13.14 | 11.65 |
|  | 757.5343 | 5.208 | 2 | 7.67 | 7.63 | 7.67 | 7.61 | 7.63 | 7.69 | 5.79 | 0.44 | 2.53 |


|  | 2303.786 | 5.613 | 13 | 6.93 | 6.88 | 6.91 | 7.05 | 6.99 | 6.93 | 5.82 | 17.16 | 2.94 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 568.5327 | 9.628 | 7 | 3.16 | 2.89 | 3.23 | 3.22 | 2.83 | 3.20 | 5.89 | 8.84 | 5.55 |
|  | 494.32 | 2.746 | 9 | 4.16 | 3.99 | 4.36 | 4.14 | 3.99 | 4.32 | 5.91 | 5.87 | 8.03 |
|  | 1894.289 | 1.481 | 19 | 2.17 | 1.37 | 1.91 | 2.16 | 1.34 | 1.92 | 6.06 | 24.92 | 24.24 |
|  | 1643.564 | 9.624 | 8 | 5.97 | 5.68 | 5.87 | 6.02 | 5.72 | 5.88 | 6.08 | 7.52 | 2.69 |
|  | 996.9496 | 3.376 | 15 | 2.37 | 2.48 | 2.53 | 2.48 | 2.50 | 2.52 | 6.12 | 9.34 | 4.59 |
|  | 3718.417 | 1.555 | 16 | 3.68 | 2.95 | 3.47 | 3.56 | 3.26 | 3.51 | 6.16 | 49.97 | 14.26 |
|  | 820.5448 | 5.224 | 3 | 6.20 | 6.26 | 6.08 | 6.20 | 6.07 | 6.10 | 6.23 | 23.20 | 3.88 |
|  | 440.2339 | 1.588 | 19 | 3.94 | 3.23 | 3.75 | 3.84 | 3.54 | 3.79 | 6.24 | 49.77 | 14.31 |
|  | 1500.088 | 5.227 | 19 | 4.23 | 4.10 | 4.17 | 4.13 | 3.99 | 4.19 | 6.24 | 13.34 | 12.51 |
|  | 441.3119 | 2.711 | 12 | 3.67 | 3.62 | 3.71 | 3.56 | 3.57 | 3.68 | 6.25 | 8.48 | 4.94 |
|  | 539.1703 | 3.912 | 14 | 1.95 | 1.71 | 1.79 | 1.77 | 1.66 | 1.84 | 6.25 | 29.82 | 10.05 |
|  | 3055.387 | 5.617 | 17 | 5.38 | 5.32 | 5.39 | 5.35 | 5.46 | 5.35 | 6.31 | 19.14 | 5.24 |
|  | 843.0178 | 5.239 | 10 | 3.26 | 3.57 | 3.12 | 3.28 | 3.31 | 3.16 | 6.34 | 29.30 | 6.22 |
|  | 1344.368 | 1.474 | 14 | 2.05 | 1.34 | 1.83 | 2.07 | 1.39 | 1.83 | 6.37 | 32.12 | 22.50 |
|  | 700.5189 | 3.34 | 21 | 1.99 | 2.44 | 2.11 | 2.26 | 2.40 | 2.27 | 6.43 | 5.21 | 23.60 |
|  | 940.9144 | 9.627 | 22 | 3.55 | 3.11 | 3.52 | 3.46 | 3.09 | 3.62 | 6.43 | 10.90 | 13.58 |
|  | 1650.527 | 9.628 | 3 | 3.37 | 3.42 | 3.50 | 3.38 | 3.54 | 3.46 | 6.49 | 15.27 | 7.77 |
|  | 757.6164 | 5.623 | 15 | 3.30 | 3.60 | 3.35 | 3.35 | 3.58 | 3.38 | 6.56 | 8.39 | 8.61 |
|  | 1225.026 | 9.679 | 14 | 6.75 | 7.21 | 6.84 | 6.80 | 7.09 | 6.83 | 6.67 | 21.81 | 2.52 |
|  | 706.7674 | 10.033 | 11 | 1.12 | 0.49 | 0.86 | 1.20 | 0.60 | 0.84 | 6.69 | 27.66 | 10.96 |
|  | 326.3372 | 2.366 | 23 | 1.36 | 0.61 | 1.45 | 1.36 | 0.77 | 1.49 | 6.75 | 41.01 | 7.25 |
|  | 206.5661 | 9.619 | 13 | 1.11 | 0.93 | 0.98 | 1.16 | 1.03 | 1.03 | 6.86 | 14.01 | 6.68 |
|  | 478.3845 | 5.792 | 23 | 1.36 | 0.70 | 1.52 | 1.28 | 0.48 | 1.64 | 6.94 | 38.30 | 29.05 |
|  | 478.4497 | 3.079 | 6 | 1.29 | 0.56 | 0.53 | 1.33 | 0.77 | 0.58 | 6.94 | 45.31 | 36.16 |
|  | 514.3759 | 2.447 | 21 | 3.36 | 2.97 | 3.32 | 3.27 | 2.87 | 3.34 | 6.95 | 15.79 | 3.26 |


|  | 1246.828 | 1.449 | 20 | 1.49 | 0.60 | 1.24 | 1.42 | 0.51 | 1.16 | 6.97 | 16.02 | 12.32 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1644.567 | 9.625 | 6 | 3.70 | 3.37 | 3.58 | 3.71 | 3.34 | 3.59 | 6.98 | 3.96 | 3.64 |
|  | 485.3383 | 2.663 | 6 | 4.83 | 4.98 | 5.00 | 4.92 | 5.03 | 4.99 | 7.01 | 11.31 | 1.53 |
|  | 573.3133 | 1.449 | 4 | 1.60 | 0.76 | 1.35 | 1.55 | 0.69 | 1.30 | 7.06 | 17.63 | 7.64 |
|  | 916.6678 | 4.385 | 11 | 4.12 | 4.08 | 4.11 | 4.12 | 4.03 | 4.17 | 7.16 | 17.75 | 11.10 |
|  | 790.5601 | 5.622 | 10 | 6.11 | 6.15 | 6.16 | 6.19 | 6.09 | 6.16 | 7.18 | 11.42 | 1.64 |
|  | 950.7536 | 8.087 | 18 | 1.22 | 0.61 | 1.34 | 1.12 | 0.77 | 1.40 | 7.32 | 30.15 | 12.65 |
|  | 821.6098 | 5.669 | 17 | 3.62 | 3.43 | 3.74 | 3.67 | 3.60 | 3.86 | 7.32 | 26.91 | 24.02 |
|  | 1850.195 | 1.572 | 26 | 3.92 | 3.12 | 3.68 | 3.77 | 3.33 | 3.69 | 7.37 | 42.45 | 15.86 |
|  | 624.5619 | 11.253 | 22 | 2.60 | 3.18 | 2.89 | 2.69 | 3.11 | 2.82 | 7.41 | 10.55 | 17.82 |
|  | 806.481 | 1.587 | 25 | 3.55 | 2.84 | 3.85 | 3.44 | 3.09 | 3.39 | 7.48 | 48.41 | 46.69 |
|  | 375.3706 | 4.194 | 14 | 2.15 | 2.18 | 2.16 | 2.20 | 2.18 | 2.11 | 7.51 | 1.41 | 5.96 |
|  | 526.3793 | 2.648 | 12 | 3.87 | 3.69 | 3.80 | 3.71 | 3.72 | 3.80 | 7.57 | 3.94 | 4.23 |
|  | 506.3221 | 2.648 | 3 | 6.32 | 6.41 | 6.50 | 6.39 | 6.39 | 6.48 | 7.59 | 3.71 | 6.44 |
|  | 591.6506 | 7.28 | 4 | 2.98 | 1.68 | 2.40 | 3.05 | 1.41 | 2.50 | 7.59 | 40.85 | 21.27 |
|  | 3716.417 | 1.562 | 21 | 3.73 | 2.98 | 3.51 | 3.58 | 3.25 | 3.55 | 7.62 | 46.75 | 15.14 |
|  | 481.5488 | 5.321 | 6 | 1.79 | 0.54 | 1.57 | 1.77 | 0.38 | 1.61 | 7.70 | 49.83 | 11.29 |
|  | 424.4466 | 6.345 | 8 | 1.09 | 0.16 | 0.85 | 1.05 | 0.07 | 0.91 | 7.80 | 36.49 | 16.77 |
|  | 835.7501 | 9.623 | 5 | 8.21 | 8.15 | 8.25 | 8.22 | 8.13 | 8.30 | 7.85 | 3.81 | 7.24 |
|  | 597.3228 | 2.621 | 15 | 3.60 | 3.13 | 3.34 | 3.44 | 3.09 | 3.26 | 7.87 | 4.92 | 9.27 |
|  | 805.6671 | 7.353 | 20 | 1.20 | 1.77 | 1.10 | 1.23 | 1.43 | 1.14 | 7.89 | 39.18 | 5.64 |
|  | 868.8215 | 9.629 | 22 | 3.74 | 3.47 | 3.83 | 3.68 | 3.44 | 3.69 | 7.90 | 19.10 | 27.02 |
|  | 3012.172 | 5.212 | 11 | 2.03 | 1.78 | 1.82 | 1.99 | 1.84 | 1.77 | 8.09 | 12.08 | 16.09 |
|  | 677.6798 | 11.256 | 7 | 1.83 | 1.93 | 2.11 | 1.72 | 1.97 | 2.14 | 8.09 | 10.90 | 8.55 |
|  | 757.5725 | 5.204 | 20 | 4.47 | 4.64 | 4.54 | 4.47 | 4.31 | 4.60 | 8.11 | 36.51 | 7.20 |
|  | 658.6465 | 11.246 | 7 | 5.38 | 5.28 | 5.42 | 5.37 | 5.31 | 5.41 | 8.14 | 16.54 | 2.40 |

$\left.\begin{array}{|l|r|r|r|r|r|r|r|r|r|r|r|r|r|}\hline & & 550.588 & 5.017 & 5 & 2.30 & 0.97 & 2.04 & 2.28 & 0.70 & 1.96 & 8.16 & 39.99 & 10.31 \\ \hline & & 922.7192 & 8.038 & 24 & 1.25 & 0.56 & 1.34 & 1.16 & 0.70 & 1.26 & 8.21 & 32.92 & 14.39 \\ \hline & & 1177.862 & 5.623 & 8 & 5.35 & 5.12 & 5.23 & 5.39 & 5.33 & 5.22 & 8.28 & 28.29 & 1.80 \\ \hline & & 834.6036 & 5.13 & 10 & 3.05 & 3.17 & 3.00 & 2.94 & 3.04 & 2.91 & 8.31 & 16.99 & 12.02 \\ \hline & & 1178.365 & 5.623 & 15 & 5.57 & 5.38 & 5.49 & 5.62 & 5.66 & 5.48 & 8.36 & 37.59 & 4.78 \\ \hline & & 1720.01 & 1.525 & 25 & 3.92 & 3.12 & 3.70 & 3.76 & 3.29 & 3.75 & 8.41 & 38.26 & 17.12 \\ \hline & & 706.5159 & 8.033 & 19 & 3.48 & 2.86 & 3.39 & 3.33 & 3.01 & 3.54 & 8.41 & 41.84 & 30.23 \\ \hline & & 2280.799 & 5.618 & 12 & 5.72 & 5.67 & 5.64 & 5.67 & 5.76 & 5.70 & 8.42 & 10.76 & 7.14 \\ \hline & & 843.8072 & 9.623 & 5 & 6.43 & 6.36 & 6.54 & 6.42 & 6.30 & 6.53 & 8.45 & 8.03 & 1.92 \\ \hline & & 366.3856 & 6.625 & 7 & 2.15 & 0.95 & 1.81 & 2.16 & 1.03 & 1.81 & 8.46 & 30.99 & 5.24 \\ \hline & & 443.2888 & 1.449 & 26 & 2.80 & 1.24 & 1.36 & 2.71 & 1.40 & 1.26 & 8.47 & 46.49 & 23.54 \\ \hline & & 1202.329 & 7.964 & 9 & 2.22 & 1.87 & 2.36 & 2.16 & 2.06 & 2.27 & 8.48 & 44.95 & 12.43 \\ \hline & & 762.5278 & 5.21 & 13 & 2.99 & 2.75 & 2.91 & 2.89 & 2.76 & 2.93 & 8.51 & 1.59 & 2.04 \\ \hline & & 1998.929 & 11.244 & 8 & 5.86 & 5.62 & 5.93 & 5.95 & 5.96 & 5.94 & 8.55 & 43.99 & 2.32 \\ \hline & & 216.1873 & 11.258 & 19 & 3.21 & 3.41 & 3.28 & 3.22 & 3.27 & 3.17 & 8.55 & 22.28 & 20.53 \\ \hline & & 524.24 & 1.724 & 26 & 9.33 & 8.94 & 9.29 & 9.24 & 9.06 & 9.33 & 8.56 & 48.99 & 31.48 \\ \hline & & 296.2905 & 1.915 & 20 & 1.48 & 0.57 & 1.43 & 1.36 & 0.60 & 1.62 & 8.57 & 11.75 & 37.78 \\ \hline & & 463.3423 & 3.394 & 15 & 4.01 & 3.39 & 3.90 & 3.85 & 3.41 & 3.96 & 8.59 & 5.96 & 13.98 \\ \hline & & 530.4782 & 5.537 & 9 & 1.79 & 1.20 & 1.73 & 1.64 & 1.26 & 1.70 & 8.66 & 11.45 & 4.89 \\ \hline & & & 568.5328 & 5.214 & 13 & 3.19 & 3.28 & 3.17 & 3.12 & 3.34 & 3.19 & 8.68 & 7.14 \\ \hline & 3.88 \\ \hline & & & 1292.378 & 7.745 & 30 & 1.88 & 1.54 & 1.92 & 1.92 & 1.52 & 1.98 & 8.69 & 12.32\end{array}\right) 8.659$.

|  |  | 808.5793 | 4.856 | 5 | 2.31 | 2.47 | 2.15 | 2.20 | 2.27 | 2.17 | 9.08 | 27.41 | 12.01 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | 3810.001 | 5.618 | 20 | 3.78 | 4.02 | 3.95 | 3.93 | 4.03 | 3.94 | 9.13 | 5.97 | 11.75 |
|  |  | 609.1759 | 5.688 | 14 | 1.96 | 2.11 | 2.27 | 2.01 | 2.10 | 2.29 | 9.15 | 10.00 | 7.70 |
|  |  | 945.6222 | 3.532 | 10 | 1.11 | 0.80 | 1.05 | 1.06 | 0.88 | 0.97 | 9.17 | 15.96 | 12.77 |
|  |  | 814.7751 | 9.386 | 11 | 2.95 | 2.74 | 2.92 | 2.98 | 2.73 | 2.92 | 9.27 | 1.76 | 1.21 |
|  |  | 1499.193 | 8.066 | 12 | 1.11 | 0.54 | 1.22 | 1.06 | 0.76 | 1.35 | 9.44 | 37.83 | 16.85 |
|  |  | 702.4513 | 1.74 | 17 | 6.42 | 5.19 | 5.83 | 5.95 | 5.51 | 5.93 | 9.50 | 49.71 | 13.05 |
|  |  | 1317.295 | 11.254 | 10 | 6.28 | 6.19 | 6.32 | 6.25 | 6.36 | 6.31 | 9.51 | 22.33 | 1.55 |
|  |  | 846.5212 | 5.228 | 22 | 2.65 | 3.19 | 2.73 | 2.72 | 3.23 | 2.65 | 9.51 | 28.32 | 17.67 |
|  |  | 549.3671 | 2.644 | 8 | 4.65 | 4.47 | 4.43 | 4.52 | 4.47 | 4.56 | 9.55 | 0.22 | 16.14 |
|  |  | 510.2474 | 3.514 | 28 | 3.98 | 3.83 | 3.90 | 3.88 | 4.14 | 4.01 | 9.63 | 43.23 | 22.84 |
|  |  | 1152.73 | 1.469 | 12 | 1.62 | 0.92 | 1.43 | 1.59 | 0.91 | 1.41 | 9.65 | 38.13 | 19.63 |
|  |  | 994.9604 | 6.8 | 7 | 1.31 | 0.30 | 0.97 | 1.43 | 0.39 | 0.98 | 9.67 | 34.47 | 11.89 |
|  |  | 675.6728 | 11.254 | 9 | 8.82 | 8.89 | 8.90 | 8.84 | 8.93 | 8.89 | 9.69 | 10.29 | 5.76 |
|  |  | 427.3768 | 2.675 | 10 | 3.30 | 2.92 | 2.88 | 3.14 | 2.92 | 2.92 | 9.70 | 22.47 | 7.98 |
|  |  | 800.5752 | 4.838 | 2 | 2.95 | 3.24 | 2.70 | 2.85 | 2.81 | 2.79 | 9.71 | 45.44 | 17.05 |
|  |  | 2450.811 | 3.597 | 11 | 3.03 | 3.21 | 3.06 | 3.26 | 3.16 | 3.05 | 9.73 | 11.22 | 12.63 |
|  |  | 1579.505 | 1.471 | 21 | 2.06 | 1.21 | 1.79 | 1.95 | 1.07 | 1.83 | 9.82 | 17.26 | 27.68 |
|  |  | 241.2763 | 3.374 | 13 | 1.83 | 1.67 | 1.97 | 1.77 | 1.60 | 1.93 | 9.85 | 24.91 | 21.00 |
|  |  | 816.9386 | 3.592 | 19 | 3.25 | 3.42 | 3.27 | 3.47 | 3.42 | 3.26 | 9.92 | 2.56 | 13.74 |
|  |  | 1028.683 | 9.618 | 8 | 2.83 | 2.83 | 2.92 | 2.84 | 2.82 | 2.93 | 9.93 | 4.74 | 4.15 |
|  |  | 587.3087 | 2.79 | 24 | 1.12 | 0.47 | 1.23 | 0.95 | 0.36 | 1.17 | 10.04 | 15.60 | 37.76 |
|  |  | 2306.46 | 1.518 | 26 | 2.20 | 1.07 | 1.85 | 2.01 | 0.93 | 1.79 | 10.09 | 19.06 | 8.41 |
|  |  | 994.7624 | 3.881 | 16 | 3.91 | 3.92 | 4.08 | 3.89 | 3.81 | 4.10 | 10.11 | 13.08 | 2.88 |
|  |  | 440.4051 | 3.586 | 16 | 1.69 | 1.51 | 1.75 | 1.71 | 1.50 | 1.78 | 10.19 | 4.99 | 4.26 |
|  |  | 2299.502 | 1.555 | 24 | 4.09 | 3.30 | 3.85 | 3.92 | 3.53 | 3.91 | 10.19 | 41.27 | 16.62 |


|  |  | 2279.795 | 5.618 | 27 | 5.78 | 5.53 | 5.70 | 5.61 | 5.56 | 5.65 | 10.24 | 7.00 | 5.29 |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  |  | 535.1578 | 4.989 | 7 | 1.18 | 1.27 | 1.36 | 1.24 | 1.25 | 1.35 | 10.27 | 5.65 | 1.55 |
|  |  | 1649.523 | 9.623 | 12 | 5.60 | 5.63 | 5.81 | 5.77 | 5.61 | 5.77 | 10.28 | 7.58 | 7.04 |
|  |  | 1246.836 | 5.16 | 28 | 3.61 | 3.70 | 3.60 | 3.50 | 3.64 | 3.50 | 10.29 | 35.09 | 21.11 |
|  |  | 507.3525 | 3.475 | 19 | 5.35 | 2.66 | 5.37 | 5.59 | 2.20 | 5.40 | 10.29 | 46.57 | 30.05 |
|  |  | 739.5908 | 5.215 | 7 | 3.97 | 4.05 | 3.91 | 3.86 | 3.92 | 3.90 | 10.39 | 16.49 | 2.66 |
|  |  | 399.4066 | 3.948 | 17 | 2.38 | 2.06 | 2.16 | 2.09 | 1.94 | 2.21 | 10.41 | 17.81 | 14.67 |
|  |  | 2282.806 | 5.628 | 22 | 4.89 | 4.95 | 4.99 | 4.96 | 5.04 | 4.96 | 10.42 | 14.98 | 3.75 |
|  |  | 312.3575 | 2.81 | 4 | 1.56 | 1.52 | 1.42 | 1.66 | 1.48 | 1.44 | 10.52 | 8.16 | 21.78 |
|  |  | 1216.618 | 1.467 | 25 | 2.14 | 1.22 | 1.86 | 2.00 | 1.17 | 1.90 | 10.57 | 21.56 | 28.16 |
|  |  | 437.189 | 3.074 | 20 | 1.93 | 1.07 | 2.31 | 1.84 | 1.36 | 2.21 | 10.59 | 44.16 | 11.59 |
|  |  | 1330.302 | 11.25 | 24 | 9.73 | 8.93 | 9.76 | 9.73 | 8.75 | 9.76 | 10.64 | 37.00 | 6.02 |
|  |  | 1163.653 | 9.624 | 20 | 2.76 | 3.25 | 3.06 | 2.86 | 3.31 | 2.90 | 10.70 | 9.05 | 19.55 |
|  |  | 960.7032 | 8.575 | 12 | 1.03 | 0.82 | 0.96 | 1.13 | 0.89 | 0.94 | 10.72 | 19.20 | 3.51 |
|  |  | 515.3503 | 2.791 | 26 | 3.74 | 2.03 | 3.42 | 3.86 | 1.97 | 3.44 | 10.73 | 27.34 | 33.14 |
|  |  | 833.2306 | 7.396 | 13 | 2.34 | 2.28 | 2.44 | 2.39 | 2.32 | 2.53 | 10.74 | 9.19 | 13.63 |
|  |  | 559.4418 | 2.748 | 7 | 4.10 | 4.01 | 3.73 | 3.76 | 4.03 | 3.76 | 10.81 | 12.79 | 17.45 |
|  |  | 618.4307 | 2.793 | 22 | 1.93 | 0.72 | 2.63 | 2.04 | 0.70 | 2.50 | 10.83 | 39.21 | 38.12 |
|  |  | 756.5487 | 5.256 | 18 | 4.42 | 4.64 | 4.42 | 4.36 | 4.55 | 4.42 | 10.84 | 13.50 | 2.89 |
|  |  |  | 545.3616 | 1.692 | 9 | 7.94 | 7.37 | 7.84 | 7.85 | 7.10 | 7.84 | 10.91 | 46.34 | 2.52.


|  |  | 797.4412 | 1.447 | 17 | 1.30 | 0.59 | 1.08 | 1.19 | 0.61 | 1.09 | 11.26 | 29.54 | 13.16 |
| ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  |  | 594.6505 | 11.294 | 8 | 1.68 | 0.53 | 1.46 | 1.96 | 0.46 | 1.44 | 11.28 | 43.34 | 21.36 |
|  |  | 1109.638 | 3.518 | 4 | 6.12 | 3.82 | 5.92 | 6.04 | 3.75 | 5.71 | 11.32 | 16.56 | 29.87 |
|  |  | 866.6479 | 3.575 | 20 | 1.98 | 2.10 | 1.59 | 2.32 | 2.12 | 1.57 | 11.38 | 7.79 | 8.94 |
|  |  | 781.5704 | 3.438 | 11 | 4.04 | 4.49 | 3.63 | 3.91 | 4.37 | 3.75 | 11.41 | 23.84 | 41.54 |
|  |  | 1646.513 | 9.625 | 4 | 9.44 | 9.28 | 9.36 | 9.62 | 9.31 | 9.35 | 11.42 | 6.84 | 1.44 |
|  |  | 634.6818 | 10.759 | 11 | 1.90 | 0.62 | 1.87 | 2.10 | 0.35 | 1.83 | 11.42 | 33.25 | 18.02 |
|  |  | 2851.844 | 1.539 | 24 | 4.51 | 3.63 | 4.30 | 4.43 | 3.79 | 4.34 | 11.52 | 41.39 | 13.28 |
|  |  | 2305.791 | 5.614 | 22 | 3.57 | 3.65 | 3.60 | 3.82 | 3.74 | 3.58 | 11.62 | 20.02 | 10.40 |
|  |  | 1218.352 | 5.688 | 22 | 1.67 | 1.77 | 2.03 | 1.74 | 1.82 | 1.96 | 11.86 | 17.74 | 9.82 |
|  |  | 751.3263 | 1.937 | 12 | 2.30 | 1.57 | 2.30 | 2.19 | 1.82 | 2.36 | 11.95 | 36.36 | 26.23 |
|  |  | 351.1446 | 1.508 | 19 | 2.37 | 1.58 | 2.21 | 2.17 | 1.40 | 1.94 | 11.95 | 38.73 | 29.22 |
|  |  | 429.3814 | 3.504 | 11 | 2.67 | 2.47 | 3.04 | 3.18 | 2.18 | 2.97 | 12.10 | 40.48 | 27.55 |
|  |  | 1110.884 | 3.507 | 18 | 7.58 | 7.38 | 7.79 | 7.80 | 7.52 | 7.62 | 12.12 | 45.42 | 26.54 |
|  |  | 995.3019 | 7.291 | 10 | 2.75 | 2.92 | 2.84 | 2.67 | 2.91 | 2.89 | 12.12 | 2.58 | 11.56 |
|  |  | 819.7898 | 3.39 | 22 | 2.35 | 0.88 | 2.28 | 2.34 | 1.11 | 2.18 | 12.18 | 39.74 | 11.75 |
|  |  | 506.2542 | 1.614 | 24 | 3.69 | 3.03 | 3.55 | 3.64 | 3.34 | 3.63 | 12.28 | 45.34 | 14.78 |
|  |  | 454.2885 | 3.412 | 10 | 2.69 | 2.80 | 2.68 | 2.79 | 2.84 | 2.69 | 12.31 | 8.68 | 5.04 |
|  |  | 1487.117 | 5.2 | 15 | 2.93 | 2.94 | 2.91 | 2.83 | 2.99 | 2.89 | 12.32 | 18.71 | 3.63 |
|  |  |  | 1876.852 | 5.789 | 12 | 2.65 | 1.84 | 2.85 | 2.59 | 1.86 | 2.99 | 12.34 | 28.60 |
| 39.08 |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  | 539.1699 | 7.755 | 21 | 1.39 | 0.24 | 1.68 | 1.28 | 0.56 | 1.57 | 12.36 | 47.33 |
|  | 22.67 |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  | 1095.666 | 9.626 | 20 | 2.99 | 3.05 | 2.99 | 2.95 | 3.13 | 3.00 | 12.42 | 20.40 |$| 1.649$.


|  |  | 466.4939 | 3.58 | 15 | 1.11 | 0.17 | 1.24 | 1.22 | 0.09 | 1.37 | 12.74 | 32.17 | 22.70 |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  |  | 665.7245 | 8.614 | 11 | 1.13 | 0.19 | 0.73 | 1.34 | 0.51 | 0.78 | 12.77 | 47.81 | 20.39 |
|  |  | 1416.009 | 6.052 | 11 | 1.15 | 0.14 | 0.73 | 1.24 | 0.05 | 0.78 | 12.84 | 43.66 | 14.37 |
|  |  | 720.6459 | 8.054 | 18 | 1.00 | 0.63 | 1.14 | 1.09 | 0.76 | 1.14 | 12.85 | 28.21 | 14.86 |
|  |  | 3057.395 | 5.62 | 15 | 4.74 | 4.68 | 4.66 | 4.89 | 4.81 | 4.67 | 12.91 | 20.53 | 3.41 |
|  |  | 2566.894 | 3.703 | 15 | 1.76 | 1.59 | 2.14 | 1.94 | 1.80 | 2.05 | 12.98 | 30.67 | 18.50 |
|  |  | 550.5879 | 4.78 | 7 | 4.38 | 2.68 | 4.22 | 4.10 | 2.25 | 4.23 | 13.00 | 49.23 | 4.91 |
|  |  | 474.2801 | 1.347 | 14 | 1.71 | 1.07 | 1.48 | 1.60 | 0.95 | 1.52 | 13.00 | 20.50 | 42.37 |
|  |  | 557.2616 | 3.914 | 19 | 1.65 | 1.44 | 1.66 | 1.85 | 1.42 | 1.74 | 13.04 | 3.33 | 10.62 |
|  |  | 881.7893 | 11.226 | 11 | 5.84 | 5.02 | 6.25 | 5.83 | 4.69 | 5.98 | 13.16 | 43.16 | 46.24 |
|  |  | 841.7877 | 7.624 | 16 | 2.40 | 2.19 | 2.35 | 2.53 | 2.21 | 2.33 | 13.23 | 4.61 | 6.22 |
|  |  | 1331.308 | 11.246 | 7 | 8.36 | 8.21 | 8.45 | 8.28 | 8.40 | 8.45 | 13.34 | 25.58 | 2.05 |
|  |  | 1014.736 | 2.651 | 15 | 2.43 | 2.60 | 2.70 | 2.57 | 2.72 | 2.68 | 13.39 | 21.44 | 8.36 |
|  |  | 621.0969 | 3.248 | 17 | 1.70 | 1.68 | 1.94 | 1.53 | 1.72 | 1.83 | 13.53 | 6.02 | 29.55 |
|  |  | 221.1066 | 2.314 | 24 | 2.53 | 1.34 | 2.15 | 2.14 | 1.31 | 2.15 | 13.54 | 37.77 | 2.89 |
|  |  | 421.3397 | 2.793 | 7 | 2.17 | 1.75 | 2.21 | 2.13 | 1.75 | 2.14 | 13.57 | 9.36 | 10.63 |
|  |  | 1672.111 | 5.628 | 26 | 2.58 | 2.48 | 2.65 | 2.66 | 2.47 | 2.57 | 13.57 | 13.36 | 13.03 |
|  |  | 602.5453 | 7.754 | 14 | 2.09 | 1.94 | 2.03 | 1.98 | 1.90 | 2.14 | 13.58 | 20.45 | 34.26 |
|  |  | 1526.185 | 5.617 | 7 | 7.31 | 6.95 | 7.21 | 7.57 | 7.01 | 7.20 | 13.58 | 23.75 | 22.72 |
|  |  |  | 1178.866 | 5.623 | 22 | 4.84 | 4.51 | 4.74 | 4.63 | 4.65 | 4.73 | 13.61 | 19.44 |$| 7.679$.



|  | 395.2883 | 1.495 | 6 | 1.26 | 0.48 | 0.90 | 1.50 | 0.42 | 0.94 | 15.84 | 12.30 | 12.80 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 368.5357 | 3.475 | 29 | 3.64 | 3.39 | 3.28 | 3.37 | 3.52 | 3.05 | 15.86 | 27.99 | 32.64 |
|  | 696.6547 | 11.254 | 14 | 3.72 | 3.95 | 3.73 | 3.67 | 3.96 | 3.67 | 15.94 | 4.21 | 9.95 |
|  | 644.2819 | 1.478 | 17 | 2.00 | 1.29 | 1.77 | 1.76 | 1.26 | 1.85 | 16.14 | 16.19 | 15.90 |
|  | 959.9227 | 11.22 | 9 | 3.26 | 1.96 | 3.55 | 3.30 | 1.85 | 3.35 | 16.19 | 14.95 | 46.68 |
|  | 509.3918 | 2.776 | 17 | 1.91 | 2.04 | 2.20 | 2.12 | 2.04 | 2.15 | 16.20 | 6.10 | 9.80 |
|  | 3113.345 | 5.619 | 21 | 3.91 | 3.65 | 3.91 | 3.86 | 3.89 | 3.94 | 16.21 | 42.59 | 8.03 |
|  | 1010.771 | 3.572 | 13 | 3.13 | 3.09 | 3.08 | 3.06 | 2.98 | 3.03 | 16.22 | 13.81 | 10.27 |
|  | 517.2668 | 1.785 | 26 | 6.06 | 5.14 | 5.86 | 5.97 | 5.36 | 5.90 | 16.25 | 39.20 | 15.63 |
|  | 796.9205 | 3.547 | 16 | 2.88 | 2.97 | 2.82 | 2.71 | 2.92 | 2.73 | 16.27 | 7.12 | 10.19 |
|  | 1523.155 | 5.192 | 22 | 3.00 | 2.68 | 2.87 | 2.97 | 2.97 | 2.86 | 16.38 | 37.71 | 4.06 |
|  | 1144.788 | 1.486 | 15 | 2.24 | 1.29 | 1.92 | 2.22 | 1.08 | 1.92 | 16.43 | 34.82 | 26.40 |
|  | 901.1191 | 3.251 | 14 | 1.87 | 1.16 | 1.80 | 1.90 | 1.15 | 1.75 | 16.44 | 1.84 | 11.53 |
|  | 877.8362 | 11.225 | 3 | 5.95 | 5.05 | 6.25 | 5.93 | 4.64 | 6.06 | 16.46 | 43.47 | 46.19 |
|  | 349.3188 | 2.778 | 23 | 3.23 | 3.05 | 3.69 | 2.97 | 3.04 | 3.63 | 16.47 | 30.21 | 30.81 |
|  | 836.753 | 9.628 | 15 | 6.10 | 5.85 | 6.01 | 5.94 | 5.81 | 6.00 | 16.53 | 7.41 | 1.51 |
|  | 722.4102 | 3.102 | 8 | 1.32 | 0.30 | 1.08 | 1.56 | 0.24 | 0.87 | 16.63 | 37.79 | 26.99 |
|  | 340.1854 | 1.292 | 5 | 1.64 | 0.72 | 1.42 | 1.78 | 0.63 | 1.47 | 16.75 | 29.07 | 10.60 |
|  | 652.2344 | 1.924 | 16 | 2.40 | 1.65 | 2.35 | 2.23 | 1.95 | 2.46 | 16.95 | 41.72 | 23.96 |
|  | 587.4391 | 2.871 | 24 | 2.84 | 2.50 | 3.37 | 3.12 | 2.61 | 3.04 | 17.07 | 26.07 | 36.76 |
|  | 663.5485 | 6.378 | 19 | 3.97 | 2.91 | 3.80 | 4.07 | 2.89 | 4.09 | 17.27 | 49.60 | 44.99 |
|  | 1802.239 | 3.244 | 16 | 2.12 | 1.42 | 2.06 | 2.15 | 1.41 | 2.00 | 17.29 | 2.44 | 11.21 |
|  | 340.3527 | 3.904 | 10 | 2.18 | 0.81 | 1.81 | 2.30 | 0.69 | 1.80 | 17.43 | 36.99 | 22.83 |
|  | 964.9219 | 11.497 | 10 | 3.40 | 2.45 | 3.77 | 3.46 | 2.51 | 3.47 | 17.53 | 11.15 | 35.88 |
|  | 1874.848 | 5.791 | 10 | 4.37 | 3.60 | 4.61 | 4.41 | 3.61 | 4.60 | 17.67 | 18.59 | 30.93 |
|  | 500.1936 | 2.271 | 12 | 1.53 | 0.80 | 1.48 | 1.48 | 0.49 | 1.52 | 17.71 | 36.90 | 6.68 |





|  |  | 2681.975 | 3.804 | 16 | 2.10 | 2.04 | 2.44 | 1.98 | 2.07 | 2.66 | 22.92 | 13.13 |
| ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |


|  | 367.2848 | 2.258 | 9 | 3.40 | 2.65 | 2.66 | 3.58 | 2.73 | 2.52 | 24.89 | 36.89 | 21.26 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 435.3282 | 1.477 | 17 | 3.59 | 2.74 | 2.89 | 3.45 | 2.78 | 3.01 | 24.91 | 8.36 | 16.67 |
|  | 503.6945 | 3.339 | 15 | 2.15 | 1.40 | 2.11 | 1.78 | 1.38 | 2.23 | 24.94 | 7.90 | 31.13 |
|  | 769.5358 | 1.522 | 12 | 5.57 | 3.31 | 4.75 | 5.18 | 3.31 | 4.41 | 25.02 | 12.10 | 37.63 |
|  | 1617.508 | 3.532 | 23 | 1.75 | 2.38 | 1.96 | 1.89 | 2.44 | 2.03 | 25.03 | 8.16 | 33.92 |
|  | 579.9089 | 2.643 | 9 | 3.89 | 3.28 | 3.42 | 3.70 | 3.24 | 3.44 | 25.05 | 9.61 | 8.25 |
|  | 1158.817 | 2.644 | 8 | 3.66 | 3.14 | 3.30 | 3.13 | 3.08 | 3.33 | 25.14 | 7.52 | 16.50 |
|  | 593.6204 | 8.057 | 17 | 2.02 | 0.84 | 1.32 | 1.94 | 0.84 | 1.35 | 25.15 | 43.23 | 40.43 |
|  | 1543.427 | 11.23 | 12 | 4.96 | 3.72 | 5.26 | 4.99 | 3.70 | 4.91 | 25.17 | 19.43 | 47.77 |
|  | 579.6229 | 4.487 | 14 | 1.14 | 0.57 | 0.95 | 1.09 | 0.74 | 0.93 | 25.18 | 43.29 | 43.59 |
|  | 1366.948 | 4.49 | 10 | 3.84 | 2.96 | 4.25 | 3.94 | 3.05 | 4.03 | 25.33 | 40.39 | 49.04 |
|  | 689.4738 | 2.617 | 4 | 4.43 | 3.95 | 3.94 | 4.20 | 4.01 | 3.82 | 25.62 | 21.66 | 17.81 |
|  | 1510.052 | 3.025 | 7 | 4.13 | 3.64 | 4.11 | 3.88 | 3.59 | 4.02 | 25.63 | 10.55 | 26.03 |
|  | 213.1724 | 2.758 | 16 | 1.00 | 1.54 | 1.13 | 0.86 | 1.59 | 1.07 | 25.63 | 21.64 | 18.82 |
|  | 842.5761 | 2.984 | 20 | 2.89 | 2.59 | 3.19 | 2.83 | 2.72 | 3.05 | 25.67 | 18.05 | 29.66 |
|  | 889.7361 | 4.397 | 18 | 1.24 | 0.16 | 2.18 | 1.47 | 0.12 | 2.12 | 25.84 | 35.29 | 34.31 |
|  | 805.6177 | 4.838 | 4 | 2.91 | 2.24 | 3.24 | 2.89 | 2.15 | 3.10 | 25.84 | 23.49 | 43.44 |
|  | 474.2799 | 1.678 | 7 | 7.27 | 7.13 | 7.12 | 7.13 | 7.11 | 7.09 | 25.91 | 32.63 | 6.20 |
|  | 393.4175 | 5.587 | 21 | 1.85 | 0.55 | 1.81 | 2.01 | 0.27 | 2.12 | 25.92 | 44.92 | 40.16 |
|  | 751.067 | 3.363 | 13 | 2.66 | 2.70 | 2.76 | 2.90 | 2.73 | 2.76 | 25.94 | 5.53 | 5.00 |
|  | 994.9103 | 3.578 | 20 | 1.04 | 1.24 | 0.71 | 1.10 | 0.81 | 0.72 | 25.97 | 48.00 | 6.22 |
|  | 307.3232 | 2.34 | 17 | 2.25 | 0.90 | 1.71 | 2.32 | 0.81 | 1.72 | 26.10 | 36.56 | 3.16 |
|  | 568.5332 | 7.309 | 18 | 2.26 | 2.25 | 1.82 | 2.16 | 2.35 | 1.77 | 26.18 | 17.58 | 8.35 |
|  | 1643.162 | 3.3 | 13 | 2.73 | 2.25 | 2.70 | 2.23 | 2.32 | 2.71 | 26.45 | 18.13 | 9.21 |
|  | 622.4453 | 3.108 | 1 | 2.67 | 2.23 | 2.75 | 2.65 | 2.20 | 2.68 | 26.53 | 5.36 | 26.69 |
|  | 845.6315 | 2.911 | 21 | 1.68 | 2.05 | 2.16 | 2.48 | 1.90 | 2.17 | 26.65 | 20.58 | 10.00 |


|  |  | 425.4228 | 2.959 | 25 | 1.62 | 1.30 | 0.79 | 1.63 | 1.36 | 0.95 | 26.68 | 8.70 | 39.24 |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  |  | 623.9363 | 2.634 | 8 | 4.53 | 4.03 | 3.90 | 4.02 | 4.04 | 3.91 | 26.95 | 23.71 | 22.42 |
|  |  | 420.4435 | 2.995 | 19 | 1.12 | 0.39 | 1.20 | 1.24 | 0.58 | 1.17 | 26.97 | 25.87 | 4.41 |
|  |  | 495.8686 | 3.562 | 4 | 3.36 | 2.98 | 3.26 | 3.10 | 2.99 | 3.29 | 27.05 | 3.24 | 21.49 |
|  |  | 982.7256 | 9.267 | 26 | 2.77 | 1.86 | 2.22 | 2.50 | 1.89 | 2.25 | 27.08 | 9.00 | 23.21 |
|  |  | 1714.186 | 3.275 | 10 | 1.14 | 0.66 | 1.17 | 1.09 | 0.58 | 1.12 | 27.11 | 8.75 | 10.41 |
|  |  | 503.3596 | 3.34 | 8 | 3.25 | 2.67 | 3.24 | 2.85 | 2.71 | 3.37 | 27.31 | 8.35 | 22.73 |
|  |  | 523.7017 | 3.004 | 14 | 2.37 | 2.01 | 2.24 | 2.44 | 2.12 | 1.94 | 27.36 | 16.52 | 34.66 |
|  |  | 1550.051 | 5.205 | 22 | 2.89 | 2.96 | 2.75 | 2.75 | 3.20 | 2.96 | 27.68 | 32.93 | 27.41 |
|  |  | 721.6492 | 8.084 | 3 | 3.75 | 3.85 | 3.98 | 4.02 | 3.88 | 4.16 | 27.82 | 30.98 | 30.86 |
|  |  | 490.8689 | 3.181 | 5 | 3.51 | 3.06 | 3.47 | 3.46 | 3.12 | 3.53 | 27.92 | 9.52 | 26.97 |
|  |  | 547.4443 | 3.841 | 19 | 1.91 | 1.54 | 1.76 | 1.65 | 1.52 | 1.68 | 28.05 | 10.86 | 10.99 |
|  |  | 942.7382 | 11.224 | 18 | 3.61 | 1.56 | 3.86 | 3.44 | 1.44 | 3.52 | 28.09 | 37.20 | 49.39 |
|  |  | 1215.744 | 5.402 | 18 | 2.06 | 1.48 | 2.41 | 2.23 | 1.34 | 2.56 | 28.54 | 25.80 | 34.20 |
|  |  | 553.0514 | 2.982 | 11 | 2.74 | 2.10 | 2.82 | 2.17 | 2.08 | 2.69 | 28.62 | 5.78 | 16.94 |
|  |  | 468.8553 | 3.201 | 12 | 2.27 | 1.95 | 2.30 | 2.33 | 1.93 | 2.44 | 28.95 | 3.37 | 46.42 |
|  |  | 342.3321 | 3.678 | 18 | 1.86 | 0.59 | 1.74 | 1.86 | 0.53 | 1.69 | 29.00 | 47.35 | 6.67 |
|  |  | 355.3638 | 3.915 | 19 | 2.24 | 2.42 | 2.43 | 2.13 | 2.24 | 2.41 | 29.01 | 32.57 | 7.22 |
|  |  | 374.3388 | 3.522 | 17 | 3.94 | 3.93 | 3.86 | 4.11 | 3.97 | 3.98 | 29.11 | 18.12 | 27.44 |
|  |  |  | 1043.013 | 11.251 | 17 | 3.67 | 3.36 | 2.95 | 3.64 | 3.22 | 2.83 | 29.26 | 16.17 |
|  |  |  | 18.94 |  |  |  |  |  |  |  |  |  |  |
|  |  |  | 783.5909 | 4.892 | 21 | 4.40 | 3.61 | 4.89 | 4.44 | 3.64 | 4.52 | 29.59 | 40.10 | 44.92.


|  |  | 437.3193 | 3.718 | 12 | 2.39 | 0.92 | 2.58 | 2.49 | 1.07 | 2.45 | 30.16 | 44.46 |
| ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |


|  |  | 502.2748 | 1.66 | 20 | 6.09 | 6.46 | 5.89 | 5.96 | 6.40 | 5.77 | 34.13 | 26.21 |
| ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| 20.01 |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | 712.0009 | 3.05 | 13 | 1.93 | 1.26 | 2.16 | 1.77 | 1.36 | 1.90 | 34.45 | 21.86 |


|  |  | 1509.094 | 5.112 | 5 | 4.35 | 5.21 | 5.46 | 4.56 | 5.12 | 5.75 | 41.78 | 13.29 |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| 37.98 |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | 1498.405 | 8.518 | 10 | 3.15 | 2.44 | 3.05 | 2.70 | 2.37 | 3.35 | 42.08 | 18.67 |
|  |  | 2361.741 | 5.621 | 24 | 5.20 | 4.64 | 4.49 | 4.44 | 4.53 | 4.22 | 42.63 | 26.53 |
|  |  | 626.1074 | 8.083 | 22 | 1.53 | 0.73 | 0.91 | 1.37 | 0.66 | 0.91 | 45.50 | 21.18 |
|  |  | 512.3595 | 3.427 | 18 | 1.91 | 0.38 | 2.12 | 1.91 | 0.29 | 2.08 | 45.56 | 13.47 |
|  |  | 978.5478 | 5.636 | 19 | 2.38 | 3.12 | 2.78 | 3.10 | 3.18 | 3.02 | 45.95 | 19.99 |
|  |  | 489.3923 | 2.717 | 13 | 1.91 | 0.07 | 0.58 | 1.24 | 0.09 | 0.48 | 47.06 | 8.37 |
|  |  | 1584.116 | 3.316 | 7 | 1.64 | 1.16 | 1.68 | 1.63 | 1.19 | 1.58 | 48.73 | 11.59 |
|  |  | 428.2678 | 3.536 | 13 | 1.45 | 0.80 | 1.35 | 2.14 | 0.56 | 1.31 | 48.80 | 46.46 |
|  |  | 1845.261 | 3.238 | 13 | 2.40 | 1.84 | 2.42 | 2.30 | 1.82 | 2.27 | 48.87 | 6.91 |
|  |  |  | 411.1811 | 2.312 | 18 | 4.78 | 3.48 | 4.13 | 4.40 | 3.55 | 3.77 | 49.23 |
|  |  |  | 859.6442 | 3.53 | 15 | 1.62 | 0.81 | 1.16 | 2.02 | 0.50 | 0.86 | 49.74 |
|  |  |  |  |  | 40.09 | 40.79 |  |  |  |  |  |  |

## REFERENCES

1. McLean, M. A., Gregory, M. C., and Sligar, S. G. (2018) Nanodiscs: A Controlled Bilayer Surface for the Study of Membrane Proteins. Annual Review of Biophysics 47, 107-124
2. Overington, J. P., Al-Lazikani, B., and Hopkins, A. L. (2006) How many drug targets are there? Nat Rev Drug Discov 5, 993-996
3. Dean, M., and Annilo, T. (2005) EVOLUTION OF THE ATP-BINDING CASSETTE (ABC) TRANSPORTER SUPERFAMILY IN VERTEBRATES. Annual Review of Genomics and Human Genetics 6, 123-142
4. Tarling, E. J., Vallim, T. Q. D. A., and Edwards, P. A. (2013) Role of ABC transporters in lipid transport and human disease. 24, 342-350
5. Vasiliou, V., Vasiliou, K., and Nebert, D. W. (2008) Human ATP-binding cassette (ABC) transporter family. Human Genomics 3, 281
6. Jones, P. M., and George, A. M. (2004) The ABC transporter structure and mechanism: perspectives on recent research. Cellular and Molecular Life Sciences (CMLS) 61, 682-699
7. Dawson, R. J. P., and Locher, K. P. (2006) Structure of a bacterial multidrug ABC transporter. Nature 443, 180-185
8. Hollenstein, K., Dawson, R. J., and Locher, K. P. (2007) Structure and mechanism of ABC transporter proteins. Current Opinion in Structural Biology 17, 412-418
9. Dawson, R. J. P., and Locher, K. P. (2007) Structure of the multidrug ABC transporter Sav1866 fromStaphylococcus aureusin complex with AMP-PNP. FEBS Letters 581, 935-938
10. Hopfner, K.-P., Karcher, A., Shin, D. S., Craig, L., Arthur, L. M., Carney, J. P., and Tainer, J. A. (2000) Structural Biology of Rad50 ATPase. 101, 789-800
11. Smith, P. C., Karpowich, N., Millen, L., Moody, J. E., Rosen, J., Thomas, P. J., and Hunt, J. F. (2002) ATP Binding to the Motor Domain from an ABC Transporter Drives Formation of a Nucleotide Sandwich Dimer. Molecular Cell 10, 139-149
12. Chen, J., Lu, G., Lin, J., Davidson, A. L., and Quiocho, F. A. (2003) A Tweezerslike Motion of the ATP-Binding Cassette Dimer in an ABC Transport Cycle. 12, 651-661
13. Gerber, S., Comellas-Bigler, M., Goetz, B. A., and Locher, K. P. (2008) Structural Basis of Trans-Inhibition in a Molybdate/Tungstate ABC Transporter. Science 321, 246-250
14. Hohl, M., Briand, C., Grütter, M. G., and Seeger, M. A. (2012) Crystal structure of a heterodimeric ABC transporter in its inward-facing conformation. 19, 395402
15. Abele, R., and Tampé, R. (2009) Peptide trafficking and translocation across membranes in cellular signaling and self-defense strategies. 21, 508-515
16. Prieß, M., Göddeke, H., Groenhof, G., and Schäfer, L. V. (2018) Molecular Mechanism of ATP Hydrolysis in an ABC Transporter. ACS Central Science
17. Locher, K. P. (2016) Mechanistic diversity in ATP-binding cassette (ABC) transporters. Nature Structural \& Molecular Biology 23, 487-493
18. Schmitt, L. (2002) Structure and mechanism of ABC transporters. 12, 754-760
19. Zaitseva, J., Jenewein, S., Jumpertz, T., Holland, I. B., and Schmitt, L. (2005) H662 is the linchpin of ATP hydrolysis in the nucleotide-binding domain of the ABC transporter HlyB. 24, 1901-1910
20. Jardetzky, O. (1966) Simple Allosteric Model for Membrane Pumps. Nature 211, 969-970
21. (1995) The catalytic cycle of P-glycoprotein. FEBS Letters 377, 285-289
22. Van Veen, H. W. (2000) The homodimeric ATP-binding cassette transporter LmrA mediates multidrug transport by an alternating two-site (two-cylinder engine) mechanism. 19, 2503-2514
23. Khare, D., Oldham, M. L., Orelle, C., Davidson, A. L., and Chen, J. (2009) Alternating Access in Maltose Transporter Mediated by Rigid-Body Rotations. Molecular Cell 33, 528-536
24. Oldham, M. L., Khare, D., Quiocho, F. A., Davidson, A. L., and Chen, J. (2007) Crystal structure of a catalytic intermediate of the maltose transporter. Nature 450, 515-521
25. Oldham, M. L., Davidson, A. L., and Chen, J. (2008) Structural insights into ABC transporter mechanism. Current Opinion in Structural Biology 18, 726-733
26. Zou, P., and McHaourab, H. S. (2009) Alternating Access of the Putative Substrate-Binding Chamber in the ABC Transporter MsbA. 393, 574-585
27. Davidson, A. L., and Chen, J. (2004) ATP-Binding Cassette Transporters in Bacteria. Annual Review of Biochemistry 73, 241-268
28. Delannoy, S., Urbatsch, I. L., Tombline, G., Senior, A. E., and Vogel, P. D. (2005) Nucleotide Binding to the Multidrug Resistance P-Glycoprotein as Studied by ESR Spectroscopy. Biochemistry 44, 14010-14019
29. Van Der Does, C., and Tampé, R. (2004) How do ABC transporters drive transport? 385
30. Higgins, C. F., and Linton, K. J. (2004) The ATP switch model for ABC transporters. Nature Structural \& Molecular Biology 11, 918-926
31. George, A. M., and Jones, P. M. (2012) Perspectives on the structure-function of ABC transporters: The Switch and Constant Contact Models. Progress in Biophysics and Molecular Biology 109, 95-107
32. Aller, S. G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P. M., Trinh, Y. T., Zhang, Q., Urbatsch, I. L., and Chang, G. (2009) Structure of PGlycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding. Science 323, 1718-1722
33. Jones, P. M., O’Mara, M. L., and George, A. M. (2009) ABC transporters: a riddle wrapped in a mystery inside an enigma. 34, 520-531
34. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2010) Human P-glycoprotein is active when the two halves are clamped together in the closed conformation. 395, 436-440
35. Sauna, Z. E., Kim, I.-W., Nandigama, K., Kopp, S., Chiba, P., and Ambudkar, S. V. (2007) Catalytic Cycle of ATP Hydrolysis by P-Glycoprotein: Evidence for Formation of the E•S Reaction Intermediate with ATP- $\gamma$-S, a Nonhydrolyzable Analogue of ATP $\dagger$. 46, 13787-13799
36. Siarheyeva, A., Liu, R., and Sharom, F. J. (2010) Characterization of an Asymmetric Occluded State of P-glycoprotein with Two Bound Nucleotides: IMPLICATIONS FOR CATALYSIS. 285, 7575-7586
37. Ford, R. C., and Beis, K. (2019) Learning the ABCs one at a time: structure and mechanism of ABC transporters. Biochemical Society Transactions 47, 23-36
38. Riordan, J., Rommens, J., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., Chou, J., and al., e. (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245, 1066-1073
39. Hrycyna, C. A., Airan, L. E., Germann, U. A., Ambudkar, S. V., Pastan, I., and Gottesman, M. M. (1998) Structural Flexibility of the Linker Region of Human PGlycoprotein Permits ATP Hydrolysis and Drug Transport $\dagger .37,13660-13673$
40. Qian, H., Zhao, X., Cao, P., Lei, J., Yan, N., and Gong, X. (2017) Structure of the Human Lipid Exporter ABCA1. Cell 169, 1228-1239.e1210
41. Baker, J. M. R., Hudson, R. P., Kanelis, V., Choy, W.-Y., Thibodeau, P. H., Thomas, P. J., and Forman-Kay, J. D. (2007) CFTR regulatory region interacts with NBD1 predominantly via multiple transient helices. 14, 738-745
42. Hwang, T. C. (1993) Functionally distinct phospho-forms underlie incremental activation of protein kinase-regulated Cl - conductance in mammalian heart. 101, 629-650
43. Drumm, M., Wilkinson, D., Smit, L., Worrell, R., Strong, T., Frizzell, R., Dawson, D., and Collins, F. (1991) Chloride conductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytes. Science 254, 1797-1799
44. O'Riordan, C. R., Lachapelle, A. L., Marshall, J., Higgins, E. A., and Cheng, S. H. (2000) Characterization of the oligosaccharide structures associated with the cystic fibrosis transmembrane conductance regulator. 10, 1225-1233
45. Hall, R. A., Ostedgaard, L. S., Premont, R. T., Blitzer, J. T., Rahman, N., Welsh, M. J., and Lefkowitz, R. J. (1998) A C-terminal motif found in the 2-adrenergic receptor, P2Y1 receptor and cystic fibrosis transmembrane conductance regulator determines binding to the $\mathrm{Na}+/ \mathrm{H}+$ exchanger regulatory factor family of PDZ proteins. 95, 8496-8501
46. Short, D. B., Trotter, K. W., Reczek, D., Kreda, S. M., Bretscher, A., Boucher, R. C., Stutts, M. J., and Milgram, S. L. (1998) An Apical PDZ Protein Anchors the Cystic Fibrosis Transmembrane Conductance Regulator to the Cytoskeleton. 273, 19797-19801
47. Wang, S., Raab, R. W., Schatz, P. J., Guggino, W. B., and Li, M. (1998) Peptide binding consensus of the NHE-RF-PDZ1 domain matches the C-terminal sequence of cystic fibrosis transmembrane conductance regulator (CFTR). 427, 103-108
48. Zhang, Z., and Chen, J. (2016) Atomic Structure of the Cystic Fibrosis Transmembrane Conductance Regulator. Cell 167, 1586-1597.e1589
49. Li, N., Wu, J.-X., Ding, D., Cheng, J., Gao, N., and Chen, L. (2017) Structure of a Pancreatic ATP-Sensitive Potassium Channel. 168, 101-110.e110
50. Johnson, Z. L., and Chen, J. (2017) Structural Basis of Substrate Recognition by the Multidrug Resistance Protein MRP1. Cell 168, 1075-1085.e1079
51. Martin, G. M., Yoshioka, C., Rex, E. A., Fay, J. F., Xie, Q., Whorton, M. R., Chen, J. Z., and Shyng, S.-L. (2017) Cryo-EM structure of the ATP-sensitive potassium channel illuminates mechanisms of assembly and gating. Elife $\mathbf{6}$, e24149
52. Peters, K., Qi, J., Johnson, J., Watkins, S., and R, F. (2001) Role of snare proteins in CFTR and ENaC trafficking. 443, S65-S69
53. Naren, A. P., Quick, M. W., Collawn, J. F., Nelson, D. J., and Kirk, K. L. (1998) Syntaxin 1A inhibits CFTR chloride channels by means of domain-specific protein-protein interactions. 95, 10972-10977
54. Lu, Y., Xiong, X., Helm, A., Kimani, K., Bragin, A., and Skach, W. R. (1998) Co- and Posttranslational Translocation Mechanisms Direct Cystic Fibrosis Transmembrane Conductance Regulator N Terminus Transmembrane Assembly. 273, 568-576
55. Carveth, K., Buck, T., Anthony, V., and Skach, W. R. (2002) Cooperativity and Flexibility of Cystic Fibrosis Transmembrane Conductance Regulator Transmembrane Segments Participate in Membrane Localization of a Charged Residue. 277, 39507-39514
56. Kleizen, B., van Vlijmen, T., de Jonge, H. R., and Braakman, I. (2005) Folding of CFTR is predominantly cotranslational. Mol Cell 20, 277-287
57. Khushoo, A., Yang, Z., Arthur, and William. (2011) Ligand-Driven Vectorial Folding of Ribosome-Bound Human CFTR NBD1. 41, 682-692
58. Kim, S. J., and Skach, W. R. (2012) Mechanisms of CFTR Folding at the Endoplasmic Reticulum. 3
59. Xiong, X., Bragin, A., Widdicombe, J. H., Cohn, J., and Skach, W. R. (1997) Structural cues involved in endoplasmic reticulum degradation of G85E and G91R mutant cystic fibrosis transmembrane conductance regulator. 100, 10791088
60. Du, K., and Lukacs, G. L. (2009) Cooperative Assembly and Misfolding of CFTR Domains In Vivo. 20, 1903-1915
61. Pitonzo, D., Yang, Z., Matsumura, Y., Johnson, A. E., and Skach, W. R. (2009) Sequence-specific retention and regulated integration of a nascent membrane protein by the endoplasmic reticulum Sec61 translocon. Mol Biol Cell 20, 685698
62. Enquist, K., Fransson, M., Boekel, C., Bengtsson, I., Geiger, K., Lang, L., Pettersson, A., Johansson, S., von Heijne, G., and Nilsson, I. (2009) Membraneintegration characteristics of two ABC transporters, CFTR and P-glycoprotein. $J$ Mol Biol 387, 1153-1164
63. Farinha, C. M., and Canato, S. (2017) From the endoplasmic reticulum to the plasma membrane: mechanisms of CFTR folding and trafficking. Cellular and Molecular Life Sciences 74, 39-55
64. Meacham, G. C., Lu, Z., King, S., Sorscher, E., Tousson, A., and Cyr, D. M. (1999) The Hdj-2/Hsc70 chaperone pair facilitates early steps in CFTR biogenesis. EMBO J 18, 1492-1505
65. Oberdorf, J., Pitonzo, D., and Skach, W. R. (2005) An energy-dependent maturation step is required for release of the cystic fibrosis transmembrane conductance regulator from early endoplasmic reticulum biosynthetic machinery. J Biol Chem 280, 38193-38202
66. Farinha, C. M., Nogueira, P., Mendes, F., Penque, D., and Amaral, M. D. (2002) The human DnaJ homologue (Hdj)-1/heat-shock protein (Hsp) 40 co-chaperone is required for the in vivo stabilization of the cystic fibrosis transmembrane conductance regulator by Hsp70. Biochem J 366, 797-806
67. Roxo-Rosa, M., Xu, Z., Schmidt, A., Neto, M., Cai, Z., Soares, C. M., Sheppard, D. N., and Amaral, M. D. (2006) Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide-binding domain of CFTR by different mechanisms. Proc Natl Acad Sci U S A 103, 17891-17896
68. Yang, Y., Janich, S., Cohn, J. A., and Wilson, J. M. (1993) The common variant of cystic fibrosis transmembrane conductance regulator is recognized by hsp70 and degraded in a pre-Golgi nonlysosomal compartment. Proc Natl Acad Sci U S A 90, 9480-9484
69. Loo, M. A., Jensen, T. J., Cui, L., Hou, Y., Chang, X. B., and Riordan, J. R. (1998) Perturbation of Hsp90 interaction with nascent CFTR prevents its maturation and accelerates its degradation by the proteasome. EMBO J 17, 68796887
70. Younger, J. M., Ren, H. Y., Chen, L., Fan, C. Y., Fields, A., Patterson, C., and Cyr, D. M. (2004) A foldable CFTR \{Delta\}F508 biogenic intermediate accumulates upon inhibition of the Hsc70-CHIP E3 ubiquitin ligase. J Cell Biol 167, 1075-1085
71. Grove, D. E., Fan, C. Y., Ren, H. Y., and Cyr, D. M. (2011) The endoplasmic reticulum-associated Hsp40 DNAJB12 and Hsc70 cooperate to facilitate RMA1 E3-dependent degradation of nascent CFTRDeltaF508. Mol Biol Cell 22, 301-314
72. Matsumura, Y., Sakai, J., and Skach, W. R. (2013) Endoplasmic reticulum protein quality control is determined by cooperative interactions between Hsp/c70 protein and the CHIP E3 ligase. J Biol Chem 288, 31069-31079
73. Patrick, A. E., Karamyshev, A. L., Millen, L., and Thomas, P. J. (2011) Alteration of CFTR transmembrane span integration by disease-causing mutations. Mol Biol Cell 22, 4461-4471
74. Pind, S., Riordan, J. R., and Williams, D. B. (1994) Participation of the endoplasmic reticulum chaperone calnexin (p88, IP90) in the biogenesis of the
cystic fibrosis transmembrane conductance regulator. J Biol Chem 269, 1278412788
75. Harada, K., Okiyoneda, T., Hashimoto, Y., Ueno, K., Nakamura, K., Yamahira, K., Sugahara, T., Shuto, T., Wada, I., Suico, M. A., and Kai, H. (2006) Calreticulin negatively regulates the cell surface expression of cystic fibrosis transmembrane conductance regulator. J Biol Chem 281, 12841-12848
76. Rosser, M. F., Grove, D. E., Chen, L., and Cyr, D. M. (2008) Assembly and misassembly of cystic fibrosis transmembrane conductance regulator: folding defects caused by deletion of F508 occur before and after the calnexin-dependent association of membrane spanning domain (MSD) 1 and MSD2. Mol Biol Cell 19, 4570-4579
77. Hammond, C., Braakman, I., and Helenius, A. (1994) Role of N-linked oligosaccharide recognition, glucose trimming, and calnexin in glycoprotein folding and quality control. Proc Natl Acad Sci U S A 91, 913-917
78. Michelsen, K., Yuan, H., and Schwappach, B. (2005) Hide and run. Argininebased endoplasmic-reticulum-sorting motifs in the assembly of heteromultimeric membrane proteins. EMBO Rep 6, 717-722
79. Santos, J. D., Canato, S., Carvalho, A. S., Botelho, H. M., Aloria, K., Amaral, M. D., Matthiesen, R., Falcao, A. O., and Farinha, C. M. (2019) Folding Status Is Determinant over Traffic-Competence in Defining CFTR Interactors in the Endoplasmic Reticulum. Cells 8, 353
80. Wang, X., Matteson, J., An, Y., Moyer, B., Yoo, J. S., Bannykh, S., Wilson, I. A., Riordan, J. R., and Balch, W. E. (2004) COPII-dependent export of cystic fibrosis transmembrane conductance regulator from the ER uses a di-acidic exit code. $J$ Cell Biol 167, 65-74
81. Nishimura, N., and Balch, W. E. (1997) A di-acidic signal required for selective export from the endoplasmic reticulum. Science 277, 556-558
82. Farinha, Carlos M., King-Underwood, J., Sousa, M., Correia, Ana R., Henriques, Bárbara J., Roxo-Rosa, M., Da Paula, Ana C., Williams, J., Hirst, S., Gomes, Cláudio M., and Amaral, Margarida D. (2013) Revertants, Low Temperature, and Correctors Reveal the Mechanism of F508del-CFTR Rescue by VX-809 and Suggest Multiple Agents for Full Correction. Chemistry \& Biology 20, 943-955
83. Amaral, M. D., Farinha, C. M., Matos, P., and Botelho, H. M. (2016) Investigating Alternative Transport of Integral Plasma Membrane Proteins from the ER to the Golgi: Lessons from the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). Methods Mol Biol 1459, 105-126
84. Grieve, A. G., and Rabouille, C. (2011) Golgi bypass: skirting around the heart of classical secretion. Cold Spring Harb Perspect Biol 3
85. Bannykh, S. I., Bannykh, G. I., Fish, K. N., Moyer, B. D., Riordan, J. R., and Balch, W. E. (2000) Traffic pattern of cystic fibrosis transmembrane regulator through the early exocytic pathway. Traffic 1, 852-870
86. Hu, W., Howard, M., and Lukacs, G. L. (2001) Multiple endocytic signals in the C-terminal tail of the cystic fibrosis transmembrane conductance regulator. Biochem J 354, 561-572
87. Peter, K., Varga, K., Bebok, Z., McNicholas-Bevensee, C. M., Schwiebert, L., Sorscher, E. J., Schwiebert, E. M., and Collawn, J. F. (2002) Ablation of internalization signals in the carboxyl-terminal tail of the cystic fibrosis transmembrane conductance regulator enhances cell surface expression. J Biol Chem 277, 49952-49957
88. Gentzsch, M., Aleksandrov, A., Aleksandrov, L., and Riordan, J. R. (2002) Functional analysis of the C-terminal boundary of the second nucleotide binding domain of the cystic fibrosis transmembrane conductance regulator and structural implications. Biochem J 366, 541-548
89. Weixel, K. M., and Bradbury, N. A. (2000) The carboxyl terminus of the cystic fibrosis transmembrane conductance regulator binds to AP-2 clathrin adaptors. $J$ Biol Chem 275, 3655-3660
90. Swiatecka-Urban, A., Brown, A., Moreau-Marquis, S., Renuka, J., Coutermarsh, B., Barnaby, R., Karlson, K. H., Flotte, T. R., Fukuda, M., Langford, G. M., and Stanton, B. A. (2005) The short apical membrane half-life of rescued \{Delta\}F508-cystic fibrosis transmembrane conductance regulator (CFTR) results from accelerated endocytosis of $\{$ Delta $\}$ F508-CFTR in polarized human airway epithelial cells. J Biol Chem 280, 36762-36772
91. Short, D. B., Trotter, K. W., Reczek, D., Kreda, S. M., Bretscher, A., Boucher, R. C., Stutts, M. J., and Milgram, S. L. (1998) An apical PDZ protein anchors the cystic fibrosis transmembrane conductance regulator to the cytoskeleton. J Biol Chem 273, 19797-19801
92. Hall, R. A., Ostedgaard, L. S., Premont, R. T., Blitzer, J. T., Rahman, N., Welsh, M. J., and Lefkowitz, R. J. (1998) A C-terminal motif found in the beta2adrenergic receptor, P 2 Y 1 receptor and cystic fibrosis transmembrane conductance regulator determines binding to the $\mathrm{Na}+/ \mathrm{H}+$ exchanger regulatory factor family of PDZ proteins. Proc Natl Acad Sci U S A 95, 8496-8501
93. Wang, S., Raab, R. W., Schatz, P. J., Guggino, W. B., and Li, M. (1998) Peptide binding consensus of the NHE-RF-PDZ1 domain matches the C-terminal sequence of cystic fibrosis transmembrane conductance regulator (CFTR). FEBS Lett 427, 103-108
94. Ranganathan, R., and Ross, E. M. (1997) PDZ domain proteins: scaffolds for signaling complexes. Curr Biol 7, R770-773
95. Cushing, P. R., Fellows, A., Villone, D., Boisguerin, P., and Madden, D. R. (2008) The relative binding affinities of PDZ partners for CFTR: a biochemical basis for efficient endocytic recycling. Biochemistry 47, 10084-10098
96. Guggino, W. B., and Stanton, B. A. (2006) New insights into cystic fibrosis: molecular switches that regulate CFTR. Nat Rev Mol Cell Biol 7, 426-436
97. Sun, F., Hug, M. J., Lewarchik, C. M., Yun, C. H., Bradbury, N. A., and Frizzell, R. A. (2000) E3KARP mediates the association of ezrin and protein kinase A with the cystic fibrosis transmembrane conductance regulator in airway cells. J Biol Chem 275, 29539-29546
98. Haggie, P. M., Kim, J. K., Lukacs, G. L., and Verkman, A. S. (2006) Tracking of quantum dot-labeled CFTR shows near immobilization by C-terminal PDZ interactions. Mol Biol Cell 17, 4937-4945
99. Anderson, M. P., Gregory, R. J., Thompson, S., Souza, D. W., Paul, S., Mulligan, R. C., Smith, A. E., and Welsh, M. J. (1991) Demonstration that CFTR is a Chloride Channel by Alteration of its Anion Selectivity. Science 253, 202-205
100. Anderson, M. P., Rich, D. P., Gregory, R. J., Smith, A. E., and Welsh, M. J. (1991) Generation of cAMP-activated chloride currents by expression of CFTR. Science (New York, N.Y.) 251, 679-682
101. Bear, C. E., Duguay, F., Naismith, A. L., Kartner, N., Hanrahan, J. W., and Riordan, J. R. (1991) Cl- channel activity in Xenopus oocytes expressing the cystic fibrosis gene. The Journal of biological chemistry 266, 19142-19145
102. Tabcharani, J. A., Chang, X.-B., Riordan, J. R., and Hanrahan, J. W. (1991) Phosphorylation-regulated CI- channel in CHO cells stably expressing the cystic fibrosis gene. 352, 628-631
103. Rich, D. P., Gregory, R. J., Anderson, M. P., Manavalan, P., Smith, A. E., and Welsh, M. J. (1991) Effect of deleting the R domain on CFTR-generated chloride channels. Science 253, 205
104. Berger, H. A., Anderson, M. P., Gregory, R. J., Thompson, S., Howard, P. W., Maurer, R. A., Mulligan, R., Smith, A. E., and Welsh, M. J. (1991) Identification and regulation of the cystic fibrosis transmembrane conductance regulatorgenerated chloride channel. 88, 1422-1431
105. Chang, X. B., Tabcharani, J. A., Hou, Y. X., Jensen, T. J., Kartner, N., Alon, N., Hanrahan, J. W., and Riordan, J. R. (1993) Protein kinase A (PKA) still activates CFTR chloride channel after mutagenesis of all 10 PKA consensus phosphorylation sites. Journal of Biological Chemistry 268, 11304-11311
106. Cheng, S. H., Rich, D. P., Marshall, J., Gregory, R. J., Welsh, M. J., and Smith, A. E. (1991) Phosphorylation of the R domain by cAMP-dependent protein kinase regulates the CFTR chloride channel. Cell 66, 1027-1036
107. Hwang, T. C., Nagel, G., Nairn, A. C., and Gadsby, D. C. (1994) Regulation of the gating of cystic fibrosis transmembrane conductance regulator C 1 channels by phosphorylation and ATP hydrolysis. 91, 4698-4702
108. Winter, M. C., and Welsh, M. J. (1997) Stimulation of CFTR activity by its phosphorylated R domain. Nature 389, 294-296
109. Anderson, M. P., Berger, H. A., Rich, D. P., Gregory, R. J., Smith, A. E., and Welsh, M. J. (1991) Nucleoside triphosphates are required to open the CFTR chloride channel. Cell 67, 775
110. Baukrowitz, T., Hwang, T.-C., Nairn, A. C., and Gadsby, D. C. (1994) Coupling of CFTR Cl- channel gating to an ATP hydrolysis cycle. Neuron 12, 473-482
111. Carson, M. R., Travis, S. M., and Welsh, M. J. (1995) The Two Nucleotidebinding Domains of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Have Distinct Functions in Controlling Channel Activity. Journal of Biological Chemistry 270, 1711-1717
112. Gunderson, K. L., and Kopito, R. R. (1995) Conformational states of CFTR associated with channel gating: The role of ATP binding and hydrolysis. 82, 231239
113. Ko, Y. H., and Pedersen, P. L. (1995) The First Nucleotide Binding Fold of the Cystic Fibrosis Transmembrane Conductance Regulator Can Function as an Active ATPase. 270, 22093-22096
114. Li, C., Ramjeesingh, M., Wang, W., Garami, E., Hewryk, M., Lee, D., Rommens, J. M., Galley, K., and Bear, C. E. (1996) ATPase Activity of the Cystic Fibrosis Transmembrane Conductance Regulator. Journal of Biological Chemistry 271, 28463-28468
115. Tabcharani, J. A., Seibert, F. S., Chang, X. B., Dulhanty, A. M., Mathews, C., Hanrahan, J. W., and Riordan, J. R. (1995) cAMP-dependent Protein Kinasemediated Phosphorylation of Cystic Fibrosis Transmembrane Conductance Regulator Residue Ser-753 and Its Role in Channel Activation. 270, 2158-2162
116. Picciotto, M. R., Cohn, J. A., Bertuzzi, G., Greengard, P., and Nairn, A. C. (1992) Phosphorylation of the cystic fibrosis transmembrane conductance regulator. Journal of Biological Chemistry 267, 12742-12752
117. Jia, Y., Mathews, C. J., and Hanrahan, J. W. (1997) Phosphorylation by Protein Kinase C Is Required For Acute Activation of Cystic Fibrosis Transmembrane Conductance Regulator by Protein Kinase A. 272, 4978-4984
118. Wilkinson, D. J., Strong, T. V., Mansoura, M. K., Wood, D. L., Smith, S. S., Collins, F. S., and Dawson, D. C. (1997) CFTR activation: additive effects of stimulatory and inhibitory phosphorylation sites in the R domain. American Journal of Physiology-Lung Cellular and Molecular Physiology 273, L127-L133
119. Vais, H., Zhang, R., and Reenstra, W. W. (2004) Dibasic phosphorylation sites in the R domain of CFTR have stimulatory and inhibitory effects on channel activation. 287, C737-C745
120. Csanady, L. (2005) Preferential Phosphorylation of R-domain Serine 768 Dampens Activation of CFTR Channels by PKA. 125, 171-186
121. Hegedűs, T., Aleksandrov, A., Mengos, A., Cui, L., Jensen, T. J., and Riordan, J. R. (2009) Role of individual R domain phosphorylation sites in CFTR regulation by protein kinase A. 1788, 1341-1349
122. Rich, D. P., Berger, H. A., Cheng, S. H., Travis, S. M., Saxena, M., Smith, A. E., and Welsh, M. J. (1993) Regulation of the cystic fibrosis transmembrane conductance regulator Cl- channel by negative charge in the R domain. Journal of Biological Chemistry 268, 20259-20267
123. Seibert, F. S., Chang, X. B., Aleksandrov, A. A., Clarke, D. M., Hanrahan, J. W., and Riordan, J. R. (1999) Influence of phosphorylation by protein kinase A on CFTR at the cell surface and endoplasmic reticulum. 1461, 275-283
124. Sheppard, D. N., and Welsh, M. J. (1999) Structure and Function of the CFTR Chloride Channel. Physiological Reviews 79, S23-S45
125. Ma, J., Zhao, J., Drumm, M. L., Xie, J., and Davis, P. B. (1997) Function of the R Domain in the Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channel. 272, 28133-28141
126. Liu, F., Zhang, Z., Csanády, L., Gadsby, D. C., and Chen, J. (2017) Molecular Structure of the Human CFTR Ion Channel. Cell 169, 85-95.e88
127. Zhang, Z., Liu, F., and Chen, J. (2017) Conformational Changes of CFTR upon Phosphorylation and ATP Binding. Cell 170, 483-491.e488
128. Zhang, Z., Liu, F., and Chen, J. (2018) Molecular structure of the ATP-bound, phosphorylated human CFTR. Proceedings of the National Academy of Sciences 115, 12757-12762
129. Jih, K. Y., and Hwang, T. C. (2012) Nonequilibrium Gating of CFTR on an Equilibrium Theme. 27, 351-361
130. Rahman, K. S., Cui, G., Harvey, S. C., and McCarty, N. A. (2013) Modeling the Conformational Changes Underlying Channel Opening in CFTR. 8, e74574
131. Randak, C., Neth, P., Auerswald, E. A., Eckerskorn, C., Assfalg-Machleidt, I., and Machleidt, W. (1997) A recombinant polypeptide model of the second nucleotide-binding fold of the cystic fibrosis transmembrane conductance regulator functions as an active ATPase, GTPase and adenylate kinase. FEBS Letters 410, 180-186
132. Bear, C. E., Li, C., Kartner, N., Bridges, R. J., Jensen, T. J., Ramjeesingh, M., and Riordan, J. R. (1992) Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell 68, 809-818
133. Hildebrandt, E., Zhang, Q., Cant, N., Ding, H., Dai, Q., Peng, L., Fu, Y., Delucas, L. J., Ford, R., Kappes, J. C., and Urbatsch, I. L. (2014) A survey of detergents for the purification of stable, active human cystic fibrosis transmembrane conductance regulator (CFTR). 1838, 2825-2837
134. Hildebrandt, E., Khazanov, N., Kappes, J. C., Dai, Q., Senderowitz, H., and Urbatsch, I. L. (2017) Specific stabilization of CFTR by phosphatidylserine. 1859, 289-293
135. Linsdell, P., Tabcharani, J. A., Rommens, J. M., Hou, Y. X., Chang, X. B., Tsui, L. C., Riordan, J. R., and Hanrahan, J. W. (1997) Permeability of wild-type and mutant cystic fibrosis transmembrane conductance regulator chloride channels to polyatomic anions. The Journal of general physiology 110, 355-364
136. Bridges, R. J. (2012) Mechanisms of Bicarbonate Secretion: Lessons from the Airways. Cold Spring Harbor Perspectives in Medicine 2
137. Linsdell, P., and Hanrahan, J. W. (1998) Glutathione permeability of CFTR. American Journal of Physiology-Cell Physiology 275, C323-C326
138. Frizzell, R. A., and Hanrahan, J. W. (2012) Physiology of Epithelial Chloride and Fluid Secretion. Cold Spring Harbor Perspectives in Medicine 2, a009563a009563
139. Norimatsu, Y., Ivetac, A., Alexander, C., Kirkham, J., O’Donnell, N., Dawson, D. C., and Sansom, M. S. P. (2012) Cystic Fibrosis Transmembrane Conductance Regulator: A Molecular Model Defines the Architecture of the Anion Conduction Path and Locates a "Bottleneck" in the Pore. 51, 2199-2212
140. Tabcharani, J. A., Low, W., Elie, D., and Hanrahan, J. W. (1990) Lowconductance chloride channel activated by cAMP in the epithelial cell line T 84. 270, 157-164
141. Tabcharani, J. A. (1997) Halide Permeation in Wild-Type and Mutant Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channels. 110, 341354
142. McCarty, N. A. (1993) Voltage-dependent block of the cystic fibrosis transmembrane conductance regulator Cl - channel by two closely related arylaminobenzoates. 102, 1-23
143. Tao, T., Xie, J., Drumm, M. L., Zhao, J., Davis, P. B., and Ma, J. (1996) Slow conversions among subconductance states of cystic fibrosis transmembrane conductance regulator chloride channel. 70, 743-753
144. Cui, G., Song, B., Turki, H. W., and McCarty, N. A. (2012) Differential contribution of TM6 and TM12 to the pore of CFTR identified by three sulfonylurea-based blockers. 463, 405-418
145. Zhang, Z. R., Cui, G., Liu, X., Song, B., Dawson, D. C., and McCarty, N. A. (2005) Determination of the Functional Unit of the Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channel: ONE POLYPEPTIDE FORMS ONE PORE. 280, 458-468
146. Cui, G., Zhang, Z.-R., O’Brien, A. R. W., Song, B., and McCarty, N. A. (2008) Mutations at Arginine 352 Alter the Pore Architecture of CFTR. 222, 91-106
147. Cotten, J. F., and Welsh, M. J. (1999) Cystic Fibrosis-associated Mutations at Arginine 347 Alter the Pore Architecture of CFTR: EVIDENCE FOR DISRUPTION OF A SALT BRIDGE. 274, 5429-5435
148. Cui, G., Freeman, C. S., Knotts, T., Prince, C. Z., Kuang, C., and McCarty, N. A. (2013) Two Salt Bridges Differentially Contribute to the Maintenance of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channel Function. 288, 20758-20767
149. Harrington, M. A., and Kopito, R. R. (2002) Cysteine Residues in the Nucleotide Binding Domains Regulate the Conductance State of CFTR Channels. 82, 12781292
150. McCarty, N. A. (2000) Permeation through the CFTR chloride channel. Journal of Experimental Biology 203, 1947-1962
151. Linsdell, P. (2014) Functional architecture of the CFTR chloride channel. 31, 116
152. McCarty, N. A., and Zhang, Z.-R. (2001) Identification of a region of strong discrimination in the pore of CFTR. American Journal of Physiology-Lung Cellular and Molecular Physiology 281, L852-L867
153. De Boeck, K., Zolin, A., Cuppens, H., Olesen, H. V., and Viviani, L. (2014) The relative frequency of CFTR mutation classes in European patients with cystic fibrosis. Journal of Cystic Fibrosis 13, 403-409
154. Solomon, G. M., Marshall, S. G., Ramsey, B. W., and Rowe, S. M. (2015) Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors. Pediatric Pulmonology 50, S3-S13
155. Veit, G., Avramescu, R. G., Chiang, A. N., Houck, S. A., Cai, Z., Peters, K. W., Hong, J. S., Pollard, H. B., Guggino, W. B., Balch, W. E., Skach, W. R., Cutting, G. R., Frizzell, R. A., Sheppard, D. N., Cyr, D. M., Sorscher, E. J., Brodsky, J. L., and Lukacs, G. L. (2016) From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations. Molecular Biology of the Cell 27, 424-433
156. Rosenberg, M. F., Kamis, A. B., Aleksandrov, L. A., Ford, R. C., and Riordan, J. R. (2004) Purification and Crystallization of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). 279, 39051-39057
157. Rosenberg, M. F., O'Ryan, L. P., Hughes, G., Zhao, Z., Aleksandrov, L. A., Riordan, J. R., and Ford, R. C. (2011) The Cystic Fibrosis Transmembrane Conductance Regulator (CFTR): THREE-DIMENSIONAL STRUCTURE AND LOCALIZATION OF A CHANNEL GATE. 286, 42647-42654
158. Li, J., Jaimes, K. F., and Aller, S. G. (2014) Refined structures of mouse Pglycoprotein. 23, 34-46
159. Serohijos, A. W. R., Hegedus, T., Aleksandrov, A. A., He, L., Cui, L., Dokholyan, N. V., and Riordan, J. R. (2008) Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function. 105, 3256-3261
160. Mornon, J. P., Lehn, P., and Callebaut, I. (2008) Atomic model of human cystic fibrosis transmembrane conductance regulator: Membrane-spanning domains and coupling interfaces. 65, 2594-2612
161. Mornon, J.-P., Lehn, P., and Callebaut, I. (2009) Molecular models of the open and closed states of the whole human CFTR protein. 66, 3469-3486
162. Corradi, V., Vergani, P., and Tieleman, D. P. (2015) Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). 290, 22891-22906
163. Furukawa-Hagiya, T., Furuta, T., Chiba, S., Sohma, Y., and Sakurai, M. (2013) The Power Stroke Driven by ATP Binding in CFTR As Studied by Molecular Dynamics Simulations. 117, 83-93
164. Dalton, J., Kalid, O., Schushan, M., Ben-Tal, N., and Villà-Freixa, J. (2012) New Model of Cystic Fibrosis Transmembrane Conductance Regulator Proposes Active Channel-like Conformation. 52, 1842-1853
165. Mornon, J.-P., Hoffmann, B., Jonic, S., Lehn, P., and Callebaut, I. (2015) Fullopen and closed CFTR channels, with lateral tunnels from the cytoplasm and an
alternative position of the F508 region, as revealed by molecular dynamics. 72, 1377-1403
166. Strickland, K. M., Stock, G., Cui, G., Hwang, H., Infield, D. T., Schmidt-Krey, I., McCarty, N. A., and Gumbart, J. C. (2019) ATP-Dependent Signaling in Simulations of a Revised Model of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). The Journal of Physical Chemistry B 123, 3177-3188
167. Corradi, V., Gu, R.-X., Vergani, P., and Tieleman, D. P. (2018) Structure of Transmembrane Helix 8 and Possible Membrane Defects in CFTR. Biophysical Journal 114, 1751-1754
168. Negoda, A., Hogan, M. S., Cowley, E. A., and Linsdell, P. (2019) Contribution of the eighth transmembrane segment to the function of the CFTR chloride channel pore. Cellular and Molecular Life Sciences
169. Farkas, B., Tordai, H., Padányi, R., Tordai, A., Gera, J., Paragi, G., and Hegedűs, T. (2019) Discovering the chloride pathway in the CFTR channel. Cellular and Molecular Life Sciences
170. Liu, F., Zhang, Z., Levit, A., Levring, J., Touhara, K. K., Shoichet, B. K., and Chen, J. (2019) Structural identification of a hotspot on CFTR for potentiation. Science 364, 1184-1188
171. Fay, J. F., Aleksandrov, L. A., Jensen, T. J., Cui, L. L., Kousouros, J. N., He, L., Aleksandrov, A. A., Gingerich, D. S., Riordan, J. R., and Chen, J. Z. (2018) CryoEM Visualization of an Active High Open Probability CFTR Anion Channel. Biochemistry 57, 6234-6246
172. Vorobiev, S. M., Wang, C., Yang, Z., Clarke, O. B., Jiang, F., Aleksandrov, A., Fu, Z., Grassucci, R. A., Wu, S., and Mezzell, A. (2019) THERMODYNAMIC ENGINEERING ENABLES DETERMINATION OF NEAR-ATOMIC RESOLUTION CRYO-EM STRUCTURES OF HUMAN F508DEL-CFTR IN DIVERSE CONFORMATIONAL STATES. In PEDIATRIC PULMONOLOGY Vol. 54 pp. S81-S82, WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
173. Seddon, A. M., Curnow, P., and Booth, P. J. (2004) Membrane proteins, lipids and detergents: not just a soap opera. Biochim Biophys Acta 1666, 105-117
174. Pollock, N. L., Lee, S. C., Patel, J. H., Gulamhussein, A. A., and Rothnie, A. J. (2018) Structure and function of membrane proteins encapsulated in a polymerbound lipid bilayer. Biochimica et Biophysica Acta (BBA) - Biomembranes 1860, 809-817
175. Bogdanov, M., Mileykovskaya, E., and Dowhan, W. (2008) Lipids in the Assembly of Membrane Proteins and Organization of Protein Supercomplexes: Implications for Lipid-linked Disorders. pp. 197-239, Springer Netherlands
176. Saliba, A.-E., Vonkova, I., and Gavin, A.-C. (2015) The systematic analysis of protein-lipid interactions comes of age. Nature Reviews Molecular Cell Biology 16, 753-761
177. Contreras, F. X., Ernst, A. M., Wieland, F., and Brugger, B. (2011) Specificity of Intramembrane Protein-Lipid Interactions. Cold Spring Harbor Perspectives in Biology 3, a004705-a004705
178. Popot, J. L. (2010) Amphipols, nanodiscs, and fluorinated surfactants: three nonconventional approaches to studying membrane proteins in aqueous solutions. Annu Rev Biochem 79, 737-775
179. Denisov, I. G., and Sligar, S. G. (2017) Nanodiscs in Membrane Biochemistry and Biophysics. Chemical Reviews 117, 4669-4713
180. Overduin, M., and Esmaili, M. (2019) Native Nanodiscs and the Convergence of Lipidomics, Metabolomics, Interactomics and Proteomics. Applied Sciences 9, 1230
181. Ravula, T., Hardin, N. Z., and Ramamoorthy, A. (2019) Polymer nanodiscs: Advantages and limitations. Chemistry and Physics of Lipids 219, 45-49
182. Bayburt, T. H., Carlson, J. W., and Sligar, S. G. (1998) Reconstitution and imaging of a membrane protein in a nanometer-size phospholipid bilayer. J Struct Biol 123, 37-44
183. Bayburt, T. H., Grinkova, Y. V., and Sligar, S. G. (2002) Self-Assembly of Discoidal Phospholipid Bilayer Nanoparticles with Membrane Scaffold Proteins. Nano Letters 2, 853-856
184. Denisov, I. G., Grinkova, Y. V., Lazarides, A. A., and Sligar, S. G. (2004) Directed self-assembly of monodisperse phospholipid bilayer Nanodiscs with controlled size. J Am Chem Soc 126, 3477-3487
185. Grinkova, Y. V., Denisov, I. G., and Sligar, S. G. (2010) Engineering extended membrane scaffold proteins for self-assembly of soluble nanoscale lipid bilayers. Protein Eng Des Sel 23, 843-848
186. Hagn, F., Etzkorn, M., Raschle, T., and Wagner, G. (2013) Optimized Phospholipid Bilayer Nanodiscs Facilitate High-Resolution Structure Determination of Membrane Proteins. 135, 1919-1925
187. Inagaki, S., Ghirlando, R., and Grisshammer, R. (2013) Biophysical characterization of membrane proteins in nanodiscs. Methods 59, 287-300
188. Rouck, J. E., Krapf, J. E., Roy, J., Huff, H. C., and Das, A. (2017) Recent advances in nanodisc technology for membrane protein studies (2012-2017). FEBS Lett 591, 2057-2088
189. Civjan, N. R., Bayburt, T. H., Schuler, M. A., and Sligar, S. G. (2003) Direct solubilization of heterologously expressed membrane proteins by incorporation into nanoscale lipid bilayers. BioTechniques 35, 556-563
190. Yeh, V., Lee, T.-Y., Chen, C.-W., Kuo, P.-C., Shiue, J., Chu, L.-K., and Yu, T.-Y. (2018) Highly Efficient Transfer of 7TM Membrane Protein from Native Membrane to Covalently Circularized Nanodisc. Scientific Reports 8, 13501
191. Dörr, J. M., Koorengevel, M. C., Schäfer, M., Prokofyev, A. V., Scheidelaar, S., Van Der Cruijsen, E. A. W., Dafforn, T. R., Baldus, M., and Killian, J. A. (2014) Detergent-free isolation, characterization, and functional reconstitution of a tetrameric K + channel: The power of native nanodiscs. 111, 18607-18612
192. Knowles, T. J., Finka, R., Smith, C., Lin, Y.-P., Dafforn, T., and Overduin, M. (2009) Membrane Proteins Solubilized Intact in Lipid Containing Nanoparticles Bounded by Styrene Maleic Acid Copolymer. Journal of the American Chemical Society 131, 7484-7485
193. Orwick, M. C., Judge, P. J., Procek, J., Lindholm, L., Graziadei, A., Engel, A., Gröbner, G., and Watts, A. (2012) Detergent-Free Formation and Physicochemical Characterization of Nanosized Lipid-Polymer Complexes: Lipodisq. 51, 4653-4657
194. Dörr, J. M., Scheidelaar, S., Koorengevel, M. C., Dominguez, J. J., Schäfer, M., Van Walree, C. A., and Killian, J. A. (2016) The styrene-maleic acid copolymer: a versatile tool in membrane research. European Biophysics Journal 45, 3-21
195. Xue, M., Cheng, L., Faustino, I., Guo, W., and Marrink, S. J. (2018) Molecular Mechanism of Lipid Nanodisc Formation by Styrene Maleic Acid Copolymers. Biophysical Journal
196. Scheidelaar, S., Martijn, Cornelius, Juan, Jonas, and J. (2016) Effect of Polymer Composition and pH on Membrane Solubilization by Styrene-Maleic Acid Copolymers. Biophysical Journal 111, 1974-1986
197. Lee, S. C., Knowles, T. J., Postis, V. L. G., Jamshad, M., Parslow, R. A., Lin, Y.P., Goldman, A., Sridhar, P., Overduin, M., Muench, S. P., and Dafforn, T. R. (2016) A method for detergent-free isolation of membrane proteins in their local lipid environment. Nature Protocols 11, 1149-1162
198. Scheidelaar, S., Martijn, Juan, Johannes, Breukink, E., and J. (2015) Molecular Model for the Solubilization of Membranes into Nanodisks by Styrene Maleic Acid Copolymers. Biophysical Journal 108, 279-290
199. Dominguez Pardo, J. J., Dörr, J. M., Iyer, A., Cox, R. C., Scheidelaar, S., Koorengevel, M. C., Subramaniam, V., and Killian, J. A. (2016) Solubilization of lipids and lipid phases by the styrene-maleic acid copolymer.
200. Teo, A. C. K., Lee, S. C., Pollock, N. L., Stroud, Z., Hall, S., Thakker, A., Pitt, A. R., Dafforn, T. R., Spickett, C. M., and Roper, D. I. (2019) Analysis of SMALP co-extracted phospholipids shows distinct membrane environments for three classes of bacterial membrane protein. Scientific Reports 9
201. Fiori, M. C., Jiang, Y., Altenberg, G. A., and Liang, H. (2017) Polymer-encased nanodiscs with improved buffer compatibility. Scientific Reports 7
202. Oluwole, A. O., Danielczak, B., Meister, A., Babalola, J. O., Vargas, C., and Keller, S. (2017) Solubilization of Membrane Proteins into Functional LipidBilayer Nanodiscs Using a Diisobutylene/Maleic Acid Copolymer. Angewandte Chemie International Edition 56, 1919-1924
203. Hall, S. C. L., Tognoloni, C., Charlton, J., Bragginton, É. C., Rothnie, A. J., Sridhar, P., Wheatley, M., Knowles, T. J., Arnold, T., Edler, K. J., and Dafforn, T. R. (2018) An acid-compatible co-polymer for the solubilization of membranes and proteins into lipid bilayer-containing nanoparticles. Nanoscale 10, 1060910619
204. Ravula, T., Hardin, N. Z., Ramadugu, S. K., Cox, S. J., and Ramamoorthy, A. (2018) Formation of pH-Resistant Monodispersed Polymer-Lipid Nanodiscs. Angew Chem Int Ed Engl 57, 1342-1345
205. Lindhoud, S., Carvalho, V., Pronk, J. W., and Aubin-Tam, M.-E. (2016) SMASH: Modified Styrene-Maleic Acid Copolymer for Functionalization of Lipid Nanodiscs. Biomacromolecules 17, 1516-1522
206. Schmidt, V., and Sturgis, J. N. (2018) Modifying styrene-maleic acid co-polymer for studying lipid nanodiscs. Biochimica et Biophysica Acta (BBA) Biomembranes 1860, 777-783
207. Sosnay, P. R., Siklosi, K. R., Van Goor, F., Kaniecki, K., Yu, H., Sharma, N., Ramalho, A. S., Amaral, M. D., Dorfman, R., Zielenski, J., Masica, D. L., Karchin, R., Millen, L., Thomas, P. J., Patrinos, G. P., Corey, M., Lewis, M. H., Rommens, J. M., Castellani, C., Penland, C. M., and Cutting, G. R. (2013) Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. 45, 1160-1167
208. Kartner, N., Hanrahan, J. W., Jensen, T. J., Naismith, A. L., Sun, S., Ackerley, C. A., Reyes, E. F., Tsui, L.-C., Rommens, J. M., Bear, C. E., and Riordan, J. R. (1991) Expression of the cystic fibrosis gene in non-epithelial invertebrate cells produces a regulated anion conductance. Cell 64, 681-691
209. Hyde, S. C., Emsley, P., Hartshorn, M. J., Mimmack, M. M., Gileadi, U., Pearce, S. R., Gallagher, M. P., Gill, D. R., Hubbard, R. E., and Higgins, C. F. (1990) Structural model of ATP-binding proteing associated with cystic fibrosis, multidrug resistance and bacterial transport. 346, 362-365
210. Rees, D. C., Johnson, E., and Lewinson, O. (2009) ABC transporters: the power to change. Nature Reviews Molecular Cell Biology 10, 218-227
211. Wang, W., and Linsdell, P. (2012) Alternating Access to the Transmembrane Domain of the ATP-binding Cassette Protein Cystic Fibrosis Transmembrane Conductance Regulator (ABCC7). 287, 10156-10165
212. Ter Beek, J., Guskov, A., and Slotboom, D. J. (2014) Structural diversity of ABC transporters. The Journal of General Physiology 143, 419-435
213. Denning, G. M., Anderson, M. P., Amara, J. F., Marshall, J., Smith, A. E., and Welsh, M. J. (1992) Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358, 761-764
214. Dalemans, W., Barbry, P., Champigny, G., Jallat, S., Jallat, S., Dott, K., Dreyer, D., Crystal, R. G., Pavirani, A., Lecocq, J.-P., and Lazdunski, M. (1991) Altered chloride ion channel kinetics associated with the $\Delta$ F508 cystic fibrosis mutation. 354, 526-528
215. Csanády, L. (2017) CFTR gating: Invisible transitions made visible. jgp. 201711777
216. Choudhury, H. G., Tong, Z., Mathavan, I., Li, Y., Iwata, S., Zirah, S., Rebuffat, S., Van Veen, H. W., and Beis, K. (2014) Structure of an antibacterial peptide ATP-binding cassette transporter in a novel outward occluded state. 111, 91459150
217. Trabuco, L. G., Villa, E., Mitra, K., Frank, J., and Schulten, K. (2008) Flexible Fitting of Atomic Structures into Electron Microscopy Maps Using Molecular Dynamics. Structure 16, 673-683
218. Šali, A., and Blundell, T. L. (1993) Comparative Protein Modelling by Satisfaction of Spatial Restraints. Journal of Molecular Biology 234, 779-815
219. Trabuco, L. G., Schreiner, E., Gumbart, J., Hsin, J., Villa, E., and Schulten, K. (2011) Applications of the molecular dynamics flexible fitting method. 173, 420427
220. Wriggers, W. (2012) Conventions and workflows for using Situs. 68, 344-351
221. Phillips, J. C., Braun, R., Wang, W., Gumbart, J., Tajkhorshid, E., Villa, E., Chipot, C., Skeel, R. D., Kalé, L., and Schulten, K. (2005) Scalable molecular dynamics with NAMD. Journal of Computational Chemistry 26, 1781-1802
222. Chan, K.-Y., Gumbart, J., McGreevy, R., Jean, B, and Schulten, K. (2011) Symmetry-Restrained Flexible Fitting for Symmetric EM Maps. 19, 1211-1218
223. Simhaev, L., McCarty, N. A., Ford, R. C., and Senderowitz, H. (2017) Molecular Dynamics Flexible Fitting Simulations Identify New Models of the Closed State of the Cystic Fibrosis Transmembrane Conductance Regulator Protein. Journal of Chemical Information and Modeling 57, 1932-1946
224. Atwell, S., Brouillette, C. G., Conners, K., Emtage, S., Gheyi, T., Guggino, W. B., Hendle, J., Hunt, J. F., Lewis, H. A., Lu, F., Protasevich, I. I., Rodgers, L. A., Romero, R., Wasserman, S. R., Weber, P. C., Wetmore, D., Zhang, F. F., and Zhao, X. (2010) Structures of a minimal human CFTR first nucleotide-binding domain as a monomer, head-to-tail homodimer, and pathogenic mutant. 23, 375384
225. Haffke, M., Menzel, A., Carius, Y., Jahn, D., and Heinz, D. W. (2010) Structures of the nucleotide-binding domain of the human ABCB6 transporter and its complexes with nucleotides. 66, 979-987
226. Humphrey, W., Dalke, A., and Schulten, K. (1996) VMD: Visual molecular dynamics. Journal of Molecular Graphics 14, 33-38
227. Pastor, R. W., and Mackerell, A. D. (2011) Development of the CHARMM Force Field for Lipids. 2, 1526-1532
228. Best, R. B., Zhu, X., Shim, J., Lopes, P. E. M., Mittal, J., Feig, M., and Mackerell, A. D. (2012) Optimization of the Additive CHARMM All-Atom Protein Force Field Targeting Improved Sampling of the Backbone $\phi, \psi$ and Side-Chain $\chi 1$ and $\chi 2$ Dihedral Angles. Journal of Chemical Theory and Computation 8, 3257-3273
229. Denning, E. J., Priyakumar, U. D., Nilsson, L., and Mackerell, A. D. (2011) Impact of 2'-hydroxyl sampling on the conformational properties of RNA: Update of the CHARMM all-atom additive force field for RNA. Journal of Computational Chemistry 32, 1929-1943
230. Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W., and Klein, M. L. (1983) Comparison of simple potential functions for simulating liquid water. The Journal of Chemical Physics 79, 926-935
231. Darden, T., York, D., and Pedersen, L. (1993) Particle mesh Ewald: An N• $\log (\mathrm{N})$ method for Ewald sums in large systems. The Journal of Chemical Physics 98, 10089-10092
232. Gumbart, J., and Schulten, K. (2006) Molecular Dynamics Studies of the Archaeal Translocon. 90, 2356-2367
233. Smart, O. S., Neduvelil, J. G., Wang, X., Wallace, B. A., and Sansom, M. S. P. (1996) HOLE: A program for the analysis of the pore dimensions of ion channel structural models. 14, 354-360
234. Michaud-Agrawal, N., Denning, E. J., Woolf, T. B., and Beckstein, O. (2011) MDAnalysis: a toolkit for the analysis of molecular dynamics simulations. Journal of computational chemistry 32, 2319-2327
235. Wang, W., Roessler, B. C., and Kirk, K. L. (2014) An Electrostatic Interaction at the Tetrahelix Bundle Promotes Phosphorylation-dependent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channel Opening. Journal of Biological Chemistry 289, 30364-30378
236. Mense, M., Vergani, P., White, D. M., Altberg, G., Nairn, A. C., and Gadsby, D. C. (2006) In vivo phosphorylation of CFTR promotes formation of a nucleotidebinding domain heterodimer. The EMBO Journal 25, 4728-4739
237. Csanady, L. (2004) Functional Roles of Nonconserved Structural Segments in CFTR's NH2-terminal Nucleotide Binding Domain. 125, 43-55
238. Travis, S. M. (1995) The Two Nucleotide-binding Domains of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Have Distinct Functions in Controlling Channel Activity. 270, 1711-1717
239. Szollosi, A., Muallem, D. R., Csanady, L., and Vergani, P. (2011) Mutant cycles at CFTR's non-canonical ATP-binding site support little interface separation during gating. 137, 549-562
240. Tsai, M. F., Li, M., and Hwang, T. C. (2010) Stable ATP binding mediated by a partial NBD dimer of the CFTR chloride channel. 135, 399-414
241. Vergani, P., Lockless, S. W., Nairn, A. C., and Gadsby, D. C. (2005) CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains. 433, 876-880
242. Chaves, L. A. P., and Gadsby, D. C. (2015) Cysteine accessibility probes timing and extent of NBD separation along the dimer interface in gating CFTR channels. 145, 261-283
243. Szöllősi, D., Szakács, G., Chiba, P., and Stockner, T. (2018) Dissecting the Forces that Dominate Dimerization of the Nucleotide Binding Domains of ABCB1. Biophysical Journal 114, 331-342
244. Vergani, P. (2002) On the Mechanism of MgATP-dependent Gating of CFTR ClChannels. 121, 17-36
245. Berger, A. L., Ikuma, M., and Welsh, M. J. (2005) Normal gating of CFTR requires ATP binding to both nucleotide-binding domains and hydrolysis at the second nucleotide-binding domain. 102, 455-460
246. Li, J., Shaikh, S. A., Enkavi, G., Wen, P. C., Huang, Z., and Tajkhorshid, E. (2013) Transient formation of water-conducting states in membrane transporters. 110, 7696-7701
247. Norimatsu, Y., Ivetac, A., Alexander, C., O'Donnell, N., Frye, L., Sansom, M. S. P., and Dawson, D. C. (2012) Locating a Plausible Binding Site for an OpenChannel Blocker, GlyH-101, in the Pore of the Cystic Fibrosis Transmembrane Conductance Regulator. 82, 1042-1055
248. Infield, D. T., Cui, G., Kuang, C., and McCarty, N. A. (2016) Positioning of extracellular loop 1 affects pore gating of the cystic fibrosis transmembrane conductance regulator. Am J Physiol Lung Cell Mol Physiol 310, L403-L414
249. St-Pierre, J.-F., Bunker, A., Róg, T., Karttunen, M., and Mousseau, N. (2012) Molecular Dynamics Simulations of the Bacterial ABC Transporter SAV1866 in the Closed Form. The Journal of Physical Chemistry B 116, 2934-2942
250. Moradi, M., and Tajkhorshid, E. (2013) Mechanistic picture for conformational transition of a membrane transporter at atomic resolution. 110, 18916-18921
251. Cui, G., Rahman, K. S., Infield, D. T., Kuang, C., Prince, C. Z., and McCarty, N. A. (2014) Three charged amino acids in extracellular loop 1 are involved in maintaining the outer pore architecture of CFTR. The Journal of General Physiology 144, 159-179
252. Alexander, C., Ivetac, A., Liu, X., Norimatsu, Y., Serrano, J. R., Landstrom, A., Sansom, M., and Dawson, D. C. (2009) Cystic Fibrosis Transmembrane Conductance Regulator: Using Differential Reactivity toward Channel-Permeant and Channel-Impermeant Thiol-Reactive Probes To Test a Molecular Model for the Pore. 48, 10078-10088
253. Linsdell, P. (1996) Disease-associated Mutations in the Fourth Cytoplasmic Loop of Cystic Fibrosis Transmembrane Conductance Regulator Compromise Biosynthetic Processing and Chloride Channel Activity. 271, 15139-15145
254. Dalmas, O., Orelle, C., Foucher, A.-E., Geourjon, C., Crouzy, S., Di Pietro, A., and Jault, J.-M. (2005) The Q-loop Disengages from the First Intracellular Loop during the Catalytic Cycle of the Multidrug ABC Transporter BmrA. Journal of Biological Chemistry 280, 36857-36864
255. Chong, P. A., Farber, P. J., Vernon, R. M., Hudson, R. P., Mittermaier, A. K., and Forman-Kay, J. D. (2015) Deletion of Phenylalanine 508 in the First Nucleotidebinding Domain of the Cystic Fibrosis Transmembrane Conductance Regulator Increases Conformational Exchange and Inhibits Dimerization. 290, 22862-22878
256. He, L., Aleksandrov, A. A., Serohijos, A. W. R., Hegedus, T., Aleksandrov, L. A., Cui, L., Dokholyan, N. V., and Riordan, J. R. (2008) Multiple MembraneCytoplasmic Domain Contacts in the Cystic Fibrosis Transmembrane

Conductance Regulator (CFTR) Mediate Regulation of Channel Gating. 283, 26383-26390
257. Cui, G., Hong, J., Chung-Davidson, Y.-W., Infield, D., Xu, X., Li, J., Simhaev, L., Khazanov, N., Stauffer, B., Imhoff, B., Cottrill, K., Blalock, J. E., Li, W., Senderowitz, H., Sorscher, E., McCarty, N. A., and Gaggar, A. (2019) An Ancient CFTR Ortholog Informs Molecular Evolution in ABC Transporters. Developmental Cell 51, 421-430.e423
258. Galián, C., Manon, F., Dezi, M., Torres, C., Ebel, C., Lévy, D., and Jault, J.-M. (2011) Optimized Purification of a Heterodimeric ABC Transporter in a Highly Stable Form Amenable to 2-D Crystallization. 6, e19677
259. Infed, N., Hanekop, N., Driessen, A. J. M., Smits, S. H. J., and Schmitt, L. (2011) Influence of detergents on the activity of the ABC transporter LmrA. Biochimica et Biophysica Acta (BBA) - Biomembranes 1808, 2313-2321
260. Ellinger, P., Kluth, M., Stindt, J., Smits, S. H. J., and Schmitt, L. (2013) Detergent Screening and Purification of the Human Liver ABC Transporters BSEP (ABCB11) and MDR3 (ABCB4) Expressed in the Yeast Pichia pastoris. PLoS ONE 8, e60620
261. Xu, J., Sun, H., Huang, G., Liu, G., Li, Z., Yang, H., Jin, L., Cui, X., Shi, L., Ma, T., Kameyama, A., and Dong, W. (2019) A fixation method for the optimisation of western blotting. Scientific Reports 9, 6649
262. Alam, A., Kowal, J., Broude, E., Roninson, I., and Locher, K. P. (2019) Structural insight into substrate and inhibitor discrimination by human P-glycoprotein. Science 363, 753-756
263. Taylor, N. M. I., Manolaridis, I., Jackson, S. M., Kowal, J., Stahlberg, H., and Locher, K. P. (2017) Structure of the human multidrug transporter ABCG2. Nature 546, 504
264. Sonoda, Y., Cameron, A., Newstead, S., Omote, H., Moriyama, Y., Kasahara, M., Iwata, S., and Drew, D. (2010) Tricks of the trade used to accelerate highresolution structure determination of membrane proteins. FEBS Letters 584, 2539-2547
265. Hanson, M. A., Cherezov, V., Griffith, M. T., Roth, C. B., Jaakola, V.-P., Chien, E. Y. T., Velasquez, J., Kuhn, P., and Stevens, R. C. (2008) A Specific Cholesterol Binding Site Is Established by the $2.8 \AA$ Structure of the Human $\beta 2$ Adrenergic Receptor. Structure 16, 897-905
266. Lichty, J. J., Malecki, J. L., Agnew, H. D., Michelson-Horowitz, D. J., and Tan, S. (2005) Comparison of affinity tags for protein purification. Protein Expression and Purification 41, 98-105
267. Bao, H., Dalal, K., Wang, V., Rouiller, I., and Duong, F. (2013) The maltose ABC transporter: Action of membrane lipids on the transporter stability, coupling and ATPase activity. 1828, 1723-1730
268. Dang, S., Feng, S., Tien, J., Peters, C. J., Bulkley, D., Lolicato, M., Zhao, J., Zuberbühler, K., Ye, W., Qi, L., Chen, T., Craik, C. S., Jan, Y. N., Minor, D. L., Jr., Cheng, Y., and Jan, L. Y. (2017) Cryo-EM structures of the TMEM16A calcium-activated chloride channel. Nature 552, 426-429
269. Tang, G., Peng, L., Baldwin, P. R., Mann, D. S., Jiang, W., Rees, I., and Ludtke, S. J. (2007) EMAN2: An extensible image processing suite for electron microscopy. Journal of Structural Biology 157, 38-46
270. Mindell, J. A., and Grigorieff, N. (2003) Accurate determination of local defocus and specimen tilt in electron microscopy. Journal of Structural Biology 142, 334347
271. Gao, Y., Cao, E., Julius, D., and Cheng, Y. (2016) TRPV1 structures in nanodiscs reveal mechanisms of ligand and lipid action. Nature 534, 347-351
272. Zhou, M., Morgner, N., Barrera, N. P., Politis, A., Isaacson, S. C., MatakVinkovic, D., Murata, T., Bernal, R. A., Stock, D., and Robinson, C. V. (2011) Mass Spectrometry of Intact V-Type ATPases Reveals Bound Lipids and the Effects of Nucleotide Binding. 334, 380-385
273. Gupta, K., Li, J., Liko, I., Gault, J., Bechara, C., Wu, D., Hopper, J. T. S., Giles, K., Benesch, J. L. P., and Robinson, C. V. (2018) Identifying key membrane protein lipid interactions using mass spectrometry. Nature protocols 13, 11061120
274. Abu-Arish, A., Pandzic, E., Goepp, J., Matthes, E., John, and Paul. (2015) Cholesterol Modulates CFTR Confinement in the Plasma Membrane of Primary Epithelial Cells. 109, 85-94
275. Schymanski, E. L., Jeon, J., Gulde, R., Fenner, K., Ruff, M., Singer, H. P., and Hollender, J. (2014) Identifying Small Molecules via High Resolution Mass Spectrometry: Communicating Confidence. Environmental Science \& Technology 48, 2097-2098
276. Lange, Y., Echevarria, F., and Steck, T. L. (1991) Movement of zymosterol, a precursor of cholesterol, among three membranes in human fibroblasts. Journal of Biological Chemistry 266, 21439-21443
277. Jenkins, B., West, J., and Koulman, A. (2015) A Review of Odd-Chain Fatty Acid Metabolism and the Role of Pentadecanoic Acid (C15:0) and Heptadecanoic Acid (C17:0) in Health and Disease. Molecules 20, 2425-2444
278. Cui, G., Stauffer, B. B., Imhoff, B. R., Rab, A., Hong, J. S., Sorscher, E. J., and McCarty, N. A. (2019) VX-770-mediated potentiation of numerous human CFTR disease mutants is influenced by phosphorylation level. Scientific Reports 9
279. Andréll, J., and Tate, C. G. (2013) Overexpression of membrane proteins in mammalian cells for structural studies. Molecular Membrane Biology 30, 52-63
280. Cheung, R. C. F., Wong, J. H., and Ng, T. B. (2012) Immobilized metal ion affinity chromatography: a review on its applications. Applied Microbiology and Biotechnology 96, 1411-1420
281. Wood, D. W. (2014) New trends and affinity tag designs for recombinant protein purification. Current Opinion in Structural Biology 26, 54-61
282. Blanksby, S. J., and Mitchell, T. W. (2010) Advances in Mass Spectrometry for Lipidomics. Annual Review of Analytical Chemistry 3, 433-465

